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Abstract 
RNA interference (RNAi) is a natural mechanism of cellular defence against 
exogenous double stranded RNA (dsRNA). The discovery of small dsRNA 
molecules which can be processed by the RNAi pathway in mammalian cells 
was one of the key advances in the study of functional genomics. These 
molecules can be designed to downregulate the expression of specific genes. 
Collections or libraries of dsRNA molecules targeting an extensive number of 
genes are now available. Using these libraries, numerous studies have 
implemented high-throughput screens for the study of molecular effectors of 
numerous phenotypes. 
The process of designing an RNAi screen requires the consideration of several 
critical factors during both the experimental and analysis phases. The 
experimental screen should aim to reproduce the biological phenomenon 
studied as closely as possible by choosing an adequate model and screening 
conditions. Phenotype evaluation and assessment of knockdown effects need 
careful consideration. The results obtained from large-scale RNAi screens are 
often complex. An analysis pipeline should be implemented which integrates the 
biological basis of the phenomenon and facilitates the interpretation of the data. 
This project designed and implemented an unbiased shRNA screen in two in 
vitro models relevant to carcinogenesis and diabetes. The first screen 
implemented used a model of neighbour suppression to study the molecular 
effectors of the response in tumorigenic cells to growth suppression cues from 
the surrounding tissue, a cellular interaction relevant in early tumorigenesis. The 
second screen studied two phenotypes relevant to diabetes: proliferation and 
resistance to lipotoxicity of β-cells in a reversibly immortalised  cell line. An 
integrative analysis pipeline was also developed to apply network biology and 
functional enrichment analysis methods for the interpretation of the data 
obtained from both screens.
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 Chapter 1. Introduction 
1.1. Functional genomics 
Functional genomics seeks to study of the function of genes and non-genic 
elements in the DNA, nucleic acid and the proteins encoded by DNA in a 
genome-wide manner (Pevsner 2009). The study of gene function was 
classically performed using approach which could be broadly categorized in two 
main categories: forward genetics and reverse genetics. 
Before genome-wide sequencing information was available, researchers were 
limited in prior hypotheses and therefore the most useful approaches were 
those which required no information on the gene but rather depended on the 
observation of phenotypes. This was the major advantage of forward genetics, 
which starts with the observation of a phenotype of interest and then 
investigates the genetic cause. Reverse genetics, on the other hand, requires 
the researcher to hypothesize on the genetic cause to then investigate whether 
the phenotype could be caused by manipulation of the hypothesized causing 
gene. 
Forward genetic approaches were used in medicine with success for many 
years as a tool to identify the genetic causes of inherited diseases. Two 
examples of the success of this approach are the characterization of mutations 
in CFTR as the cause of cystic fibrosis (Kerem, Rommens et al. 1989, Riordan, 
Rommens et al. 1989, Rommens, Iannuzzi et al. 1989) and the role of BRCA1 
in breast carcinoma (Miki, Swensen et al. 1994).  
The three articles describing the mutations in CFTR as the cause of cystic 
fibrosis were published on the same issue of Science. Previously, linkage 
analysis had uncovered a region in chromosome 7 which was associated with 
cystic fibrosis (Eiberg, Mohr et al. 1985, Knowlton, Cohen-Haguenauer et al. 
1985, Tsui, Buchwald et al. 1985). A putative gene was then identified using 
chromosome walking and chromosome jumping (Rommens, Iannuzzi et al. 
1989), its cDNA was cloned and analysed (Riordan, Rommens et al. 1989) and 
an extensive analysis of the locus was performed in affected individuals and 
their families to characterize the causative mutations (Kerem, Rommens et al. 
1989). 
32 
 
BRCA1 was identified following a similar strategy: linkage analysis revealed an 
association of familial breast (Hall, Lee et al. 1990) and ovarian (Narod, 
Feunteun et al. 1991) cancer to a locus on chromosome 17q. The region was 
then more finely mapped using a larger number of patients and a dense set of 
genetic markers (Easton, Bishop et al. 1993, Simard, Feunteun et al. 1993). A 
physical map of the region was constructed (Neuhausen, Swensen et al. 1994). 
Miki and colleagues built on this knowledge and identified and characterized the 
cDNA sequence, which allowed them to study several mutations present in the 
transcript of affected individuals (Miki, Swensen et al. 1994). 
The completion of the first draft of the human genome in 2001 (Lander, Linton 
et al. 2001, Venter, Adams et al. 2001) produced a great amount of information 
about the structure of the human genome and greatly influenced the 
development of genomics research. The mouse genome was also sequenced 
(Waterston, Lindblad-Toh et al. 2002). Information was now available about the 
genome but the function of most of the genes were unknown. The possibility to 
make hypotheses was there, facilitating the use of reverse genetics techniques 
to the study of functional genomics. 
 
1.2. Forward functional genomics screens 
The main characteristic of forward genetics, its observational nature, has been 
adapted to the functional genomics era by increasing the frequency of the 
phenotypes of interest. Mutant cells or organisms are created using different 
approaches: exposure to X-rays (Russell, Montgomery et al. 1982) or 
mutagenic chemicals such as ethylnitrosurea or ENU (Coghill, Hugill et al. 
2002), or introduction of exogenous DNA which causes mutations on insertion 
such as transposons (Collier, Carlson et al. 2005, Dorr, Janik et al. 2015). The 
resulting mutants are screened for the phenotype of interest and the mutation 
causing the phenotype is then identified. The development of transposons as 
tools to cause insertional mutagenesis in mice (Collier, Carlson et al. 2005, 
Dupuy, Akagi et al. 2005, Dupuy, Rogers et al. 2009) led to the discovery of 
many genes involved in several cancer phenotypes. For example, transposons 
were used to identify a role for Csf1 in astrocytomas (Bender, Collier et al. 
2010), to nominate candidate genes for histiocytic sarcoma (Been, Linden et al. 
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2014) and to uncover the role of Cux1 as a tumour suppressor (Wong, 
Martincorena et al. 2014). 
It is also possible to perform overexpression screens using forward genetics 
approaches. Misexpression of endogenous genes is achieved through the 
random insertion of transposable elements into the genome. In the screens 
performed by Nakayama and collaborators (Nakayama, Ishibashi et al. 2014) 
and Cruz and colleagues (Cruz, Glavic et al. 2009) in Drosophila, the inserted 
transposon includes a binding site for a yeast transcription factor. Crossing the 
flies with the transposon with flies with the transcription factor led to the 
production of flies where the transcription factor binds to the transposon and as 
it lacks a STOP signal, the adjoined gene is also expressed under the control of 
that transcription factor. This type of activation screen using transposons has 
also been adapted for mammalian cells (Chen, Stuart et al. 2013). 
These screens have the same principal advantage as the classic forward 
genetics approach to the identification of genes causing a disease: no previous 
hypothesis or knowledge about the causative gene’s structure or sequence are 
required. Gene expression is altered at random and if the phenotype of interest 
is observed the altered gene then needs to be identified. 
 
1.3. Reverse functional genomics screens 
The reasoning behind reverse genetic approaches to functional genomics can 
be over-simplistically summarized in a question: “What happens if I alter the 
normal expression of this gene?” In a genome-wide approach, this question 
may be formulated as “What happens if I alter the normal expression of each 
gene in the genome?” This question is not posed as generically of course, as 
the researcher using these techniques will be interested in a certain phenotype. 
This researcher may then ask “The alteration of the normal expression of which 
genes in the genome may result in the phenotype I seek?” Answering this 
question would result in the proposition of a gene or group of genes which have 
an effect on the phenotype of interest. Reverse functional genomics screens 
therefore seek to analyse the effect of the alteration of gene expression in a 
phenotype. Gene expression can be altered in two directions: increasing the 
levels of expression (gain-of-function) or decreasing them (loss-of-function). 
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Both strategies require a prior knowledge about the gene or genes to be studied, 
although a hypothesis-free approach can be implemented if all the genes in the 
genome are studied. 
 
1.4. Gain-of-function studies 
The logic behind the use of gain-of-function approaches to the study of 
functional genomics resides in that the overexpression of a gene with a certain 
function will exacerbate such function and cause an observable phenotype. The 
overexpression of a gene in reverse genetics may be caused by the introduction 
of exogenous cDNA. 
cDNA sequences can be cloned into expression vectors from which they are 
transcribed into mRNA. A single cDNA expression construct may be used to 
study the effect of overexpressing one particular gene. However, a functional 
genomics approach is feasible with the available libraries or collections of cDNA 
sequences in expression vectors. One example is the “Expression Ready MGC 
cDNA libraries” available from Dharmacon. These genome-wide libraries are 
available for human, mouse and rat and are derived from the Mammalian Gene 
Consortium efforts to provide at least one full cDNA clone for all the human and 
mouse genes, and from at least 6,200 rat genes (Strausberg, Feingold et al. 
2002, Gerhard, Wagner et al. 2004, Temple, Gerhard et al. 2009). Another 
example of expression library is the more recently constructed hORFeome v 8.1 
(Yang, Boehm et al. 2011). These and other libraries have enabled high-
throughput gain-of-function studies (Pritsker, Ford et al. 2006, Arnoldo, 
Kittanakom et al. 2014). 
 
1.5. Loss-of-function studies 
Loss-of-function studies comprise the reduction of gene expression followed by 
the observation of the resulting phenotype which indicates the potential function 
of the disrupted transcript. Loss-of-function can be exerted in a number of ways: 
1.5.1. Homologous recombination 
Also called “gene targeting”, homologous recombination as a functional 
genetics technique consists in the disruption of a gene’s sequence by inserting 
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a piece of DNA (defective copy of the targeted gene for example) flanked by the 
sequence complementary to the gene to be disrupted (Smithies, Gregg et al. 
1985). Homologous recombination includes this exogenous piece of DNA into 
the targeted gene sequence, leading to disruption of the gene’s normal function. 
A systematic approach to the design of gene targeting vectors enabled the 
production of a genome-wide resource to study gene function in a mouse model 
(Collier, Carlson et al. 2005). 
1.5.2. Genome editing 
Genome editing strategies rely on the mechanism of non-homologous end-
joining (NHEJ) to repair double strand breaks (DSB). During NHEJ the 
fragments produced by DSB are repaired by re-ligation, without the need for a 
template sequence and it is therefore error-prone, often resulting in insertions or 
deletions (indels) at the break point (Moore and Haber 1996). NHEJ can be 
induced in a specific place in the genome using nucleases which recognize a 
sequence and introduce a DSB. Genome editing can be used to decrease gene 
function by either mutation or deletion of the gene of interest. 
To introduce a mutation the DSB is induced in the coding region of the targeted 
gene. NHEJ will often produce a small indel causing a frameshift (Bibikova, 
Golic et al. 2002). 
A region of the genome can be deleted by flanking the region with two DSBs 
(Bauer, Kamran et al. 2013). 
Genome editing techniques may also be used to introduce exogenous DNA, but 
the DSB is repaired using homologous recombination instead of NHEJ. 
Homologous recombination uses a template to repair the DSB and so if the 
exogenous DNA is used as a template for repair it gets integrated in the 
genome (Rouet, Smih et al. 1994). 
A requirement of all these methods is the introduction of DSBs, for which a 
nuclease is used. There are four main families of nucleases currently used: 
1.5.2.1. Zinc finger nucleases 
These nucleases are composed by a DNA cleaving domain and a DNA binding 
domain (Kim, Cha et al. 1996). The DNA binding domain can recognize up to 18 
bp, enough to be unique in the genome (Bibikova, Carroll et al. 2001). They 
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have been used in different organisms (Bibikova, Golic et al. 2002, Doyon, 
McCammon et al. 2008, Santiago, Chan et al. 2008, Geurts, Cost et al. 2009) 
1.5.2.2. Meganucleases 
Endonucleases which recognize DNA sequences of 12 to 40 bp (Thierry and 
Dujon 1992). There are six families of meganucleases of which the 
LAGLIDADG family is the most common and used in genome editing. There 
have been efforts to engineer these nucleases into recognizing specific 
sequences of interest to produce targeted DSB (Arnould, Chames et al. 2006, 
Ashworth, Havranek et al. 2006, Rosen, Morrison et al. 2006, Jarjour, West-
Foyle et al. 2009, Zaslavskiy, Bertonati et al. 2014) 
1.5.2.3. TALENS 
Transcription activator-like effector nucleases are the fusion of transcription 
activator-like effectors (TALEs) to the catalytic domain of FokI, an endonuclease 
(Christian, Cermak et al. 2010). TALEs are natural proteins from plant 
pathogenic bacteria which are translocated into their hosts’ cells (Büttner and 
He 2009). They then enter the nucleus and bind DNA sequences, activating 
gene expression which results in increased pathogenicity or activation of 
defences (Büttner and He 2009). The DNA-binding domain is composed of 33 
to 35 amino acids. There is a one-to-one code in that domain which was de-
cyphered (Boch, Scholze et al. 2009, Moscou and Bogdanove 2009) and then 
used to produce TALENs capable of recognizing specific sequences (Christian, 
Cermak et al. 2010). 
1.5.2.4. CRISPR/Cas9 
CRISPR/Cas systems (clustered, regularly interspaced short palindromic 
repeats – CRISPR associated systems) mediate a mechanism of adaptable 
immune response in bacteria (Bolotin, Quinquis et al. 2005, Mojica, Diez-
Villasenor et al. 2005, Pourcel, Salvignol et al. 2005, Barrangou, Fremaux et al. 
2007). CRISPR are composed of repeats of 25 to 50 bp separated by non-
repeat sequences or spacers of similar length of extrachromosomal origin 
(Mojica, Diez-Villasenor et al. 2005). These spacers are transcribed into RNA 
and guide the cleavage of exogenous DNA (Brouns, Jore et al. 2008, Marraffini 
and Sontheimer 2008) in conjunction with a second RNA sequence (Deltcheva, 
Chylinski et al. 2011). Cas endonucleases (of which Cas9 is a type) DNA 
cleavage is specifically produced within a sequence in the CRISPR, the 
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protospacer adjacent motif (PAM) (Garneau, Dupuis et al. 2010) which is 
common to all CRISPR sequences and drives target recognition (Bolotin, 
Quinquis et al. 2005). 
Jiang and colleagues reported their success in harnessing the CRISPR/Cas 
system to edit bacterial DNA (Jiang, Bikard et al. 2013). Cong and colleagues 
engineered two CRISPR-cas systems to produce targeted cleavage of DNA 
guided by short RNA sequences in human cells (Cong, Ran et al. 2013), an 
advance reported simultaneously by Mali et al (Mali, Yang et al. 2013). This 
system has also been reported in vivo in a range of organisms (Hwang, Fu et al. 
2013, Li, Qiu et al. 2013, Shen, Zhang et al. 2013, Yang, Xu et al. 2014). 
These first reports of success in targeted genome editing led to the production 
of libraries or extensive collections of short RNA sequences which could act as 
guides for the CRISPR/Cas9 cleavage of DNA. Using these libraries numerous 
knockout screens have been performed in different in vitro models and for 
varying phenotypes of interest (Koike-Yusa, Li et al. 2014, Shalem, Sanjana et 
al. 2014, Wang, Wei et al. 2014, Bassett, Kong et al. 2015, Lu, Qi et al. 2015, 
Schmid-Burgk, Chauhan et al. 2016) 
1.5.3. RNA interference 
RNAi is a mechanism of post-trancriptional regulation of gene expression. Fire 
and Mello described the RNAi response to the introduction of exogenous long 
dsRNA molecules into C. elegans (Fire, Xu et al. 1998) although they could not 
describe the mechanism at play. Endogenous short dsRNA molecules inducing 
RNAi in the cells were later described and termed miRNA (Lau, Lim et al. 2001). 
DNA sequences coding for miRNA molecules are estimated to represent as 
much as 5% of the human genome and are found scattered around the genome 
(Berezikov, Guryev et al. 2005). The expression of at least 30% of the genes in 
the human genome are predicted to be regulated by miRNA-mediated RNAi 
(Lewis, Burge et al. 2005). 
miRNA coding sequences are transcribed by polII into a 100bp molecule (pri-
miRNA) with a strong secondary structure (Lee, Kim et al. 2004). This 
secondary structure is recognized by Drosha, which cleaves the pri-miRNA into 
a still immature 70 bp molecule termed pre-miRNA (Lee, Ahn et al. 2003). This 
pre-miRNA is exported to the cytoplasm by Exportin-5 (Yi, Qin et al. 2003), 
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where it is recognized and cleaved by Dicer (Bernstein, Caudy et al. 2001). The 
resulting molecule is a 21-22 nucleotide long RNA sequence that determines 
the site of cleavage in the mRNA (Zamore, Tuschl et al. 2000). These short 
dsRNA sequences are by a multicomponent protein complex to form the 
cytoplasmic RNA-induced silencing complex, known as RISC (Hammond, 
Bernstein et al. 2000). The dsRNA molecule in RISC is then unwound in an 
ATP-dependant reaction (Nykänen, Haley et al. 2001). One of the strands, 
named the passenger strand is degraded while the other, the guide strand, 
remains associated with RISC (Khvorova, Reynolds et al. 2003, Schwarz, 
Hutvagner et al. 2003). It is unknown whether miRNA mediate cleavage or 
inhibition of translation of target transcripts (Baek, Villen et al. 2008, Selbach, 
Schwanhausser et al. 2008). 
The implementation of RNAi as a tool for loss-of-function studies in mammalian 
cells required some further adjustments from the techniques used in other 
models. Long dsRNA molecules elicit an interferon response in mammalian 
cells which results in cell death (Lee and Esteban 1994). RNAi-mediated 
reduction of gene expression was later demonstrated in mammalian cells using 
short dsRNA molecules (small interfering RNA, siRNA) which did not cause an 
interferon response (Elbashir, Harborth et al. 2001), and the first study of RNAi-
induced phenotypes was published shortly after (Harborth, Elbashir et al. 2001). 
Two main types of molecules (siRNA and shRNA) with different structures are 
now used to induce RNAi-mediated changes in gene expression. The RNAi 
pathway for each of the two types is schematically depicted in Figure 1.1. 
1.5.3.1. siRNA 
Artificially generated siRNA molecules can be transfected to the cell cytoplasm 
(Chiu, Ali et al. 2004). There, they are incorporated into RISC and guide the 
cleavage of mRNA (Hammond, Bernstein et al. 2000, Elbashir, Harborth et al. 
2001, Elbashir, Martinez et al. 2001, Martinez, Patkaniowska et al. 2002). As a 
finite number of molecules are delivered to each cell, the knockdown produced 
by siRNA is transient (Yang, Tutton et al. 2001). 
1.5.3.2. shRNA 
Short hairpin RNA (shRNA) molecules are formed by two reverse 
complementary RNA sequences separated by a spacer or hairpin which can be 
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encoded in a plasmid vector (Brummelkamp, Bernards et al. 2002) and 
delivered by transfection or more efficiently, using viral encapsulation (Barton 
and Medzhitov 2002, Brummelkamp, Bernards et al. 2002, Devroe and Silver 
2002, Shen, Buck et al. 2003, Stewart, Dykxhoorn et al. 2003). Delivery of 
shRNA coding plasmids using retroviruses facilitate the incorporation of the 
shRNA coding sequence into the host cells genome. The retrovirus delivers the 
RNA into the cytoplasm, where a viral retro transcriptase converts it into dsDNA 
that is integrated into the cell genomic DNA. The DNA sequence coding for the 
shRNA molecule has a promoter site for polIII. The shRNA DNA is translated 
into a pre-shRNA molecule which is recognized by Drosha. Drosha modifies the 
molecule, which is then exported to the cytoplasm by Exportin 5 (Ohrt, Merkle et 
al. 2006). The molecule is processed by DICER into an siRNA and then 
recognized by RISC to produce knockdown. Retroviral delivery of shRNA 
enables long term knockdown experiments as shRNA molecules are being 
produced in the cells. 
1.5.3.3. RNAi high throughput screens (HTS) 
The relative ease of RNAi induction in cells for loss-of-function study of 
functional genomics led to the implementation of large-scale screens in a 
multitude of phenotypes. For a few recent examples see (Breusegem and 
Seaman 2014, Goh, Seah et al. 2014, O'Reilly, Long et al. 2014, Burleigh, 
McKinney et al. 2015, Dopie, Rajakyla et al. 2015, Maia, Tanenbaum et al. 2015, 
Galeev, Baudet et al. 2016, Jolly, Luan et al. 2016, Zugasti, Thakur et al. 2016). 
Many collections or libraries of siRNA and shRNA are now available which have 
been used to study different phenotypes. Some examples of human libraries 
are the collection of “Silencer siRNA libraries” available from Thermo Fisher 
which in total cover 21,686 human genes with three siRNA per gene, the NKI 
human shRNA library (23,742 sequences targeting 7,914 genes (Berns, 
Hijmans et al. 2004)) and the Hannon library v2 (Silva, Li et al. 2005) composed 
of 79,805 shRNAs targeting 30,728 genes. Screens have been implemented in 
two different formats: arrayed and pooled. 
1.5.3.4. Arrayed screens 
Arrayed screening strategies consist of the independent assay of the effect of 
individual RNAi inducing sequences. This can be achieved by the distribution of 
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these sequences in different wells of multi-well plates. Cells are then plated 
onto the wells and targeting molecules are inserted into the cells, e.g. by 
reverse transfection. Experiments can be then carried out and the phenotype 
assayed. If the sequence in each well is known, effects in the phenotype are 
assigned to the knockdown of the gene targeted by the sequence. There are 
many examples of arrayed RNAi screens in the literature, such as (Zhou, Xu et 
al. 2008, Hu, Kim et al. 2009, Paulsen, Soni et al. 2009, Smith, White et al. 
2010, Genovesio, Giardini et al. 2011, Gilot, Le Meur et al. 2011). 
The arrayed screening format allows the investigation of different phenotypes 
although specialist equipment may be required to perform the experiments 
(such as automated liquid handling) and to evaluate the phenotype readout 
(fluorescence plate readers, automated imaging systems or others). More than 
one phenotype can be assayed simultaneously for example by detection of 
multiple antibodies or dyes (Gilbert, Erdmann et al. 2011) or multi-parametric 
analysis of imaging data (Collinet, Stoter et al. 2010). 
1.5.3.5. Pooled screens 
In pooled screens the shRNA sequences used to elicit RNAi are mixed and 
cells are transduced en masse. Then the cells undergo the experimental 
screening process, which typically result in a change of cell number. As shRNA 
sequences are integrated into the cells genome, they can be used as a 
“molecular barcode” for the cells. To evaluate a change in cell number, the 
shRNA sequence composition of a reference sample (usually from the initial 
time point in the experiment or a no-treatment control) is compared to the 
experimental endpoint. The evaluation of cell number changes was initially 
performed using microarrays (Berns, Hijmans et al. 2004, Brummelkamp, 
Fabius et al. 2006, Berns, Horlings et al. 2007). With the development of next 
generation sequencing (NGS) technologies, changes in cell number as 
indicated by changes in shRNA sequence representation started to be assayed 
by sequencing (Burgess, Doles et al. 2008, Silva, Marran et al. 2008, Bassik, 
Lebbink et al. 2009, Zuber, McJunkin et al. 2011). 
The use of NGS eliminates the need to design microarrays with custom probes 
to detect the targeting sequences and it facilitates multiplexing as only two 
samples can be used per microarray while many samples may be sequenced at 
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the same time. NGS also has a higher sensitivity and dynamic range than 
microarrays (Marioni, Mason et al. 2008) and is not restricted to the 
identification of a set number of sequences unlike microarrays. However, the 
use of NGS requires careful optimisation of the steps previous to sequence 
(PCR amplification of the targeting sequences and sequencing library 
preparation) as any bias introduced in these steps will reflect in the sequencing 
results.  
Also, data analysis of NGS output for pooled screens can be challenging. 
Several statistic and bioinformatic approaches have been developed to aid the 
correct interpretation of data derived from them (Birmingham, Selfors et al. 2009, 
Sims, Mendes-Pereira et al. 2011, Kumar, Goh et al. 2013, Dai, Sheridan et al. 
2014, Diaz, Qin et al. 2015). There are many aspects which need considering 
such as the initial representation of the sequences in the library and the control 
cell population (Birmingham, Selfors et al. 2009). If the library is divided into 
sub-libraries or pools, the screening or sampling conditions may vary slightly 
between pools and potentially bias the results obtained. All sources of variability 
need assessing and if possible correcting for in the analysis steps. 
42 
 
1.6. Summary 
Gene function can be studied using functional genomics approaches. In the last 
two decades RNA interference has been used to produce knockdown of genes 
and observe the phenotypes resulting from the reduction in expression. We now 
have several approaches available to experimentally elicit an RNAi response in 
mammalian cells. Importantly, genome-wide screens are now feasible and can 
be used to evaluate the impact of gene knockdown in phenotypes which result 
in cell number changes. The combination of genome-wide RNAi screens with 
next-generation sequencing technologies allow an unprecedented quantitative 
assessment of knockdown effects on cell number under various experimental 
conditions. However, the screening conditions need extensive optimization 
processes and data analysis must be performed carefully and taking into 
consideration the nature of the experiments and the phenotype assessed. 
Pooled shRNA screens are ideally suited to identify molecular mechanisms for 
phenomena resulting in a change in rates of proliferation, death or both. I have 
chosen two biological phenomena that have important medical translation and 
for which limited or no molecular mechanism is currently known. One is related 
to the cancer microenvironment (neighbour suppression) and the other to 
diabetes (β-cell proliferation and resistance to death by lipids). For each of 
these screens I describe the optimization procedures pre-screening, the 
screening process and the data analysis. 
The aims of the three screens introduced here were similar: to analyse the 
effect of the reduction of gene expression at a genome-wide scale in an in vitro 
model of each of the phenomena studied using shRNA-mediated RNAi. These 
aims were stated under the hypothesis that neighbour suppression, β-cell 
proliferation and β-cell resistance to death by lipids are influenced by the 
reduction of expression levels of certain genes. 
To model neighbour suppression in vitro I used a co-culture system in which 
SV40-transformed 3T3 mouse fibroblasts are used as a model tumourigenic 
cells and co-cultured with contact inhibited non-transformed 3T3 mouse 
fibroblasts as a model of normal counterparts. I used two isogenic non-
transformed cell lines: 3T3supp+, which suppresses the growth of the transformed 
cells when in co-culture; and 3T3supp-, which lacks this suppressive effect. 
As a model of β-cells I have used R7T1 cells, a reversibly inmortalised mouse 
β-cell line. 
43 
 
 
shRNA molecules stably reduce gene expression and can therefore be used in 
longer experiments than siRNA. This facilitates the study of phenotypes which 
may take a relatively long time to manifest or to be detectable, such as subtle 
changes in proliferation rates in β-cells or in the suppression of tumourigenic 
cell colony growth. Furthermore, they do not eliminate gene expression all 
together, allowing the study of genes which upon complete knockout may cause 
cell death. The use of shRNA molecules stably integrated in the genome of cells 
as molecular barcodes to identify changes in cell growth rate allows the study of 
a large collection of shRNA targeting sequences simultaneously, in a pooled 
screen which can be then deconvoluted in the analysis stage. This type of 
pooled approach is especially suitable for high-throughput and genome-wide 
studies of phenomena where the molecular mechanisms are unknown or poorly 
characterized as it does not require a prior hypothesis to design shRNA 
molecules. Given that both neighbour suppression and, to a lesser extent, β-cell 
proliferation and death remain poorly characterized, I used a high-throughput 
pooled shRNA screen to identify genes with a potential effect on both 
phenomena. 
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Figure 1.1. Schematic depiction of the RNAi mechanism of mRNA degradation by shRNA 
and siRNA.
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 Chapter 2. Material and methods 
This chapter describes the material and methods that were used during the 
course of the projects described in this thesis. Each subsequent chapter will 
introduce a detailed account of the methods specific for that chapter.  
2.1 Cell culture  
2.1.1 List of materials 
Dulbecco's Modified Eagle's Medium (DMEM), high glucose, GlutaMAX, 
pyruvate (31966) (Life technologies, Paisley, UK) 
DMEM, high glucose, L-glutamine (41965) (Life technologies, Paisley, UK) 
Opti-MEM Reduced Serum Medium, GlutaMAX Supplement (10592) (Life 
Technologies, Paisley, UK) 
HyClone Newborn Calf Serum (USA) (10500) (GE Healthcare Life Sciences, 
Little Chalfont, UK) 
Tet System Approved Foetal Bovine Serum (FBS) (USA) (631106) (Takara Bio 
Europe/Clontech, Saint-Germain-en-Laye, France) 
FBS, qualified, heat inactivated (E.U.-approved) (10500) (Life Technologies, 
Paisley, UK) 
Penicillin Streptomycin (5,000 Units/mL Penicillin, 5,000 µg/mL Streptomycin) 
(15070) (Life technologies, Paisley, UK) 
Dulbecco's phosphate-buffered saline (DPBS), no calcium, no magnesium 
(14190) (Life technologies, Paisley, UK) 
0.25 % Trypsin (25200) (Life technologies, Paisley, UK) 
Dimethyl sulfoxide, anhydrous, 99.7% (10103483) (Fisher Scientific, 
Loughborough, UK) 
Disinfectant, Virkon (12358667) (Fisher Scientific, Loughborough, UK) 
Puromycin dihydrochloride (10054207) (Fisher Scientific, Loughborough, UK) 
Turbofect (10304780) (Fisher Scientific, Loughborough, UK) 
Polybrene (H9268) (Sigma-Aldrich, Poole, UK) 
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ProFection® Mammalian Transfection System (E1200) (Promega, Southampton, 
UK) 
Viraductin™ Retrovirus transduction kit (RV-201) (200 Transductions) 
(Cambridge Bioscience, Cambridge, UK) 
Ecotropic Receptor Booster (631471) (Takara-Clontech, Saint-Germain-en-
Laye, France) 
Retro-X Concentrator (631455) (Takara-Clontech, Saint-Germain-en-Laye, 
France) 
Polyethylene glycol 8000 (PEG) (P5413) (Sigma-Aldrich, Poole, UK) 
Paraformaldhyde (PFA) (10131580) (Fisher Scientific, Loughborough, UK) 
Ethanol absolute (≥99.8 %) (32221) (Sigma-Aldrich, Poole, UK) 
Nitro-blue tetrazolium (NBT) (Thermo Scientific, Loughborough, UK) 
5-bromo-4-chloro-3'-indolyphosphate p-toluidine salt (BCIP) (Thermo Scientific, 
Loughborough, UK) 
Dimethylformamide (≥99.8 %) (Sigma-Aldrich, Poole, UK) 
Mouse anti-SV40 Large T/ small t antigen (pAb419) (Monoclonal antibody 
service, ICRF / CR UK, London, UK) 
Monoclonal mouse anti BrDU (M0744) (Dako, Ely, UK) 
Polyclonal Goat Anti-Mouse Immunoglobulins (AP) (Dako, Ely, UK) 
BrDU labelling reagent (Fisher Scientific, Loughborough, UK) 
Propidium iodide (PI) – 1.0 g/mL solution in water (Fisher Scientific, 
Loughborough, UK) 
Methanol (≥99.8 %) (Sigma-Aldrich, Poole, UK) 
1.8 mL Cryotube vials (Thermo Scientific, Loughborough, UK) 
Mr. Frosty freezing container (Thermo Scientific, Loughborough, UK) 
15 mL conical centrifuge tubes (VWR, Lutterworth, UK) 
50 mL conical centrifuge tubes (VWR, Lutterworth, UK) 
Cell culture dish with vents, 100 x 20 mm, sterile (Greiner Bio-One, Stonehouse, 
UK) 
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Cell culture multi-well plate, 6 well, crystal-clear, with lid, sterile (Greiner Bio-
One, Stonehouse, UK) 
Cell culture flask, 50 ml, 25 cm², filter screw cap red, clear, sterile (Greiner Bio-
One, Stonehouse, UK) 
Cell culture flask, 250 ml, 75 cm², filter screw cap red, clear, sterile (Greiner Bio-
One, Stonehouse, UK) 
Corning® cell scrapers, blade L 30 cm, handle L 39 cm (Sigma Aldrich, Poole, 
UK) 
2.1.2 Cell lines 
Phoenix - ECO: Variant of the highly transfectable 293T cell line (human 
embryonic kidney cell line). This cell line expresses Moloney Murine Leukemia 
Virus (M-MLV) viral packaging proteins (gag-pol) and an ecotropic envelope 
protein. It can be used to produce retroviral particles that infect dividing mouse 
or rat cells (Swift, Lorens et al. 2001). They were routinely grown in DMEM 
(high glucose, GLUTAMAX, pyruvate) supplemented with 10% FBS and 1% 
Penicillin Streptomycin. 
Cell lines used specifically in each chapter will be described in their relevant 
sections. 
2.1.3 General tissue culture procedures 
For clarity and brevity in the methods it can be assumed that unless otherwise 
specified, the following procedures were performed following the protocols and 
using the materials and equipment stated below: 
 Cell culture sterile conditions: All cell culture procedures were carried 
out inside a class II microbiological safety cabinet (MSC) that was 
sprayed with 70% ethanol and wiped down with tissue prior to use. Any 
material entering the MSChad previously been sprayed with 70% ethanol.  
 Decontamination of biological material: Consumables that had been 
in contact with biological samples were decontaminated with 1% 
(weight/volume) Virkon for at least 20 minutes before disposal. 
 Pre-warming medium: Growth medium was placed in a 37ªC water bath 
for at least 30 minutes before use. 
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 Pelleting cells: A tube containing cells in suspension was centrifuged at 
500 g for 5 minutes to pellet cells. 
 Aspirating: Liquid was removed using an autoclaved unplugged glass 
Pasteur pipette (Fisherbrand), connected with rubber tubing to a Dry 
Laboratory Vacuum / Pressure Station (Free Flow 9.2L/Min 230V 50Hz 
Vacuum 292Mbar Pressure 2.3Bar) (Fisherbrand).  
 Growth medium: DMEM supplemented with serum and antibiotics as 
stated for each cell line. 
 Cell culture conditions: all cell lines were cultured in incubators at 37ºC 
and 5% CO2. 
 Trypsinizing cells: Growth medium was aspirated, cells were washed 
twice with DPBS and trypsin was added to the flask or dish according to 
its growing surface (approximately 0.02 mL per cm2). The flask or dish 
was placed in an incubator set to standard tissue culture growing 
conditions for approximately 3 minutes or until cells were detached from 
the growth surface. Then, growth medium was added (at least 2:1 ratio to 
trypsin) to inactivate trypsin. 
 Freezing medium: freezing medium was prepared as a 10% 
(volume/volume) dilution of DMSO in the serum used in the growth 
medium. 
2.1.4 Sub-culturing cells 
Cells were not allowed to reach more than 70% confluency when being 
routinely cultured. Sub-confluent flasks or dishes of cells were trypsinized and 
plated at a ratio dependent on starting confluency (e.g. 1 in 5 of the total cells), 
or counted using a haemocytometer (2.1.7) to plate a specific number of cells. 
2.1.5 Freezing cells 
Cells were considered to be apt for freezing when they had reached 50% to 
70% confluency. Cells were trypsinized, the cell suspension was transferred to 
a 15 mL tube and cells were pelleted. The supernatant was aspirated and cells 
were re-suspended in freezing medium. This cell suspension was transferred to 
a sterile CryoTube vial, which was tightly closed and placed in a Mr. Frosty 
Freezing container. This was placed in a -80ºC freezer for at least 24 hours and 
the cryovial was transferred to a liquid nitrogen dewer for long term storage. 
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2.1.6 Thawing cells 
To thaw a vial of cells, it was removed from the liquid nitrogen tank and placed 
in a 37ºC water bath for 3-5 minutes. When the cell solution had defrosted it 
was transferred to a 15 mL plastic tube containing 9 mL of pre-warmed growth 
medium. Cells were pelleted, supernatant was aspirated and the pellet was 
gently re-suspended into 2 mL of pre-warmed growth medium. The cell 
suspension was added to a 10 cm tissue culture dish containing 12 mL of pre-
warmed growth medium and cells were grown until ready to sub-culture. 
2.1.7 Counting cells 
Cells were counted using a glass haemocytometer (Fisher Scientific). Both the 
haemocytometer and the coverslip were cleaned with 70% ethanol before use 
and the coverslip was placed on top of the haemocytometer. Trypsinized cells 
were pelleted and gently re-suspended in an appropriate volume of growth 
medium, dependant on the estimated number of cells. The cell suspension was 
pipetted between the coverslip and the haemocytometer until the chambers 
were full. Cells in the shaded areas in Figure 2.1 were counted. The sum of all 
cells in these areas was divided by 4 to get an average number per individual 
shaded area. The concentration of cells in the cell suspension was calculated 
as: (average number of cells per shaded area)*104=cells/mL in suspension 
 
50 
 
 
Figure 2.1. Diagrammatic representation of a haemocytometer chamber. Cells in grey 
shaded areas were counted. 
51 
 
 
2.1.8 Puromycin kill curve 
Cells were seeded at approximately 30% confluence in a 6-well cell culture 
multi-well plate and grown for 24 hours. Then, medium in the wells was 
aspirated and replaced with growth medium containing a range of 
concentrations of puromycin (0 to 10 µg/mL). Cell survival was assessed after 
48 hours using a Nikon Eclipse TS100-F inverted light microscope (Nikon UK 
Ltd). The lowest concentration at which all cells in the well had died was used 
as the working concentration for puromycin selection. 
2.1.9 Puromycin selection of transduced cells. 
Selection medium was prepared by transferring 12mL of growth medium to a 
15mL tube and adding puromycin to reach the appropriate concentration 
(determined using a kill curve performed as described in section 2.1.8). The 
growth medium in the dish was aspirated and replaced with selection medium, 
and the dish was returned to the incubator. A non-transduced dish was used as 
a control in each batch of selections to control for potential variations in 
antibiotic resistance. The rate of cell death was monitored after 48 hours of 
selection. If the non-transduced dish had a death rate of 100%, transduced cells 
were considered selected and living cells were considered puromycin resistant. 
2.1.10 Harvesting cells for DNA extraction 
Growth medium was aspirated and cells were washed twice with DPBS. After 
the last wash, a volume of DPBS proportional to the growth surface area was 
added and cells were detached from the surface and into the DPBS using a cell 
scraper. This cell suspension was transferred to a 15 mL tube and cells were 
pelleted. The supernatant was aspirated and the pellet was used to extract DNA.
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2.2 Molecular biology 
2.2.1. List of materials 
Tris HCl (T3253) (Sigma-Aldrich, Poole, UK) 
Ethylenediaminetetraacetic acid (EDTA) (E9884) (Sigma-Aldrich, Poole, UK) 
Sodium dodecyl sulphate (SDS) (463143) (Sigma-Aldrich, Poole, UK) 
RNase A (E1008) (Cambridge Bioscience, Cambridge, UK) 
Proteinase K DNase and RNase free (10407583) (Fisher Scientific, 
Loughborough, UK) 
Phenol:chloroform (17909) (Fisher Scientific, Loughborough, UK) 
Qubit dsDNA HS Assay Kit (Q32851) (Fisher Scientific, Loughborough, UK) 
Q5® High-Fidelity Polymerase (M0491) (New England Biolabs, Herts, UK) 
Eppendorf® PCR 0.2 mL tubes (Z316156) (Sigma-Aldrich, Poole, UK) 
96-well clear plates (4483348) (Fisher Scientific, Loughborough, UK) 
Agarose broad separation range for DNA/RNA, Genetic Analysis Grade 
(10688973) (Fisher Scientific, Loughborough, UK) 
Zymoclean Gel DNA Recovery Kit (D4008) (Cambridge Bioscience, Cambridge, 
UK) 
QIAquick Gel Extraction Kit (28706) (Qiagen, Manchester, UK) 
Ethidium Bromide, 10 mg/mL (15585011) (Fisher Scientific, Loughborough, UK) 
Gel loading dye (Purple) (B7024) (New England Biolabs, Herts, UK) 
Scalpel disposable sterile No. 22 (11758353) (Fisher Scientific, Loughborough, 
UK) 
EcoRI (R0101) (New England Biolabs, Herts, UK) 
XhoI (R0146) (New England Biolabs, Herts, UK) 
RevertAid H Minus Reverse Transcriptase (200 U/µL) (EP0451) (Fisher 
Scientific, Loughborough, UK) 
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Deoxynucleotide (dNTP) Solution Mix (R0447S) (New England Biolabs, Herts, 
UK) 
Oligo(dT)20 Primer (18418020) (Fisher Scientific, Loughborough, UK) 
26G needle (BD, 14-826-10) (Fisher Scientific, Loughborough, UK) 
2.2.2. Phenol:chloroform extraction of DNA from cell lines 
Pelleted cells obtained as per section 2.1.10 were re-suspended in an adequate 
volume of TE buffer (10 mM Tris HCl (pH 8.0) 10 mM EDTA) to obtain an 
estimated cell concentration of 107 cells/mL. 10% SDS and RNase were added 
to a final concentration of 0.5% SDS and 2ul/mL RNase, and mixed thoroughly. 
This solution was incubated for at least 1 hour at 37ºC in a water bath. 
Proteinase K (10mg/mL) was added to reach a final concentration of 200 µg/mL, 
and incubated at 55ºC in a water bath for at least 2 hours. DNA was then 
purified according to the method by Sambrook and Russell (Sambrook and 
Russell 2006). 
2.2.3. Quantification of nucleic acids 
RNA and DNA (except samples that were to be sent for Illumina Next 
Generation Sequencing) were quantified routinely using a Nanodrop 8000 UV-
Vis spectrophotometer (Thermo Scientific) according to the manufacturer 
instructions. Samples sent for Illumina Next Generation Sequencing were 
quantified with a Qubit 2.0 Fluorometer (Invitrogen) using a Qubit dsDNA HS 
Assay Kit (Invitrogen) and a Tapestation 2200 (Agilent), according to their 
respective manufacturer instructions. 
2.2.4. PCR amplification of DNA 
The shRNA sequences inserted in the pSuperRetroPuro plasmid were amplified 
by PCR using Q5 high fidelity DNA polymerase. PCR reaction mixtures were 
set up in 0.2 mL flat cap thin wall tubes or 96-well plates if amplifying more than 
24 samples simultaneously. The final composition of an individual PCR reaction 
is shown in Table 2.1. Primers used and cycling conditions are experiment-
specific and will be indicated in their relevant sections. 
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Component Stock 
concentration 
Volume Final 
concentration 
Q5 Reaction 
Buffer 
5X 5 µl 1X 
dNTP mix  10mM 0.5 µl 0.2 mM 
Forward Primer 10 µM 1.25 µl 0.5 µM 
Reverse Primer 10 µM 1.25 µl 0.5 µM 
Q5 High Fidelity 
DNA Polymerase 
2 U/ µl 0.25 µl 0.02 U/µl 
DNA Variable Variable <40 ng/ul 
PCR grade H2O NA To 25 µl NA 
Table 2.1. Composition of an individual PCR reaction 
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2.2.5. Preparation of agarose gels 
A volume of 1X gel running buffer (TBE: 0.1 M Tris base, 0.1 M boric acid, 2mM 
EDTA or TAE: 40 mM Tris base, 20 mM acetic acid, 1mM EDTA), dependent on 
the size of gel to be run, was measured using a measuring cylinder and 
transferred to a clean Pyrex glass bottle. The appropriate weight of agarose to 
be added was calculated as agarose(g) = (percentage of agarose in gel) * 
volume (mL) / 100.  
Agarose was dissolved in the running buffer using a microwave to heat up the 
solution until no agarose particles were visible. When the solution was 
homogenous it was left to cool down at room temperature. When the bottle was 
cold enough to be handled, ethidium bromide was added to a final 
concentration of 1µg/mL. The solution was swirled to evenly distribute the 
ethidium bromide and then poured in the appropriate tray to cast the agarose 
gel. 
2.2.6. Agarose gel electrophoresis of DNA 
Agarose gels were prepared as per 2.2.5. DNA Gel loading dye was added to 
the DNA samples and DNA size ladders to a final concentration of 1X. DNA 
samples and DNA size ladders were loaded into the gels using micropipettes. 
Gels were run using a Bio-Rad Model 200/2.0 power supply (Bio-Rad, Hemel 
Hempstead, UK)  
2.2.7. DNA extraction from agarose gel 
After the electrophoresis had completed, DNA in the gels was visualized under 
UV light using a Corning Labnet Enduro UV Transiluminator. Pictures of the 
gels were taken using a BioRad ChemiDoc XRS. Fragments of the gel 
containing the DNA of interest were cut out from the gel using a disposable 
sterile scalpel (Fisher Scientific). 
DNA was extracted from the agarose gel fragments using either a QIAquick Gel 
Extraction Kit (Qiagen) or a Zymoclean Gel DNA Recovery Kit (Zymo Research, 
California, USA), according to the manufacturer’s instructions. 
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2.2.8. Sequencing 
Purified DNA samples were sent to be sequenced in the University of Exeter 
Sequencing Service, using the standard TruSeq v.3 protocol on an Illumina 
HiSeq2500.
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2.3 Cloning 
2.3.1 List of materials 
LB Broth High Salt (L1704) (Melford, Ipswich, UK) 
Agar-agar, pure, granular powder (10548030) (Fisher Scientific, Loughborough, 
UK) 
Petri dish 150x20mm Triple Vented (82.1184) (Sarstedt, Leicester, UK) 
Spreader inoculating, L-shape (11836191) (Fisher Scientific, Loughborough, UK) 
CaCl2 (C1016) (Sigma-Aldrich, Poole, UK) 
BRAND® microcentrifuge tube, 0.5 mL with lid (Z334006) (Sigma-Aldrich, Poole, 
UK) 
T4 DNA Ligase (M0202) (New England Biolabs, Herts, UK) 
EcoRI (R0101) (New England Biolabs, Herts, UK) 
XhoI (R0146) (New England Biolabs, Herts, UK) 
HindIII (R0104) (New England Biolabs, Herts, UK) 
BglII (R0144) (New England Biolabs, Herts, UK) 
2.3.2 Bacterial growing medium 
Bacteria were grown using Luria Bertani (LB) medium. LB medium was 
prepared using a commercial mix of components, dissolving the mix in an 
appropriate volume of distilled water to produce the following composition: 0.5 
% (w/v) Yeast Extract, 1 % (w/v) NaCl and 1 % (w/v) Tryptone. PH was 
adjusted to 7.2 using a S220 SevenCompact pH/Ion meter (Mettler Toledo), and 
the medium was then autoclaved. 
2.3.3 LB agar plates 
Agar plates for bacterial growth were prepared by addition of 1.5% (w/v) agar to 
LB medium in glass bottles. This mix was autoclaved and then left to cool down 
until temperature was lower than 55ºC. Then, selection antibiotic was added to 
the solution, which was mixed and poured into a Petri dish and allowed to set at 
room temperature. Plates were stored inverted at 4ºC. 
2.3.4  Preparation of competent bacteria 
Competent bacteria for plasmid DNA propagation (Escherichia coli (E. coli), 
DH5α strain) were prepared by spreading 10µl of DH5α on a LB-agar plate 
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using a disposable sterile plastic cell spreader. The plate was left for 5 minutes 
and then inverted and incubated at 37ºC for approximately 16 hours. A single 
colony was picked from the plate using a sterile wooden toothpick and 
inoculated into 100 mL of sterile LB medium. Bacteria were incubated for 
approximately 12 hours in a Minitron AB70 bacterial shaker (INFORS HT) at 
37°C shaking at 250 rpm. Then, 1 mL was inoculated into 100 mL of sterile LB 
medium and the culture was grown in the same conditions as above until the 
optical density (OD600) was 0.4-0.5. The culture was then incubated on ice for 
20 minutes, transferred to pre-cooled 50 ml centrifuge tubes and centrifuged at 
4000g for 10 minutes at 4ºC. The supernatant was discarded and the pellet in 
each tube was re-suspended in 10 mL of ice-cold 0.1M CaCl2 before being 
centrifuged again using the same conditions. Supernatant was discarded and 
the pellet was re-suspended in 1mL of ice-cold 0.1M CaCl2 with 10 % (w/v) 
glycerol and placed on ice. 0.5mL microcentrifuge tubes were pre-cooled on dry 
ice for 5 minutes. The cell suspensions were then pipetted into the tubes in 100 
µL aliquots and stored at -80°C. 
2.3.5 Heat-shock transformations 
An aliquot of competent DH5α cells (2.3.4) was thawed on ice before adding 10 
ng of the plasmid to be transformed. The tube was gently mixed to distribute the 
DNA evenly and incubated on ice for 30 minutes. Then, bacteria were heat-
shocked by placing the tube at 42ºC for 45 seconds and back on ice for 2 
minutes. The mix was added to 3ml of LB medium in a 15 ml tube and 
incubated at 37ºC in a shaking incubator at 250rpm. The tube was then 
centrifuged at 3200xg for 5 minutes in a cooled centrifuge at 4ºC. The 
supernatant was discarded and the pellet re-suspended in 200 µl of LB medium. 
An appropriate volume of this solution was pipetted onto an LB-agar plate and 
evenly spread using a disposable sterile plastic cell spreader. The plate was left 
at room temperature for 5 minutes and then inverted and placed into an 
incubator set to 37ºC for approximately 16 hours.  
2.3.6 Plasmid isolations 
Individual colonies from transformed DH5α cells were picked using a sterile 
wooden toothpick and placed into tubes containing LB medium with the 
appropriate selection antibiotic for expansion of the clonal bacteria. The tubes 
were placed in a shaking incubator at 190 rpm and bacteria were left to grow for 
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approximately 12 hours. Plasmids were then extracted using the Plasmid Midi 
or Mini Kit (Qiagen) according to the manufacturer instructions. 
2.4 NKI mouse shRNA Library 
The NKI (Netherlands Kanker Instituut) mouse shRNA library is composed of 
approximately 28,000 different shRNA sequences that target approximately 
14,000 genes with a two-fold redundancy. These shRNA constructs are inserted 
into the pSUPER.retro.puro plasmid, a retroviral expression vector derived from 
the Murine Embryonic Stem Cell virus (pMSCV). The structure of 
pSUPER.retro .puro is depicted in Figure 2.2. Important elements of this 
plasmid are: 
- Ampicillin resistance gene (AMP). Allows propagation of the plasmid in 
bacteria using ampicillin to select transformed bacterial colonies. 
- Puromycin resistance gene (puro). Allows selection of mammalian cells 
containing the plasmid. 
- Viral packaging signal. Necessary for the production of retroviral particles by 
the packaging cell line. 
- EcoRI and XhoI restriction sites. They flank the shRNA sequence. 
- Hairpin sequence. Composed of a sense 19 nucleotide (19-mer) sequence, a 
hairpin loop and an antisense 19-mer, reverse complement of the sense 19-mer. 
Its transcript is processed into a 19 nucleotide siRNA that ultimately produces 
the RNAi response. 
The NKI library was a gift from Dr Roderick Beijersbergen and amplified in-
house as described in (Nicholls 2015). The in-house amplified library was used 
throughout the projects described in this thesis. The plasmids in this library are 
distributed into 73 different tubes which constitute the different “pools” of the 
library. Each pool contains approximately 384 different constructs.  
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Figure 2.2. Schematic depiction of the pSuperRetroPuro plasmid containing the shRNA 
constructs 
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2.5 Re-annotation of the NKI shRNA library 
A standalone version of BLAST+ version 2.2.30 was downloaded from the NCBI 
BLAST FTP server (ftp://ftp.ncbi.nlm.nih.gov/blast/executables/blast+/LATEST/) 
on 17th March 2015 as a WINDOWS executable file. This was installed on a PC 
with an Intel Core i7 processor and 8 GB of RAM. The RefSeq mRNA database 
for Mus musculus was downloaded from NCBI nucleotide 
(http://www.ncbi.nlm.nih.gov/nuccore) as a FASTA file. A database was 
constructed from that FASTA file using BLAST+. 
A text file containing all shRNA constructs designed to be in the library and 
constructs present in previous sequencing runs was built. These sequences 
were aligned to the mouse transcriptome using the standalone BLAST+. A 
detailed account of the commands and options used for building the RefSeq 
mRNA database and for the re-annotation process can be found on Appendix 1. 
2.6 Preparation of plasmids with custom shRNA constructs 
Pairs of oligonucleotides with the structure depicted in (Figure 2.3) were 
purchased from Sigma-Aldrich. The targeting sequence will for each oligo used 
will be specified in their relevant sections. Oligonucleotides were dissolved in 
DNA-grade H2O to a concentration of 3 mg/mL. An annealing buffer was 
prepared (100 mM NaCl and 50 mM HEPES pH 7.4) and the annealing reaction 
was set up by mixing 2 µL of each oligo in the pair with 46 µL of annealing 
buffer. The mix was incubated at 90ºC for 5 minutes on a heater block and then 
removed and left to cool down at room temperature. Annealed oligo pairs were 
stored at 20ºC until needed. Meanwhile, pSuper.retro.puro was linearized by 
digestion with XhoI and BglII as described in Table 2.2. Annealed oligo pairs 
were ligated into linearized plasmid as described in Table 2.3, and the reactions 
were treated with BglII prior to transformation by adding 1 µL of BglII to the 
reaction and incubating at 37ºC for 30 minutes. This step reduces background 
transformation of unsuccessful ligations, as the BglII site is destroyed upon 
ligation of the oligo pairs. Ligation products were used to transform competent 
bacteria as described in 2.3.5. At least three different colonies were picked and 
plasmids were grown and isolated as described in 2.3.6.  
62 
 
 
 
 Stock 
concentration 
Volume Final 
concentration 
pSuper.retro.puro Variable Variable 4 µg 
XhoI/HindIII 20 U/ µL 4 µL 0.8 U/ µL 
BglII 10 U/ µL 4 µL 0.4 U/ µL 
Buffer 10 X 10 1X 
H2O Not applicable Up to 100µL Not applicable 
Table 2.2. Composition of a restriction digestion reaction to linearize pSuperRetroPuro. 
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 Stock 
concentration 
Volume Final 
concentration 
Annealed 
oligonucleotides 
240 µg/ mL 2 µL 48 µg/ mL 
Linearized 
plasmid 
500 µg/mL 1 µL 50 µg/ mL 
T4 ligase buffer 10X 1 µL 1X 
T4 DNA ligase 400 U/ µL 1 µL 40 U/ µL 
H2O Not applicable 5 µL Not applicable 
Table 2.3. Composition of an individual ligation reaction to introduce the annealed shRNA 
oligonucleotides into pSuperRetroPuro.
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Figure 2.3 Structure of the custom oligonucleotides used to produce alternative shRNA 
constructs using pSuperRetroPuro as backbone. 
A: Structure of the oligonucleotides as designed before annealing, and legend. B: 
Oligonucleotides after annealing.
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2.7 Analysis 
The initial processing steps of sequencing data were performed using pipelines 
specific for each project and therefore they will be explained in their respective 
chapters. Later steps of the analysis were common to both projects and are 
explained below. This analysis process is graphically summarized in Figure 2.4. 
2.7.1 Building gene networks 
Gene networks were built for the genes selected as genes of interest (GOI) 
using FunCoup (http://funcoup.sbc.su.se/) (Schmitt, Ogris et al. 2014). Default 
parameters were used except for the expansion depth, under “Advanced 
search”. This was set to 0 so FunCoup would produce networks using only the 
GOI list. Network files were downloaded and imported into Cytoscape 3.3.0 for 
visualization and analysis of gene interactions. 
2.7.2 Analysis of gene interactions 
Gene networks were analysed using Cytoscape 
(Tools>>NetworkAnalyzer>>Network Analysis>>Analyze Network). The 
analysed files were exported and opened using Microsoft Excel. A text file was 
exported from Excel containing gene names and number of interactors in the 
queried genes. 
2.7.3 Enrichment in gene interactors 
The FunCoup compact database of interactions in Mus musculus was 
downloaded from the FunCoup website (http://funcoup.sbc.su.se/downloads/, 
downloaded file: FC3.0_M.musculus_compact.gz). The database file was 
extracted and opened using TextPad. Interactions were filtered by confidence 
threshold, producing a smaller file with interactions above 0.8 confidence score 
(referred to as “interaction file” from now). A Python script (Appendix 6) was 
written to produce 1000 random samples of constructs that included the gene to 
be analysed for enrichment of interactors. The script then used the interaction 
file to search for interactors in each sample produced and outputted a file with 
each gene name and the number of random samples where the number of 
interactors was the same or above the number of interactors for the same gene 
in the GOI list. This number divided by 10 to reflect percentages and was used 
as a p-value for enrichment in interactors.
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Figure 2.4. Schematic diagram of the random sampling approach to detect enrichment in 
interactors using data from FunCoup. 
GOI list from screen 
Interactions amongst GOI 
Network of GOI 
Number of interactions in GOI 
list per gene 
FunCoup interaction database 
Interactions above 0.8 
confidence score 
For each GOI: 1000 random 
samples of same size as GOI 
list including the gene being 
tested 
For each GOI: Number of random samples where 
number of interactors>number of interactions in 
the original GOI list 
p-value: % of random samples where 
number of interactors>number of 
interactions in the original GOI list 
67 
 
 Chapter 3. A pooled genome-wide shRNA screen of neighbour 
suppression effectors in tumorigenic cells 
3.1. Introduction 
3.1.1. Cancer 
Multicellular organisms can be viewed as ecosystems where a balance in cell 
number is required to maintain the body’s structure and order. This is achieved 
through cell proliferation, death and survival (Pienta, McGregor et al. 2008). The 
initiation of cancer may be defined in base of this view as a perturbation of the 
balance by some cells. These tumorigenic cells acquire mutations which can 
confer them with certain advantages which result in a higher rate of proliferation 
or lower rate of cell death (Pienta, McGregor et al. 2008). This over-simplistic 
view does not fully explain the nature of cancer but outlines the concept of 
tumorigenesis as a process that starts with a cell surrounded by other cells of 
the same genetic background. This genetic background changes in the 
tumorigenic cell while it is still in a homotypic environment. 
Although the incidence of cancer may seem high given the number of new 
cases diagnosed each year (352,197 in the UK in 2013 according to Cancer 
Research UK (Cancer Research UK, http://www.cancerresearchuk.org/health-
professional/cancer-statistics, Accessed June 2016)), the prevalence in the 
worldwide population of all types of cancer combined is 0.2% (Ferlay, I. et al. 
2012). Considering the exposure to mutagenic stimuli, the prevalence of 
spontaneous mutations and the number of cells in the average human body, 
cancer is not as prevalent as expected (Seshadri, Kutlaca et al. 1987, Araten, 
Golde et al. 2005). Furthermore it has been observed that the occurrence of 
cancer in animals is not directly predicted by the number of cells they are 
formed by and their lifespans, which points to discrepancies in the resistance to 
carcinogenesis (Cairns 1975, Peto, Roe et al. 1975). 
3.1.2. Mechanisms of resistance to carcinogenesis 
Many intra- and inter-cellular mechanisms have been described that can result 
in a lower incidence of carcinogenesis than expected. The intra-cellular 
mechanisms of resistance to carcinogenesis include genetic and epi-genetic 
aspects and regulation of tumorigenic cell death. These intra-cellular 
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mechanisms will not be discussed in this introduction as the focus of this thesis 
lies in a type of inter-cellular carcinogenesis suppression. 
Of the inter-cellular mechanisms of resistance against carcinogenesis, 
inmmunosurveillance is perhaps the most commonly studied. The focus of this 
chapter, however, is on neighbour suppression, a mechanism of growth 
suppression of tumorigenic cells by normal cells which form part of the same 
tissue.  
3.1.3. Neighbour suppression 
Berenblum noted in 1941 that the development of tumours in mice skin 
following the application of a cancer promoter substance was uncommon unless 
a pre-treatment with a cancer initiator was applied (Berenblum 1941). A 
hypothesis was formed that carcinogenesis was a two-stage process. This 
characteristic may explain the presence of genotypically abnormal and even 
premalignant epithelial mammary cells in half of American healthy women with 
no elevated risk of developing breast cancer (Holst, Nuovo et al. 2003). The 
prevalence of breast cancer in American women is 12%, which indicates that 
those abnormal cells do not always acquire a carcinogenic phenotype. 
Numerous in vivo studies have been performed which suggest this 
phenomenon is stronger in early development (Dolberg, Hollingsworth et al. 
1985) but is present in a range of tissues (Medina, Shepherd et al. 1978, 
Terzaghi-Howe 1987, Strickland, Ueda et al. 1992, Widschwendter, Berger et al. 
1997, Javaherian, Vaccariello et al. 1998, Roberts, Min et al. 2002, Holst, 
Nuovo et al. 2003). 
Despite the apparent involvement of ’normal’ cells in halting the growth of 
precancerous cells, the molecular mechanism of the phenomenon remains 
elusive. Early in vitro work performed by Rubin showed that a high proportion of 
cultured cells needed to be infected with an oncogenic virus (Rous Sarcoma 
Virus or RSV) for the infected cells to display the phenotype associated with 
RSV infection (Rubin 1960). A similar phenomenon was described by Stoker, 
Todaro and Green also in the 1960’s. Using polyoma virus-transformed mouse 
fibroblast as a model for carcinogenic cells, they showed that their growth could 
be suppressed by a monolayer of density-dependent growth inhibited mouse 
fibroblasts by a mechanism dependent on direct contact between both types of 
cells (Stoker 1964, Stoker, Shearer et al. 1966, Todaro and Green 1966). 
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Fibroblasts transformed by Myc but not Src and Ras have also been shown to 
be suppressed by non-transformed counterparts (Bignami, Rosa et al. 1988) 
while suppression is seen in myoblasts transformed with Myc and Src (La 
Rocca, Grossi et al. 1989). 
The role of neighbouring cells in controlling cell growth has been studied under 
different terms such as “contact inhibition” or “postconfluence inhibition of cell 
division” (Martz and Steinberg 1972). This inhibition of cell growth by 
surrounding cells was experimentally observed as a plateau in growth rate and 
a reversible cell cycle arrest in G1 phase in monolayers of fibroblasts (Eagle 
and Levine 1967, Rubin 1971, Deleu, Fuks et al. 1998). The loss of contact 
inhibition in tumour cells is considered a hallmark of cancer (Hanahan and 
Weinberg 2011) and has been used to produce a prognosis in cancer 
development and as a tool to identify oncogenes (Bargmann, Hung et al. 1986) 
(Fuse, Tanikawa et al. 2000). Contact inhibition has been observed and 
described in the context of homologous cells, i.e. cells of the same type or 
genetic background. However, in the context of cancer initiation tumourigenic 
cells are not yet surrounded by other tumourigenic cells but rather by “normal” 
cells. Therefore, the mechanism of growth suppression of these tumourigenic 
cells by their surrounding cells may be considered different from the mechanism 
of contact inhibition. The distinction of these two forms of growth inhibition will 
be possible once the molecular mechanism for both phenomena are identified. 
This phenomenon of carcinogenic cell growth inhibition has been demonstrated 
using human cancer cells as opposed to virus-transformed cell lines. For 
example, Flaberg and collaborators reported the inhibitory effect of primary 
human fibroblasts on the growth of human cancer cell lines (Flaberg, Markasz 
et al. 2011). They found that variation in the extent of this suppressive 
behaviour was at least partially explained by the age of the fibroblast donor as 
well as the site of origin of the fibroblast explant. 
A few in vivo studies have also highlighted a mechanism of tumour growth 
suppression by surrounding cells. An early example is the work of Illmensee 
(Illmensee and Mintz 1976), who found that when mouse teratocarcinoma cells 
were injected in mouse blastocysts these cells contributed to the development 
of various tissues in tumour-free mice.  
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- Cell-cell contact and gap junctions in neighbour suppression. 
Neighbour suppression has been demonstrated to be dependent on contact or 
close proximity with growth inhibited cells (Stoker 1964) and not a result of 
nutrient depletion in the medium (Stoker 1967). This requirement for close 
proximity lead to the study of cell communication between the suppressive and 
the suppressed cells. Gap junctions were shown to be essential for this type of 
growth suppression (Mehta, Bertram et al. 1986). It was hypothesized that the 
suppressive cells may send growth inhibitory signals to the suppressed cells 
using gap junctions, and that conversely the suppressed cells may release 
growth-promoting signals to the neighbouring not transformed cells. However, 
almost 20 years after this study, Alexander and collaborators showed using 
cells derived from connexin knockout mice that, although direct cell contact 
between transformed and non-transformed cells was required for neighbour 
suppression, this phenomenon was not dependent on the formation of gap 
junctions (Alexander, Ichikawa et al. 2004). 
The aim of this chapter has been to design, optimize, execute and analyse a 
non-biased RNAi screen to find molecular effectors of neighbour suppression in 
the tumorigenic cells. It was hoped that molecules could be identified in the 
tumourigenic cells that were required for the growth suppression by non- 
tumourigenic neighbours. 
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3.2. Material and methods 
This section introduces methods that are specific to this chapter. All materials 
used are listed in Chapter 2. Generic methods are referenced back to the 
relevant section in this thesis when needed. 
3.2.1. Cell lines 
3T3supp- and 3T3supp+. Isogenic derivatives of early passage Swiss 3T3 mouse 
embryonic fibroblasts (Allard, Stoker et al. 2003), (Todaro and Green 1963). 
SVE. Derivative of the 3T3supp+ cell line, transformed using Simian virus 40 
(SV40) (Eddy, Borman et al. 1962).  
SVE-6. Derivative of the SVE cell line (Nicholls 2015). Expresses high levels of 
cytoplasmic green fluorescent protein (eGFP) from a lentivirus expression 
construct (Marr, Guan et al. 2004). 
These 4 cell lines were routinely grown in DMEM (high glucose, GlutaMAX, 
pyruvate) supplemented with 10% (v/v) NCS and 1% (v/v) Penicillin 
Streptomycin. 
3.2.2. Production of retroviral particles using Phoenix cells 
Phoenix cells were trypsinized and seeded 24 hours before transfection in a 
100 X 20 mm sterile cell culture dish so that they were 70% confluent on the 
day of transfection. Cells were transfected using Turbofect as follows: 10 µg of 
the plasmid to be transfected were diluted into 1 mL of Opti-MEM Reduced 
Serum Medium in a sterile 1.5 mL microcentrifuge tube and mixed by vortexing. 
A vial of Turbofect was vortexed briefly and 40 µl were added to the DNA 
solution. The mixture was incubated for 20 minutes at room temperature. The 
growth medium from the Phoenix cell dish was aspirated and replaced with 3 
mL of fresh growth medium. The Turbofect mix was then added dropwise into 
the dish. To ensure even distribution of the mix, the dish was gently rocked and 
returned to the incubator. After 24 hours of incubation the transfection medium 
was aspirated and cells were very gently washed once with DPBS. 12 mL of 
growth medium were added to the dish before returning it to the incubator. After 
24 hours the medium was removed and transferred to a 15 mL tube. Phoenix 
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cells and cell debris in the tube were pelleted, and the supernatant containing 
viral particles was transferred to another 15 mL tube. Polybrene was added to a 
final concentration of 8 µg/ml. 
3.2.3. Transduction of SVE-6 cells 
SVE-6 cells were seeded 24 hours before transduction in a 100 X 20 mm sterile 
cell culture dish at a density that would give approximately 50% confluence. To 
perform the transduction, the growth medium in the dish was removed and 
replaced with 10 mL of viral medium containing polybrene. The dish was 
returned to the incubator for 24 hours, after which the viral medium was 
aspirated and replaced with 10 mL of viral growth medium. Cells were returned 
to the incubator and grown for 24 hours before puromycin selection. 
3.2.4. Seeding monolayers 
3T3supp+, 3T3supp- and SVE cells were trypsinized and seeded at approximately 
25% confluency. Cells were grown under standard conditions and monitored 
daily. When they had reached confluency (i.e., reached 100% density) they 
were cultured for another 24 hours before considered to have formed a 
monolayer of cells and used for further experiments. 
3.2.5. Plating SVE-6 cells on monolayers and plastic 
Monolayers of 3T3supp+, 3T3supp- or SVE cells were prepared as per section 
3.2.4. To plate SVE-6 on plastic, the appropriate volume of growth medium was 
added to the same type of tissue culture dish, flask or multi-well plate used to 
plate the monolayers. SVE-6 cells were trypsinized and counted as described in 
section 2.1.7. Growth medium was added to the cell suspension to adjust the 
concentration of cells so that the number of cells to be plated was contained in 
at least 20µl. The appropriate volume of cell suspension was pipetted on the 
monolayer and plastic dishes and they were gently swirled to distribute the cells 
as homogenously as possible. 
3.2.6. Restriction enzyme digestion of genomic DNA 
Genomic DNA was sheared with a 26G needle. The DNA solution was passed 
through the needle 20 times or until the viscosity of the solution had been 
reduced enough to allow accurate pipetting. Genomic DNA was then 
fragmented using EcoRI and XhoI. Digestions were set up as in Table 3.1 and 
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incubated overnight. A higher amount of DNA was used on the 3T3supp+ 
digestions due to a lower ratio of target sequences to genomic DNA in these co-
cultures. Loading buffer was added to each digestion reaction for a final 
concentration of 1X. The digested DNA was separated by electrophoresis in 
1.5% agarose gels prepared as explained in section 2.2.5. A band around the 
size of the shRNA construct was extracted as in section 2.2.7 
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 Plastic 3T3supp- 3T3Esupp+ 
Needle-sheared 
DNA 
100 µl 100 µl 500 µl 
EcoRI 2 µl 3 µl 5 µl 
XhoI 2 µl 3 µl 5 µl 
Buffer 22 µl 22 µl 110 µl 
H2O 94 µl 92 µl 480 µl 
Table 3.1. Composition of a single genomic DNA restriction digestion reaction for each 
sample in the screen.
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3.2.7. PCR amplification and purification of shRNA constructs 
ShRNA sequences were PCR amplified using Q5 High fidelity polymerase as 
explained in section 2.2.4 using the primers in Table 3.2 and conditions in Table 
3.3. PCR reactions were mixed with loading buffer at a final 1X concentration 
and separated in a 1.5% agarose gel prepared as in section 2.2.5. 
Electrophoresis was run and bands extracted as explained in section 2.2.7.  
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Primer name Sequence Sample 
HiSeq 1 forward TCGAGGTCGACGGTATCGATA 3T3supp- 
HiSeq 2 forward ATCTCTCGAGGTCGACGGTA 3T3supp+ 
HiSeq 4 forward GAGGTCGACGGTATCGAT Plastic 
HiSeq reverse  TGTCTTTGGATTTGGGAATC Common to all samples 
Table 3.2. Primers used to PCR amplify the shRNA constructs in each of the three samples  
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Step Temperature Time 
Initial denaturation 98ºC 30 seconds 
28 cycles 98ºC 
52ºC 
72ºC 
5 seconds 
15 seconds 
15 seconds 
Final extension 72ºC 2 minutes 
Hold 4ºC  
Table 3.3. PCR cycling conditions used for amplification of shRNA sequences.
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3.2.8. Analysis of sequencing data 
Figure 3.1 depicts the definitive analysis pipeline. The sequencing output was 
received as .fastq files. These files were moved to a UNIX server. Sequencing 
reads containing the primer sequence used for the amplification of each sample 
were extracted from the .fastq files using the command “grep” in the server (see 
format of the command in Appendix 1). Custom Python scripts (in Appendix 2) 
were written to extract the shRNA constructs from the files and build a plain text 
file which contained the shRNA constructs present in the sequencing output 
and the number of times that each shRNA construct was present. Briefly, the 
shRNA sequences were detected by locating the shRNA loop sequence in the 
sequencing reads. If the loop was present in a read, the 19 letters before the 
start of the loop were considered to be a potential shRNA construct. Then, the 
script counted how many times each construct appeared and outputted the 
shRNA sequence and the number of reads found in the sequencing. These text 
files were merged using Stata with a plain text file containing the shRNA 
constructs that were designed to be in the shRNA library. Constructs with less 
than 50 reads in the control sample (Plastic) were counted as absent to avoid 
random fluctuations in subsequent analysis steps. 
Reads were converted to reads per million per pool (rpmp), and two ratios were 
calculated: (rpmp 3T3supp+)/(rpmp Plastic) and (rpmp 3T3supp-)/(rpmp Plastic). 
These ratios were used to calculate a robust z-score per pool (see Stata do-file 
in Appendix 3 for particulars of calculations). 
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Figure 3.1. Schematic depiction of the analysis pipeline used.  
Sequencing reads were extracted from the .fastq files in a UNIX server using the 
command “grep”. Reads were aligned to the shRNA library and counted to produce a file 
containing the number of reads per shRNA construct. These raw number of reads were 
converted to reads per million per library pool. A ratio of each experimental condition to 
the growth control (Plastic, “P”) was calculated and used to build robust z -scores as 
estimates of shRNA construct effect sizes.
Raw fastq. file 
3T3supp- sample reads 3T3supp+ sample reads Plastic sample reads 
Grep primer 1 
Grep primer 2 
Grep primer 3 
3T3supp- reads per 
construct 
Plastic reads per 
construct 
3T3supp+ reads 
per construct 
3T3supp- reads per 
million per pool 
Plastic reads per 
million per pool 
3T3supp+ reads 
per million per 
pool 
3T3supp- rpmp/Plastic rpmp 3T3supp+ rpmp/Plastic rpmp 
3T3supp- z-score 3T3supp+ z-score 
Python script Python script Python script 
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3.2.9. Recursive partitioning analysis of tumour expression data 
Microarray expression data from various types of tumour were obtained from Dr 
Sarah Vowler, who also provided the R scripts to perform the recursive 
partitioning analysis. This analysis finds genes whose expression are correlated 
with survival rates of patients and is based on a method described first by 
Breiman (Breiman, Friedman et al. 1984). Distant metastasis free survival was 
used as the dependent variable as neighbour suppression is thought to be 
relevant for the initial phase of tumour growth. Although neighbour suppression 
is not amenable to study in vivo when it is expected to be taken place (i.e., 
when tumorigenic cells are still not forming tumours but either as single or few 
cells), the closest stage is represented by the establishment of metastasis. 
Metastasised cells need to settle in a new environment and grow. However, the 
surrounding tissue may exert a neighbour suppression effect on them, delaying 
or impeding the appearance of distant metastasis. 
The different datasets used are explained in Table 3.4. The detection of a high 
number of genes whose expression correlates with distant metastasis in the 
datasets used cannot be directly interpreted without evaluating whether this 
number of genes is unexpected. For this, an approach was designed to 
calculate the frequency at which the same or higher number of genes in a 
random group of genes were detected as being correlated with distant 
metastasis. 
Enrichment for significant effects in the list of GOI was tested using a random 
sampling approach (see Appendix 4 for the Python script to perform this 
analysis). Briefly, the entire shRNA library was fed to the recursive partitioning 
R script and then random samples of genes of the same size as the GOI list 
were picked. The output consisted on the number of significant effects found in 
each sample for each dataset. 
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Dataset name Type of tumour Sample size Publication 
Taylor Prostate cancer 218 (Taylor, Schultz et al. 2010) 
Shedden Lung adenocarcinoma 442 (Shedden, Taylor et al. 2008) 
Loi Breast cancer 335 (Loi, Haibe-Kains et al. 2007) 
Desmedt Breast cancer 198 (Desmedt, Piette et al. 2007) 
Table 3.4. Human tumour expression datasets used for the recursive partitioning analysis of effects of gene expression on metast asis-free 
survival of cancer patients. 
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3.2.10. Gene set enrichment analysis 
Data were analysed for enrichment in gene set members using GSEA 
PreRanked. shRNA constructs were ranked using different metrics: 3T3supp+ z-
score, 3T3supp- z-score or difference of z-scores ((3T3supp- z-score)-(3T3supp+ z-
score)). Duplicate gene names were resolved by removing duplicates in Excel. 
This was done after sorting the constructs on z-score (high to low or low to high 
depending on the sample, further details are explained in 3.3.11.5), absolute z-
score or alphabetically. Each combination of ranking and duplicate removal 
approaches was tried and analysed separately. The following parameters were 
used in all analyses: 
 Gene set database: “c2.all.v5.1.symbols.gmt”. 
 Collapse probes into gene names: False. 
 Scoring scheme: Classic. 
 Minimum size of sets to analyse: 15. 
 Maximum size of sets to analyse: 500. 
 Number of permutations: 1000. 
 Seed for randomisation: timestamp. 
3.2.11. Design of the screening process 
The screening process was designed to uncover molecular effectors of 
neighbour suppression in tumorigenic cells. More details of the screening will be 
given in the Results section of this chapter (section 3.3.1), but a simplified 
schematic depiction of the screening process is shown below (Figure 3.2). 
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Figure 3.2. Schematic simplified overview of the screening process
In-house shRNA library 
plasmids 
Retroviral particles with 
shRNA constructs 
SVE-6 tumorigenic cells 
with shRNA constructs 
integrated into DNA SVE-6 plated onto 
3T3supp+, 3T3supp- 
and plastic 
Packaging with Phoenix cells 
Transduction of SVE-6 cells 
7 days of growth 
SVE-6 colonies on 
3T3supp+ 
SVE-6 colonies on 
3T3supp- 
SVE-6 colonies on 
plastic 
Sequencing of shRNA constructs on SVE-6 in all 3 conditions 
Overrepresented shRNA constructs on 3T3supp+ compared to plastic: cells 
escape neighbour suppression when targeted gene is knocked-down 
Underrepresented shRNA constructs on 3T3supp- compared to plastic: 
neighbour suppression is stimulated when targeted gene is knocked-down 
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3.3. Results 
3.3.1. Description of the screening process 
3T3supp- and 3T3supp+ are two isogenic cell lines derived from mouse embryonic 
fibroblasts that differ in their ability to suppress the growth of oncogene-
transformed derivatives in co-culture. Such effect is depicted in Figure 3.3, 
where SV40-transformed 3T3supp+ expressing GFP (SVE-6 cells) were added on 
top of confluent monolayers of either 3T3supp- or 3T3supp+ cells and cultured for 
seven days. The aim of the screening process was to detect genes which upon 
reduction of expression in the tumorigenic cells would either allow the growth of 
these cells in suppressive co-cultures (co-culture with 3T3supp+ cells) or 
suppress growth in non-suppressing co-cultures (co-culture with 3T3supp-). 
A schematic depiction of the screening process is represented in Figure 3.2. 
The in-house NKI mouse shRNA library was transfected into a packaging cell 
line (Phoenix ECO), which produced ecotropic (murine-specific) retroviral 
particles containing the shRNA targeting constructs. One 10 cm dish of Phoenix 
cells was used per library pool. Tumorigenic (SVE-6) cells were transduced with 
the retroviral particles and selected for stable integration using puromycin. One 
10 cm dish of SVE-6 cells was used per library pool. Monolayers of 3T3supp+ and 
3T3supp- were established in T175 and T75 flasks as explained in section 3.2.4. 
An average of 100 cells per shRNA construct (38400 cells per library pool) were 
screened. Puromycin selected SVE-6 cells were added on top of confluent 
3T3supp+ and 3T3supp- monolayers and to the same area of tissue culture plastic. 
Co-cultures were grown for seven days, with growth medium being renewed 
every three days. After seven days, cells were harvested and genomic DNA 
extracted. As cells were harvested together, genomic DNA from both the 
monolayer and the SVE-6 cells was extracted. 
3.3.2. Overview of the NKI shRNA library used 
The NKI shRNA library, described in section 2.4 was amplified in-house as 
previously described (Nicholls 2015). Using the data obtained by Nicholls, a file 
was constructed that contained the shRNA constructs present in the in-house 
shRNA library, and the pool in which they were expected to be as indicated by 
Dr Roderick Beijersbergen (NKI). This file also contained the name of the 
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transcripts that were expected to be targeted by the sequences in the library. 
However, this annotation was not been performed with the latest release of the 
mouse transcriptome reference. To update the annotation provided, the shRNA 
targeting sequences in this library file were re-aligned to the mouse 
transcriptome using a standalone version of BLAST (section 2.5).  
Not all sequences were found to have only one match: 3,367 sequences were 
found to be duplicated. This does not mean that 3,367 targeting sequences 
aligned to two RefSeq mRNA sequences as some of those might be the same 
sequence which has matched to more than two mRNAs. Of the matches 
produced, 2,185 (of 33,547) were not present in the original library design and 
25,163 had an e-value as calculated by BLAST of 0.004. The e-value is a 
measure of the probability of finding another mRNA sequence with the same 
degree of match to the sequence blasted. E-values of less than 0.06 were 
assigned to 25,655 sequences in total, with the rest of them (7,892) presenting 
an e-value ranging from 0.23 to 866. Of these 7,892 sequences with a high e-
value 1,991 were found to be duplicated and 2,056 were not in the original 
library design.  
3.3.3. Optimization of multiplicity of infection (MOI) 
It was important for this screen that the resolving power was as high as possible 
to detect moderate effects of knock-downs. If the tumorigenic cells were 
transduced with more than one plasmid, the effects of a functional plasmid 
could be dampened by the effects of the others present in the same cell. Also, it 
is possible that the knock-down of more than one gene simultaneously would 
produce an effect that the knock-down of each of them separately would not 
exert. This would result in false positives as the effect would be detected for all 
the genes knocked-down equally and it would not be possible to resolve their 
individual effects. As viral infections are binomial phenomena (a viral particle 
either infects or not a cell), their behaviour is modelled by the Poisson 
distribution (Figure 3.3). The probability of a multiple transduction decreases 
with the MOI, but if the MOI is too low the efficiency of the experiment also 
decreases as it produces a very low number of transduced cells. To satisfy both 
conditions a MOI of 0.3 was chosen. As seen in Figure 3.3, when cells are 
transduced at a 0.3 MOI, most (22% of total cells or 73% of the infected cells) 
are transduced with a single construct. This produced enough infected cells for 
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a library pool in a 10 cm dish without too many cells containing multiple 
sequences. This multiple sequence integration issue is a common limitation in 
pooled RNAi screens and requires a balance between optimal conditions for the 
experiment (i.e. it would be optimal to eliminate the possibility of multiple 
sequences inside the cells) and efficiency (i.e. to eliminate this possibility one 
would need to perform the transfections with a lower MOI, which increases the 
number of cells needed).  
To optimize the conditions in order to obtain the target 0.3 MOI, PHOENIX cells 
were transfected with a Turbofect/DNA mixture (as in section 3.2.2) but with 
varying ratios of Turbofect/DNA. The retroviral supernatant harvested from 
these various conditions was used to transduce SVE-6 cells as in 3.2.3. Cells 
were puromycin selected and the survival rate examined. The conditions which 
produced a cell survival of approximately 30% were chosen as the ideal 
conditions for the screen and maintained throughout the screening process. As 
pools were transfected and transduced separately they were monitored for 
consistency. If any pool showed a survival rate substantially higher or lower 
than approximately 30%, those SVE-6 cells were discarded and not used in the 
screen. 
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Figure 3.3. Distribution of null (0, black bars), single (1, green bar) and multiple (2 or 
more, red bar) transduction events in the cell population for different MOI.  
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3.3.4. Optimization of co-cultures 
To maximize the resolution of the screen it was critical to establish the co-
culture conditions that would produce a maximum difference in growth of 
transformed cells in suppressive and non-suppressive conditions. Two 
parameters were considered of most importance: seeding density of 
transformed cells and length of co-culture. Seeding transformed cells in too 
close proximity could result in their growth being impeded by space limitations, 
which in co-cultures with 3T3supp- would cause a decrease in SVE-6 colony size. 
Modest decreases in colony size would not be detected as all colonies would be 
smaller than that achieved by unhindered growth. Seeding cells too sparsely 
could affect the plating efficiency but of more concern was the practical 
limitation from increasing the scale of the screen. 
To optimize the co-culturing conditions, monolayers of 3T3supp+ and 3T3supp- 
were seeded (section 3.2.4). SVE-6 cells were plated at different densities on 
top of these monolayers and directly on plastic (section 3.2.5). Growth of SVE-6 
cells was monitored using a fluorescence microscope every 24 hours for up to 
ten days. Although the difference in SVE-6 growth was maximal after ten days 
of co-culture, it was noted that monolayers started to detach from the tissue 
culture plastic surface, which could confound the results as SVE-6 could start 
growing on plastic instead of on monolayer. Seven days of co-culture provided 
the maximum resolution without causing the underlying monolayer to detach. It 
was determined by examination of the cell colonies that 166 SVE-6 cells per 
cm2 could be plated without their growth being limited by the proximity of other 
colonies (Figure 3.4). 
Having chosen the appropriate seeding density, it was important to calculate 
how many cells per construct would be necessary to minimize a potential bias 
due to sampling effects. As the effect on reduction of expression for each 
targeting sequence was unknown and therefore power calculations could not be 
performed, this parameter was researched in the available literature. Most RNAi 
screens have been performed using a dropout protocol, where knockdown of 
genes are expected to increase the survival of cells to a certain stimulus. For 
this type of dropout screen, literature suggests a 1,000 fold representation. The 
screen being described here however was based on cellular proliferation and 
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therefore the number of cells per hairpin was expected to increase. In a dropout 
screen, the number of cells required per hairpin to maintain representation of 
the original library is higher due to the number of cells per hairpin decreasing 
upon exposure to the stimulus causing the dropout effect. Chapter 4 will present 
a dropout screen where 1,000 cells per hairpin were used. 
The effect of shRNA hairpin fold representation in pooled screens was 
examined by Strezoska (Strezoska, Licon et al. 2012) who concluded that 
although using 500 cells per hairpin sequence resulted in a higher level of 
reproducibility between biological replicates, using a 100 fold representation still 
resulted in highly reproducible results: 65% of GOI overlap using 100 cells per 
hairpin compared to 73% using 500 cells per hairpin. Considering the trade-off 
between reproducibility and feasibility in this type of screen, 100 cells per 
hairpin were used. 
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 41.5 cells/cm2 83 cells/cm2 166 cells/cm2 
3T3supp+ 
   
3T3supp- 
   
Plastic 
   
Figure 3.4. Fluorescence microscopy photographs showing the SVE-6 colony size on both co-cultures and on plastic. 
The number of SVE-6 cells per surface unit plated in each experiment is indicated on the top row of the table. SVE -6 cells were plated on 
monolayers or plastic and cultured for 7 days. Cells were fixed and a fluorescence microscope was used with a 4X objective an d a FITC filter 
to take the photographs.
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Condition GFP Visible Merge 
3T3supp+ 
   
3T3supp- 
   
Plastic 
   
Figure 3.5. Neighbour suppression effect of 3T3supp+ cells on SVE-6 cells.  
Monolayers of 3T3supp+ and 3T3supp- were set up and SVE-6 cells were plated on top of both monolayers and alone on plastic. Colonies of 
SVE-6 cells were imaged using fluorescence microscopy with a 10X objective after 7 days of growth. Monolayers were imaged using p hase 
contrast on the same microscope. GFP mages were artificially coloured and merged with monolayer images using ImageJ.  
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3.3.5. Optimization of shRNA construct recovery from SVE-6 cells 
The readout of the screen used second generation Illumina sequencing to 
assess the change on cell number as estimated by changes on representation 
of the shRNA constructs integrated in the tumorigenic cells genome. As cells 
were antibiotic selected, only those cells with a stably integrated shRNA 
sequence were used in the screening process. This provided in effect a 
molecular barcode such that sequencing through the targeting sequence 
integrated in the genomic DNA would be a proxy of the number of cells 
containing that targeting sequence. This barcoding strategy was first described 
in the context of RNAi pooled screens by Berns and collaborators (Berns, 
Hijmans et al. 2004). To use this barcoding approach, targeting sequences 
needed to be recovered from the cells, PCR amplified and sequenced. Two 
steps were optimized in the recovery of the shRNA constructs from the 
tumorigenic cells: the preparation of DNA for amplification and the amplification 
of the shRNA constructs itself. 
As the growth of tumorigenic cells is significantly different on 3T3supp+ and 
3T3supp- monolayers and on plastic, the proportion of shRNA constructs to 
genomic DNA varied considerably between the three culture conditions. While 
on plastic for each copy of genomic DNA there was approximately one shRNA 
construct, DNA samples from the co-cultures included genomic DNA from the 
underlying monolayers of 3T3supp+ and 3T3supp-, which increased the proportion 
of genomic DNA to shRNA construct. This was particularly prominent in the 
suppressive co-culture as the growth of tumorigenic cells is very limited. 
Therefore, to achieve the same amount of template DNA (shRNA targeting 
sequences) a variable amount of genomic DNA would need to be used in PCR 
amplification for each screening condition. 
PCR amplification is known to be inhibited by the presence of high DNA 
concentration in the PCR reaction, which limited the amount of genomic DNA 
that could be used in each PCR reaction. A possible solution for this limitation is 
to simply reduce the DNA to be amplified. This would reduce the template DNA 
proportionally, which could lead to sampling effects that could alter the 
representation of targeting sequences. The literature suggests that to limit 
sampling effects an average of 1,000 copies of each shRNA construct should 
be PCR amplified (Sims, Mendes-Pereira et al. 2011, Strezoska, Licon et al. 
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2012), which would not be practical if the amount of DNA template per tube was 
to be reduced. An alternative solution was then explored: to maintain the 
amount of DNA to be amplified, but increase the number of PCR reactions 
performed such that the concentration of DNA in each reaction was in effect 
reduced. To achieve the amplification of the equivalent to 1,000 copies of each 
targeting sequenced it was estimated that it would be necessary to perform a 
minimum of 25 PCR reactions per pool for the 3T3supp- and 100 per pool for the 
3T3supp+ samples. 
To circumvent the impracticality of reducing the input DNA using these 
approaches, solutions were explored to increase the template DNA to genomic 
DNA ratio. Targeting sequences in the library had been cloned into the 
pSuperRetroPuro vector using the restriction enzymes EcoRI and XhoI and 
their recognition sequence is maintained when they are integrated in the 
genomic DNA. It was therefore reasoned that it would be possible to excise a 
region of the viral DNA containing the targeting sequences from the genomic 
DNA. It was necessary that the recognition sequence for both enzymes was not 
included into any of the targeting sequences such they would not be cleaved by 
the enzymes. If this was the case, the cleaved targeting sequences would not 
be PCR amplified or sequenced. It was expected that the targeting sequences 
would not contain the recognition sequence for any of the two enzymes as the 
original library was designed to be cloned into the vector plasmid with these 
enzymes, but this was still investigated to be certain this step would not alter the 
composition of the samples. A file with the original sequences provided by the 
library providers was searched for the recognition sequence and no matches 
were found. Therefore, this digestion step was incorporated into the protocol. 
The composition of the restriction digestion reactions were then optimized with 
respect to the amount of DNA that could be digested in a reaction and the units 
of each enzyme to be used. Concentration of DNA in the reaction seemed to 
limit the performance of the enzymes, leading to undigested DNA (Figure 3.6). 
To increase the efficiency of the reaction, overnight digestions with varying 
amounts of enzymes were performed (Figure 3.7). Digestions appeared to be 
incomplete, with very prominent high weight bands which could be a result of 
genomic DNA not being digested. 
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Genomic DNA samples were highly concentrated, at an estimated 
concentration of 5 µg/µl. Viscous DNA solutions reduce enzyme diffusion and 
can limit the efficiency of the digestion reactions. To reduce the viscosity of the 
solution, DNA samples were sheared before enzymatic digestion using a 26G 
needle. To investigate the effect that shearing DNA could have on restriction 
digestion and subsequent PCR reactions, two DNA samples were processed in 
parallel. One of them was sheared, and both samples (sheared and un-sheared) 
were digested using EcoRI and XhoI overnight. The digestion reactions were 
analysed on an agarose gel (Figure 3.8). These sheared samples show a more 
complete digestion of DNA with the restriction enzymes such that a soft smear 
is visible instead of the sharp band visualized in the un-sheared sample. A 
sample of sheared un-digested genomic DNA was also visualized and no DNA 
fragmentation is evident. 
A band around the expected size for the EcoRI-XhoI region of the shRNA 
targeting vector was extracted to be used as template for the PCR amplification 
of the targeting sequences. Before amplification, two parameters of the PCR 
required optimization. The optimal annealing temperature was investigated 
using a gradient PCR which results in the same cycling conditions in several 
wells of the thermocycler except for the annealing temperature, which varies. A 
range of temperatures from 50ºC to 72ºC were used to determine the optimal 
annealing temperature of the primers. Figure 3.9 shows the results of an 
electrophoresis on an agarose gel of the products of these reactions. Reactions 
with annealing temperature between 50ºC and 59ºC resulted in successful 
strong amplification. 52ºC was chosen as the optimal annealing temperature, as 
it resulted in successful PCR amplification with no unexpected bands that could 
be result of unspecific primer binding and the band obtained appeared to be the 
brightest by eye. 
Once the annealing temperature had been optimized, the number of 
amplification cycles was investigated. It was critical that PCR amplification did 
not alter the relative representation of targeting sequences so that the 
sequencing output could be used for quantitative analysis of the library 
composition after co-culture. To establish the optimal number of cycles that 
would yield products still in the exponential phase of the PCR, reactions were 
amplified for different number of cycles and compared on an agarose gel 
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(Figure 3.10). The brightness of the amplified band increased with each 
increase in cycle number up to 38 cycles. As the band produced after 26 cycles 
seemed to be slightly faint, and to accommodate variation in DNA concentration 
in the digested sample DNA templates, 28 cycles were performed in the PCR 
amplifications. 
Using the optimal annealing temperature and number of cycles, PCR 
amplification of the band extracted from the sheared and un-sheared DNA 
digestions was examined. The effect of DNA concentration was also 
investigated. 
A band of the expected size was observed in both sets of reactions, sheared 
and un-sheared DNA, showing that shearing did not affect PCR amplification 
(Figure 3.11). Increasing amounts of template DNA produced molecules of 
higher molecular weight. These molecules have been described before as 
annealed shRNA molecules and named “X-molecules” (Du, Ge et al. 2006). To 
minimize the proportion of X-molecules in the samples, 1 ng of template DNA 
was used. The shearing step was included into the DNA processing protocol. 
The optimal DNA processing pipeline is depicted in Figure 3.12. This process 
was used with all the samples in the final screen. 
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Figure 3.6. Results of a restriction digestion of genomic DNA and library plasmid with 
XhoI and EcoRI.  
10 µg of DNA were digested with 10 units of each enzyme at 37ºC for 3 hours in a total 
volume of 50 µl and run on a 1.2% agarose gel. L1: NEB 100 bp DNA ladder. E: empty. 
gDNA: Genomic DNA extracted from a co-culture experiment. L2: NEB 1 kb DNA ladder. 
Plasmid: library plasmid  
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Figure 3.7. Results of a restriction digestion of genomic DNA and library plasmid with 
varying amounts of XhoI and EcoRI.  
10 µg of DNA was digested in a total volume of 50 µl for each reaction at 37ºC overnight 
and run on a 1.2% agarose gel. L1: NEB 100 bp DNA ladder. P1: library plasmid digested 
with 12 units of each enzyme. P2: library plasmid digested with 4 units of each enzyme. 
P3: library plasmid digested with 20 units of each enzyme. gD1: genomic DNA digested 
with 12 units of each enzyme. gD2: genomic DNA digested with 4 units of each enzyme. 
gD3: genomic DNA digested with 20 units of each enzyme. L2: NEB 1kb DNA ladder. The 
blue rectangle indicates the portion of gel that was extracted from each lane.  
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Figure 3.8. Results of a restriction digestion of sheared and un-sheared genomic DNA 
and library plasmid digested with 6 units of XhoI and EcoRI in a total volume of 50 µl for 
each reaction.  
Samples were incubated at 37ºC overnight and run on a 1.2% agarose gel. L1: NEB 100 
bp DNA ladder. P: library plasmid digested with 12 units of each enzyme. gD1: 5 µg of 
sheared genomic DNA. gD2: 2 µg of sheared genomic DNA. gD3: 5 µg of un-sheared 
genomic DNA. gD4: undigested sheared DNA. L2: NEB 1kb DNA ladder. 
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Figure 3.9. Temperature gradient PCR results.  
0.2 µg of library plasmid were amplified using a pair of HiSeq primers ( 3.2.7) with the 
annealing temperature set to the temperature above the lanes. L1 and L2: NEB 100 bp 
DNA ladder. 
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Figure 3.10. Results of the optimization of PCR amplification cycles.  
0.01 µg of library plasmid were amplified using a pair of HiSeq primers (3.2.7) for the 
number of cycles specified on the lane names. L1 and L2: NEB 100bp DNA ladder.
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Figure 3.11. PCR amplification results of un-sheared and sheared gDNA samples.  
L1 and L2: NEB 100 bp DNA ladder. U1: 1 ng of un-sheared DNA. U2: 2 ng of un-sheared 
DNA. U3: 4 ng of un-sheared DNA. U4: 4 ng of un-sheared DNA, not amplified. S1: 1 ng 
of sheared DNA. S2: 2 ng of sheared DNA. S3: 4 ng of sheared DNA. S4: 4  ng of sheared 
DNA, not amplified. E: empty reaction, no DNA negative control..  
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Figure 3.12. DNA processing pipeline from extraction of DNA to amplification.  
The amplified band obtained from this pipeline was then sequenced by the University of 
Exeter Sequencing Service.
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3.3.6. Reproducibility of the screening process 
To investigate the biological and technical variability of the screening process, 
three library pools were processed in duplicate. Both replicates were carried out 
in parallel but using independent cell cultures and reactions. Monolayers were 
set up using the same cell stocks but in separate flasks, and viral particles were 
derived from separate transfections of the packaging cell line. All further 
processes were carried out in parallel. Each condition (co-cultures and plastic 
culture) was PCR amplified using a different forward primer. PCR amplified 
shRNA constructs were sequenced using a different Illumina adaptor for each 
duplicate but on the same sequencing lane. As an indicator of the efficiency of 
the primers used for PCR amplification, PCR reactions were performed with the 
same DNA template using the four available forward primers.  
Figure 3.13 shows the result of the amplification reactions. Although this is not 
quantitative there seems to be a slightly higher amount of DNA in the reaction 
using primer 2. Even if this is the case, an increase in efficiency would not alter 
the results because relative abundance of targeting sequences within a sample 
is used in the data analysis rather than absolute number of targeting sequences. 
It would not alter reproducibility either as long as this efficiency was maintained 
because the same condition was amplified using the same primer for both 
duplicates. 
A total of 112,995,003 reads were obtained for duplicate A across all conditions, 
and 131,096,006 for duplicate B. Figure 3.17 shows the sequence of the PCR 
primers for each condition and how their differences are used to separate the 
sequencing reads that belong to each of the samples. All primers have a 
common sequence, which was used to extract the reads to a file containing the 
reads for all 3 samples (referred to as “general” below). Part of the sequence 
was common to both co-culture samples and it was used to extract the reads to 
a file containing the reads for both samples (referred to as “co-culture” below). 
Another part of the sequence was specific to the 3T3supp+ monolayer samples 
and it was used to produce a file containing only these sequences (referred to 
as “supp+” below). To detect potential shRNA constructs (sequencing reads 
with the expected structure of a shRNA) in these files, a Python script was 
written (Appendix 3) which identifies reads containing the exact sequence for 
the shRNA loop and extracts the 19bp before the start of the loop as a targeting 
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sequence. The script then counts how many times that targeting sequence is 
found in the sequencing reads and outputs a file with each unique targeting 
sequence and the number of times it appears in the sample. 
These files were imported into Stata such that each targeting sequence was an 
observation and each sample a variable. To resolve the incomplete separation 
of the samples due to partial overlapping of the amplification primers, the 
numbers of reads in the samples were subtracted as follows: “general”-“co-
culture” produced the “Plastic” sample; “co-culture”-“supp+” produced the 
“supp-” sample. After these operations, the file contained variables with the 
number of times each construct was detected in each of the three samples.  
The number of potential shRNA constructs obtained per sample is shown in 
Table 3.5. Potential shRNA construct sequences were aligned against a file 
with the expected shRNA targeting sequences of the library. Only sequences 
that align 100% to the targeting sequences designed to be present in the library 
were used in subsequent analysis. Between 92.1% and 93.8% of the constructs 
designed to be in the pools screened were detected in the different samples 
(Table 3.6). This incomplete representation can be explained by the 
composition of the library. The in-house library was sequenced to analyse the 
shRNA targeting sequences contained in it, revealing that not all expected 
targeting sequences were detectable at the read depth used (Nicholls 2015). 
When only those targeting sequences detected in the library sequencing (1,024 
out of 1,152) are considered to be in the library, between 92.2% and 99.1% of 
the sequences are found (Table 3.7). Therefore, not all of the sequences 
present in the library as determined through sequencing were detected. Three 
main reasons can explain this finding. The sequences might have not been 
sequenced in the screen due to insufficient read depth, their effects might be 
deleterious for the cells and therefore these are not present in the screen, or 
they might not have been transduced into the cells due to their low 
representation in the library. The average of reads for those targeting 
sequences in the in-house library sequencing dataset is approximately ten 
times lower than the average sequence in the same dataset, suggesting that at 
least part of the sequences are not present in the screening process due to 
their low representation in the library. 
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z-scores were produced for both replicates as explained in section 3.2.8. 
shRNA construct reads, reads per million per pool (rpmp) and z-scores were 
plotted for both replicates using Stata. Dotplots comparing both replicates at 
each state of the analysis are depicted in Figure 3.16. Correlation of z-scores as 
calculated by Stata between both replicates was 0.27 for 3T3supp- and 0.54 for 
3T3supp+. Complete tables of correlations for the various steps of the analysis 
are depicted in Table 3.8, Table 3.9 and Table 3.10. Correlations coefficients 
were in general higher between the different conditions of the same replicate 
than between both replicates of the same condition. This reveals an effect on 
either the transfection and transduction steps or during amplification and 
sequencing, or both. More than 100,000 packaging cells per targeting sequence 
were transfected, and that representation was kept during the transduction of 
the sequences into SVE-6. This fold representation is high and therefore 
unlikely to be the source of variation. A lower representation (100 cells per 
targeting sequence) was used when seeding SVE-6 and that may be a source 
of error, but it has been previously explained why increasing the number of 
SVE-6 cells seeded on monolayers would not be viable. 
Therefore, PCR amplification and sequencing were targeted for improvement 
before the full-scale screen was carried out. The following modifications were 
included in the final pipeline. The amount of genomic DNA used as template for 
shRNA sequence amplification was doubled for all conditions. A higher 
sequencing depth was also requested when performing the full-scale screen 
(average of 2,000 reads instead of 1,000 reads per construct) as many of the 
sequencing reads obtained did not correspond to the samples but rather to 
Illumina adaptor dimers (Figure 3.18). Other sequences were detected to be 
overrepresented in the sequencing output but could not be assigned to an 
Illumina adaptor. These sequences could not be mapped to the mouse genome 
or transcriptome using BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) nor to 
the plasmid vector sequence. 
In general, most constructs detected in this pilot screen were common to all 
conditions, as shown in Figure 3.14 (replicate A) and Figure 3.15 (replicate B). 
This indicates that even though the PCR amplification and the sequencing was 
not optimal, the pipeline was robust enough to avoid loss of targeting 
sequences from some conditions and not others. 
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Applying the analysis pipeline that was to be used with the final output of the 
screen, one targeting sequence was detected to have an effect on 3T3supp+ on 
both replicates, while 36 were detected only in one replicate. These were 
selected using a double threshold method, shown in Figure 3.19 and Figure 
3.20. The objective of this method was to avoid those targeting sequences that 
had the same effect on both co-cultures. This requirement is a consequence of 
the in vitro model used. Tumorigenic cell growth on 3T3supp+ is strongly 
suppressed and therefore an increase in suppression in this co-culture is highly 
unlikely to represent an effect on suppression but rather a less specific cell 
growth effect. Therefore, sequences that exert this effect on both co-cultures 
are most likely having an effect on tumorigenic cell growth and are outside the 
scope of this work. The same reasoning can be applied for 3T3supp- co-cultures, 
where a targeting sequence is unlikely to trigger a reduction of suppression 
given that this is almost non-existent. Therefore, for a construct to have an 
effect in the 3T3supp+ co-cultures, the z-score must be in the top 5% of the z-
score distribution in the 3T3supp+ sample but at the same time it must not be in 
the top 5% of the z-score distribution in the 3T3supp-. Complementarily, for a 
construct to be a considered a GOI on 3T3supp- its z-score must be in the bottom 
5% of the z-score distribution in the 3T3supp- sample while its z-score in 3T3supp+ 
must not be in the bottom 5% of the z-score distribution in the 3T3supp+. 
Two GOI (Pax2 and Tyk2) were found to be targeted by two constructs in 
replicate A in 3T3supp+, meaning that both targeting sequences for those two 
genes were detected to have had an effect. In replicate B, no GOI were 
targeted by two constructs. Taf6l was identified as a GOI in both replicates in 
3T3supp+. 
No constructs were detected to have an effect on 3T3supp- on both replicates, 
with 12 being detected in either one of the replicates but not in the other. 
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Figure 3.13. Results of the PCR amplification of 0.1 ng of library plasmid with the 
available primers for targeting sequence amplification.  
L1: NEB 100bp DNA ladder. 1: PCR amplification using primer HiSeq 4. 2: PCR 
amplification using primer HiSeq 8. 3: PCR amplification using HiSeq 1. 4: PCR 
amplification using HiSeq 2.
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 Replicate A Replicate B 
Plastic 76,844 108,342 
3T3supp+ 306,836 392,206 
3T3supp- 90,859 107,758 
Table 3.5. Number of potential shRNA constructs found in the pilot sequencing data 
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 Replicate A Replicate B 
Plastic 1,061 (92.1%) 1,070 (92.9%) 
3T3supp+ 1,071 (93.0%) 1,081 (93.8%) 
3T3supp- 1,061 (92.1%) 1,070 (92.9%) 
Table 3.6. Number of shRNA constructs designed to be in the library found in the pilot 
sequencing data.  
Numbers inside brackets are percentages of expected shRNA constructs according to the 
theoretical composition of the library.  
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 Replicate A Replicate B 
Plastic 944 (92.2%) 960 (93.8%) 
3T3supp+ 1,008 (98.4%) 1,015 (99.1%) 
3T3supp- 1,003 (97.9%) 1,011 (98.7%) 
Table 3.7. Number of shRNA constructs designed to be in the library found in the pilot 
sequencing data when only those constructs previously sequenced are considered.  
Numbers inside brackets are percentages of expected shRNA constructs according to the 
composition of the library determined by sequencing.
111 
 
 3T3supp+A 3T3supp-A Plastic A 3T3supp+B 3T3supp-B Plastic B 
3T3supp+A 1.00      
3T3supp-A 0.82 1.00     
Plastic A 0.67 0.94 1.00    
3T3supp+B 0.53 0.39 0.28 1.00   
3T3supp-B 0.68 0.57 0.47 0.86 1.00  
Plastic B 0.71 0.92 0.94 0.44 0.60 1.00 
Table 3.8. Correlation matrix of sequencing reads in the pilot project.  
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 3T3supp+ A 3T3supp- A Plastic A 3T3supp+ B 3T3supp- B Plastic B 
3T3supp+ A 1.00      
3T3supp- A 0.83 1.00     
Plastic A 0.75 0.88 1.00    
3T3supp+ B 0.80 0.92 0.75 1.00   
3T3supp- B 0.80 0.88 0.80 0.85 1.00  
Plastic B 0.70 0.92 0.84 0.88 0.83 1.00 
Table 3.9. Correlation matrix of reads per million per pool (rpmp) in the pilot project  
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 3T3supp+A 3T3supp-A 3T3supp+B 3T3supp-B 
3T3supp+A 1.00    
3T3supp-A 0.73 1.00   
3T3supp+B 0.54 0.41 1.00  
3T3supp-B 0.36 0.27 0.70 1.00 
Table 3.10. Correlation matrix of z-scores 
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Figure 3.14. Venn diagram showing the intersection of constructs present in replicate A 
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Figure 3.15. Venn diagram showing the intersection of constructs present in replicate B  
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 Raw read number Rpmp rpmp ratio to P ln (rpmp to P) zscore 
3T3supp+ 
     
3T3supp- 
     
P 
  
Not applicable Not applicable Not applicable 
Figure 3.16. Dotplots comparing replicates A and B of the pilot project.
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Figure 3.17. Primers used for PCR amplification of the samples.  
The sequence marked with the red rectangle was common to all samples and used to 
extract the reads to a file. Reads containing the red+blue marked sequence were 
removed from that file (which now contained the “plastic” reads) and placed into a “co -
culture reads” file. From this file, reads containing the sequence marked in green were 
removed (generating a “3T3supp-” file) and placed into a “3T3supp+” file 
.  
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B) 
 
Figure 3.18. Overrepresented sequences table from FastQC report on quality control of A): 
duplicate A and B): duplicate B.  
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Figure 3.19. Graphical demonstration of the double threshold system used to select GOI 
for the 3T3supp+ co-culture sample.  
A) Targeting sequences in the higher 5% of the 3T3supp+ z-score distribution (to the right 
of the red vertical line) are selected as potential GOIs. For illustration purposes, three 
arrows have been drawn to represent three random targeting sequences. B) Histogram 
for the 3T3supp- z-score distribution. Arrows represent the same three targeting 
sequences as in A. The purple arrow is situated in the bottom 5% of the distribution for 
3T3supp-, the red arrow is in the 90% around the average z-score and the blue arrow is 
situated in the top 5% of the distribution for 3T3supp-.C) The purple and red arrows are 
included in the 3T3supp+ GOI list. The blue arrow has been determined to have the same 
effect in both co-cultures and therefore is not included in any GOI list.  
3T3supp+ GOI list:  
A) 
B) 
C) Same effect in both co-
cultures (Not a GOI):         
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Figure 3.20. Graphical demonstration of the double threshold system used to select GOI 
for the 3T3supp- co-culture sample.  
A) Targeting sequences in the lower 5% of the 3T3supp- z-score distribution (to the left of 
the red vertical line) are selected as potential GOIs. For illustrat ion purposes, three 
arrows have been drawn to represent three random targeting sequences. B) Histogram 
for the 3T3supp+ z-score distribution. Arrows represent the same three targeting sequences 
as in A. The purple arrow is situated in the top 5% of the dis tribution for 3T3supp+, the red 
arrow is in the 90% around the average z-score and the blue arrow is situated in the 
bottom 5% of the distribution for 3T3supp+.C) The purple and red arrows are included in the 
3T3supp+ GOI list. The blue arrow has been determined to have the same effect in both co-
cultures and therefore is not included in any GOI list.  
 
3T3supp- GOI list:  
B) 
C) 
Same effect in both co-
cultures (Not a GOI):  
A) 
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3.3.7. Running the genome-wide shRNA screening process 
The full screen was performed with all 73 pools following the revised, optimal 
protocol and analysis pipeline identified in section 3.3.6. Only one replicate of 
the genome-wide screen was performed. Pools were run in batches of 10, with 
each pool being physically separate as indicated for the pilot pools. DNA 
samples were kept separate until combining them for loading into the HiSeq 
flow-cell. At that point, DNA samples were quantified using a Qubit fluorimeter 
and mixed in equal proportions. The mixture was then processed and 
sequenced by the University of Exeter Sequencing Service. 
3.3.8. Sequencing output of the screening process. 
All 73 library pools were screened until the point of extracting genomic DNA. 
However, 3 library pools (9, 45 and 48) failed to PCR amplify in at least one 
condition. Those pools were therefore not included in the samples that were 
sequenced and are absent from any further analysis. 
Sequencing results were received as a .fastq file which contained the reads for 
all the conditions pooled together. A total of 84,652,417 sequencing reads were 
obtained from the sequencing run. This file was managed as explained in 
section 3.3.6, producing a file with shRNA construct sequences and the 
corresponding reads containing that sequence in each of the samples. The 
number of potential shRNA targeting sequences (19bp preceding the shRNA 
loop sequence) detected in each sample is specified in Table 3.11, and the 
number of shRNA constructs designed to be in the library that were found in 
each sample is in Table 3.12. Robust z-scores were calculated for each 
targeting sequence as explained in section 3.3.6. Correlation matrices for the 
different data transformations are shown in Table 3.13 (raw read numbers), 
Table 3.14 (reads per million per pool) and Table 3.15 (z-scores). 
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Plastic 163,731 
3T3supp+ 266,787 
3T3supp- 155,801 
Table 3.11. Number of potential shRNA constructs found in the sequencing data 
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Plastic 25,246 (93.9%) 
3T3supp+ 25,610 (95.3%) 
3T3supp- 25,357 (94.3%) 
Table 3.12. Number of shRNA constructs designed to be in the library found in each 
sample in the sequencing data. 
In brackets, percentage of the number of shRNA constructs screened according to the 
library design. 
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 3T3supp+ 3T3supp- Plastic  
3T3supp+ 1   
3T3supp- 0.8593 1  
Plastic  0.9574 0.8910 1 
Table 3.13. Correlation matrix of raw sequencing reads 
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 3T3supp+ 3T3supp- Plastic  
3T3supp+ 1   
3T3supp- 0.9673 1  
Plastic  0.4381 0.4882 1 
Table 3.14. Correlation matrix of reads per million per pool 
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 3T3supp+ 3T3supp- 
3T3supp+ 1  
3T3supp- 0.6014 1 
Table 3.15. Correlation matrix of z-scores 
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3.3.9. Selection of potential effectors of neighbour suppression in the 
sequencing data 
Several methods of analysis of the sequencing data were considered. The 
objective of the analysis pipeline was to detect constructs that had a specific 
effect on each of the co-culture samples as explained in section 3.3.6. 
First it was considered to use the reads per million per pool (RPMP) as a proxy 
for cell number. However, the variation in the different pools in the three 
conditions studied was not homogenous and therefore this direct comparison 
was considered inefficient and biased. Histograms of RPMP for four of the pools 
in the three conditions studied are depicted in Figure 3.21 to illustrate this point. 
The density distribution for RPMP in these four pools is different and also varies 
between conditions. If a threshold was to be set using one of the pools and 
consider any constructs above this threshold in any of the other pools as having 
had an effect, the threshold would be very different depending on the pools 
used to set it. 
To account for this, an analysis method using z-scores calculated from reads 
per million per pool was investigated. Although this method accounted for 
differences in the variability levels amongst pools it was difficult to detect effects 
due to the nature of the screen. For a construct to be considered of interest, it 
needs to have an effect in one of the co-cultures but not in the other co-culture 
and also not on plastic monoculture. To achieve this, a system of three 
thresholds was studied. For each pool, a threshold would need to be 
implemented for each of the co-cultures and the monocultures. Targeting 
sequences would have needed to pass a threshold in a co-culture, a different 
one in the other co-culture to ensure that the effects were not the same in both 
co-cultures and then a third one to discard any sequences with an effect on 
growth as a monoculture. Given the number of pools screened, this approach 
although logical was considered inefficient and an alternative solution was 
sought. To reduce this system of multiple thresholds, a ratio of co-culture z-
scores to plastic z-scores was tried next. Due to the distributions of z-scores, 
which ranged from negative to positive numbers some artefacts were detected 
for negative z-scores. Finally, an analysis pipeline was devised where reads per 
million per pool for each construct in 3T3supp+ and 3T3supp- were divided by the 
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reads per million per pool for the same construct in plastic. The distribution of 
these ratios was very variable amongst pools. To achieve a more homogenous 
range of distributions, the ratios were converted to logarithms. A robust z-score 
was built from these log(ratios). To select potential effectors in each co-culture 
sample, a double threshold system was used. Constructs on the top or bottom 
5% of one of the conditions but not on the other were considered to have an 
effect. 
A total of 593 constructs were selected using this method, 281 from 3T3supp+ 
and 312 from 3T3supp-. Eight genes were targeted by two constructs: Ttbk1, 
Cd5l, Snap23 and Coa3 in the 3T3supp+ GOI list, and Rrp7a, Nr2c2ap, Actrt3 
and Gapdh in the 3T3supp-. As the library is composed of two constructs per 
gene, having detected an effect with both constructs may be an indicator of 
robustness of the effect. It may also however be due to chance and those GOI 
would still need replication. 
In total, 277 genes were selected as GOI for 3T3supp+ and 308 for 3T3supp-.
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Figure 3.21. Histograms of RPMP for pools 1 to 4.  
A) 3T3supp- co-culture sample. B) 3T3supp+ co-culture sample. C) Plastic sample. 
C) 
A) B) 
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3.3.10. Network analysis of the sequencing output 
As this screen used a comprehensive genome-wide, non-biased approach it 
was possible that the genes targeted by some of the constructs selected as 
having an effect could be part of protein complexes or have a function in the 
same pathway. Therefore gene interactions were investigated using network 
analysis. It was hoped that this analysis would result in the production of a list of 
potential “essential” genes or a pathway essential to the phenotype – those 
connected with many other GOI. With this aim of producing a second list of GOI 
to follow-up based on their connections with other GOI, network analysis was 
produced using two different approaches. 
3.3.10.1. Network analysis using STRING 
STRING (available at http://string-db.org/) was initially used to build gene 
networks. The list of GOI for each condition was uploaded to STRING and 
networks were built using the “High confidence” setting (confidence of the 
interaction higher than or equal to 0.7). “Textmining” was not used to predict 
interactions as this method links any proteins that are mentioned in the same 
abstract of published paper, which was thought to result in non-specific or non-
validated connections. 
Networks for both co-culture samples GOI are shown in Figure 3.22 (3T3supp-) 
and Figure 3.23 (3T3supp+). A network was also produced for both lists combined 
(Figure 3.24). STRING provides some basic network analysis. For the 3T3supp+ 
network, STRING indicates that there are 65 interactions and 23 were expected 
under the null hypothesis that the network is not enriched for interactions. It 
produced a p-value for enrichment in interactions of 3.95*10-13. The same 
analysis of the 3T3supp- revealed that although 32 interactions were expected 
the sample contains 63, which is a significant enrichment with a p-value of 
1.38*10-6. When the network produced for the combined list containing both 
3T3supp+ and 3T3supp-, STRING indicated that 110 interactions were expected 
but 261 were found (p-value for enrichment was reported as 0, which indicates 
it is under the minimum computed by STRING). If the connections were only 
found between pairs of gene inside the individual co-culture networks, 128 
connections were to be expected and that is not the case, which suggests the 
genes from both GOI lists are interconnected. To visualize this, the genes in 
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Figure 3.24 have been colour-coded according to whether they pertain to either 
the 3T3supp+ or the 3T3supp-. There is no apparent differential distribution of GOI 
according to which sample they were identified in. 3T3supp+ GOI are often 
connected to 3T3supp- GOI and not only to 3T3supp+ GOI. This level of inter-
sample connection may suggest the involvement of a common mechanism in 
the tumorigenic cells response to suppressive cues from neighbouring cells and 
their growth in absence of those suppressive cues. 
To analyse the networks and identify “hubs” or genes with more connections 
than expected by chance (section 3.3.11), it was first necessary to be able 
identify all the possible interactors of each gene in the screened genes. 
Unfortunately, the interaction database used by STRING to produce networks is 
not readily available for download. No further analyses were therefore produced 
using these networks and an alternative database that could be fully analysed 
was used instead.
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Figure 3.22. Gene network for 3T3supp- built using STRING and visualised in Cytoscape.  
Circles represent genes, colour coded by the number of interactions in the sample. Lines between two genes  represent the interaction 
between them. Genes with no interactors are not represented in this network.
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Figure 3.23. Gene network for 3T3supp+ built using STRING and visualized in Cytoscape.  
Circles represent genes, colour coded by the number of interactions in the sample. Lines between two genes represent the interaction 
between them. Genes with no interactors are not represented in this network  
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Figure 3.24. Gene network for the combined GOI list built using STRING and visualized in Cytoscape.  
Circles represent genes, with filling colour representing the number of interactions in the sample. Blue marks genes that hav e more than 9 
connections in the sample. Lines between two genes represent the interaction between them. Circles with dark blue border are 3T3 supp+ GOI 
and red border marks 3T3supp- GOI. Genes with no interactors are not represented in this network
135 
 
3.3.10.2. Network analysis using FunCoup 
FunCoup v 3.0 (Schmitt, Ogris et al. 2014) is available online at 
http://funcoup.sbc.su.se/search/. It produces networks of genes using data from 
a number of sources, with some but not all of them overlapping with the sources 
used by STRING. Table 3.16 compares the data sources used by STRING and 
FunCoup. The protein interaction database used by FunCoup is available to 
download from the same website. 
Gene interaction networks were built using FunCoup. Only queried genes were 
used to build the networks by setting the “Expansion depth” to 0. A confidence 
threshold of 0.8 was used to filter interactions between pairs of genes. This 
threshold retains only those connections with a high level of confidence as 
calculated by FunCoup from the evidence the database uses. Connections 
among genes were exported as text files. These files consist on a list of 
connections with the names of the two genes and the score for the diverse type 
of connections evaluated. The type of connection with the higher score is 
reported as the most likely connection, and the score of that connection is 
reported as the connection strength. The files for 3T3supp+ and 3T3supp- were 
imported into Cytoscape 3.3.0 for visualization and initial analysis. 
General views of the networks are represented in Figure 3.25 (3T3supp+) and 
Figure 3.26 (3T3supp-). A network was also produced for the combined GOI list 
(Figure 3.27) obtained in section 3.3.10.1. FunCoup does not produce any 
analysis of the connections in the network and therefore no enrichment in 
connections is available for these networks. However, Cytoscape does indicate 
the number of genes and connections amongst them when a network is 
displayed. The network produced by FunCoup from the 3T3supp+ GOI list has 78 
genes connected by 192 interactions. The 3T3supp- network is composed of 92 
genes and 441 interactions, which indicates the average number of interactions 
per gene is higher in the 3T3supp- network than in the 3T3supp+ network. In a 
similar manner to the results obtained with STRING, the network produced from 
the combination of both GOI lists has more genes with at least one connection 
(200) than the sum of both individual networks (170). A total of 1247 
interactions connect these 200 genes. When the combined network (Figure 
3.27) is examined it is apparent that genes from both GOI lists interact and 
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there is not a clear separation between the individual GOI lists. This interaction 
between pairs of genes from both GOI lists was also observed in the network 
obtained using STRING in the previous section.
137 
 
 STRING FunCoup 
Conserved 
neighbourhood 
Genes that appear closely 
together (less than 300bp of 
separation between genes) 
in prokaryotic genomes 
Not considered 
Co-occurrence Linked proteins are either 
present or absent across 
species 
Gene conservation across 
species obtained from 
InParanoid 
Co-expression The expression levels of 
pairs of genes correlate in 
the same or other species 
(by homology) 
mRNA (from GEO datasets) and 
protein co-expression (from 
Human Protein Atlas) 
Protein-protein 
interactions 
(PPI) 
PPI has been demonstrated 
experimentally and 
published 
Combined PPIs from iRefIndex. 
The score depends on the 
number of publications 
confirming it and the scale of the 
experiments (larger scale 
experiments have less weight) 
Text-mining Data extracted from paper 
abstracts that mention both 
proteins 
Not considered 
Genetic 
interactions 
Linked genes are fused in 
some species 
Considers interactions between 
pathways under the assumption 
that a gene in pathway A will 
probably interact with a gene in 
pathway B if any gene in 
pathway A interacts with any 
gene in pathway B 
Shared 
transcription 
factor binding 
sites 
Not considered Presence of binding sites for the 
same transcription factor near 
two genes is considered as 
evidence of functional coupling 
Co-regulation 
by miRNA 
Not considered Regulation of expression by a 
common miRNA is considered 
as evidence of functional 
coupling 
Sub-cellular 
localization 
Not considered From GO terms weighted on 
specificity of location 
Domain 
interaction 
Not considered From UniDomInt, interactions 
between protein domains are 
used. 
Table 3.16. Comparison of the data sources used by String and FunCoup to infer 
interactions between pairs of proteins. 
138 
 
139 
 
 
Figure 3.25. Gene network for 3T3supp+ GOI list built using FunCoup.  
Circles represent genes, colour coded for number of interactors in the GOI list. Blue: 9 interactors or more, and continuous spectrum of green from more interactors (dark green) to fewer (light green). Black lines 
represent the connections between pairs of genes, with thickness representing the strength of the interaction as per FunCoup.
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Figure 3.26. Gene network for 3T3supp- GOI list built using FunCoup.  
Circles represent genes, colour coded for number of interactors in the GOI list. Blue: 9 interactors or more, and continuous spectrum of green from more interactors (dark green) to fewer (light green). Black lines 
represent the connections between pairs of genes, with thickness representing the strength of the interaction as per FunCoup.  
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Figure 3.27. Gene network for combined GOI list built using FunCoup.  
Circles represent genes, colour coded for number of interactors in the GOI list. Blue: 9 interactors or more, and continuous spectrum of green from more interactors (dark green) to fewer (light green). Black lines 
represent the connections between pairs of genes. Circles with dark blue border are 3T3supp+ GOI and red border marks 3T3supp- GOI. Genes with no interactors are not represented in this network  
 
142 
 
143 
 
3.3.10.3. Prioritization of potential effectors of neighbour suppression 
in the network analysis data 
The network analysis data was used to determine which genes to prioritise in 
the further confirmation experiments 
The networks produced by FunCoup were analysed for the presence of genes 
with a higher number of connections than expected given the number of 
interacting genes present in the screened genes. 
Genes were first ranked by the number of connections they had with other 
genes in the GOI list, obtained from the “NetworkAnalyzer” tool in Cytoscape 
(section 2.7.2). A script was written in Python and used to test the significance 
of the number of connections for each gene using a random sampling approach 
(Appendix 6). 
The database of gene interactions in Mus musculus used by FunCoup was 
downloaded and filtered for connections with more than 0.8 confidence score 
(same threshold used for queried genes). The logic behind the script structure is 
summarised in Figure 3.28. Basically, the script iterated through the list of GOI 
producing 1,000 random samples of the same size of the GOI list, all including 
the gene currently being tested. Random samples were drawn without 
replacement from the list of constructs in the library. The script then iterated 
through the genes in the random sample and checked whether they interacted 
with the gene being tested according to the FunCoup database. For each GOI a 
count of how many samples had the same or higher number of interactions than 
in the GOI list was outputted. The proportion of the samples with same or higher 
number of connections was used as a p-value for significance of enrichment of 
gene interactors in the GOI list. A total of 25 genes were found to have a 
significantly higher number of interactors in the GOI list with a 0.05 level of 
significance. Nine of these genes belonged to the 3T3supp+ co-culture (Table 
3.18) and sixteen to the 3T3supp- co-culture (Table 3.17). Networks for these 
hyper-connected genes in the GOI lists are depicted in Figure 3.29 (3T3supp-) 
and Figure 3.30 (3T3supp+). 
The same analysis was performed using the combined GOI list produced in 
section 3.3.10.2 (network in Figure 3.31). In this case 29 genes (Table 3.19) 
were statistically enriched (p-value<0.05) in connections. Of those, fourteen 
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genes had been determined as statistically enriched for connections in their 
respective GOI list – seven in each of the conditions. These fourteen genes 
have been highlighted in Table 3.19. Fifteen genes had not been previously 
determined to be enriched for connections. Some of them did not have any 
interactors at all in their original GOI list whilst others did but gained more 
interactors when the GOI lists were combined. 
 
145 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.28. Graphical depiction of the script used to produce random-sampling estimates 
of enrichment in connectors for each gene in the networks produced with FunCoup.  
A) List of GOI with 1 or more interacting genes in the network, containing the number of 
interacting genes. B) Random sample process. Briefly, a random sample of the same size 
as the GOI list is drawn from a list that contains all the genes targeted by at least one 
sequence identified in the sequencing output of the screen. One of the genes in this 
random sample is always the gene being assessed for enrichment. The script searches 
for interactions between the gene being assessed and the rest of the genes in the random 
sample. The interactors are counted. This process is repeated 1,000 times. C) Of the 
1,000 samples the script counts how many have at least the same number of genes 
interacting with the gene under assessment as interactors were found for that gene in the 
GOI list. P-value is then calculated as the proportion of random samples with at least the 
same number of interactors. B and C are repeated for each gene in the GOI list.  
Gene 1: 30 interactors 
Gene 2: 10 interactors 
… 
Gene n: 1 interactor 
Random sample 1: Gene 1+ (n-1) random genes 
Gene 1 - Gene 2 
Gene 1 – Gene 3 
… 
Random sample 1: Gene 1 has 20 interactors 
Repeat 1000 
times 
Gene 1: 10 random samples have 30 or more interactors. P-
value: 10/1000=0.01 
A) 
B) 
C) 
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Gene Potential interactors 
screened 
Interactors in 
GOI list 
p-value 
Prkrir 1 1 <0.001 
Spred1 3 1 0.002 
Zfp57 6 1 0.008 
Dut 705 29 0.009 
Tlr4 6 1 0.012 
Vezf1 9 1 0.015 
Plek 7 1 0.016 
Pole2 140 8 0.017 
Rab43 7 1 0.017 
Hspe1 480 20 0.027 
Odc1 86 5 0.029 
Sel1l 228 10 0.032 
Prkag1 253 11 0.036 
Ncf4 35 2 0.041 
Ube2v1 157 7 0.045 
Rps5 853 31 0.049 
Table 3.17. Genes found to be enriched (p-value<0.05) in interactors in the 3T3supp- GOI 
list. 
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Figure 3.29. Gene network for the 3T3supp- GOI list.  
Only those genes determined to be statistically enriched in connections (red circles) and 
the genes interacting with them are depicted. 
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Gene Potential interactors 
screened 
Interactors in GOI 
list 
p-value 
Mxi1 2 1 0.001 
Npcd 10 2 0.001 
Tspan7 4 1 0.001 
Ankrd6 5 1 0.002 
Twf2 209 10 0.008 
Txnrd3 12 1 0.028 
Agxt2 13 1 0.029 
Pck2 14 1 0.03 
Hipk2 13 1 0.035 
Table 3.18. Genes found to be enriched (p-value<0.05) in interactors in the 3T3supp+ 
GOI list. 
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Figure 3.30. Gene network for the 3T3supp+ GOI list.  
Only those genes determined to be statistically enriched in connections (red circles) and 
the genes interacting with them are depicted.
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Gene Potential interactors screened Interactors in GOI list P-value 
Dmpk 1 1 <0.001 
Prkrir 1 1 <0.001 
Ptma 1 1 <0.001 
Zfp57 6 2 <0.001 
Agxt2 13 3 0.001 
Npcd 10 3 0.001 
Mxi1 2 1 0.002 
Spred1 3 1 0.004 
Tspan7 4 1 0.004 
Hsd11b1 3 1 0.006 
Papd5 171 15 0.006 
Wt1 3 1 0.009 
Snap23 62 7 0.012 
F11r 3 1 0.013 
Pnkd 42 5 0.013 
Tnnt2 10 2 0.015 
Cdipt 198 16 0.022 
Hipk2 13 2 0.023 
Hnrnpa0 249 20 0.024 
Tsta3 6 1 0.031 
Gata2 5 1 0.032 
Txnrd3 12 2 0.032 
Tlr4 6 1 0.034 
Sel1l 228 16 0.039 
Zfp110 30 3 0.039 
Pcsk1 6 1 0.04 
Twf2 209 16 0.041 
Dut 705 46 0.044 
Plek 7 1 0.046 
Table 3.19. Genes found to be enriched (p-value<0.05) in interactors in the combined GOI 
list.  
Shaded in blue: genes statistically enriched in connections in the 3T3 supp+ GOI list. In 
green: genes statistically enriched in connections in the 3T3 supp- GOI list. In white: genes 
not found to be statistically enriched in their original GOI list.
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Figure 3.31. Gene network for the combined GOI list.  
Only those genes determined to be statistically enriched in connect ions (red circles) and 
the genes interacting with them are depicted. Circles with dark blue border are 3T3 supp+ 
GOI and red border marks 3T3supp- GOI. 
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3.3.11. Functional enrichment analysis of GOI 
Functional enrichment analysis provides information about the 
overrepresentation of genes involved in certain biological pathways, expressed 
in specific cellular components or with certain molecular functions. This type of 
analysis can highlight putative mechanisms at work in the phenotype studied. 
As the molecular mechanism of neighbour suppression is unknown, functional 
enrichment was used to investigate whether the data obtained from the screen 
could highlight any biological pathway or molecular function of importance to it. 
For the same reason this functional enrichment analysis was performed using 
different methods followed by combination of these results. The following 
subsections describe five functional enrichment analysis approaches (three 
web-based and two standalone applications) and their outcomes. 
3.3.11.1. Functional enrichment analysis using STRING 
STRING was used for building protein interaction networks as described in 
section 3.3.10. However, it also produces a functional enrichment analysis of 
the gene list inputted. It uses three gene ontology (GO) categories: biological 
process, molecular function and cellular component; the pathway database 
KEGG; and the protein domain databases PFAM and INTERPRO. STRING 
does not allow the use of a custom background for the enrichment analysis and 
performs it using the whole genome as the background. As such, this method 
may include false positive enrichments due to the targeting sequences 
screened providing an incomplete coverage of the mouse genome.  
Functional enrichment analysis of the 3T3supp+ GOI list using STRING resulted 
in 64 biological process, ten molecular function, 26 cellular component and six 
KEGG pathway terms being significantly enriched. This enrichment was defined 
as a false discovery rate (FDR) under 0.05. The fifteen enriched terms with the 
lowest FDR from the GO categories (biological process, molecular function and 
cellular component) are displayed in Table 3.20. This analysis yielded some 
interesting enriched categories such as “homotypic cell-cell adhesion” and 
several categories related to the extracellular matrix and membrane-bound 
vesicles. Neighbour suppression has been shown to depend upon cell-cell 
contact between the tumorigenic cells and the cells exerting the suppression 
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and so these results were encouraging. Table 3.21 shows the enriched KEGG 
pathways for the same dataset and method of analysis. 
This analysis was performed for the 3T3supp- GOI list. In this case, only GO 
terms were found to be enriched in the list with no KEGG pathways passing the 
FDR threshold. Table 3.22 contains the fifteen enriched GO terms with the 
lowest FDR. 
The combined GOI list generated for the network analysis in section 3.3.10.1 
was also analysed for functional enrichment using STRING. Three KEGG 
pathways were identified as significantly enriched, with 368 biological process 
terms, 37 molecular function terms and 47 cellular component terms passing 
the threshold for enrichment in the GO terms analysis. The fifteen enriched GO 
terms with the lowest FDR are indicated in Table 3.23 and the enriched KEGG 
pathways in Table 3.24. 
The functional enrichment results were analysed for overlapping and specific 
annotations in both co-cultures and the combined list. A Venn diagram 
representing the overlapping categories is depicted in Figure 3.32. All the terms 
in common between both co-culture samples are also enriched in the combined 
list. In 3T3supp+ enrichment was detected for 11 categories (Table 3.25) which 
were not enriched in the 3T3supp- or the combined GOI list. These include three 
categories related to cancer which are encouraging as neighbour suppression 
is hypothesized to be relevant in the early stages of carcinogenesis. Four 
categories were detected as enriched exclusively in the 3T3supp- GOI list (Table 
3.26).
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Pathway ID Pathway description Observed 
gene count 
FDR 
GO.0008150 biological_process 183 4.06x10-07 
GO.0005488 Binding 150 2.20x10-06 
GO.0097159 organic cyclic compound binding 96 2.20x10-06 
GO.1901363 heterocyclic compound binding 95 2.20x10-06 
GO.0065007 biological regulation 141 1.52x10-05 
GO.0009987 cellular process 167 1.63x10-05 
GO.0050789 regulation of biological process 134 5.54x10-05 
GO.0005575 cellular_component 199 1.06x10-04 
GO.0003674 molecular_function 162 2.29x10-04 
GO.0043167 ion binding 93 5.91x10-04 
GO.0005737 Cytoplasm 140 6.80x10-04 
GO.0044424 intracellular part 163 6.80x10-04 
GO.0005622 Intracellular 165 7.09x10-04 
GO.0005623 Cell 178 7.09x10-04 
GO.0044763 single-organism cellular process 138 8.89x10-04 
Table 3.20. Top 15 enriched GO terms in the 3T3supp+ GOI list ranked by their false 
discovery rate (FDR). 
The enrichment analysis was performed with STRING using the whole mouse genome as 
the background. 
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Pathway ID Pathway description Observed 
gene count 
FDR 
4151 PI3K-Akt signaling pathway 13 0.029 
5200 Pathways in cancer 12 0.029 
5216 Thyroid cancer 4 0.029 
5222 Small cell lung cancer 6 0.029 
5410 Hypertrophic cardiomyopathy (HCM) 6 0.029 
5414 Dilated cardiomyopathy 6 0.030 
Table 3.21. Enriched KEGG pathways in the 3T3supp+ GOI list ranked by their false 
discovery rate (FDR). 
The enrichment analysis was performed with STRING using the whole mouse genome as 
the background. 
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Pathway ID Pathway description Observed 
gene count 
FDR 
GO.0003674 molecular_function 189 5.98x10-06 
GO.0050789 regulation of biological process 154 8.00x10-06 
GO.0050794 regulation of cellular process 147 1.04x10-05 
GO.0019222 regulation of metabolic process 113 1.66x10-05 
GO.0065007 biological regulation 155 2.96x10-05 
GO.0044763 single-organism cellular process 159 4.01x10-05 
GO.0032501 multicellular organismal process 105 5.51x10-05 
GO.0048519 negative regulation of biological 
process 
87 5.51x10-05 
GO.0005623 cell 206 6.05x10-05 
GO.0044464 cell part 205 6.05x10-05 
GO.0044707 single-multicellular organism 
process 
102 7.42x10-05 
GO.0050896 response to stimulus 108 1.43x10-04 
GO.0005488 binding 160 2.26x10-04 
GO.0048518 positive regulation of biological 
process 
96 2.47x10-04 
GO.0050767 regulation of neurogenesis 25 2.47x10-04 
Table 3.22. Top 15 enriched GO terms in the 3T3supp- GOI list ranked by their false 
discovery rate (FDR). 
The enrichment analysis was performed with STRING using the whole mouse genome as 
the background. 
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Pathway ID Pathway description Observed 
gene count 
FDR 
GO.0050789 regulation of biological process 286 1.09x10-12 
GO.0065007 biological regulation 294 1.16x10-12 
GO.0005488 binding 309 2.35x10-12 
GO.0003674 molecular_function 348 9.19x10-12 
GO.0009987 cellular process 344 5.61x10-11 
GO.0050794 regulation of cellular process 268 5.61x10-11 
GO.0044763 single-organism cellular process 295 1.02x10-10 
GO.0097159 organic cyclic compound binding 187 5.07x10-10 
GO.0019222 regulation of metabolic process 203 5.08x10-10 
GO.0005623 cell 383 5.80x10-10 
GO.1901363 heterocyclic compound binding 184 9.82x10-10 
GO.0044464 cell part 380 1.13x10-09 
GO.0005575 cellular_component 413 1.54x10-09 
GO.0044424 intracellular part 345 1.54x10-09 
GO.0005634 nucleus 208 3.61x10-09 
Table 3.23. Top 15 enriched GO terms in the combined GOI list ranked by their false 
discovery rate (FDR). 
The enrichment analysis was performed with STRING using the whole mouse genome as 
the background. 
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Pathway ID Pathway description Observed 
gene count 
FDR 
4114 Oocyte meiosis 10 0.028 
4151 PI3K-Akt signaling pathway 21 0.028 
5410 Hypertrophic cardiomyopathy (HCM) 9 0.028 
Table 3.24. Enriched KEGG pathways in the combined GOI list ranked by their false 
discovery rate (FDR). 
The enrichment analysis was performed with STRING using the whole mouse genome as 
the background 
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Figure 3.32. Venn diagram showing the overlaps in enriched functional categories (GO 
terms and KEGG pathways) in the 3T3supp+ and 3T3supp- GOI lists and the combined list 
containing the genes from both lists. 
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nephron development 
Pathways in cancer 
Thyroid cancer 
Small cell lung cancer 
Dilated cardiomyopathy 
extracellular matrix 
purine nucleobase transmembrane transporter 
activity 
pyrimidine nucleobase transmembrane 
transporter activity 
nucleobase transmembrane transporter activity 
positive regulation of cell-substrate adhesion 
contractile fiber part 
Table 3.25. Functional categories enriched in 3T3supp+ but not in 3T3supp- or the combined 
list according to STRING. 
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regulation of dendrite development 
response to prostaglandin E 
regulation of dendrite morphogenesis 
semicircular canal development 
Table 3.26. Functional categories enriched in 3T3supp- but not in 3T3supp+ or the combined 
list according to STRING. 
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3.3.11.2. Functional enrichment analysis using FunCoup 
FunCoup provides some basic results on GO enrichment on the list of genes 
used when networks are computed. These include “Cellular component”, 
“Biological process” and “Molecular function”. No terms were found to be 
enriched in any of the GOI lists analysed. No information is available on how 
this analysis is performed. 
3.3.11.3. Functional enrichment analysis using DAVID 
DAVID (https://david.ncifcrf.gov/) is an on-line resource commonly used to 
perform functional annotation and enrichment analysis. However, the 
performance of this system is limited when long lists of genes are analysed. As 
the shRNA library used might already be enrichment for some functional 
categories, this analysis would require the use of the list of genes screened (i.e. 
those genes that have more than 50 reads in the sequencing) as a background. 
Despite various attempts to set the list of screened genes as a background in 
DAVID this analysis could not be performed as the server could not accept a list 
of genes of that size as a background. Therefore a pre-existent background had 
to be used. The results of the functional enrichment analysis (Table 3.27, Table 
3.28, and Table 3.29) thus indicate enrichment with respect to the entire Mus 
musculus genome and may include a bias caused by the potential enrichment 
of the screened genes list in the same functional categories. 
Only two categories were considered statistically enriched (Benjamini adjusted 
p-value below 0.05) in the 3T3supp+ GOI list (Table 3.27): “phosphoproteins” and 
“isopeptide bonds”. Using the unadjusted p-value, 122 categories were 
enriched in the 3T3supp+ GOI list. 
No categories were found to be statistically enriched using the Benjamini 
adjusted p-value in the 3T3supp- GOI list (Table 3.28). Using the unadjusted p-
value to judge enrichment, 71 terms were enriched in this list. 
It was reasoned that the same pathways might be of relevance for both 
suppressive and permissive signal integration, therefore both GOI lists were 
combined and analysed for functional enrichment using DAVID (Table 3.29). 
Three terms were found to be enriched above the statistical significance 
threshold using the Benjamini p-value adjustment: “phosphoproteins”, 
163 
 
“acetylation” and “nucleus”. Using the unadjusted p-values, 183 terms were 
enriched in the combined list. 
The overlap of the functional enrichment analyses (unadjusted p-values below 
0.05) for the different GOI lists was visualised using a Venn diagram (Figure 
3.33). Only 10 terms were found to be common to all GOI lists, with 61 being 
shared between 3T3supp+ and the combined list and 28 between 3T3supp- and the 
combined list. The terms that form part of each of the overlaps between the 
different GOI lists are available in Appendices 9, 10 and 11. 
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Category Term % of GOI in 
the category 
P-Value Fold 
Enrichment 
Benjamini 
SP_PIR_KEYWORDS phosphoprotein 44.664 6.28E-05 1.355 0.018 
SP_PIR_KEYWORDS isopeptide bond 5.138 3.20E-04 3.550 0.046 
GOTERM_CC_FAT GO:0008287~protein serine/threonine 
phosphatase complex 
1.976 9.96E-04 11.077 0.110 
GOTERM_CC_FAT GO:0000159~protein phosphatase 
type 2A complex 
1.581 5.86E-04 23.177 0.128 
KEGG_PATHWAY mmu05414:Dilated cardiomyopathy 2.372 0.008 4.737 0.239 
KEGG_PATHWAY mmu05200:Pathways in cancer 4.348 0.012 2.474 0.255 
KEGG_PATHWAY mmu05216:Thyroid cancer 1.581 0.007 10.018 0.296 
KEGG_PATHWAY mmu00310:Lysine degradation 1.581 0.018 7.086 0.307 
SP_PIR_KEYWORDS nucleus 26.877 0.005 1.351 0.326 
SP_PIR_KEYWORDS ubl conjugation 6.324 0.004 2.310 0.331 
Table 3.27. Results of functional enrichment in the 3T3supp+ GOI list performed using the online tool DAVID, ranked by Benjamini adjusted p -
value. 
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Category Term % of GOI in the category P-Value Fold Enrichment Benjamini 
GOTERM_CC_FAT GO:0042995~cell 
projection 
5.841924 0.005 2.149 0.516 
SP_PIR_KEYWORDS acetylation 17.86942 0.003 1.501 0.527 
GOTERM_CC_FAT GO:0005829~cytosol 5.841924 0.004 2.251 0.605 
SP_PIR_KEYWORDS dna-binding 10.99656 0.017 1.530 0.716 
SP_PIR_KEYWORDS cytoplasm 20.27491 0.022 1.307 0.727 
SP_PIR_KEYWORDS nucleus 24.39863 0.027 1.251 0.739 
SP_PIR_KEYWORDS CBS domain 1.030928 0.032 10.598 0.742 
SP_PIR_KEYWORDS nucleotide-binding 11.68385 0.042 1.399 0.753 
SP_PIR_KEYWORDS DNA binding 3.092784 0.039 2.341 0.770 
SP_PIR_KEYWORDS P-loop 1.37457 0.072 4.130 0.793 
Table 3.28. Results of functional enrichment in the 3T3supp- GOI list performed using the online tool DAVID, ranked by Benjamini adjusted p -
value. 
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Category Term % of GOI in the category P-Value Fold Enrichment Benjamini 
SP_PIR_KEYWORDS phosphoprotein 41.58965 4.40E-06 1.276 0.002 
SP_PIR_KEYWORDS acetylation 17.92976 4.09E-05 1.493 0.008 
SP_PIR_KEYWORDS nucleus 25.69316 3.66E-04 1.306 0.046 
GOTERM_CC_FAT GO:0005829~cytosol 5.730129 1.79E-04 2.095 0.057 
SP_PIR_KEYWORDS isopeptide bond 3.512015 8.17E-04 2.454 0.075 
SP_PIR_KEYWORDS cytoplasm 20.7024 0.001 1.323 0.083 
SP_PIR_KEYWORDS metal-binding 18.48429 0.002 1.334 0.093 
SP_PIR_KEYWORDS ubl conjugation 5.175601 0.002 1.912 0.104 
SP_PIR_KEYWORDS dna-binding 10.72089 0.003 1.478 0.108 
SP_PIR_KEYWORDS nucleotide-binding 12.01479 0.003 1.426 0.117 
Table 3.29. Results of functional enrichment in the combined GOI list performed using the online tool DAVID, ranked by Benjamini adjusted p-
value. 
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Figure 3.33. Venn diagram showing the overlap in functional enrichment in both GOI lists 
and the combined list. Enrichment analysis was performed using DAVID.  
168 
 
3.3.11.4. Functional enrichment analysis using FunRich 
FunRich (http://funrich.org/) is a freely available functional enrichment analysis 
tool developed by Pathan and colleagues (Pathan, Keerthikumar et al. 2015). 
FunRich 2.1.2 was obtained from the FunRich website and installed locally. The 
GOI lists for both co-culture samples were used as input and analysed for 
enrichment in “Cellular component”, “Molecular function”, “Biological process”, 
and “Transcription factor”. This last category is equivalent to the analysis 
performed using Opossum in section 3.3.14. 
FunRich does not accept a custom list of genes as the background for 
enrichment. Furthermore, its custom database integrating evidence from 
different publicly available sources is not available for mouse and thus the 
mouse gene names were converted to their homologs in human. To do this, a 
human-mouse homology database was downloaded from HomoloGene 
(http://www.ncbi.nlm.nih.gov/homologene/) and gene names were converted by 
merging this database with the gene lists. HomoloGene uses sequence 
similarity to determine homology between species. Not all genes in the shRNA 
library could be assigned a human homologue. Out of 13,342 genes identified 
in the library composition file 12,283 were assigned a human gene name. 
Analysis of the 3T3supp+ GOI list highlighted one significantly enriched 
(Benjamini adjusted p-value < 0.05) functional term: “Protein serine/threonine 
phosphatase activity”. An alternative q-value is reported by FunRich, the Storey 
and Tibshirani q-value (Storey and Tibshirani 2003). This type of adjustment is 
a false discovery rate (FDR) based measure of significance which indicates the 
proportion of false positives expected if the functional category is regarded as 
significant. Using this q-value as a measurement of enrichment, 24 functional 
terms were found to be enriched (q-value<0.05) in the 3T3supp+ GOI list. The 10 
categories with the lowest q-value are reported in Table 3.30. 
The analysis of the 3T3supp- produced no significantly enriched (Benjamini 
adjusted p-value < 0.05) functional categories. Four functional categories have 
a q-value under 0.05: “cytoplasm” and “cytoplasmic part”, “cell leading edge” 
and “eukaryotic translation initiation factor 2B complex”. 
A combined GOI list composed of the GOI from both co-culture conditions was 
also analysed for enrichment using FunRich (Table 3.25). Three functional 
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categories have Benjamini adjusted p-value under 0.05: “cytoplasm”, “TFAP4” 
(indicating enrichment in binding sites for that transcription factor) and “nucleus”. 
Enrichment for transcription factor binding sites is the biggest contributor to the 
list of functional terms with q-value below 0.05, which is composed of 141 
terms – 135 are transcription factors. The other six terms are “cytoplasm”, 
“signal transduction”, “protein serine/threonine phosphatase activity”, “cell 
communication” and “muscle contraction”. 
Given that FunRich does not accept custom background gene lists I 
investigated which terms were enriched in the screened genes to determine 
whether the above functional enrichment resulted from the selected genes that 
were screened. Enrichment analysis was therefore performed on the list of all 
the genes that were targeted by the sequences screened (Table 3.33). A total 
of 156 functional terms were detected as significantly enriched (Benjamini 
adjusted p-value under 0.05). 
To non-formally assess the differences in enriched terms between the screened 
genes and the co-culture GOI lists, all functional categories with an unadjusted 
p-value below 0.05 were examined for overlap amongst the lists (Figure 3.34). 
Three functional categories were found to be enriched in all lists of genes using 
that threshold: “cytoplasm”, “signal transduction” and “TFAP4”. The number of 
functional terms found to be enriched in either of the screening co-culture 
conditions and the screened gene list are quite similar: 17 in common between 
the screened genes and the 3T3supp+ GOI list (Table 3.34) and 19 between the 
screened genes and the 3T3supp- GOI list (Table 3.35). This overlap analysis 
indicates that half of the functional categories enriched in the 3T3supp- GOI list 
and almost half in the 3T3supp+ GOI list are enriched in the list of screened 
genes. Those categories might therefore be enriched in the GOI list due to the 
enrichment in the background. Furthermore, all the categories enriched in both 
GOI lists are also enriched in the background, suggesting there might not be an 
overlap in the mechanism behind both phenotypes. 
The list of functional categories enriched exclusively in the 3T3supp- (Table 3.36) 
is composed amongst others of transcription factors and cytoskeleton, 
membrane and vesicle-related terms. This may suggest a role of cell membrane 
and motility in the formation of tumorigenic cell colonies in a permissive co-
culture.  
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The categories enriched exclusively in the 3T3supp+ GOI list (Table 3.37) 
however are mostly transcription factors, extracellular matrix component and 
chromosome-related terms, suggesting an involvement of transcription events 
and importance of the extracellular matrix in the response of tumorigenic cells to 
a suppressive cue by neighbouring cells.
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Term % of GOI 
in the term 
Fold 
enrichment 
Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and 
Tibshirani q-value 
Protein serine/threonine phosphatase 
activity 
2.119 10.666 <0.001 0.016 0.007 
Protein phosphatase type 2A complex 1.508 21.444 0.001 0.079 0.021 
BRCA1-A complex 1.005 28.325 0.004 0.089 0.024 
Cytoplasm 48.744 1.254 0.003 0.101 0.024 
Basement membrane 1.508 13.734 0.003 0.112 0.024 
DNA polymerase III complex 0.503 71.901 0.014 0.124 0.033 
Eukaryotic translation initiation factor 4F 
complex 
1.005 22.798 0.006 0.125 0.033 
Chromosome 2.010 6.265 0.009 0.130 0.033 
Dystrophin-associated glycoprotein 
complex 
1.005 20.772 0.008 0.133 0.033 
Cell communication 26.695 1.316 0.014 0.133 0.032 
Table 3.30. Top 10 functional terms (by Benjamini p-value) enriched in the 3T3supp+ GOI list.  
The analysis was performed with FunRich
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Term % of GOI in 
the term 
Fold enrichment Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and Tibshirani 
q-value 
Cytoplasm 49.351 1.268 0.001 0.108 0.023 
Cell leading edge 0.866 27.791 0.004 0.144 0.030 
Cytoplasmic part 0.866 21.782 0.007 0.197 0.041 
Ion channel activity 1.866 6.277 0.003 0.198 0.110 
Eukaryotic translation initiation 
factor 2B complex 
0.866 27.791 0.004 0.216 0.030 
Muscle contraction 0.373 23.955 0.073 0.254 0.082 
Transcription factor activity 8.209 1.848 0.007 0.258 0.143 
Electron transport 0.373 20.651 0.086 0.269 0.087 
Vesicle docking 0.373 28.518 0.059 0.273 0.082 
Regulation of immune response 0.373 16.186 0.114 0.289 0.093 
Table 3.31. Top 10 functional terms in the 3T3supp- GOI list ranked by increasing Benjamini adjusted p-values. 
The analysis was performed using FunRich.
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Term % of GOI in 
the term 
Fold 
enrichment 
Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and 
Tibshirani q-value 
Cytoplasm 49.065 1.258 1.42x10-05 0.003 0.001 
TFAP4 13.304 1.608 <0.001 0.048 0.003 
Signal transduction 27.545 1.271 0.001 0.049 0.016 
Transcription factor activity 7.784 1.715 0.001 0.060 0.037 
Muscle contraction 0.399 18.549 0.007 0.098 0.031 
Protein serine/threonine 
phosphatase activity 
1.198 5.845 0.001 0.110 0.037 
Receptor signaling complex 
scaffold activity 
3.593 2.138 0.004 0.128 0.079 
Cell communication 25.150 1.231 0.007 0.139 0.031 
Eukaryotic translation initiation 
factor 4F complex 
0.701 13.908 0.002 0.170 0.054 
Translation regulator activity 1.597 3.227 0.007 0.174 0.108 
Table 3.32. Top 10 functional terms in the combined GOI list ranked by increasing Benjamini adjusted p-values.  
The analysis was performed using FunRich 
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Term % of GOI in the 
term 
Fold 
enrichment 
Unadjusted p-value Benjamini 
adjusted p-value 
Storey and Tibshirani 
q-value 
Cytoplasm 43.833 1.121 4.15x10-37 2.83x10-34 9.8x10-35 
Transport 8.767 1.298 8.77x10-27 1.34x10-24 9.82x10-25 
Signal 
transduction 
25.073 1.145 4.72x10-26 3.61x10-24 2.64x10-24 
Energy pathways 11.265 1.245 6.23x10-25 3.18x10-23 2.33x10-23 
Metabolism 11.558 1.238 1.89x10-24 7.22x10-23 5.28x10-23 
Plasma membrane 27.362 1.138 1.06x10-24 3.61x10-22 1.25x10-22 
Cell 
communication 
23.599 1.147 1.96x10-23 5.99x10-22 4.38x10-22 
SP1 50.697 1.081 1.03x10-22 2.11x10-22 3.17x10-21 
Transcription 
factor activity 
5.976 1.282 7.82x10-17 1.62x10-14 1.09x10-14 
EGR1 23.670 1.123 2.08x10-16 2.13x10-14 3.2x10-14 
Table 3.33. Top 10 functional terms in the list of screened genes ranked by increasing Benjamini adjusted p -values.  
The analysis was performed using FunRich 
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Figure 3.34. Venn diagram showing the overlap in enriched functional terms (unadjusted 
p-value<0.05) amongst the GOI lists (3T3supp+ and 3T3supp-) and the genes targeted by at 
least one sequence present in the screen sequencing output (Screened).  
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Cell communication 
RREB1 
Receptor signaling complex scaffold activity 
Nucleus 
IRF1 
RXRA 
Cell surface 
ELF3 
HOXA3 
REST 
Chromosome 
Voltage-gated potassium channel complex 
FEV 
Dystrophin-associated glycoprotein complex 
Protein phosphatase type 2A complex 
VSX2 
ARID3A 
Table 3.34. Functional terms enriched (unadjusted p-value <0.05) in both the 3T3supp+ 
GOI list and the list of genes targeted by the screened sequences.  
Enrichment analysis performed using FunRich. 
177 
 
Transcription factor activity 
Exosomes 
Regulation of nucleobase, nucleoside, nucleotide and nucleic acid 
metabolism 
JUN 
JUNB 
JUND 
FOS 
FOSB 
ONECUT1 
Soluble fraction 
Translation regulator activity 
FOXA1 
NKX2-1 
Cytoplasmic part 
Centrosome 
PDX1 
E2F1 
GTPase activity 
HOXD8 
Table 3.35. Functional terms enriched (unadjusted p-value <0.05) in both the 3T3supp- GOI 
list and the list of genes targeted by the screened sequences.  
Enrichment analysis performed using FunRich. 
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Ion channel activity 
Cell leading edge 
Eukaryotic translation initiation factor 2B complex 
FOXJ1 
Ruffle membrane 
HMX1 
PLAG1 
Dense-core vesicle (None) 
Dynein complex 
SPOTS complex 
Tubulin complex 
Cytoplasmic membrane-bounded vesicle 
Cytoskeleton 
Binding 
Biological_process 
Humoral immune response 
Ion transporter activity 
Eukaryotic translation elongation factor 1 complex 
Vesicular fraction 
Condensed chromosome, centromeric region 
Table 3.36. Functional terms enriched (unadjusted p-value <0.05) exclusively in the 
3T3supp- GOI list.  
Enrichment analysis performed using FunRich
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Basement membrane 
BRCA1-A complex 
Eukaryotic translation initiation factor 4F complex 
Condensed nuclear chromosome 
Nuclear body 
Cohesin core heterodimer 
Collagen type VII 
DNA polymerase III complex 
Protein phosphatase type 1 complex 
M band 
BRCA1-BARD1 complex 
Ribosome 
Protein serine/threonine phosphatase activity 
Catalase activity 
Kinase activity 
Water channel activity 
Cytoskeletal anchoring activity 
Extracellular matrix structural constituent 
Protein kinase activity 
Helicase activity 
Glycoprotein metabolism 
Bone remodeling 
ZNF143 
HOXB3 
POU6F1 
FOXJ2 
HOXC10 
HOXB4 
Table 3.37. Functional terms enriched (unadjusted p-value <0.05) exclusively in the 
3T3supp+ GOI list.  
Enrichment analysis performed using FunRich
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3.3.11.5. Gene set enrichment analysis in the GOI lists using GSEA 
Functional enrichment analysis provides insight into the functional categories 
which may be of importance for a mechanism. However, a plethora of studies 
have been published in the last years highlighting lists of genes which are 
thought to be involved in a high number of phenotypes. These studies are not 
contemplated as functional categories and therefore not included in functional 
enrichment analysis approaches. Gene set enrichment analysis on the other 
hand does not rely on the same functional categories but includes gene sets 
defined by the literature. Given that a molecular mechanism has not as yet 
been proposed for neighbour suppression it was reasoned that a gene set 
enrichment analysis approach may identify phenotypes with mechanistic 
similarities to neighbour suppression and highlight pathways with an alternative 
approach to those used in the last sections. 
To study the potential enrichment of gene set members amongst the GOI, 
GSEA software (Broad Institute, available for download at 
http://software.broadinstitute.org/gsea) was used.  
Two factors were of most importance when using this software for analysis of 
the GOI list. Firstly, GSEA was originally designed to work with expression data. 
Secondly, the software does not analyse repeated gene names. This last issue 
is usually solved inside the software by collapsing the observations with the 
same gene name into one consensus observation which is assigned either the 
mean or the median value of the observations. This was originally used for 
expression array data where a single gene may be analysed by more than one 
probe but is applicable to shRNA screening where a single gene is targeted by 
more than one sequence. However, the first problem requires more 
consideration as a two-fold increase in the metric inputted would be interpreted 
as a two-fold increase in expression. z-scores, as used in the screen, cannot be 
directly assimilated to changes in expression, and the differences in the 
distributions of z-scores in both co-culture samples suggest that they cannot 
approximate a change of phenotype as used by GSEA. 
To avoid using z-scores as expression data, the GSEA Preranked tool was 
used. This tool uses a list of user-ranked genes and analyses the enrichment of 
members of gene sets in both tails of the rank, but it does not use a numeric 
181 
 
value for anything apart from sorting the observations. To circumvent the 
problems arising from having several constructs targeting the same gene, 
constructs were ordered by their z-score and then duplicates were removed 
retaining the first construct to appear in the list and remove any repeats further 
down the list. This approach was deemed as the least stringent as it would 
favour extreme z-scores, however it is expected that extreme z-scores are 
produced by shRNA sequences with functional effects on gene expression. This 
approach could generate a bias by favouring positive z-scores when more 
extremely negative z-scores are present for the same gene, and so the 
absolute value of z-score was explored as an alternative metric to use to 
remove duplicates. As an alternative to these approaches using a metric to 
decide which constructs would remain in the dataset, alphabetic sorting by 
Excel was also considered. Lists were ordered alphabetically using the function 
implemented in Excel and duplicates were then removed as above. 
Two approaches were used to rank the constructs after removing duplicates. 
Initially, two lists were produced where genes were ranked on either 3T3supp+ or 
3T3supp- z-scores, and then analysed separately. To rank genes in an order that 
was consistent with the analysis method used, a new metric named “z-score 
distance” was calculated as the difference in z-score between 3T3supp+ and 
3T3supp-. 
GSEA Preranked outputs a report indicating the p-values for enrichment of the 
different gene sets analysed in the top or bottom of the GOI list. However, this is 
not equivalent to finding enrichment in the GOI list with respect to the genes 
screened but rather to enrichment of gene sets in high z-scores in a pre-defined 
list of GOI. With this in mind, the entire list of constructs screened was used as 
the GOI list, ordered as indicated above. The different analyses performed 
were: 
1) Genes screened, ranked by 3T3supp+ z-scores, duplicates removed using 
3T3supp+ z-scores. 
2) Genes screened, ranked by 3T3supp+ z-scores, duplicates removed using 
the absolute value of 3T3supp+ z-scores. 
3) Genes screened, ranked by 3T3supp+ z-scores, duplicates removed using 
the Excel alphabetical sorting. 
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4) Genes screened, ranked by 3T3supp- z-scores, duplicates removed using 
3T3supp- z-scores. 
5) Genes screened, ranked by 3T3supp- z-scores, duplicates removed using 
the absolute value of 3T3supp- z-scores. 
6) Genes screened, ranked by 3T3supp- z-scores, duplicates removed using 
the Excel alphabetical sorting. 
7) Genes screened, ranked by (3T3supp+-3T3supp-) z-scores, duplicates 
removed using (3T3supp+-3T3supp-) z-scores. 
8) Genes screened, ranked by (3T3supp+-3T3supp-) z-scores, duplicates 
removed using the absolute value of (3T3supp+-3T3supp-) z-scores. 
9) Genes screened, ranked by (3T3supp+-3T3supp-) z-scores, duplicates 
removed using the Excel alphabetical sorting. 
GSEA Preranked orders the input files by descending order, meaning that the 
constructs would be ordered from higher to lower z-score. Thus, gene sets were 
considered enriched in the 3T3supp+ GOI list in cases 1, 2 and 3 above if they 
were enriched on the top of the appropriate list (higher z-scores). Equivalently, 
gene sets were considered enriched in the 3T3supp- GOI list in cases 4, 5 and 6 
if they were enriched on the bottom of the appropriate list (lower z-scores). 
When analysis was performed using the differences in z-scores (cases 7, 8 and 
9 above), gene set enrichment was considered only at the top of the list as the 
bottom of the list would be composed of constructs with no effects. This ranking 
prioritizes gene sets enriched in constructs with an effect on both conditions. 
The enrichment analysis in 3T3supp+ identified 98 gene sets enriched in case 1 
(Table 3.38), 45 in case 2 (Table 3.39) and 101 in case 3 (Table 3.40). The 
overlap of the gene sets detected as being enriched with a p-value lower than 
0.05 is shown in Figure 3.35. The absolute (z-score) method is the most 
conservative, producing the lowest overlaps with the two other methods. Of all 
the gene sets that this method shares with the other two, only one gene set is 
shared between the absolute (z-score) results and only one of the other 
methods (z-score). This gene set is “KEGG_THYROID_CANCER” and its p-
value in the alphabetical method is 0.051. The gene sets identified using all 
three approaches (Table 3.41) include a mix of cancer-related terms and 
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various gene sets with no apparent relationship to each other. Although the 
apparent robustness of cancer gene sets may be encouraging it could also be a 
result of a high number of studies being focused in the identification of de-
regulated pathways in carcinogenesis. 
The enrichment analysis in 3T3supp- identified 130 gene sets enriched in case 4 
(Table 3.42), 86 in case 5 (Table 3.43) and 122 in case 6 (Table 3.44). Figure 
3.36 depicts the overlap of the gene sets determined as enriched in 3T3supp-. 
The absolute (z-score) method is again the most conservative with a lower 
number of gene sets detected as enriched. The overlap between the different 
combinations of methods is lower than for 3T3supp+, although the number of 
gene sets identified using all approaches (Table 3.45) is the same. There are 
less cancer-related gene sets, which may indicate that the gene set enrichment 
in 3T3supp+ is not totally derived from a high number of studies in cancer as 
suggested above. The list of enriched gene sets identified with all approaches 
in this case is more heterogeneous, with a higher number of “classical” 
pathways identified (i.e. pathways defined by KEGG, Reactome and Biocarta, 
susceptible of analysis with functional enrichment). These pathways include the 
Rac1 and TNF pathways amongst others. 
Using the difference in z-scores to rank the screened genes detected 147 gene 
sets enriched in the higher ranks of the list when duplicate gene names were 
resolved by removing the constructs with lower difference in z-scores (Table 
3.46, case 7). Using the absolute difference in z-score to remove duplicates 
(case 8), 156 gene sets were detected to be enriched in the top of the list 
(Table 3.47). In case 9 above, 181 gene sets were detected as enriched in 
constructs with high difference in z-scores (Table 3.48). The degree of overlap 
in enriched gene sets detected with these three methods (Figure 3.37) follows 
the same tendencies as the individual z-score methods: using the absolute 
difference in z-scores to remove duplicate gene names produces a list of 
enriched gene sets which overlap the least with the other two. Table 3.49 
contains the list of gene sets detected using all three methods. The list is again 
a mix of gene sets most of which do not have an apparent relationship. Two of 
the gene sets are cancer-related, one refers to cell death and two to signalling 
by GPCR. The gene sets found to be enriched using this difference of z-scores 
approach may represent an unspecific response mechanism to both 
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phenomena (response to suppressive cues and growth in absence of 
suppressive cues).
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Name of gene set p-value 
REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES <0.001 
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP <0.001 
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 <0.001 
KIM_MYCN_AMPLIFICATION_TARGETS_DN <0.001 
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN <0.001 
LIN_MELANOMA_COPY_NUMBER_DN 0.002 
WANG_BARRETTS_ESOPHAGUS_UP 0.002 
PID_PI3KCI_PATHWAY 0.004 
AKL_HTLV1_INFECTION_UP 0.006 
ASTON_MAJOR_DEPRESSIVE_DISORDER_DN 0.006 
Table 3.38. Top 10 enriched gene sets in 3T3supp+. Duplicate gene names were removed using their alphabetical order.  
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Name of gene set p-value 
REACTOME_TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES <0.001 
KIM_MYCN_AMPLIFICATION_TARGETS_DN <0.001 
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 <0.001 
LIN_MELANOMA_COPY_NUMBER_DN <0.001 
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP 0.002 
GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN 0.002 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S 0.004 
KEGG_VIBRIO_CHOLERAE_INFECTION 0.004 
JECHLINGER_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN 0.006 
PENG_LEUCINE_DEPRIVATION_UP 0.006 
Table 3.39. Top 10 enriched gene sets in 3T3supp+. Duplicate gene names were solved by removing the construct with the lowest 3T3 supp+ z-
score.
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Name of gene set p-value 
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 <0.001 
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_DN 0.002 
REACTOME_CLASS_B_2_SECRETIN_FAMILY_RECEPTORS 0.002 
LIN_MELANOMA_COPY_NUMBER_DN 0.004 
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS 0.004 
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP 0.004 
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_4HR 0.004 
PENG_LEUCINE_DEPRIVATION_UP 0.004 
ELLWOOD_MYC_TARGETS_DN 0.006 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S 0.006 
Table 3.40. Top 10 enriched gene sets in 3T3supp+. Duplicate gene names were solved by removing the construct with the lowest absolute 
3T3supp+ z-score.
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Figure 3.35. Venn diagram showing the overlapping results of the 3 methods used to 
analyse the 3T3supp+ results with GSEA.
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KIM_MYCN_AMPLIFICATION_TARGETS_DN 
MIKKELSEN_MCV6_ICP_WITH_H3K27ME3 
LIN_MELANOMA_COPY_NUMBER_DN 
KRIGE_RESPONSE_TO_TOSEDOSTAT_24HR_UP 
REACTOME_ACTIVATION_OF_CHAPERONE_GENES_BY_XBP1S 
PENG_LEUCINE_DEPRIVATION_UP 
BREDEMEYER_RAG_SIGNALING_VIA_ATM_NOT_VIA_NFKB_UP 
REACTOME_INWARDLY_RECTIFYING_K_CHANNELS 
ELLWOOD_MYC_TARGETS_DN 
KAYO_CALORIE_RESTRICTION_MUSCLE_UP 
SERVITJA_LIVER_HNF1A_TARGETS_DN 
MAGRANGEAS_MULTIPLE_MYELOMA_IGG_VS_IGA_DN 
KAMIKUBO_MYELOID_CEBPA_NETWORK 
RORIE_TARGETS_OF_EWSR1_FLI1_FUSION_DN 
ROZANOV_MMP14_TARGETS_DN 
RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_MODERATELY_DN 
SATO_SILENCED_BY_METHYLATION_IN_PANCREATIC_CANCER_1 
KYNG_ENVIRONMENTAL_STRESS_RESPONSE_NOT_BY_GAMMA_IN_WS 
KUMAR_AUTOPHAGY_NETWORK 
BIOCARTA_IGF1MTOR_PATHWAY 
SASSON_RESPONSE_TO_FORSKOLIN_UP 
REACTOME_G_ALPHA_S_SIGNALLING_EVENTS 
REACTOME_FORMATION_OF_TUBULIN_FOLDING_INTERMEDIATES_BY_CCT_
TRIC 
ZHANG_TLX_TARGETS_36HR_UP 
LINDSTEDT_DENDRITIC_CELL_MATURATION_D 
MODY_HIPPOCAMPUS_PRENATAL 
HU_GENOTOXIN_ACTION_DIRECT_VS_INDIRECT_4HR 
Table 3.41. Gene sets identified by GSEA as enriched in the 3T3supp+ co-culture results 
using three different duplicate gene name removal systems. 
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Name of gene set p-value 
BIOCARTA_NFKB_PATHWAY <0.001 
PID_RAC1_PATHWAY <0.001 
DAIRKEE_CANCER_PRONE_RESPONSE_BPA_E2 <0.001 
REACTOME_INNATE_IMMUNE_SYSTEM <0.001 
PID_BCR_5PATHWAY 0.002 
FORTSCHEGGER_PHF8_TARGETS_UP 0.002 
VERHAAK_GLIOBLASTOMA_NEURAL 0.002 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 0.002 
BILANGES_SERUM_RESPONSE_TRANSLATION 0.002 
RAO_BOUND_BY_SALL4_ISOFORM_B 0.002 
Table 3.42. Top 10 enriched gene sets in 3T3supp-. Duplicate gene names were removed 
using their alphabetical order
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Name of gene set p-value 
BIOCARTA_PPARA_PATHWAY <0.001 
REACTOME_INNATE_IMMUNE_SYSTEM <0.001 
BIOCARTA_KERATINOCYTE_PATHWAY <0.001 
VANHARANTA_UTERINE_FIBROID_DN <0.001 
BIOCARTA_RACCYCD_PATHWAY <0.001 
PID_TNF_PATHWAY 0.002 
RAO_BOUND_BY_SALL4_ISOFORM_B 0.002 
PID_AVB3_OPN_PATHWAY 0.002 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 0.002 
VERHAAK_GLIOBLASTOMA_NEURAL 0.004 
Table 3.43. Top 10 enriched gene sets in 3T3supp-. Duplicate gene names were solved by 
removing the construct with the highest 3T3supp- z-score 
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Name of gene set p-value 
PID_TNF_PATHWAY <0.001 
PID_CDC42_PATHWAY <0.001 
BIOCARTA_NFKB_PATHWAY <0.001 
KUROKAWA_LIVER_CANCER_CHEMOTHERAPY_DN <0.001 
ST_TUMOR_NECROSIS_FACTOR_PATHWAY <0.001 
PID_PRL_SIGNALING_EVENTS_PATHWAY <0.001 
ACEVEDO_FGFR1_TARGETS_IN_PROSTATE_CANCER_MODEL_UP <0.001 
REACTOME_INNATE_IMMUNE_SYSTEM 0.002 
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 0.002 
LIEN_BREAST_CARCINOMA_METAPLASTIC 0.002 
Table 3.44. Top 10 enriched gene sets in 3T3supp-. Duplicate gene names were solved by removing the construct with the highest absolute 
3T3supp- z-score. 
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Figure 3.36. Venn diagram showing the overlapping results of the 3 methods used to 
analyse the 3T3supp- results with GSEA. 
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BIOCARTA_PPARA_PATHWAY 
REACTOME_INNATE_IMMUNE_SYSTEM 
BIOCARTA_KERATINOCYTE_PATHWAY 
VANHARANTA_UTERINE_FIBROID_DN 
BIOCARTA_RACCYCD_PATHWAY 
PID_TNF_PATHWAY 
PID_AVB3_OPN_PATHWAY 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 
VERHAAK_GLIOBLASTOMA_NEURAL 
KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY 
PID_RAC1_PATHWAY 
PID_CDC42_PATHWAY 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_1 
ST_TUMOR_NECROSIS_FACTOR_PATHWAY 
SENESE_HDAC3_TARGETS_UP 
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING 
LIAN_LIPA_TARGETS_3M 
WOOD_EBV_EBNA1_TARGETS_DN 
PID_S1P_S1P1_PATHWAY 
COULOUARN_TEMPORAL_TGFB1_SIGNATURE_UP 
ZHANG_TLX_TARGETS_60HR_DN 
SIG_CD40PATHWAYMAP 
PLASARI_TGFB1_SIGNALING_VIA_NFIC_1HR_DN 
TING_SILENCED_BY_DICER 
BIOCARTA_TOLL_PATHWAY 
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR
4_SIGNALING_REPERTOIRE 
BILANGES_SERUM_RESPONSE_TRANSLATION 
Table 3.45. Gene sets identified by GSEA as enriched in the 3T3 supp- co-culture results 
using three different duplicate gene name removal systems. 
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NAME P-value 
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE <0.001 
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN <0.001 
REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE <0.001 
KEGG_MAPK_SIGNALING_PATHWAY <0.001 
KEGG_CELL_CYCLE <0.001 
BIOCARTA_MAPK_PATHWAY <0.001 
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING 0.002 
BIOCARTA_TOLL_PATHWAY 0.002 
BURTON_ADIPOGENESIS_10 0.002 
ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS 0.002 
Table 3.46. Top 10 enriched gene sets enriched in the shRNA constructs with higher z-score differences between co-culture samples. 
Duplicate gene names were solved by removing the construct with the lowest difference in z -scores.
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NAME P-value 
KEGG_PURINE_METABOLISM <0.001 
REACTOME_NEURONAL_SYSTEM <0.001 
LIAN_LIPA_TARGETS_6M <0.001 
LIAN_LIPA_TARGETS_3M <0.001 
REACTOME_MHC_CLASS_II_ANTIGEN_PRESENTATION <0.001 
REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNSTREAM_TRANSMISSION_IN_T
HE_POSTSYNAPTIC_CELL 
<0.001 
REACTOME_GAP_JUNCTION_TRAFFICKING <0.001 
REACTOME_TRANSMISSION_ACROSS_CHEMICAL_SYNAPSES <0.001 
KEGG_LYSOSOME <0.001 
REACTOME_POTASSIUM_CHANNELS <0.001 
Table 3.47. Top 10 enriched gene sets enriched in the shRNA constructs with higher z-score differences between co-culture samples. 
Duplicate gene names were solved by removing the construct with the lowest absolute difference in z -scores 
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NAME P-value 
REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE <0.001 
REACTOME_NFKB_AND_MAP_KINASES_ACTIVATION_MEDIATED_BY_TLR4_SIGNALING_REPERTOIRE <0.001 
REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK <0.001 
BIOCARTA_RAS_PATHWAY <0.001 
COLIN_PILOCYTIC_ASTROCYTOMA_VS_GLIOBLASTOMA_DN <0.001 
ST_DIFFERENTIATION_PATHWAY_IN_PC12_CELLS <0.001 
REACTOME_TRIF_MEDIATED_TLR3_SIGNALING <0.001 
REACTOME_ABC_FAMILY_PROTEINS_MEDIATED_TRANSPORT <0.001 
SA_B_CELL_RECEPTOR_COMPLEXES <0.001 
KEGG_MAPK_SIGNALING_PATHWAY <0.001 
Table 3.48. Top 10 enriched gene sets enriched in the shRNA constructs with higher z-score differences between co-culture samples. 
Duplicate gene names were solved by removing the construct with their alphabetical order.
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Figure 3.37. Venn diagram showing the overlapping results of the 3 methods used to 
analyse the z-score difference results with GSEA
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REACTOME_CELL_DEATH_SIGNALLING_VIA_NRAGE_NRIF_AND_NADE 
KEGG_MAPK_SIGNALING_PATHWAY 
REACTOME_NRAGE_SIGNALS_DEATH_THROUGH_JNK 
RODRIGUES_THYROID_CARCINOMA_DN 
REACTOME_SIGNALING_BY_GPCR 
REACTOME_GPCR_DOWNSTREAM_SIGNALING 
KEGG_GNRH_SIGNALING_PATHWAY 
REACTOME_ION_CHANNEL_TRANSPORT 
REACTOME_P75_NTR_RECEPTOR_MEDIATED_SIGNALLING 
BIOCARTA_CREB_PATHWAY 
REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMEN
T_AND_PLATELET_PRODUCTION 
LE_EGR2_TARGETS_UP 
LIN_MELANOMA_COPY_NUMBER_DN 
REACTOME_NEUROTRANSMITTER_RECEPTOR_BINDING_AND_DOWNS
TREAM_TRANSMISSION_IN_THE_POSTSYNAPTIC_CELL 
LIAN_LIPA_TARGETS_3M 
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM 
Table 3.49. Gene sets identified by GSEA as enriched in the z-score difference results 
using three different duplicate gene name removal systems
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3.3.12. Transcription factor binding site enrichment analysis of GOI 
Transcription factors are DNA binding proteins that regulate gene expression. 
They recognize and bind to certain DNA sequences in the vicinity of the genes 
whose expression they regulate. A transcription factor may regulate the 
expression of many genes, some of which might be involved in a common 
mechanism. Therefore, transcription factors were investigated as possible 
regulators of the response to neighbour suppression in tumorigenic cells. 
OPOSSUM 3.0 (http://opossum.cisreg.ca/oPOSSUM3/) was used to investigate 
whether there were any transcription factors regulating more genes in the GOI 
list than what was expected by chance. The “Mouse Single Site Analysis” option 
was used. The GOI list for 3T3supp+ and 3T3supp- were used as the target genes, 
and the background was set to the list of genes for which at least one targeting 
sequence was analysed. All parameters were kept to their default options. 
OPOSSUM calculates a z-score and a Fisher score as enrichment statistics. 
The z-score for a transcription factor indicates how far the number of binding 
sites in the GOI list for that transcription factor is from the expected number of 
binding sites given the number of binding sites in the background list. In 
essence, a highly positive z-score indicates that the GOI list is enriched in 
binding sites for a transcription factor. On the contrary, a negative z-score 
indicates that there are less binding sites than expected. The Fisher score is 
calculated similarly but it does not take into account that genes might have 
more than one binding site for a transcription factor. Rather, it considers the 
presence of binding sites for a transcription factor as a binary event: a gene 
either has no binding sites for the transcription factor under consideration or it 
has at least one. Fisher scores were used for assessment of enrichment as the 
aim of this analysis was to find transcription factors that could regulate the 
expression of a higher number of genes than expected without taking into 
consideration the existence of multiple binding sites in the GOI. There is no 
formal statistical method of assessment of enrichment in OPPOSUM so this 
needs to be considered for each of the analyses performed. 
Results were ranked by Fisher scores. Table 3.50 contains the 10 transcription 
factors with the highest Fisher scores in the 3T3supp+ GOI list. OPPOSSUM 
recommends visualizing the distribution of the transcription factors z-scores 
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against the GC composition of their binding sites as a clustering on any of the 
extremes (high or low GC content) may be an indicative of a bias in analysis 
produced by a differential composition in binding sites in the background used 
(the screened genes in this case). The website provides this graphical 
representation. For the 3T3supp+ (Figure 3.38) there is no evident bias and the 
graphical representation indicates that the transcription factor with the highest 
Fisher score (Zfp423) is separate from the rest of the transcription factors 
detected as potentially enriched. 
The 10 transcription factors with the highest Fisher score in the 3T3supp- GOI list 
are listed in Table 3.51. The graphical representation as explained above is 
available on Figure 3.39. In this case, the two transcription factors with the 
highest Fisher score (ELK4 and EBF1) apparently cluster separate from the rest 
transcription factors again without an apparent bias in GC composition. Zfp423 
has a low Fisher score (0.256), which may suggest a difference in 
transcriptional regulation of the 3T3supp- and 3T3supp+ GOIs and points to 
different mechanisms being involved as also suggested by the functional and 
gene set enrichment data. The Fisher scores for ELK4 and EBF1 are not as low 
in 3T3supp+ however: EBF1 has a Fisher score of 3.688 and is included in the 
top 10 and ELK4 has a Fisher score of 1.572. 
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Name Class Family Target 
gene hits 
Target gene 
non-hits 
Background 
gene hits 
Background 
gene non-hits 
Z-score Fisher 
score 
Zfp423 Zinc-coordinating BetaBetaAlpha-zinc 
finger 
102 153 3015 6840 2.960 6.877 
FOXD1 Winged Helix-Turn-
Helix 
Forkhead 199 56 7023 2832 5.837 4.646 
ELK1 Winged Helix-Turn-
Helix 
Ets 196 59 6942 2913 -3.223 4.251 
FOXA1 Winged Helix-Turn-
Helix 
Forkhead 199 56 7132 2723 2.598 3.695 
EBF1 Zipper-Type Helix-Loop-Helix 170 85 5956 3899 -1.422 3.688 
Egr1 Zinc-coordinating BetaBetaAlpha-zinc 
finger 
98 157 3201 6654 0.363 3.585 
Gata1 Zinc-coordinating  GATA 207 48 7515 2340 4.613 3.285 
GABPA Winged Helix-Turn-
Helix 
Ets 140 115 4862 4993 -4.405 3.095 
TEAD1 Helix-Turn-Helix Homeo 83 172 2739 7116 2.795 2.878 
Esrrb Zinc-coordinating Hormone-nuclear 
Receptor 
158 97 5606 4249 -0.967 2.818 
Table 3.50. Top 10 enriched transcription factors (ranked by Fisher scores) in the 3T3 supp+ GOI list according to OPOSSUM 
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Figure 3.38. Distribution of Fisher scores for the transcript ion factors analyzed by 
OPOSSUM and the percentage of GC in their binding sites for the 3T3 supp+ GOI list.  
The red line indicates a threshold set by OPOSSUM for graphical representation which 
may vary between samples. In this case, the threshold chosen is  1 standard deviation 
from the mean Fisher score for the transcription factors.
204 
 
Name Class Family Target 
gene hits 
Target gene 
non-hits 
Background 
gene hits 
Background 
gene non-hits 
Z-score Fisher 
score 
ELK4 Winged Helix-
Turn-Helix 
Ets 116 180 3258 6597 4.707 4.08 
EBF1 Zipper-Type Helix-Loop-
Helix 
197 99 5956 3899 -2.261 3.97 
NFKB1 Ig-fold Rel 68 228 1880 7975 5.589 2.868 
GABPA Winged Helix-
Turn-Helix 
Ets 159 137 4862 4993 2.863 2.566 
USF1 Zipper-Type Helix-Loop-
Helix 
162 134 4964 4891 0.071 2.553 
PPARG::
RXRA 
Zinc-
coordinating 
Hormone-
nuclear 
Receptor 
112 184 3335 6520 2.089 2.449 
Foxa2 Winged Helix-
Turn-Helix 
Forkhead 198 98 6297 3558 8.814 1.835 
RUNX1 Ig-fold Runt 229 67 7360 2495 4.156 1.808 
Zfx Zinc-
coordinating 
BetaBetaAlpha-
zinc finger 
158 138 4960 4895 1.891 1.803 
ESR1 Zinc-
coordinating 
Hormone-
nuclear 
Receptor 
8 288 175 9680 4.636 1.796 
Table 3.51. Top 10 enriched transcription factors (ranked by Fisher scores) in the 3T3 supp- GOI list according to OPOSSUM
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Figure 3.39. Distribution of Fisher scores for the transcription factors analyzed by 
OPOSSUM and the percentage of GC in their binding sites for the 3T3 supp- GOI list.  
The red line indicates a threshold set by OPOSSUM for graphical representation which 
may vary between samples. In this case, the threshold chosen is 1 standard deviation 
from the mean Fisher score for the transcription factors
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3.3.13. Confirmation of gene knock-down effects on neighbour 
suppression 
RNAi screens are known to produce a high number of false positives. It was 
therefore imperative to re-test the effect of GOI gene knockdown on neighbour 
suppression. A list of genes to be confirmed was built based on different criteria. 
Genes selected for confirmation are listed in Table 3.52. 
Firstly, genes from the 3T3supp+ and the 3T3supp- GOI lists were selected if two 
targeting sequences had been included in the relevant GOI list and at least one 
of the targeting sequences was in the top 10 targeting sequences with the 
biggest effects as approximated by their z-score. This was the case for Rrp7a in 
3T3supp- and Ttbk1, Cd5l, Snap23 and Coa3 in 3T3supp+. 
Next, genes were included in the confirmation list based on their z-scores. Ten 
genes were selected from the 3T3supp- GOI list and eight from the 3T3supp+ GOI 
list using this approach. 
Upon network analysis using STRING, three additional genes were added to 
the list of genes to be confirmed based on the apparent high number of genes 
in the GOI list they interacted with. Two of these genes (Tp53 and Wt1) were 
part of the 3T3supp+ GOI list and one (Rac1) belonged to the 3T3supp- GOI list. 
Three genes were added to the list of confirmations after network analysis using 
FunCoup.  
When possible, shRNA constructs were designed using targeting sequences 
already published with available data about their knockdown efficiency. This 
was not the case for most of the genes, for which no knockdown literature 
existed. In that case, the RNAi Consortium website was used to search for 
targeting sequences. If no sequences were available they were designed using 
the same website. The plasmid containing a Tp53 shRNA targeting sequence 
and a control plasmid with a shRNA construct targeting Firefly Luciferase 
(referred to as FF below) were obtained from Addgene (Tp53 plasmid #19751 
and FF plasmid #19744). The plasmid containing the targeting sequence for 
Wt1 and its control (targeting LacZ) were a gift from Dr Abdelkader Essafi 
(University of Bristol). For Rac1, a plasmid expressing a human dominant 
negative form of RAC1, Rac1-T17N (commonly named Rac1N17) and another 
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expressing a constitutively active form of the protein, Rac1-G12V (Rac1V12) 
were obtained from Dr Fabio Luis Forti (University of Sao Paulo). Table 3.53 
has information about the different plasmids used. For all plasmids cloned into 
the pSuperRetroRuro vector a scrambled negative control was available. Empty 
cells (not transduced) were also used as a control for transduction effects. 
Plasmids were delivered to the tumorigenic cells using viral particles. Wt1 and 
LacZ targeting sequences were cloned into a lentiviral rather than a retroviral 
vector. As Phoenix cells can only produce retroviral particles, 293T cells were 
used for lentiviral packaging of Wt1 and LacZ plasmids. The lentiviral packaging 
plasmids 8.91 and DMD were obtained from Dr Giles Cory (University of 
Exeter). 293T cells were co-transduced with both packaging plasmids and 
either Wt1 or LacZ. Delivery of the viral particles to SVE-6 was performed 
following the optimized protocols for retroviral transductions. 
Stable cell lines were derived by antibiotic selection of clones containing each 
plasmids. All vectors except for pCM, containing the Rac1N17 or Rac1V12 
provided resistance to puromycin to cells upon integration. The selection marker 
for pCM in mammalian cells is gentamycin, so SVE-6 cells were selected using 
G418. 
To assess the effect that the reduction of expression of the GOI had on 
neighbour suppression, the derived cell lines were plated on top of monolayers 
of 3T3supp+ and 3T3supp-. Cells were cultured for 7 days and then fixed using 4% 
paraformaldehyde. Selecting which colonies to take pictures of was identified as 
a potential source of bias. Therefore, a systematic approach was designed. 
Each well of the 6-well plates was scanned on a Leica Widefield microscope 
using an automated scanning protocol in the Leica LasX software which 
produced a tile-scan composed of 100 pictures with a 5x objective. The pictures 
were merged together using ImageJ to produce an individual picture per well. 
All pictures were processed in ImageJ before colony quantification using the 
same approach: 
“Unsharp mask” with radius=1 and mask=0.60 
“Subtract Background” with rolling=50 
“Auto Threshold” with method=Default white 
“Make Binary” 
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An example of this processing pipeline is shown in Figure 3.40. 
The binary pictures obtained at the end of the pre-processing pipeline were then 
used to quantify the size of the colonies. A method of quantification was devised 
that could produce comparable results between technical and biological 
replicates. A degree of variability on degree of suppression had been observed 
before between monolayers formed from the same or different cell stocks of the 
same cell line. It was therefore reasoned that an absolute quantification of 
colony size would not be adequate. A normalization method was needed to 
allow a comparison between replicates and thus a control well, with non-
transduced cells, was present in all experiments.  
The shape of the SVE-6 colonies is also variable, which limits the viability of an 
accurate surface area calculation. It was reasoned that a method was needed 
where a constant surface was interrogated for GFP presence, producing a 
percentage of surface containing GFP positive cells (SVE-6). As it had been 
previously observed that a colony on a certain stock of 3T3supp- had a size 
approximating the surface area of a 20x objective picture, this was used as the 
measurement area. A square of that size was drawn in ImageJ using the 
command “Specify...”. The square was placed on the centre of each colony 
present in the picture to obtain the regions of interest (ROI), and the percentage 
of GFP positive area was then calculated for each ROI using the “Measure” 
command.  
The percentage of GFP positive area for all the ROI in each well were imported 
into GraphPad for graphical interpretation. 
Two replicates were performed for the first set of clones designed from the 
initial z-score list and STRING analysis. The results of the first replicate are 
depicted in Figure 3.41 for the 3T3supp+ co-cultures and Figure 3.42 for the 
3T3supp- co-cultures. It can be seen that the control conditions (SVE-6 cells 
either un-transduced or transduced with a scrambled targeting sequence) 
produce smaller colonies when plated on 3T3supp- , which makes interpretation 
difficult. However, it is still possible to see a difference in the colony size of 
some clones (Flt4, Rrp7a, Cd5l and Ttbk1) compared with the rest of the clones. 
On the 3T3supp+ co-culture, the same tendency of the controls to be smaller than 
the clones is still maintained. Within the clones selected for confirmation from 
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the GOI list, Sh3px2bd, Psma7, Ttll1, Gab2, Plxnb3 and Serpinb3 seem to have 
a higher median colony size than the rest. 
A second replicate was performed on both co-culture conditions. This replicate 
included the genes under examination in the first replicate and three new genes: 
Rac1, p53 and Wt1. 
Results of the second replicate on the 3T3supp- are represented in Figure 3.44. 
In this case control wells were not available due to problems in the culture of the 
control cell lines and therefore a comparison amongst the different clones is 
necessary to evaluate the effect of the targeting sequences. Similarly to the first 
replicate in Figure 3.41, Flt4, Rrp7a and Ttbk1 appear to have a lower median 
than other clones, although that is not the case with Cd5l, which had been 
identified in the first replicate. Rac1 was tested with an expression vector 
containing a dominant negative form of RAC1 (RAC1N17) and a constitutively 
active form (RAC1V12). Both forms seem to produce smaller colonies than the 
targeting sequences used in pSuperRetroPuro. However, no specific negative 
control was available for comparison. Similarly, both p53 and Wt1 appear to 
reduce the colony size slightly compared to their own controls (firefly luciferase, 
labelled “FF” and LacZ respectively).  
In the case of the 3T3supp+ co-culture, the second replicate (Figure 3.43) agrees 
only partially with the first replicate. Sh3px2bd still appears to have increased 
the colony size, but the rest of the effects seen in the first replicated are not 
apparent. The targeting sequence against Snap23 appears to have increased 
the colony size greatly. However, the same effect is present in the 3T3supp- co-
culture (Figure 3.44) and upon manual inspection of the well it is evident that a 
very high density of SVE-6 cells transduced with that targeting sequence were 
plated in the well which might have confounded the analysis. Strikingly, LacZ 
appears to have increased the colony size greatly as well, and given that the 
number of colonies identified in that well is also higher than the number of 
colonies in most of the other wells it is possible that the same “over-plating” 
situation has confounded the results of this control targeting sequence. 
A third experiment was performed to include the GOI selected from the 
FunCoup network analysis and including some of the genes already included in 
the first replicates. Figure 3.45 represents the results for this third experiment in 
3T3supp+. Nptxr knockdown appears to have an effect on colony size and so 
210 
 
does the constitutively active form of RAC1 (RAC1V12). In this last case a high 
number of colonies were detected which may indicate a contribution of high 
plating density to the detected effect of this form of RAC1 
A third replicate of the 3T3supp- (Figure 3.46) suggests that the knockdown of 
Twf2 in SVE6 cells reduces the size of colonies, an effect also produced by the 
expression of a dominant negative form of RAC1 (RAC1N17). 
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Gene Condition Selection method 
Abcd1 3T3supp- Z-score 
Atp8a2 3T3supp- Z-score 
Btbd6 3T3supp- Z-score 
Flt4 3T3supp- Z-score 
Gab2 3T3supp- Z-score 
Impa1 3T3supp- Z-score 
Plxnb3 3T3supp- Z-score 
Pmvk 3T3supp- Z-score 
Rrp7a 3T3supp- Z-score 
Serpinb3a 3T3supp- Z-score 
Rac1 3T3supp- STRING network analysis 
Rps5 3T3supp- FunCoup network analysis 
Cd5l 3T3supp+ Z-score 
Cdc73 3T3supp+ Z-score 
Coa3 3T3supp+ Z-score 
Myocd 3T3supp+ Z-score 
Plxna4 3T3supp+ Z-score 
Psma7 3T3supp+ Z-score 
Sh3pxd2b 3T3supp+ Z-score 
Snap23 3T3supp+ Z-score 
Ttbk1 3T3supp+ Z-score 
Ttll1 3T3supp+ Z-score 
Wisp1 3T3supp+ Z-score 
Zeb2 3T3supp+ Z-score 
Wt1 3T3supp+ STRING network analysis 
Tp53 3T3supp+ STRING network analysis 
Twf2 3T3supp+ FunCoup network analysis 
Nptxr 3T3supp+ FunCoup network analysis 
Table 3.52. Genes selected for confirmation in both co-culture conditions.
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Gene Vector Source 
Abcd1 pSuperRetroPuro The RNAi Consortium 
Atp8a2 pSuperRetroPuro (Xu, Yang et al. 2012) 
Btbd6 pSuperRetroPuro The RNAi Consortium 
Cd5l pSuperRetroPuro The RNAi Consortium 
Cdc73 pSuperRetroPuro The RNAi Consortium 
Coa3 pSuperRetroPuro The RNAi Consortium 
Flt4 pSuperRetroPuro The RNAi Consortium 
Gab2 pSuperRetroPuro (Huang, Tong et al. 2008) 
Impa1 pSuperRetroPuro The RNAi Consortium 
Myocd pSuperRetroPuro The RNAi Consortium 
Plxna4 pSuperRetroPuro (Okada and Tomooka 2013) 
Plxnb3 pSuperRetroPuro The RNAi Consortium 
Pmvk pSuperRetroPuro The RNAi Consortium 
Psma7 pSuperRetroPuro The RNAi Consortium 
Rrp7a pSuperRetroPuro (Maserati, Dai et al. 2014) 
Serpinb3a pSuperRetroPuro The RNAi Consortium 
Sh3pxd2b pSuperRetroPuro The RNAi Consortium 
Snap23 pSuperRetroPuro (Yatsu, Ohbayashi et al. 2013) 
Ttbk1 pSuperRetroPuro The RNAi Consortium 
Ttll1 pSuperRetroPuro The RNAi Consortium 
Wisp1 pSuperRetroPuro The RNAi Consortium 
Zeb2 pSuperRetroPuro The RNAi Consortium 
RAC1N17 pCM (Espinha, Osaki et al. 2015) 
RAC1V12 pCM (Espinha, Osaki et al. 2015) 
Wt1 pLenti (Essafi, Webb et al. 2011) 
LacZ pLenti (Essafi, Webb et al. 2011) 
p53 MSCV P2Gm (Stern, Astrof et al. 2008) 
FF MSCV P2Gm (Stern, Astrof et al. 2008) 
Twf2 pSuperRetroPuro The RNAi Consortium 
Nptxr pSuperRetroPuro The RNAi Consortium 
Rps5 pSuperRetroPuro (O’Donohue, Choesmel et al. 2010) 
Table 3.53. Genes selected for confirmation, vectors in which the sequences were cloned 
and source of the sequences or plasmids for each one.
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Figure 3.40. Example of the steps in the image processing pipeline.  
1) Original merged tilescan. 2) Image in 1 after “Unsharp mask” was applied. 3) Image in 2 after “Subtract background”. 4) Im age in 3 after 
“Auto threshold”. 5) Image in 4 after “Make binary”. 6) Image in 6 with the colonies marked for quantification (yellow squares with colony 
number in white).
1) 3) 
5) 6) 4) 
2) 
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Figure 3.41. Percentages of GFP positive area in the ROI in a replicate on 3T3supp+ monolayers.  
The labels in the X axis correspond to the genes against which the targeting sequences were designed. Sve6 are untransduced c ells and 
Scrambled, cells transduced with a pSuperRetroPuro plasmid containing a scrambled targeting sequencin g. Datasets plotted in blue are those 
genes which were identified in the 3T3supp+ GOI list. Genes with data represented by black dots were identified in the 3T3 supp- GOI list. Red 
bars represent the median and interquartile range. 
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Figure 3.42. Percentages of GFP positive area in the ROI in a replicate on 3T3 supp- monolayers.  
The labels in the X axis correspond to the genes against which the targeting sequences were designed. Sve6 are untransduced cells and 
Scrambled, cells transduced with a pSuperRetroPuro plasmid containing a scrambled targeting sequencing. Datasets plotted in g reen are 
those genes which were identified in the 3T3supp- GOI list. Genes with data represented by black dots were identified in the 3T3supp+ GOI list. 
Red bars represent the median and interquartile range.
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Figure 3.43. Percentages of GFP positive area in the ROI in the second replicate on 3T3supp+ monolayers.  
The labels in the X axis correspond to the genes against which the targeting sequences were designed. Datasets in green are t he control for 
the dataset in black on their right (Lacz is the control plasmid for Wt1 and FF is the  control plasmid for p53). Datasets plotted in blue are those 
genes which were identified in the 3T3sup+- GOI list. Genes with data represented by black dots were identified in the 3T3 supp-T GOI list. Red 
bars represent the median and interquartile range. 
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Figure 3.44. Percentages of GFP positive area in the ROI in the second replicate on 3T3 supp- monolayers.  
The labels in the X axis correspond to the genes against which the target ing sequences were designed. Datasets in blue are the control for 
the dataset in black on their right (Lacz is the control plasmid for Wt1 and FF is the control plasmid for p53). Datasets plo tted in green are 
those genes which were identified in the 3T3supp- GOI list. Genes with data represented by black dots were identified in the 3T3 supp+ GOI list. 
Red bars represent the median and interquartile range.
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Figure 3.45. Percentages of GFP positive area in the ROI in the third replicate on 3T3 supp+ monolayers.  
The labels in the X axis correspond to the genes against which the targeting sequences were designed. Sve6 are un -transduced cells and 
Scrambled, cells transduced with a pSuperRetroPuro plasmid containing a scrambled targeting sequencing. Datasets plotted in blue are those 
genes which were identified in the 3T3supp+ GOI list. Genes with data represented by black dots were identified in the 3T3 supp- GOI list or are 
controls. Red bars represent the median and interquartile range.
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Figure 3.46 Percentages of GFP positive area in the ROI in the third replicate on 3T3 supp- monolayers.  
The labels in the X axis correspond to the genes against which the targeting sequences were designed. Sve6 are un -transduced cells and 
Scrambled, cells transduced with a pSuperRetroPuro plasmid containing a scrambled targeting sequencing. Datasets plotted in g reen are 
those genes which were identified in the 3T3supp- GOI list. Genes with data represented by black dots were identified in the 3T3 supp+ GOI list or 
are controls. Red bars represent the median and interquartile range.
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3.3.14. Study of differential survival rates for levels of expression of genes 
identified as potential effectors 
To perform an independent validation of the GOI lists and produce an initial 
assessment of the potential of the screen to be translated into human cancer 
biology, an approach was sought to evaluate the effect of changes in 
expression of the GOI in human tumours. 
Most cancers are epithelial in nature and therefore the use of a fibroblast in vitro 
model adds a potential complication to the extrapolation of the results to human 
biology. However, the study of gene expression of the GOI in different tumours 
may provide an insight into subsets of genes which can be altering tumour 
development or growth using a mechanism similar to the observed in this in 
vitro model. Additionally, if neighbour suppression is, as hypothesized, present 
in various cell types then the mechanisms will be observed in both epithelial 
and fibroblast systems. Furthermore, fibroblasts have been used to obtain 
molecular mechanisms in other aspects of cancer biology such as the signalling 
downstream of various oncogenes, studied in mouse embryonic fibroblasts. 
Numerous studies have attempted to use tumour expression data to predict 
prognosis of cancer patients. A few of these studies (see section 3.2.9) were 
available for analysis in-house using an R script. The files and the script were 
provided by Dr Sara Vowler (University of Cambridge). The script investigates a 
gene list provided by the user and correlates the expression level of that gene 
in the expression dataset specified with the survival rate of the patients. If a 
significant difference in terms of survival is found between high and low 
expression levels, the script then looks for the point of inflexion where that 
difference starts. The script outputs a number of files containing the results of 
the test for each gene, and for each gene that has come up as having a 
significant effect it produces a survival curve. Although net survival can be used 
as an output when dealing with clinical data, the aim of this screen was to 
identify genes potentially involved in early steps of tumorigenesis. Upon 
evaluation of the available outcomes, the script was therefore configured to look 
for effects on distant metastasis free survival. It was reasoned that the 
establishment of tumorigenic cells in a new niche after metastasis would most 
closely resemble the situation studied here, where a tumorigenic cell is found 
surrounded by non-tumorigenic neighbours. Although both situations differ, 
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most basically due to the homotypic interactions in neighbour suppression 
compared to heterotypic interactions after metastasis, the mechanisms of 
neighbour suppression may still be applicable. 
For the same reason and when possible, only primary or low stage tumour 
samples were used to increase relevance to early cancer development. In some 
datasets, this cut-off produced small subsamples without enough power to 
detect differences and therefore the entire dataset was used. Eight sub-
datasets were produced from the original datasets. The sub-datasets and the 
parameters used to create them are specified in Table 3.54. 
To search for correlation of the expression level of the GOI with metastasis free 
survival of cancer patients in these sub-datasets, the GOI lists had to be used 
as input files for the script. However the expression data is for human genes. 
The gene symbols were converted into their human sequence homologs as 
explained in 3.3.11.4.  
Expression data was not available for all genes in the GOI lists in all datasets: 
244 (of 277 GOI) genes in the 3T3supp+ GOI list were assigned a human 
homologue. Of those, 229 had at least 1 probe in Taylor, 173 in Shedden and 
Desmedt and 215 in Loi. From the 3T3supp- GOI list, 297 (of 308 GOI) genes 
were assigned a human gene name, of which 262 had at least 1 probe in 
Taylor, 195 in Shedden and Desmedt and 249 in Loi. 
The numbers of genes found to be statistically associated with metastasis-free 
survival in each dataset for each screening condition and for the library are 
specified in Table 3.55. Genes were considered associated only if the direction 
of effect was consistent with the direction predicted by the screen. As the 
knockdown of the GOI in 3T3supp+ produced an increment on cell number, 
higher expression of the genes was expected to be beneficial in patient 
metastasis-free survival. Conversely, only genes where a higher expression 
was detrimental to metastasis-free survival were considered to be associated in 
the 3T3supp- GOI list. The survival curves for some of these genes are shown in 
Figure 3.47 (3T3supp-) and Figure 3.48 (3T3supp+). 
To investigate the functional relevance of the GOI according to this expression 
approach, a score was given to genes in the GOI lists according to how many 
datasets they were found to be significant in. The top 10 genes are listed in 
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Table 3.56 (3T3supp+) and Table 3.57 (3T3supp-). Genes were ordered first by the 
number of datasets in which they were found to be associated with disease 
progression. In both GOI lists, the maximum number of datasets where a single 
gene was found to be statistically associated with disease progression was 3 (5 
genes in 3T3supp+ and 7 in 3T3supp-). From the 3T3supp+ GOI list, 19 genes were 
associated with disease progression in 2 datasets. These genes were ordered 
by increasing sum of p-values for the relevant datasets and the 5 genes with 
the lowest sum were included in the top 10. The same process was applied for 
the 3T3supp- GOI list. 
The relevance of the number of GOI for which expression levels correspond 
with survival in human patients is difficult to assess without comparing them to 
the number of screened genes which are also correlated. To investigate the 
probability of such a number of genes to be associated in these datasets if the 
GOI lists were random subsets of screened genes rather than genes with 
functional importance, a random sampling approach similar to that used in 
section 3.3.10.3 was implemented. 
First, the list of screened genes was used as the input gene list for the recursive 
partitioning script. The list of human homologs available from 3.3.11.4 was used 
as input. Similarly to the GOI, not all genes had expression data in all datasets. 
6,962 genes had probes in Taylor; 8,561 in Shedden and Desmedt (100% 
overlap); and 10,608 in Loi. 
A Python script was then written to produce random samples of constructs from 
the shRNA library of the same size as the GOI. The script then looked those 
genes up in the different expression dataset results for the library and counted 
the number of genes that were found to have a significant effect on distant 
metastasis free survival. These numbers were then compared to the results 
found using the GOI lists. 
Results from this random sampling approach are shown in Figure 3.49 
(3T3supp+) and Figure 3.50 (3T3supp-). The 3T3supp+ GOI list was found to be 
significantly enriched in genes whose expression level affected distant 
metastasis free survival in expression datasets Shedden, Loi_tamoxifen and 
Desmed_allgrades. The GOI list for 3T3supp- was deemed significantly enriched 
in genes with expression level mediated effects on distant metastasis free 
survival in both Loi expression datasets. 
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Name Dataset Survival 
measure 
Tumour type Number of 
samples 
Tumour grade Treatment 
Taylor_all Taylor DMFS Prostate cancer 140 All N/A 
Taylor_primary Taylor DMFS Prostate cancer 61 Primary tumours, low 
Gleason grade (4-6), t-stage 
2 
N/A 
Shedden_all Shedden DMFS Non-small cell lung 
cancer 
442 N/A N/A 
Loi_tamoxifen Loi DMFS Breast cancer 255 N/A Tamoxifen 
Loi_notamox Loi DMFS Breast cancer 125 N/A No 
treatment 
Desmedt_all Desmedt DMFS Breast cancer (lymph 
node negative) 
198 All N/A 
Desmedt_3 Desmedt DMFS Breast cancer (lymph 
node negative) 
83 Grade 3 N/A 
Desmedt_1 Desmedt DMFS Breast cancer(lymph 
node negative) 
30 Grade 1 N/A 
Table 3.54. Sub-datasets used for the study of gene expression changes associated to differential metastasis -free survival in cancer patients 
and parameters used to create them from the original datasets.  
DMFS: distant metastasis free survival.
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 Taylor_all Taylor_primary Shedden Loi_tamoxifen Loi_notamox Desmedt_all Desmedt_1 Desmedt_3 
Library 3,474 170 1,413 2,034 480 543 221 464 
3T3supp+ 33 3 22 38 6 8 2 3 
3T3supp- 52 1 24 46 14 8 4 7 
Table 3.55. Number of genes whose expression was found to be associated with differential metastasis -free survival using the recursive 
partitioning approach in the different datasets used.  
Note that the number of genes in “3T3supp+” and “3T3supp-“ corresponds to the number of genes found to have an effect on the direction 
predicted by the screen; i.e. 3T3supp+: lower expression is detrimental, 3T3supp-: lower expression is beneficial. On the contrary, numbers for 
the “library” dataset correspond to both directions of effect.
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Figure 3.47. Survival curves for expression of three genes selected from the 3T3 supp- GOI list.  
A) Survival curve for UBE2T from dataset Loi_tamoxifen. B) Survival curve for UBE2T from dataset Taylor_all. C) Survival curv e for RRP7A 
from dataset Loi_tamoxifen. D) Survival curve for DUT from dataset Taylor_primary. E) Survival curve for DUT from da taset Shedden. F) 
Survival curve for DUT from dataset Loi_tamoxifen
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Figure 3.48. Survival curves for expression of genes selected from the 3T3 supp+ GOI list.  
A) Survival curve for TSPAN7 from dataset Loi_tamoxifen. B) Survival curve for MYOCD from dataset Taylor_All.. C) Survival curve for BCL2 
from dataset Shedden. D) Survival curve for BCL2 from dataset Desmedt_all. E) Survival curve for MFHAS1 from dataset Shedden.  F) 
Survival curve for MFHAS1 from dataset Loi_tamoxifen. 
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Figure 3.49. Results of the random sampling approach to evaluate the significance of the recursive partitioning results in the 3T3 supp+ GOI list.  
Red arrows mark the number of genes with changes in expression associated with differential metastasis rates. A) Supp+ Taylor primary. B) 
Supp+ Taylor All. C) Shedden. D) Loi Tamoxifen. E) Loi no treatment. F) Desmedt grade 3. G) Desmedt grade 1. H) Desmedt all grades.
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Figure 3.50. Results of the random sampling approach to evaluate the significance of the recursive partitioning results in the 3T3 supp- GOI list.  
Red arrows mark the number of genes with changes in expression associated with d ifferential metastasis rates. A) Supp- Taylor primary. B) 
Supp- Taylor All. C) Shedden. D) Loi Tamoxifen. E) Loi no treatment. F) Desmedt grade 3. G) Desmedt grade 1. H) Desmedt all grades.
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Gene name Number of datasets Dataset names (p-values) 
DMD 3 Taylor_all (0.035), Shedden (0.044), desmedt_grade3 (0.04) 
MFHAS1 3 Taylor_all (0.048), Shedden (4.3*10-6), Loi_tamoxifen (0.0053) 
NDEL1 3 Taylor_primary (0.013), Taylor_all (0.00057), Loi_tamoxifen (0.0086) 
FBXO30 3 Taylor_all (0.0058), Shedden (0.039), Loi_notreatment (0.026) 
RPL37 3 Loi_tamoxifen (0.041), Desmedt_grade3 (0.0032), Desmedt_all (0.0075) 
TGIF1 2 Taylor_all (0.00027), Taylor_primary (0.021) 
PPP2CB 2 Taylor_all (0.0014), Loi_tamoxifen (0.00065) 
EIF4B 2 Loi_tamoxifen (0.0057), Desmedt_all (0.0039) 
NPC2 2 Shedden (0.0064), Loi_tamoxifen (0.008) 
COL4A3 2 Shedden (0.0067), Desmedt_grade1 (0.0085) 
PDGFRA 2 Taylor_all (0.015), Loi_tamoxifen (0.0016) 
MS4A1 2 Shedden (0.0054), Loi_notreatment (0.051) 
Table 3.56. 3T3supp+ top 10 genes with higher number of associations in the recursive partitioning datasets.  
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Gene name Number of datasets Dataset names (p-values) 
ABCD1 3 Loi_tamoxifen (0.047), Desmedt_grade3 (0.00091), Desmedt_all (0.0013) 
CCNE1 3 Taylor_all (0.0014), Shedden (0.013), Loi_tamoxifen (0.0082) 
CENPE 3 Taylor_all (0.00048), Shedden (0.0085), Loi_tamoxifen (0.00018) 
KIF18A 3 Taylor_all (0.002), Shedden (0.031), Loi_tamoxifen (0.015) 
NR2C2AP 3 Taylor_all (0.027), Loi_tamoxifen (0.0031), Loi_notreatment (0.0037) 
PLXNB3 3 Taylor_all (0.0051), Loi_tamoxifen (0.012), Loi_notreatment(0.016) 
TBX1 3 Taylor_all (0.045), Shedden (0.029), Desmedt_all (0.013) 
DUT 3 Taylor_primary (0.039), Shedden(0.041), Loi_tamoxifen (0.0099) 
EIF2S1 3 Shedden (0.015), Desmedt_grade3 (0.025), Desmedt_all (0.017) 
GATA2 2 Taylor_all (0.00048), Desmedt_grade3 (0.041) 
UBE2T 2 Taylor_all (5.7 x 10-6), Loi_tamoxifen (7.4 x10-5) 
DIAPH3 2 Taylor_all (0.00033), Loi_tamoxifen (0.016) 
Table 3.57. 3T3supp- top 10 genes with higher number of associations in the recursive partitioning datasets.  
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3.4. Discussion 
3.4.1. Design of a genome-wide shRNA screen in a homotypic co-
culture system. 
Since the advent of the RNAi approach for the study of functional genomics, 
RNAi screens have gained popularity year by year. Pooled screens such as the 
one presented here have been performed in a number of in vitro models of 
cancer in the last few years (Zhou, Patel et al. 2014, Burleigh, McKinney et al. 
2015, Kushwaha, O'Leary et al. 2015) and are amenable especially for 
phenotypes that result in an increase or decrease in cell number. An RNAi 
screen has even been performed in a co-culture model of the tumour 
microenvironment (Burleigh, McKinney et al. 2015). However the expansion of 
our knowledge about the initial phases of tumorigenesis, when tumour cells are 
surrounded by cells of the same type (that is, in a homotypic context) has been 
more conservative. To gain some insight into the molecular effectors at play in 
the initial steps of tumorigenesis and the tumour growth suppression effect 
exerted by homotypic cell interactions, a genome-wide shRNA screen was 
designed. 
Normal cells surrounding tumorigenic cells have been previously shown to 
suppress the growth of the latter by a still under-characterized mechanism. A 
genome-wide shRNA screen was designed and performed to identify the 
molecular effectors of neighbour suppression in the normal cells (Nicholls 
2015). No mechanism has as of yet been proposed to explain the response of 
the tumorigenic cells to the suppression cues they receive from their 
neighbouring non-tumorigenic cells. Therefore this unexplored signal integration 
process occurring in the tumorigenic cells was targeted. 
To investigate this process an appropriate in vitro model was first sought. To 
mimic a homotypic interaction context of tumour initiation it was necessary to 
use a non-tumorigenic cell line and a transformed counterpart. It is common that 
this type of in vitro model of homotypic interactions result in the growth 
suppression of the transformed cells. However, the 3T3supp+/3T3supp- cell lines 
provide a model of suppressive and permissive homotypic interactions when co-
cultured with a SV-40 large Tag transformed cell line derived from 3T3supp+. This 
system composed of two different co-culture conditions has the advantage of 
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allowing the study of the phenotype of interest in two ways. Molecular effectors 
of suppression can be studied through the reversal of tumorigenic cell growth 
suppression in the co-culture with 3T3supp+; but also through the induction of 
suppression in the 3T3supp- permissive co-culture condition. 
An embryonic fibroblast in vitro model for the study of the initial phases of 
tumorigenesis might not be the most relevant to an in vivo situation. However it 
can be argued that the use of any cell line would yield results that are only 
specific to tumorigenesis in the tissue from which the cell line was derived as 
cancers in different tissues differ in their mechanisms. Also, monolayers of cells 
suppress the growth of transformed cells and therefore a permissive co-culture 
condition would be difficult to translate into any other cell type. 
The decision of performing only one replicate of the entire screen after a pilot in 
duplicate is a limitation of this study. However, the implementation of this screen 
in duplicate would became a significantly larger endeavour and only 
approximately 65% of the GOI would be expected to overlap between 
duplicates (Strezoska, Licon et al. 2012). The NKI library has a twofold 
redundancy, which in the case of the GOI for which the two targeting 
sequences were detected as having an effect provides a reassurance in the 
confidence of their selection as GOI. However this is not the case for most of 
the GOI. This may be a result of different factors stemming from the RNAi 
technology itself or from the process by which the library was designed. The 
NKI library was designed using algorithms which predict the efficiency and limit 
the off-target effects of the targeting sequences. This is a limitation as far as the 
algorithm may be flawed due to either the information available to predict these 
parameters and to the design of the algorithm itself. The level of expression 
knockdown for each targeting sequence is unknown and may vary for both 
constructs that target the same gene and amongst the different genes targeted. 
The same can be said about the potential off-target effects of the targeting 
sequences. 
These limitations were considered in the design of the screening process, the 
analysis pipeline and the validation experiments. 
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3.4.2. Analysis pipeline 
Genome-wide RNAi screens provide a considerable amount of data that need 
to be carefully analysed to reduce the number of false positives as much as 
possible. Methods of analysis for this type of screening have been discussed at 
length and new applications and statistical pipelines are continuously being 
proposed (Diaz, Qin et al. 2015, Dutta, Azhir et al. 2016, List, Schmidt et al. 
2016), highlighting the lack of a strong consensus on an optimal analysis 
pipeline. 
Furthermore, most RNAi screens have been performed using a “control vs. 
treatment” approach, where only two conditions are compared. In contrast the 
screening process described here was composed of a “control” condition – 
growth on plastic; and two “treatment” conditions – co-culture with either a 
suppressive or a permissive underlying monolayer. These two conditions add 
an extra element for analysis, as effects exerted in the same direction (i.e. 
increasing or decreasing the suppressive effect in both conditions) would most 
likely represent non-specific effects in tumour cell growth or plating which are 
outside the scope of this screen. 
This pooled RNAi screen was performed in pools or groups of constructs which 
required separate normalization due to the difference in variability across pools. 
For this reason an approach based on z-scores was selected. To include both 
levels of control conditions (growth in plastic and growth in the other co-culture 
condition), the growth in plastic was used as normalization for both co-cultures 
by calculating a ratio and the z-score was then built. Given the non-normality of 
the data, robust z-scores were calculated using the median and median 
absolute deviation. A method of two thresholds, one for each co-culture 
conditions was used to select genes of interest (GOI). To my knowledge this is 
the first report of this method in RNAi screens. 
The use of integrated analysis pipelines including network biology and 
functional enrichment approaches has been advocated for as a method to 
circumvent some of the limitations of the RNAi technology (Dutta, Azhir et al. 
2016, List, Schmidt et al. 2016, Wilson, Dalin et al. 2016). A pipeline of this type 
was adopted for the analysis of this screen with the aim of exploring the 
molecular mechanisms behind the phenomenon of neighbour suppression and 
also to refine the list of GOI produced by the screen. An important limitation of 
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the use of these approaches with a pooled RNAi screen lies in the choice of a 
background from which to draw conclusions about enrichments. Although the 
ideal situation in this study has been to use the list of screened genes as the 
background, this list may still be biased. It is assumed that all screened 
constructs could be functional, an assumption that it is possibly incorrect. In 
relation to the technical aspects of the screen, the constructs may not produce 
knockdown of the targeted gene, the level of knockdown may not be sufficient 
to produce an effect in the phenotype being investigated or off-target effects of 
the constructs may result in a phenotype due to the knockdown of a non-
intended gene. Biologically, the knockdown of certain genes may not have the 
predicted effect if there is a compensation mechanism in place. 
3.4.3.  Method for validation of the GOI selected 
The validation of the GOI was performed using additional targeting sequences 
or other gene disruption techniques. Other technologies (e.g. CRISPR, TALENS) 
may have been used for these validation studies, although this would have 
required optimization of additional procedures and the value added by these 
alternative approaches was not deemed to be sufficient to justify the 
implementation efforts.  
The choice of an additional targeting sequence instead of re-validating the 
targeting sequences identified as effectors in the screen was based on the 
reasoning that using the same sequence, an approach taken in some screens 
(Cooper and Brockdorff 2013), could repeat the potential off-target effects of 
those sequences. However, this decision results in a limitation. The level of 
knockdown for the additional targeting sequence chosen may not be the same 
as the targeting sequence detected in the screen, resulting in the non-validation 
of genuine GOI. However, any GOI validated with an alternative targeting 
sequence would have greater confidence in a role in the phenotype. 
3.4.4.  Overlap in the mechanism of response to suppressive and 
permissive co-culture conditions. 
The network analysis of the GOI lists from the 3T3supp+ and the 3T3supp- co-
cultures and the list combining the GOI from both co-cultures indicates the 
existence of interaction between genes with an effect in both co-cultures. This 
may indicate that there is a shared mechanism in the response to suppressive 
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cues and the growth in permissive conditions. However, this hypothesis is not 
supported by the functional enrichment approaches. There is very little overlap 
in the functional categories enriched in both GOI lists. The functional categories 
and gene sets enriched in the 3T3supp+ GOI list include many terms related to 
cancer, which suggests a potential role for neighbour suppression evasion in 
carcinogenesis. Other functional categories and gene sets in this co-culture 
condition include cell-cell communication, junctions and membrane proteins. 
Neighbour suppression has been described as a phenomenon which needs 
cell-cell contact and therefore the enrichment in these terms supports the 
choice of the 3T3supp+/SVE-6 co-culture system as a model of neighbour 
suppression. 
The functional categories and gene sets found to be enriched in the 3T3supp- 
include a wide range of terms. 
3.4.5. Validated GOI  
The results of the experimental validation of the GOI lists are very variable for 
most genes. Considering that 100 cells were used per shRNA sequence in the 
initial screening, it was expected that approximately 65% of the GOI would be 
validated if the same sequence was used (Strezoska, Licon et al. 2012). 
However, validation was performed in this case using different sequences from 
those in the primary screen as off-target effects are not expected to be repeated 
with this approach. 
In view of the experiments performed to date in this study, Sh3pxd2b and Rac1 
would be the genes proposed to have an effect on neighbour suppression in the 
3T3supp+/SVE-6 co-culture model. The effect of Nptxr in this model has been 
replicated once. 
Sh3pxd2b encodes the protein Tks4, which is hypothesized to be an important 
component of actin-rich membrane structures called podosomes which are 
important for invasiveness (Buschman, Bromann et al. 2009). In the same study, 
Buschman and collaborators showed that knockdown of Sh3pxd2b reduced the 
ability of Src-transformed fibroblast to degrade the extracellular matrix and form 
podosomes and decreased proliferation. The increased colony size of SVE-6 
upon introduction of a shRNA construct targeting this gene is therefore 
contradictory to their conclusions. Data from the recursive partitioning approach 
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to human tumour expression analysis agrees with the effect detected in this 
RNAi screen. In the Loi dataset, decreased expression is correlated with lower 
distant metastasis free survival (Figure 3.51).  
Rac1 was detected as a GOI in the 3T3supp- co-culture sample. Rac1 is a Rho-
GTPase signal transducer implicated in the regulation of a variety of cellular 
functions (Van Aelst and D’Souza-Schorey 1997) including organization of the 
actin cytoskeleton and recruitment of integrins (Hall 1998). It has also been 
shown to be involved in cell growth and regulation of the cell cycle (Saci, 
Cantley et al. 2011), formation of cell-cell adhesions (Ehrlich, Hansen et al. 
2002) and contact inhibition of cell proliferation (Bosco, Nakai et al. 2010). Rac1 
involvement in neighbour suppression was validated using a dominant negative 
and a constitutively active form of the human protein. Introduction of both cDNA 
constructs seem to affect the colony size of SVE-6 in co-culture with 3T3supp+, 
although the magnitude of the effect for each of the constructs varied between 
replicates. Higher expression of RAC1 in human tumour samples correlates 
with lower probability of distant metastasis free survival (Figure 3.52). 
The effect of Nptxr on the SVE-6 colony size in a suppressive co-culture was 
replicated once and therefore more validation experiments will be necessary to 
decide on its involvement. The protein encoded by the Nptxr (Neuronal 
Pentraxin Receptor) gene was first described as a synapse-associated protein 
(Hsu and Perin 1995). No expression data is available for this gene in the 
human tumour datasets used by the recursive partitioning script. 
In the 3T3supp- co-culture validation experiments, the effect of four genes (Rac1, 
Flt4, Rrp7a and Ttbk1) were replicated.  
The dominant-negative form of Rac1 had the largest effect of the two forms 
used for validation, although the constitutively-active form also decreased the 
size of the SVE-6 colonies. The expression data agrees with the dominant-
negative form reducing the size of the colonies as lower expression correlates 
with higher probability of distant metastasis free survival. 
Flt4 encodes a tyrosine kinase receptor for vascular endothelial growth factors 
C and D. Inhibition of this signalling pathway was recently shown to decrease 
mammary tumour cell growth and survival (Varney and Singh 2015) and 
identified as a marker of metastasis in colorectal cancer (Xiao, Liu et al. 2015). 
Recursive partitioning analysis of the human tumour dataset Taylor (Figure 3.53) 
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indicates that higher expression of FLT4 correlates with lower probability of 
distant metastasis free survival, agreeing with those two studies and with the 
findings in this screen. However, the effect detected in the expression datasets 
may be mediated by an increase in angiogenesis and reflect the number of 
endothelial cells rather than indicating the level of expression in tumour cells. 
The available literature on Rrp7a is limited. It encodes a ribosomal RNA 
processing factor, but the single publication within Pubmed only indicates that 
expression is required for the transition between morula and blastocyst in 
mouse embryo development (Maserati, Dai et al. 2014). Expression data in 
datasets Shedden and Loi indicate that high expression in human tumours is 
correlated with low probability of distant metastasis free survival (Figure 3.54). 
Ttbk1 encodes a kinase which phosphorylates the protein TAU and has been 
suggested to be implicated in the pathology of Alzheimer’s disease (Lund, 
Cowburn et al. 2013). No publications are available on a possible role in 
carcinogenesis, but a high level of expression is correlated in Taylor with lower 
probabilities of distant metastasis free survival (Figure 3.55). 
The effect of Twf2 in the colony size of SVE-6 cells in co-culture with 3T3supp- 
was validated in one replicate. This gene was selected as a GOI in 3T3supp+ 
from the FunCoup network analysis data. The protein encoded by Twf2 binds 
actin and inhibits its polymerization (Vartiainen, Sarkkinen et al. 2003). No 
correlation between expression levels and distant metastasis free survival was 
found in the recursive partitioning datasets. 
The proportion of experimentally validated GOI was low. However, most of the 
genes which were validated by a second targeting sequence were found to 
have their expression levels associated with distant metastasis free survival. 
This suggests that an integrated approach to the analysis of pooled shRNA 
screens may aid the identification of genes involved in the phenotype studied.  
Two of the validated GOIs bind actin, which may indicate a role of the 
cytoskeleton in neighbour suppression. 
Further experiments should be performed to confirm the role of the validated 
GOI in neighbour suppression and their importance in carcinogenesis. 
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Figure 3.51. Survival curve obtained from the recursive partitioning analysis of the Loi 
dataset for SH3PXD2B.
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Figure 3.52. Survival curve obtained from the recursive partitioning analysis of the Loi 
dataset for RAC1.
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Figure 3.53. Survival curve obtained from the recursive partitioning analysis of the Taylor 
dataset for FLT4.
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Figure 3.54. Survival curves obtained from the recursive partitioning analysis of the 
Shedden (A) and Loi (B) dataset for FLT4
A) 
B) 
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Figure 3.55. Survival curve obtained from the recursive partitioning analysis of the Taylor 
dataset for TTBK1. 
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 Chapter 4. A pooled genome-wide shRNA screen for genes involved in β-
cell proliferation and resistance to death caused by lipids. 
4.1.  Introduction 
4.1.1 Type 2 diabetes and β-cell mass. 
Type 2 diabetes (T2D) is a chronic disease characterized by a disequilibrium in 
blood glucose homeostasis as a result of an increase in insulin resistance and a 
degree of β-cell dysfunction. The relative importance of both factors and the 
order in which they arise has been and still is largely discussed (Martin, Warram 
et al. 1992, Prentki, Joly et al. 2002, Weir and Bonner-Weir 2004, Kahn, Zraika 
et al. 2009). 
β-cell mass is highly regulated and normally increases by β-cell proliferation 
during development and childhood, with a marked decrease in adulthood (Dor, 
Brown et al. 2004, Georgia and Bhushan 2004, Meier, Butler et al. 2008). A β-
cell mass increase can also be demonstrated in response to pathological or 
physiological changes in insulin requirements such as obesity (Terauchi, 
Takamoto et al. , Kloppel, Lohr et al. 1985, Pick, Clark et al. 1998, Butler, 
Janson et al. 2003, Hull, Kodama et al. 2005, Gonzalez, Merino et al. 2013, 
Mao, Dillon et al. 2014, Irles, Neco et al. 2015) or pregnancy (Green and Taylor 
1972, Van Assche, Aerts et al. 1978, Sorenson and Brelje 1997). The increase 
in β-cell mass in obesity in humans is calculated to be 50% compared to non-
obese individuals (Butler, Janson et al. 2003) while in mouse this increase has 
been shown to reach nine-fold (Butler, Janson et al. 2003). 
β-cell mass is lower in diabetic patients than weight-matched controls (Maclean 
and Ogilvie 1955, Butler, Janson et al. 2003, Rahier, Guiot et al. 2008). It is 
difficult to assess in humans whether this decrease in β-cell mass is a cause or 
consequence of diabetes, but recent studies show a reduction in β-cell function 
in pre-diabetic states (Do, Gunton et al. 2016) which may indicate that β-cell 
mass loss precedes overt diabetes. 
Variations in β-cell mass can be due to an increase in proliferation, a decrease 
in apoptosis or both. An overview of the knowledge on the mechanisms of β-cell 
proliferation and apoptosis is provided in the rest of this introduction. 
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4.1.2 Overview of genes involved in β-cells proliferation 
Proliferation of β-cells has been predominantly studied in in vitro or in vivo 
rodent models due to the difficulty to obtain and culture human β-cells. 
Numerous studies performed in mouse β-cells have provided insight into the 
mechanism of proliferation in response to nutrients and growth factors.  
4.1.2.1 PI3K/AKT pathway 
The PI3K/AKT pathway is a highly conserved signalling pathway involved in the 
regulation of cell proliferation and apoptosis amongst other cellular functions. In 
mouse β-cells, insulin and insulin-like growth factor 1 (IGF) (Shepherd, Navé et 
al. 1995) and GLP-1 (Park, Dong et al. 2006) activate the PI3K/AKT pathway 
through insulin receptor substrates (IRS). Signalling via the insulin receptor is 
critical for adult β-cell mass regulation in insulin resistant mice but not for the 
early development of β-cells (Okada, Liew et al. 2007). The role of Igf1 as an 
enhancer of β-cell proliferation in mice has however been questioned (Lu, 
Herrera et al. 2004, Okada, Liew et al. 2007). Indeed, mice lacking the receptor 
for Igf1 (Igf1r) do not show a decrease in β-cell mass although they develop 
impaired glucose tolerance (Kulkarni, Holzenberger et al. 2002). 
Two IRS isoforms are ubiquitously expressed: Irs1 (Sun, Rothenberg et al. 1991) 
and Irs2 (Sun, Wang et al. 1995), but their role in β-cell proliferation signalling 
differs. Irs2 knockout mice have a significantly lower β-cell mass than Irs1 
knockouts (Withers, Gutierrez et al. 1998, Kubota, Tobe et al. 2000). Choudhury 
and colleagues provided further evidence of the requirement of Irs2 for β-cell 
mass increase by showing that β-cells expressing Irs2 repopulated the islets in 
partial knockouts (Choudhury, Heffron et al. 2005). 
The requirement of components of the PI3K/AKT pathway for β-cell proliferation 
has been demonstrated in studies where deletion of either Pi3k (Kaneko, Ueki 
et al. 2010) or Akt1 (Bernal-Mizrachi, Fatrai et al. 2004) caused a decrease in β-
cell mass. Deletion of Akt2 in mice causes diabetes due to increased insulin 
resistance despite β-cell mass increase (Cho, Mu et al. 2001, Garofalo, Orena 
et al. 2003). Therefore, Pi3k and Akt1 but not Akt2 are required for β-cell 
proliferation. 
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Pi3k modulates the activity of Akt through Pdk1. Mice lacking Pdk1 in β-cells 
develop overt uncontrolled diabetes as a result of their significantly decreased 
β-cell mass (Hashimoto, Kido et al. 2006).  
Control of cell proliferation by Akt1 in β-cells can be achieved through different 
pathways. Overexpression of constitutively active Akt1 in mice has been shown 
to increase phosphorylation of GSK3β and levels of cdk4, cyclin D1, cyclin D2, 
and p21 (Fatrai, Elghazi et al. 2006). The same study found that inactivating 
phosphorylation of Foxo1 was increased in response to the overexpression of 
active Akt1 (Fatrai, Elghazi et al. 2006). 
The PI3K/AKT pathway is modulated by Pten, which inhibits Pi3k. Mice with 
specific deletion of Pten in β-cells have increased β-cell mass and are protected 
against streptozotocin-induced diabetes (Stiles, Kuralwalla-Martinez et al. 2006). 
This role of Pten is not confined to β-cell proliferation in early development as 
deletion of Pten in adult β-cells also results in the same phenotypes (Yang, 
Bayan et al. 2014). 
4.1.2.2 Mammalian Target of Rapamycin (mTOR) 
Mammalian Target of Rapamycin (mTOR) is involved in the regulation of cell 
growth, proliferation and survival through the formation of two different 
complexes, mTORC1 and mTORC2. Growth factors induce mTORC1-mediated 
cell growth and proliferation through inactivation of TSC (tuberous sclerosis 
complex), which is inhibited by Akt (Inoki, Li et al. 2002, Manning, Tee et al. 
2002). 
mTORC1 activation through deletion of Tsc2 in mouse β-cells leads to 
increased β-cell size and number (Rachdi, Balcazar et al. 2008). This effect is 
reverted by the inhibition of mTORC1 using rapamycin (Rachdi, Balcazar et al. 
2008), which demonstrates the involvement of mTORC1 in the control of β-cell 
mass. 
mTORC1 also mediates the effect of PKCζ in β-cell proliferation (Velazquez-
Garcia, Valle et al. 2011). PKCζ has been shown to be involved in the 
stimulation of β-cell proliferation by GLP-1 using the rat insulinoma cell line 
INS1 (Buteau, Foisy et al. 2001). Hepatocyte growth factor (HGF) and 
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parathyroid hormone-related protein (PTHrP) also stimulate β-cell proliferation 
through PKCζ according to in vitro studies using INS1, MIN6 (a mouse 
insulinoma cell line) and primary mouse and human islets (Miele, Raciti et al. 
2007, Vasavada, Wang et al. 2007). Mice expressing constitutively active PKCζ 
in β-cells display increased β-cell proliferation but also an increase in 
inactivating phosphorylation of GSK3β (Velazquez-Garcia, Valle et al. 2011), 
suggesting that the effect of PKCζ on β-cell proliferation may also be mediated 
through GSK3β. 
4.1.2.3 Wnt canonical signalling 
In the canonical Wnt pathway, Wnt ligands bind the Frizzled receptor and 
initiate a cascade by which β-catenin localizes to the nucleus, where it interacts 
with transcription factors from the T-cell-specific factor/lymphoid enhancer-
binding factor family (TCF/LEF) and stimulates the transcription of Wnt 
regulated genes (reviewed in (Welters and Kulkarni 2008)). Activation of the 
Wnt pathway in INS1 cells results in higher proliferation rate (Welters, 
Oknianska et al. 2008). In mouse primary islets, the activation of Wnt signalling 
increases the expression of cyclin D2 and increased β-cell proliferation 
(Rulifson, Karnik et al. 2007). 
GLP-1 has been shown to stimulate β-cell proliferation in isolated primary islets 
and INS1 cells at least in part through activation of Wnt signalling (Liu, Remedi 
et al. 2009). 
4.1.2.4 Other pathways. 
Prolactin and growth hormone induce β-cell proliferation through Stat5, and it 
has been shown that in INS1 cells activation of Stat5 drives proliferation via 
cyclin D2 (Friedrichsen, Richter et al. 2003). Stat5 upregulates Bcl6 expression, 
which inhibits menin and promotes β-cell proliferation (Karnik, Chen et al. 2007). 
Glucose can upregulate the expression of cyclins and increase β-cell 
proliferation via ChREBP (carbohydrate response element-binding protein) 
(Metukuri, Zhang et al. 2012). It can also act through Lkb1 and calcineurin (Heit, 
Apelqvist et al. 2006, Fu, Ng et al. 2009, Fu, Ng et al. 2009, Granot, Swisa et al. 
2009, Metukuri, Zhang et al. 2012).  
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Other growth factors and pathways have been demonstrated to be involved in 
the regulation of β-cell proliferation such as the epidermal growth factor (EGF) 
(Hakonen, Ustinov et al. 2011), cAMP (Schisler, Fueger et al. 2008, Song, 
Schreiber et al. 2008), leptin (Morioka, Asilmaz et al. 2007), transforming growth 
factor- β (TGFβ) (Brown and Schneyer 2010), or platelet derived growth factor 
(PDGF) (Chen, Gu et al. 2011). 
4.1.2.5 Proliferation of human β-cells 
Much less is known about the control of β-cell mass through proliferation in 
humans. Insulin is known to affect human β-cell proliferation through a 
mechanism impaired in T2D patients (Lopez, Cypess et al. 2011, Mari, Tura et 
al. 2011, Halperin, Lopez et al. 2012). A role for mTORC has also been 
proposed (Liu, Remedi et al. 2009) and so have PKCζ (Vasavada, Wang et al. 
2007) and PDGF (Chen, Gu et al. 2011). Glucose seems to act through similar 
pathways than in mice (Metukuri, Zhang et al. 2012, Poungvarin, Lee et al. 
2012). 
Variants in one of the TCF/LEF transcription factors, TCF7L2, have been 
associated with increased risk of T2D (Damcott, Pollin et al. 2006, Florez , 
Jablonski  et al. 2006, Grant, Thorleifsson et al. 2006, Groves, Zeggini et al. 
2006, Saxena, Gianniny et al. 2006, Scott, Bonnycastle et al. 2006, Zhang, Qi 
et al. 2006), which may indicate a role of Wnt canonical signalling in human β-
cell proliferation. 
4.1.3 Apoptosis in β-cells 
The decrease in β-cell mass observed in T2D patients may be due at least in 
part to an increased level of apoptosis (Butler, Janson et al. 2003). Conditions 
associated with T2D, such as hyperglycaemia have shown to induce apoptosis 
of human β-cells (Efanova, Zaitsev et al. 1998, Maedler, Spinas et al. 2001). 
Elevated glucose leads to overexpression of pro-apoptotic genes such as Bad, 
Bid and Bik (Federici, Hribal et al. 2001). Furthermore, β-cells release 
interleukin (IL)-1β in hyperglycaemic conditions (Maedler, Sergeev et al. 2002), 
which leads to apoptosis via NF-κB. These IL-1β producing cells are found in 
pancreata from T2D patients but not in non-diabetic controls (Maedler, Sergeev 
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et al. 2002). Glucotoxicity may also be a result of increased mitochondrial 
generation of reactive oxygen species (ROS) due to excessive glucose 
metabolism. Anti-oxidant enzymes are not highly expressed in β-cells (Atkinson, 
Bluestone et al. 2011) and markers of oxidative stress are higher in pancreata 
of T2D affected individuals (Del Guerra, Lupi et al. 2005).  
High concentrations of saturated fatty acids such as palmitate are also known to 
be toxic for β-cells (Maedler, Spinas et al. 2001, Piro, Anello et al. 2002) by a 
process not completely understood but which seems to implicate ceramide 
synthesis and serine protease activity (Shimabukuro, Zhou et al. 1998, Lupi, 
Dotta et al. 2002). Lipotoxicity seems to be associated with the accumulation of 
saturated fatty acids but not with exposure to unsaturated fatty acids (Cnop, 
Hannaert et al. 2001, Maedler, Spinas et al. 2001). 
Amyloid deposits have also been investigated as pro-apoptotic stimuli in the 
pathogenesis of T2D. β-cells co-secrete islet amyloid polypeptide (IAPP) with 
insulin, although its role is still debated. It was first thought to play a role in 
insulin resistance as it inhibits insulin-stimulated glucose uptake in rat (Cooper, 
Leighton et al. 1988) and human (Zierath, Galuska et al. 1992) skeletal muscle 
in vitro. However, the concentrations used in these studies were higher than the 
physiological ranges. IAPP has been reported to affect insulin secretion in vivo 
in perfused rats (Dégano, Silvestre et al. 1993) and in vitro in cultured β-cells 
(Sandler and Stridsberg 1994) while other studies did not find an effect in insulin 
secretion (O'Brien, Westermark et al. 1990, Pettersson and Ahren 1990, 
Broderick, Brooke et al. 1991). IAPP inhibits gastric emptying (Reidelberger, 
Arnelo et al. 2001) and osteoclastic activity (Zaidi, Datta et al. 1990). 
IAPP deposits have are frequently found in β-cells from T2D affected individuals 
(Westermark and Wilander 1978, Clark, Wells et al. 1988, O'Brien, Butler et al. 
1994), and human islets cultured in the presence of high levels of glucose show 
an increase in IAPP deposits (Lorenzo, Razzaboni et al. 1994, Konarkowska, 
Aitken et al. 2006)  
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4.1.4 Aim of this chapter 
In this chapter I present two genome-wide RNAi screens to identify genes 
involved in β-cell proliferation and death by lipids in a reversibly immortalized 
mouse β-cell line. To my knowledge, no genome-wide RNAi screens have yet 
been performed in β-cell lines for any of these phenotypes. As mentioned above, 
only a few molecular mechanisms are known for these beta cell phenotypes 
which were identified predominantly through targeted investigations.  
This chapter presents the design, optimization and analysis required for these 
two screens and their potential implications for this research area. The main 
objective of both screens was to uncover genes which upon knockdown 
increased proliferation or resistance to death by lipids, two processes which 
could be of importance in the understanding of β-cell dysfunction in T2D.
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4.2. Material and methods 
4.2.1 Cell lines 
R7T1 cells were a gift from Dr Shimon Efrat. They are a mouse insulinoma cell 
line that conditionally express an oncogene (SV40 large T antigen) under the 
tet-on system (Milo-Landesman, Surana et al. 2001). R7T1 cells were derived 
from mice resulting from the crossing of transgenic mice expressing the RIP7-
rtTA (rat insulin promoter-reverse tetracycline-controlled transactivator) 
construct and transgenic mice expressing a tet-TAG construct, which consists 
of the SV40 large T antigen gene (TAG) flanked by repeats of tet operator 
sequences and a minimal promoter (Milo-Landesman, Surana et al. 2001). 
Double transgenic mice remained euglycaemic and had normal islet 
morphology unless they were treated with a tetracycline analogue, in which 
case they developed insulinomas and manifested hypoglycaemia (Milo-
Landesman, Surana et al. 2001). Milo-Landesman and collaborators 
characterized R7T1 and found that the rate of BrDU incorporation in these cells 
was 50 times higher following treatment with doxycycline, a tetracycline 
analogue (Milo-Landesman, Surana et al. 2001). R7T1 cells were routinely 
grown in DMEM (high glucose, no pyruvate) supplemented with 10% FBS 
(tetracycline-free certified) and doxycycline (DOX) at (5 µg/mL). Medium was 
renewed every 48 hours.  
4.2.2 Bromodeoxyuridine (BrDU) incorporation assay 
Bromodeoxyuridine (BrDU) stock was prepared as a 50 mM BrDU solution in 
double distilled H2O. This solution was filter-sterilised and stored at 4ºC. 
Cells were incubated overnight at standard tissue culture conditions with growth 
medium supplemented with 50 µM BrdU. Then, growth medium was aspirated 
and cells were very gently washed with DPBS. Ice cold methanol was added to 
the cells, the dish was rocked and methanol was aspirated immediately. Fresh 
ice cold methanol was added to cover the dish and it was left to incubate for 
four minutes. Cells were then washed five times with DPBS. After the last wash, 
cells were covered with 1.5 M HCl and incubated for 20 minutes at 37ºC. HCl 
was then aspirated and cells were washed five times with DPBS. Incorporation 
of BrDU was detected with an anti-BrDU mouse antibody diluted 1:100 in 10% 
FCS in DPBS, and incubated overnight at 4ºC. Cells were then washed three 
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times with DPBS before being incubated with AP conjugated goat anti-mouse 
IgG diluted 1:100 in 10% FCS in DPBS for 45 minutes. After the incubation, 
cells were washed five times with DPBS. Cells were covered with fresh AP 
substrate solution (70 ml of alkaline phosphatase buffer (100 mM NaCl, 5 mM 
MgCl2, 100 mM Tris pH 9.5) with 462 µl of NBT (Nitro-blue tetrazolium chloride, 
dissolved at 50 mg/ml in 70% dimethylformamide) and 231 µl of BCIP (5-bromo-
4-chloro-3'-indolyphosphate p-toluidine salt, dissolved at 50 mg/ml in 100% 
dimethylformamide)). SVE cells (section 3.2.1) were used as a positive control 
for incorporation of BrDU. They were cultured for 30 minutes in the presence of 
BrDU instead of overnight as they divide rapidly. Development of staining in the 
positive control was monitored under a bright field microscope until the positive 
nuclei were clearly visible. Then, the reaction was stopped by adding DPBS and 
cells were washed five times. DPBS was added to the wells and the stained 
plate was stored at 4ºC until imaged. 
4.2.3 Immunocytochemistry (ICC) of SV40 Large Tumour Antigen (Tag) 
Growth medium was aspirated and cells washed with DPBS. Cells were 
washed with ice cold methanol. Cells were incubated at room temperature with 
fresh ice cold methanol for ten minutes and then washed five times with DPBS. 
Cells were covered with a 1:1000 dilution of anti-Tag antibody in 10% FCS in 
DPBS and incubated overnight at 4ºC. Cells were washed five times with DPBS 
before being incubated for 45 minutes with AP conjugated goat anti-mouse IgG 
(1:100 in 10% FCS in DPBS). Staining was performed as in 4.2.2. 
4.2.4 Production of retroviral particles using Phoenix cells. 
Ecotropic Phoenix cells were seeded 24 hours before transfection at a density 
that would give approximately 70% confluence on the day of transfection. Cells 
were transfected using the ProFection Mammalian Transfection System 
(Promega) using 15 µg of DNA per 10 cm dish according to the manufacturer 
instructions. After 24 hours growth medium was replaced with 12 mL of fresh 
growth medium. 
4.2.5 Transduction of cells using non-concentrated retroviral particles 
Retroviral medium was collected 48 hours after transfection, transferred to 15 
mL tubes and centrifuged at 500 g for five minutes to pellet any Phoenix cells in 
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suspension. The supernatant was carefully transferred to a new 15 mL tube and 
polybrene was added to a final concentration of 8 µg/ml. Growth medium was 
aspirated from the dishes to be transduced and replaced with the retroviral 
medium. 
4.2.6 Concentration of retroviral particles using Retro-X Concentrator 
(Clontech). 
Retroviral medium was collected and centrifuged as in 4.2.5. Retroviral particles 
were concentrated according to the manufacturer instructions and re-
suspended into the appropriate volume of growth medium to reach the 
concentration factor stated in the results section for each figure. 
4.2.7 Concentration of retroviral particles using PEG 
A solution of 40% polyethylene glycol (PEG) 8000 was prepared in sterile glass 
bottles by dissolution of the appropriate amount of PEG in autoclaved ddH2O 
and stored at 4ºC. Retroviral medium was harvested as in 4.2.5. Three volumes 
of retroviral medium were mixed with one volume of PEG solution and 
incubated overnight at 4ºC on a shaker. The solution was centrifuged at 4ºC for 
45 minutes at 1000 g. The supernatant was decanted and the pellet gently re-
suspended in complete growth medium using a volume that would give the 
concentration factor stated in the results section for each figure. 
4.2.8 Transductions with Ecotropic receptor booster 
Cells were pre-treated with the Ecotropic Receptor Booster following the 
manufacturer instructions. Retroviral medium was collected and centrifuged at 
500 g for five minutes to pellet any Phoenix cells in suspension. The 
supernatant was transferred to a new 15 mL tube and polybrene was added to 
a final concentration of 8 µg/mL. 
4.2.9 Transductions with Viraductin 
Retroviral medium was collected and centrifuged as in 4.2.5. Cells were 
transduced following the manufacturer instructions. Briefly, reagent A was 
added to the retroviral medium and mixed. This was repeated with reagent B. 
The retroviral medium was then aliquoted to 2 mL microcentrifuge tubes and 
incubated at 37ºC for 30 minutes. The tubes were then centrifuged at 12,000 g 
for 10 minutes. The supernatant was carefully aspirated using a micropipette 
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and the pellet was re-suspended in a volume of growth medium determined by 
the concentration factor stated in the results section for each figure. 
4.2.10 RNA extractions 
Total RNA was extracted from cells in 10 cm dishes using the RNeasy Mini Kit 
(Qiagen) according to the manufacturer instructions. RNA was eluted in 50 µl of 
nuclease-free water. 
4.2.11 RT PCR 
cDNA was produced by RT-PCR using RevertAid™ H Minus Reverse 
Transcriptase (Fermentas). The final composition of a RT-PCR is shown in 
Table 4.1.
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Component Volume 
Template RNA (1 µg) 
Oligo (dT)20 primer 1 µL 
5X reaction buffer 4 µL 
RNase inhibitor (20 U/µL) 1 µL 
10 mM dNTP mix 2 µL 
RevertAid RT (200 U/µL) 1 µL 
RNase free water To 20 µL 
Table 4.1. Composition of a RT-PCR reaction
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4.2.12 qPCR 
cDNA obtained in 4.2.11 was diluted 1:20 using RNase-free water and qPCR 
reactions were performed on an ABI 7900HT real-time PCR system using 
SYBR Green dye. Reactions were performed in triplicates and analysed using 
the ΔΔCT method. The composition of a PCR reaction is depicted in Table 4.2. 
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Component Volume 
2X Sybr Green Master Mix 10 µL 
Forward primer (10 mM) 0.9 µL 
Reverse primer (10 mM) 0.9 µL 
cDNA 4 µL 
Water 4.2 µL 
Table 4.2. Composition of a single qPCR reaction.
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4.2.13 Palmitate dose response 
A 50 mM stock of palmitate in ethanol was prepared and stored as 200 µl 
aliquots at -20ºC. An aliquot was thawed and heated to 80ºC prior to use. 
Working solutions of different concentrations were prepared (Table 4.3) and 
incubated for at least 1 hour at 37ºC. “Dose” medium was prepared as a 1:10 
dilution of each working solutions. Growth medium was aspirated and replaced 
by palmitate-containing medium, which was refreshed every 24 hours. At the 
end of the experimental time period, cell death was assayed by PI exclusion.
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Dose (mM) Stock (mM) BSA (10%) Ethanol (50%) Palmitate (50 
mM) 
Control 0 630 µL 70 µL 0 µL 
0.025 0.25 630 µL 66.5 µL 3.5 µL 
0.05 0.5 630 µL 63 µL 7 µL 
0.1 1 630 µL 56 µL 14 µL 
0.25 2.5 630 µL 35 µL 35 µL 
0.5 5 630 µL 0 µL 70 µL 
Table 4.3. Composition of the stock solutions for the palmitate dose response.
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4.2.14 PCR amplification of shRNA constructs for sequencing 
The targeting regions of the shRNA constructs were PCR amplified in two 
steps. The first reaction was setup as in Table 4.4 with primers specified in 
Table 4.5. PCR products were separated by electrophoresis on a 1.5% agarose 
gel and purified as in section 2.2.7. PCR products of the correct size were 
extracted from the gel, quantified using Qubit and all the pools mixed in equal 
proportions. This mix was then used as template for a second round of 
amplification set up as in Table 4.6. This second round introduced sample-
specific adaptor sequences for the Illumina sequencer using a different 
combination of Nextera index primers for each sample (T0: N711 and S517, T7: 
N711 and S502, T14: N711 and S503, P: N711 and S504, Control: N711 and 
S505).
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Component Volume 
Q5 buffer 5X 20 µL 
dNTP mix (10 mM) 2 µL 
Forward primer (10 mM) 5 µL 
Reverse primer (10 mM) 5 µL 
Betaine 20 µL 
Q5 polymerase 1 µL 
DNA 3 µL 
Water 44 µL 
Table 4.4. Composition of a single PCR reaction for the first step of the shRNA targeting 
sequence amplification.
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Primer Sequence Condition 
amplified 
Twostep_hiseq1 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGTCGAGGTCGACGGTCGACGGTAT T14 and Control 
Twostep_hiseq2 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGATCTCTGAAGGTCGACGGTA T0 
Twostep_hiseq8 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCGATCTCTCGAGGTCGAC T7 
Twostep_hiseq4 TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGGAGGTCGACGGTATCGAT Palmitate 
Twostep_hiseq6 GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGTGTCTTTGGATTTGGGAATC Reverse, 
common to all 
Table 4.5. Primers used for the first step amplification of the shRNA targeting sequences for each condition.
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Component Volume 
Q5 buffer 5X 20 µL 
dNTP mix (10 mM) 2 µL 
Forward primer (10 mM) 5 µL 
Reverse primer (10 mM) 5 µL 
Betaine 20 µL 
Q5 polymerase 1 µL 
DNA 50 ng 
Water Up to 50 µL 
Table 4.6. Composition of a single PCR reaction for the second step of the shRNA 
targeting sequence amplification.
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4.2.15 Purification of amplified DNA using Agencourt Ampure XP beads. 
PCR products containing the shRNA targeting sequences amplified as in 4.2.14 
were purified using a bead system (Agencourt Ampure XP) following the 
manufacturer instructions and eluted in 40 µl of TE buffer. 
4.2.16 Analysis of sequencing data. 
The sequencing output was received as one .fastq file per sample, which were 
transferred to a UNIX server. Sequencing reads were extracted to plain text files 
using the command “grep” on the command line. As the samples were already 
in different files, reads containing shRNA targeting sequences were directly 
extracted from the corresponding file using the shRNA loop sequence instead of 
the PCR primer as in section 3.2.8. The Python scripts generated for the 
Chapter 3 were used to produce a file with the targeting sequences found in the 
reads and the number of reads containing each sequence in the sequencing 
data. These files were merged using Stata to produce one file with the number 
of reads containing each sequence in each sample. Similarly to the procedures 
in chapter 3, sequences with less than 50 reads in any of the control samples 
were coded as “missing data” in that sample. Then, raw number of reads were 
converted to reads per million per pool, and the ratio of (experimental condition) 
to (control condition) was calculated. From this ratio, a robust z-score was 
determined for assessment of construct effects. Figure 4.1 depicts this analysis 
pipeline, and the Stata do-files corresponding to this analysis steps can be 
found in Appendix 7. 
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Figure 4.1. Schematic depiction of the analysis pipeline used.  
Sequencing reads were extracted from the .fastq files in a UNIX server using the command “grep”. Reads were aligned to the shRNA library 
and counted to produce a file containing the number of reads per shRNA construct. These raw number of r eads were converted to reads per 
million per library pool. A ratio of each experimental condition to the appropriate control (T0 for the proliferation screen samples, C for the 
palmitate sample) was calculated and used to build robust z-scores as estimates of shRNA construct effect sizes. 
T0 fastq. file T7 fastq. file T14 fastq. file Control fastq. file Palmitate fastq. file 
T0 reads per 
construct 
T7 reads per 
construct 
T14 reads per 
construct 
Control reads per 
construct 
Palmitate reads per 
construct 
T0 reads per 
million per pool 
T7 reads per 
million per pool 
T14 reads per 
million per pool 
Control reads per 
million per pool 
Palmitate reads per 
million per pool 
T7 rpmp/T0 rpmp T14 rpmp/T0 rpmp P rpmp/C rpmp 
Palmitate z-score T7 z-score T14 z-score 
Proliferation screen Resistance to death by lipids screen 
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4.2.17 Design of the screening process 
A genome wide RNAi screen using a shRNA library was designed to identify 
genes with functions on β-cell proliferation and resistance to death induced by 
lipids. The screening process will be explained in more detail in the sections to 
follow, but a simplified schematic depiction of the screening strategy is shown in 
Figure 4.2 
Briefly, the library of shRNA targeting sequences described in section 2.4 was 
packaged into retroviral particles using an ecotropic packaging cell line 
(Phoenix). The retroviral particles were then used to transduce a β-cell line 
(R7T1) which conditionally expresses an oncogene in the presence of 
doxycycline. Cells containing the library sequences were selected using 
puromycin and cultured in absence of doxycycline for seven days to remove the 
expression of the oncogene. A control sample (“T0”) was then harvested and 
the rest of the cells entered one of the screening processes. 
For the first screen, cells in the ‘proliferation’ screen were cultured in absence of 
doxycycline for seven or fourteen days and then harvested, constituting the “T7” 
and “T14” proliferation samples respectively. 
For the second screen, cells in the ‘death by lipids’ screen were cultured in 
absence of doxycycline and exposed to palmitate or vehicle-only treatments for 
96 hours. Cells were then harvested to constitute the “P” and “C” samples 
respectively. 
DNA was extracted from all the samples and the shRNA targeting sequences 
were PCR amplified and sequenced to be used as a proxy for cell number. 
Increases in representation of the shRNA targeting sequences in the 
experimental samples with respect to their controls were assessed using robust 
z-scores. These z-scores were used to identify and prioritize those shRNA 
targeting sequences with a stronger effect on cell number, yielding a list of 
genes of interest (GOI) for each phenotype screened – increase of proliferation 
of a β-cell line in the absence of an oncogene and increase in the resistance to 
death induced by palmitate of a β-cell line in the absence of an oncogene. 
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Figure 4.2. Schematic simplified overview of the screening process 
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4.3. Results 
4.3.1. Description of the cell line used as a β-cell in vitro model 
R7T1 is a mouse insulinoma cell line reversibly immortalized with the SV-40 
large T oncogene expressed under a tet-on system. The oncogene expression 
is activated in the presence of tetracycline or one of its analogues. As a 
consequence, this cell line is reversibly immortalized. The cell line was 
maintained in culture with expression of the oncogene by addition of a 
tetracycline analogue (doxycycline, DOX) to the growth medium. 
R7T1 has not been extensively used as an in vitro model of β-cells and it was 
therefore necessary to assess its suitability. Expression of widely used markers 
of β-cell and non-β pancreatic cells was assessed using QRT-PCR. It was also 
of interest to investigate whether a higher level of expression of the oncogene 
affected the expression of these markers. RNA was extracted from cells 
cultured in presence of DOX to constitute an “oncogene positive” sample. An 
“oncogene negative” sample was obtained from cells cultured in the absence of 
DOX for seven days. These RNA samples were used to obtain cDNA and then 
perform qPCR. MIN-6 cells, a widely used mouse insulinoma cell line that 
expresses the SV40 large T antigen, was used as the positive control for β-cell 
markers and as a negative control for makers of other pancreatic cell lineages. 
Reactions were performed in duplicate using SYBR green dye and two 
biological replicates were analysed. Tbp was used as the housekeeping gene to 
normalise expression levels in all cell lines. Relative expression levels in R7T1 
compared to MIN6, represented as ΔΔCt, are depicted in Figure 4.3. These 
results suggest that expression of the oncogene may alter the level of 
expression of several of these markers, including insulin. Expression of insulin 
is highly downregulated when expression of the oncogene is induced in the 
presence of DOX. In the absence of oncogene expression induction, R7T1 cells 
express similar levels of β-cell markers (Ins, Pdx1, Kcnj11, Nkx6.1 and NeuroD) 
to MIN6, a widely used in vitro model of β-cells. Relative expression of markers 
for other pancreatic lineages is highly variable. This is due to the variation on 
expression of these markers in MIN6 rather than to a high level of expression in 
R7T1 cells. Expression of Cftr, a marker of duct cells, is very low in R7T1 but 
almost undetected in MIN6, which yields a high fold level of expression. This is 
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true also for Sst, a marker for δ-cells and Cpa1, expressed in exocrine 
pancreatic cells. The opposite situation is seen in the fold of expression of Gcg 
(glucagon, a marker of alpha cells). Expression of Gcg is detected in R7T1 but it 
is much higher in MIN6, which causes the fold expression to appear undetected. 
The expression of Gcg in MIN6 has been previously reported (Lima, Docherty et 
al. 2012). 
To obtain a more meaningful comparison the expression of the pancreatic 
markers was studied using a pancreatic cell line (DT508M) as a control instead 
of MIN6 (Figure 4.4). These cells are ductal cells derived from a KrasLSL-G12D/+ 
mouse (Allard et al., under review) and hence are essentially normal apart from 
hemizygous expression of Kras. This comparison indicates that the expression 
of other pancreatic cell markers in R7T1 is not very different from a non-β-cell 
pancreatic cell line. Expression levels of Gcg appear to be higher in R7T1 than 
in DT508M while Sst and Cpa1 tend to be less expressed in R7T1. 
Therefore, R7T1 cells in the absence of oncogene expression stimulation 
express similar levels of β-cell markers to MIN6 and higher levels of Cftr, Sst 
and Cpa1, and lower levels of Gcg. The expression of these last four markers of 
non-β-cell pancreatic lineages is similar to that of a non-β-cell cell line. 
The QRT-PCR results also highlighted that the presence of DOX in the growth 
medium produced a change in expression on some of the markers under study. 
Importantly, the expression of insulin was highly downregulated in the presence 
of DOX. As the presence of DOX stimulates the expression of the oncogene, 
this change in expression indicates an effect of the oncogene expression and 
provides additional value to the use of a reversibly immortalized cell-line. 
To evaluate the presence of the oncoprotein in R7T1 cells in the presence and 
absence of DOX, cells were cultured for different time lengths in the absence of 
DOX and then fixed. The oncoprotein was then detected by 
immunocytochemistry (ICC). The microscopy pictures in Figure 4.5 confirm that 
the levels of the SV40 large T antigen oncoprotein diminish in absence of DOX. 
Downregulation of oncogene expression was predicted to have a direct effect 
on cell proliferation rate. As β-cells in vivo present a very low proliferation rate 
(Butler, Janson et al. 2003, Meier, Butler et al. 2008, Reers, Erbel et al. 2009) it 
was important to determine how different the proliferation rate of R7T1 was in 
absence of DOX. BrDU incorporation was assessed in R7T1 cells cultured in 
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absence of DOX for the same length of time used for the oncoprotein. Cells 
were incubated with BrDU overnight and then fixed. BrDU incorporation was 
detected as explained in section 4.2.2. Microscopy pictures of this are shown in 
Figure 4.6. BrDU incorporation, and therefore number of cells that have 
synthesized DNA, diminishes with in the absence of DOX. This decrease 
depends on the time that the cells are cultured without DOX.
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Figure 4.3 Levels of expression of β cell markers (A, C) and markers of other pancreatic lineages (B, D) in R7T1 in presence (+ ) or absence (-) 
of DOX (A, B). 
C and D: expression levels in absence of DOX. All expressed as ΔΔCt normalized to expression in MIN6 cells.  
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Figure 4.4. Levels of expression of non-β-cell pancreatic lineages in R7T1 cells. 
 A) R7T1 in presence (+) or absence (-) of DOX. B) R7T1 in absence of DOX (bars indicate the 95% CI) All exp ressed as ΔΔCt normalized to 
expression in DT508M pancreatic cells. 
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Figure 4.5. Immunocytochemistry detection of large T Antigen (TAg) in R7T1 before and 
after withdrawal of DOX. 
 A) SVE cells, positive control for TAg. B) R7T1 cells cultured in the presence of DOX. C) 
R7T1 cells cultured in absence of DOX for 1 day. D) R7T1 cells cultured in absence of 
DOX for 2 days. E) R7T1 cells cultured in absence of DOX for 3 days. F) R7T1 cells 
cultured in absence of DOX for 5 days. G) R7T1 cells cultured in absence of DOX. H) 
R7T1 cells cultured in the presence of DOX, no primary antibody negative control. 
A) B) C) 
D) E) F) 
G) H)  
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Figure 4.6 Immunocytochemistry detection of BrDU incorportation in R7T1 before and 
after withdrawal of DOX. 
A) MIN6 cells, positive control for BrDU incorporation. B) R7T1 cells cultured in the 
presence of DOX. C) R7T1 cells cultured in absence of DOX for 1 day. D) R7T1 cells 
cultured in absence of DOX for 2 days. E) R7T1 cells cultured in absence of DOX for 3 
days. F) R7T1 cells cultured in absence of DOX for 5 days. G) R7T1 cells cultured in 
absence of DOX. H) R7T1 cells cultured in the presence of DOX, no primary antibody 
negative control. 
A) B) C) 
D) E) F) 
G) H)  
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4.3.2. Design of the screening process 
A genome wide RNAi screen using shRNA constructs was designed to search 
for genes involved in β-cell proliferation and resistance of β-cells to death 
stimulated by chronically high levels of lipids. 
A schematic representation of the screening process is depicted in Figure 4.1. 
The in-house amplified NKI library was transfected into Phoenix cells, which 
packaged the shRNA constructs into retroviral particles as described in section 
4.2.4. These retroviral particles were then used to transduce R7T1 cells.  
A schematic timeline of the different steps in the screen is depicted in Figure 4.7. 
Briefly, 72 hours after transduction cells which had stably integrated the viral 
construct were selected with puromycin. Puromycin resistant cells were cultured 
in absence of DOX for seven days before starting the experimental conditions. 
A sample was collected before any further experiments. This sample constituted 
the proliferation control and was named T0. Two screening processes took 
place simultaneously: a proliferation screen, which consisted on culturing the 
cells in absence of DOX for 7 or 14 days; and a resistance to death screen, 
which consisted in culturing the cells for 96 hours in absence of DOX and in 
presence of either a solution of palmitate in ethanol (death sample) or just 
ethanol (vehicle-only sample). Cells were collected at the end of their respective 
experiments and genomic DNA was extracted. shRNA targeting sequences 
were then amplified and sequenced. 
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Figure 4.7. Schematic timeline of the screening process.  
In tones of red, steps to prepare the cells. In blue, the resistance to death screen. In 
tones of purple, the proliferation screen. T0, T7, T14, Palmitate and Vehicle -only control 
are the four samples produced by the screen and indicate the points in the timeline when 
those samples are collected. 
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4.3.3. Optimization of the delivery of shRNA constructs 
Initial attempts at delivering the library using the protocols already optimized for 
the screening process described in Chapter 3 showed a much lower success 
rate, with no more than 1% of the cells surviving puromycin selection. To 
assess whether this was problem with the transduction efficiency or with the 
puromycin used, 3T3supp+ fibroblasts were transduced with a GFP expressing 
retroviral construct as a positive control. Transduction levels of approximately 
30% were detected when using the transduction protocol as in Chapter 3. The 
reasons for this low transduction rate in R7T1 were investigated in order to 
produce an optimized workflow. 
The transfection of the Phoenix cells was optimised to increase the number of 
retroviral particles obtained. Transfection levels were first investigated using a 
GFP expression plasmid. Transfections using Turbofect as in Chapter 3 showed 
that approximately 70% of the Phoenix packaging cells expressed the 
fluorescent protein. Although this transfection efficiency is not low it was still 
optimized to maximize the number of cells producing retroviral particles. An 
attempt to optimize the rate of transfection using Turbofect did not yield any 
higher transfection rates. However, calcium-phosphate transfection using a 
commercial kit (Promega) resulted in a higher transfection efficiency of around 
95%. 
The retroviral medium produced using the newly optimized transfection protocol 
was used to transduce R7T1 cells. However, the transduction levels were not 
changed, indicating a limiting step in the transduction. It has previously been 
reported that β-cells are not as readily transduced as other types of cells, and 
that dispersion of cells could increase the transduction rate (Dupraz, Rinsch et 
al. 1999). Dispersion of R7T1 was therefore tried as a method to increase 
transduction rates Figure 4.8). Dissociation of R7T1 did increase the 
transduction rate to approximately 5%, but that increase was not enough for an 
efficient screening process. It was then investigated whether the limiting step 
was uptake of the viral particles by the cells. 
The virus produced by the ecotropic Phoenix cells is internalized into cells after 
binding a membrane receptor (Scl7a1). This step is necessary for the virus to 
deliver the plasmid into the transduced cells. The levels of expression of the 
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ecotropic viral receptor were measured using QRT-PCR. The expression level 
of the viral receptor was 10 times lower than in the SV40 transformed 3T3 cell 
line that was successfully transduced in Chapter 3. This difference could explain 
the lower transduction rate obtained in R7T1. Several options were then studied: 
to increase the concentration of viral particles, to increase the levels of the 
ecotropic receptor on the R7T1 cell membrane and to deliver the virus using 
receptor-independent methods. 
Two methods were evaluated to increase the concentration of viral particles: a 
commercial retrovirus concentrator solution (Retro-X, Clontech) and a solution 
of polyethylene glycol (PEG). Both methods rely on the same principle: viral 
particles get included into heavy complexes during an incubation step. These 
viral complexes are then pelleted by centrifugation. Supernatant can then be 
discarded and the pellet re-suspended in a lower volume of growth medium, 
producing a concentrated retroviral medium. 
To increase the levels of the ecotropic receptor on R7T1 cell membrane, 
Clontech’s Ecotropic Receptor Booster was tested. This commercial reagent 
consists on lipid vesicles containing molecules of the receptor which are 
incorporated into the cell membrane and transiently raise the receptor levels. 
Retroviral particles were complexed with calcium phosphate and with a 
commercial solution (Viraductin) to attempt a receptor-independent delivery. 
Delivery with Viraductin can be coupled with a concentration step as the virus is 
complexed and pelleted. 
These methods were tried using the same retroviral supernatant and R7T1 cells 
grown in parallel to keep these variables constant across this comparison. 
Representative images of cells expressing GFP are shown in fluorescent 
microscopy pictures in Figure 4.9. Concentration of the virus using PEG and 
RetroX produced transduction rates of approximately 10%, similar to the rate 
obtained using the Ecotropic receptor Booster to increase virus binding to the 
membrane. Viraductin-aided delivery of 2-fold concentrated viral supernatant 
produced a transduction rate of approximately 25% while the use of virus in 
complex with calcium phosphate did not increase the transduction rate above 
1%. Thus, Viraductin-aided delivery following concentration of the viral 
supernatant 2-fold was used in the screening process.
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A) 
 
B)  
C)  D)  
E) 
 
F)  
Figure 4.8. Fluorescence (A, C, E) and visible light (B, D, F) microscopy pictures of 
3T3supp+ (A, B), R7T1 without prior dissociation (C, D) and R7T1 with dissociation prior to 
transduction (E, F).
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A)  B)  
C) D)  
E)  F)  
G)  H)  
I)  J)  
Figure 4.9. Fluorescence (A, C, E, G, I) and visible light (B, D, F, H, J) microscopy 
pictures of R7T1 cells transduced with PEG concentrated virus (A, B), RetroX 
concentrated virus (C, D); and R7T1 transduced with virus aided by the addition of 
ecotropic receptor booster (E, F), Viraductin and 2-fold concentration (G, H) and virus 
complexed with calcium phosphate (I, J)..
280 
 
4.3.4. Optimization of the screening process 
4.3.4.1 Choice of the reversibly immortalized β-cell line used 
The aim of the screen was to find genes which had an effect on any of two 
phenotypes: β-cell proliferation rate and resistance of β-cells to death caused 
by excess of lipids in the microenvironment. The proliferation rate of β-cells in 
vivo is known to be very low (Dor, Brown et al. 2004, Meier, Butler et al. 2008) 
compared to the proliferation rate of immortalised, oncogene-expressing β-cell 
lines routinely used in the literature. Therefore, studying changes in proliferation 
rate using these cell lines is not likely to yield results that are easily transferred 
to an in vivo situation. Also, the expression of an oncogene used to immortalize 
a cell line could alter the expression of other genes and lead to the detection of 
changes in the phenotype that would not happen in vivo. To better approximate 
a physiologically relevant level of cell proliferation, a reversibly immortalized β-
cell line was used. 
4.3.4.2 Optimization of the resistance to death by lipids screen 
Fatty acids are chronically elevated in type 2 diabetes (Paolisso, Tataranni et al. 
1995, Charles, Eschwe`ge et al. 1997) and elevated levels of circulating free 
fatty acids are associate with risk of T2D (Pankow, Duncan et al. 2004). 
Abnormally high levels of fatty acids have been shown to be toxic to β-cells 
(Shimabukuro, Zhou et al. 1998, Maedler, Spinas et al. 2001, Lupi, Dotta et al. 
2002, Piro, Anello et al. 2002). Although palmitate is one of the most abundant 
fatty acid in circulation and elevated in type 2 diabetes the mechanism by which 
it might cause β-cell dysfunction remains under-characterized. Therefore an 
RNAi screen was designed to investigate mechanisms of protection of β-cells 
from palmitate-induced toxicity. 
Two conditions were optimized for this screening process: the concentration of 
palmitate that cells would be exposed to and the duration of the stimulus. As 
type 2 diabetes is a chronic condition, longer exposure to a lower level of 
stimulus was thought to be more physiologically relevant. 
A palmitate dose-response curve was performed as stated in section 4.2.13 
after reversal of immortalization (Figure 4.10). Palmitate treatment is commonly 
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performed with serum-free media. However, when cells were cultured in 
absence of palmitate and without serum (Figure 4.10 A), the level of cell death 
was still high. The difference in survival between the control condition (0 mM 
palmitate) and the treatment condition limits the resolution of the screening 
process through the setting of the maximum effect size. This maximum effect 
size corresponds to the highest protection level that the downregulation of a 
certain gene may have. A targeting sequence with a full protective effect would 
approximate the number of cells surviving the palmitate treatment to the number 
of cells surviving the control condition. Therefore, if the difference between 
these two numbers is small, the maximum effect size is also small. For the 
reason explained above, the exposure to palmitate needed to be of a chronic 
nature. However, long periods of culture in the control condition produced high 
rates of cell death. One of the reasons for this high rate of cell death might have 
been a toxic effect of the vehicle. Another reason might be a starvation effect by 
which cells in complete absence of serum were dying after 96 hours. To assess 
whether this might be the case, an additional dose-response curve was 
performed in the presence of 1% FBS for 72 and 96 hours (Figure 4.10 B). The 
supplementation with 1% FBS had a protective effect on the cells. The level of 
cell death after 96 hours in culture with 0.5 mM palmitate in the presence of 1% 
FBS approximated the level of cell death after 72 hours with no serum 
supplementation. Importantly, the level of cell death in the control condition (0 
mM palmitate) was also reduced. However a lower death rate in the control 
condition with no serum was found in this second experiment. This may be due 
to a different batch of BSA being used. 
The difference in cell death rate between the control and the 0.5 mM palmitate 
treatment conditions was highest in the presence of 1% FBS for 96 hours. 
These conditions (0.5 mM palmitate in 1% BSA, 1% FBS DMEM) were selected 
for the screening process. 
4.3.4.3  Optimization of cell seeding. 
In pooled RNAi screens the targeting sequences are delivered to a stock of 
cells that are then subdivided and seeded onto the plates or dishes and 
exposed to the conditions being studied. This allows a first sample of cells being 
collected at the time of seeding that will inform of the representation of the 
targeting sequences used at the time of plating. However, several aspects had 
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to be considered in the screen being described due to the nature of the in vitro 
model used. 
Firstly, the shRNA constructs had to be delivered prior to the oncogene 
expression reversal as retroviral particles will only infect dividing cells. As the 
screen was to be performed after reversion of the oncogene expression, this 
added seven days of growth after transduction. During this time the 
representation of the targeting sequences might have changed. Hence, the 
control sample which is usually collected before the screening would have to be 
collected after the reversion time. 
Secondly, cells had to be puromycin selected before growth arrest. After seven 
days of culturing R7T1 cells in the absence of DOX cell death was evident. This 
led to a lower cell density and seemed to impair puromycin resistance even in 
those cells that expressed the resistance gene as determined by the co-
expression of a fluorescent protein. Therefore, puromycin selection was 
implemented after transduction and before the start of the growth arrest period. 
Lastly, R7T1 cells do not plate efficiently after detachment from a culture 
surface. It was observed during the culture of R7T1 that when they were 
trypsinized and plated onto a new surface less than 30% of cells seeded and 
grew. This aspect of the culture was managed during routine subculture by 
plating an excess of cells onto the new culture surface. During the screening 
process however this would require the transduction of more than three times 
the amount of cells required for the screen which in turn increased the viral 
supernatant required. Implementing these changes would reduce the efficiency 
of the screen and therefore an alternative solution was investigated. A non-
enzymatic dissociation reagent was assessed as an alternative to trypsin but 
the re-plating efficiency was not increased. The re-plating step was then 
avoided by seeded R7T1 onto the screening dishes before transduction. Cells 
were then puromycin selected and growth arrested in the plates that underwent 
the screening process, with no re-seeding steps. 
It has already been explained in Chapter 3 the importance of representation in 
RNAi screens. A literature search indicated that 1,000 cells per sequence would 
provide adequate levels of representation for a drop-out screen (Sims, Mendes-
Pereira et al. 2011). Library pools formed by 384 different shRNA constructs 
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were kept separate, so for each experiment 384,000 cells were required for 
each condition after puromycin selection and immortalization reversal, 
processes which also had an effect on cell survival. To avoid lack of 
representation due to stochastic drop out during the oncogene expression 
reversal process, it was estimated that an average of 500,000 cells should 
remain after puromycin selection and prior to reversal of oncogene expression. 
As described in section 4.3.3, the transduction protocol that I optimised resulted 
in approximately a MOI of 0.3. To obtain 500,000 cells using a 0.3 MOI, 1.5 
million cells needed to be exposed to the retroviral medium. A well in a 6-well 
multiwell plate contains approximately 1.6 million R7T1 cells at 70% confluency 
(determined experimentally). Therefore, one well was used for each screening 
condition: time 0 (T0), proliferation for seven days (T7), proliferation for fourteen 
days (T14), cells exposed to palmitate for 96 hours (P) and cells exposed to 
vehicle only for 96 hours (C). 
To facilitate the treatment of cells, each condition was performed in separate 6-
well plates, so that each 6-well plate would contain cells for six different library 
pools that underwent the same conditions during screening, one well per pool. 
This approach has been summarised in Figure 4.11. Phoenix cells were plated 
in 10 cm dishes and transfected. Five wells of R7T1 in five different plates were 
infected with the retroviral medium for each pool as explained in section 4.2.9. 
The cells were puromycin selected for 48 hours and then DOX was withdrawn 
from the growth medium. Cells were grown in the absence of DOX for seven 
days. Then, cells in the T0 6-well plates were harvested and stored at -20ºC. 
The rest of the cells were used in either the proliferation screen or the 
resistance to death by lipids screen. 
For the proliferation screen, cells in two wells per pool were kept growing in 
growth medium without DOX, which was renewed every three days. After seven 
days of growth, cells in one of the wells were harvested and stored at -20ºC, 
constituting a T7 sample. Cells in the other well were kept growing for seven 
more days and then harvested and stored at -20ºC (T14 sample). 
The resistance to death by lipids screen was carried out at the same time as the 
proliferation screen. Two wells of cells per library pool were used for this screen. 
One well was treated with palmitate (P sample) and another with ethanol, 
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vehicle-only control termed “C sample”. Wells were exposed to the appropriate 
treatment for 96 hours, with the treatment being refreshed every 24 hours. At 
the end of the treatment period cells were harvested and pelleted. Pellets were 
stored at -20ºC until DNA extraction. 
DNA extractions were performed in parallel for all the pools and all the 
conditions to avoid a potential source of technical variability that could arise 
from extracting the DNA in different days. 
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Figure 4.10. Palmitate dose-response curves. 
A) Dose-response curve for 4 time-points (24 hours, 48 hours, 72 hours and 96 hours) in absence of serum. B) Dose-response curve for two 
time-points (72 hours and 96 hours) in absence of serum and in presence of 1% FBS.  
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Figure 4.11. Simplified representation of the transduction scheme.  
Each colour represents a different library pool. Retroviral medium for each of the six pools 
represented was used to transduce five wells in five different plates, one per screening 
condition. Each 6-well plate contained cells transduced for six different pools.
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4.3.5. Optimization of shRNA construct recovery from R7T1 cells 
This screening process used sequencing and counting of the shRNA targeting 
sequences as a proxy for the number of cells containing each shRNA construct 
as each cell contained a single shRNA targeting sequence inserted into the 
genome. Cells containing a targeting sequence with a positive effect on 
proliferation will divide more rapidly than cells containing targeting sequences 
with no effect on this phenotype and hence increase the number of a particular 
shRNA targeting sequence. As the proliferation rate of R7T1 after growth arrest 
is very low, only increases in proliferation rate were considered. Similarly if the 
effect of a targeting sequence resulted in the protection from cell death caused 
by palmitate, cells containing that sequence would be more abundant in the 
palmitate sample than cells containing other sequences with no effect on 
protection. 
Targeting sequences therefore had to be extracted from the cells, amplified in a 
linear manner and sequenced to quantify their representation in the screening 
samples. 
Cells were stored as pellets at -20ºC after the screen. Cell pellets were thawed 
and genomic DNA was extracted as explained in section 2.2.2 for all samples 
simultaneously to reduce variation (Sims, Mendes-Pereira et al. 2011). DNA 
was then used as a template for PCR amplification of shRNA constructs. 
Genomic DNA extractions and PCR amplifications were performed in parallel 
for all samples again to reduce any potential variation. The expected amount of 
genomic DNA extracted from the screening samples is lower than in the screen 
in Chapter 3. This difference was also increased due to the absence of a co-
culture condition in this screen. However, the entirety of the genomic DNA 
extracted belonged to R7T1 cells containing the shRNA targeting sequences 
and therefore one copy of the targeting sequence was expected for each copy 
of genomic DNA. Therefore the extracted DNA was not further processed 
before PCR amplification as it was not necessary to enrich the DNA samples in 
targeting sequences in contrast with the screening process in Chapter 3. 
A pilot project was run to investigate the level of reproducibility of the screen 
(section 4.3.6). The shRNA targeting sequences were amplified as optimized in 
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Chapter 3 and sent to be sequenced. However, analysis of the sequencing data 
of this pilot project together with observation of agarose gel pictures revealed 
that the PCR amplification yielded multiple bands, possibly due to the formation 
of secondary structures, which could affect the sequencing output. Figure 4.12 
depicts an agarose gel picture showing both a band for the expected shRNA 
PCR product and a slower migrating band, probably the result of a 
polymerization and tertiary structure of the amplification products. 
Inspection of the sequencing data revealed that a high amount of adaptor 
dimers was seen in the sequencing output, pointing to a possible decrease in 
ligation efficiency (Figure 4.17). The presence of these adaptor primers limited 
the number of sequencing reads obtained from each HiSeq lane. To avoid any 
decrease in sequencing efficiency that these abnormal configurations could 
cause a two-step PCR amplification strategy was adopted that eliminated any 
adaptor ligation steps (section 4.2.14). A first round of amplification was 
performed with sample-specific primers that incorporated a short sequence 
complementary to a second primer pair. This second pair of primers was used 
in a second round of amplification and introduced the Illumina barcodes and 
primer binding sites necessary for the sequencing process. 
PCR amplification has the potential to alter sequence representation as has 
been discussed in Chapter 3. To reduce any bias introduced by the PCR 
reactions, amplification cycles were minimized using the optimization strategy 
described in section 3.3.5. 
The shRNA secondary structure of different DNA templates can affect PCR 
amplification. This issue has been discussed (Strezoska, Licon et al. 2012) and 
solved by the supplementation of the PCR reaction with a relaxing agent such 
as DMSO or betaine. Addition of betaine to the PCR amplification reactions 
resulted in a reduction of the slower migrating bands in the electrophoresis gels. 
Betaine was therefore used in the two rounds of PCR reactions to relax any 
secondary structures and facilitate the amplification. PCR products thus 
produced were quantified using a Qubit fluorometer and mixed in equal 
proportions. They were then purified (section 4.2.15) and quantified again using 
Qubit and Tapestation. Amplified DNA samples were then submitted for 
sequencing to the University of Exeter Sequencing Service. 
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Figure 4.12. Results of a PCR amplification of 3 samples from the pilot project.  
L: 100 bp NEB DNA ladder. 1: sample with an extra band (marked by blue rectangle), and 
a band of the expected size. 2: sample with a band of the expected size. 3: failed 
amplification. 
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4.3.6. Reproducibility of the screening process 
A pilot project (section 4.3.6) was performed to determine the reproducibility of 
the screen design before the final screening process. Although a reproducibility 
pilot had already been performed for the screening process in Chapter 3, it was 
reasoned that the screening processes were different enough both biologically 
and technically that the reproducibility needed to be assessed in this case as 
well. 
Biologically there are many differences that could alter the reproducibility when 
compared to the screening process in Chapter 3. Firstly, R7T1 cells undergo a 
period of oncogene expression reversal that results in a high rate of cell death. 
If this cell death is random and not affected by any targeting sequence it would 
be expected that the number of cells containing each sequence would be 
reduced in a similar way across all wells of any library pool as cells are 
transduced with the same stock virus. However, if the virus containing the 
targeting sequences was not distributed equally amongst the wells some of the 
targeting sequences could be represented more often in some wells than others. 
This can happen as a result of a sampling effect due to the low representation 
of certain sequences in the library, which leads to their under-representation in 
the virus and therefore in the cells. Cell death could then result in the 
elimination of those under-represented sequences from some of the wells. 
It was also considered that the proliferation rate of R7T1 cells is very low when 
the oncogene expression has been reduced. Where transformed cells in the 
screening process, described in Chapter 3, will proliferate quickly and therefore 
the screen samples will contain abundant cells with each targeting sequence, 
the number of R7T1 cells would not increase as much. This could result in a 
sampling effect if the PCR amplifications were not performed with enough 
template DNA. 
To assess the performance of the experimental design and the biological and 
technical variation introduced before the sequencing, a pilot project was run. 
Two pools were run in duplicate in parallel. Transfections, transductions and all 
tissue culture steps were performed at the same time in parallel independent 
cell cultures. DNA was extracted, amplified, purified and mixed separately. PCR 
amplification of the T14 sample in replicate A was not successful and as the 
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purpose of this pilot project was to compare both replicates the T14 sample in 
replicate B was not sequenced. 
Replicates were sequenced in the same Illumina HiSeq 2500 lane but with 
different Illumina adaptors. The sequencing output was received as two 
separate .fastq files, each one containing all conditions for one of the replicates 
as the sequencing service separated them using the Illumina adaptor 
sequences. The sequencing run produced 2,738,774 reads for replicate A and 
2,722,427 for replicate B. Of these, 172,242 reads were identified by FastQC as 
adaptor primers in sample A and 311,160 in sample B (Figure 4.13). In the latter, 
FastQC also detected two 50bp overrepresented sequences that correspond to 
the vector sequence. These sequences were removed from all subsequent 
analysis and quantification. 
The “grep” command in UNIX was used to extract the reads containing the 
correct sequencing primer sequencing for each of the conditions screened. This 
process has been explained in Chapter 3 (section 3.2.8). Table 4.7 contains the 
numbers of sequencing reads containing an exact match for the sequencing 
primer used to identify each screening condition. As the pilot project was 
composed of two library pools of 384 sequences each, 768 targeting sequences 
were expected. If all of the sequences were present in the sequencing data, an 
average of 523 reads would be obtained for each targeting sequence. This is 
one half of the target depth and therefore a higher number of sequencing reads 
was requested for the sequencing on the final screen. 
Once the reads containing the primers had been de-multiplexed into a file for 
the condition that they pertained to, the targeting sequences were extracted. 
This was performed as described for the screen in Chapter 3. Custom Python 
scripts (described in section 3.2.8 and in full in Appendix 3) were used to extract 
the shRNA targeting sequences and the number of sequencing reads which 
contained each targeting sequence to text files. Briefly, the script identifies the 
sequence of the shRNA loop when it is present in a sequencing read. Then, it 
records the 19bp sequence just before the start of the loop sequence as a 
“potential shRNA targeting sequence”. Once all the potential sequences have 
been identified, the script records the occurrence of each individual sequence. 
The potential shRNA targeting sequences identified and their occurrence are 
written to a text file. The number of potential shRNA targeting sequences found 
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at least once in each condition and replicate are summarized in Table 4.8. 
These files were imported into Stata and aligned to the expected sequences 
according to the theoretical composition of the pools screened. Table 4.9 shows 
the number of constructs that were present in the output for each condition in 
both replicates. The degree of overlap of the expected targeting sequences 
amongst the four conditions (T0, T7, P and C) was investigated for each 
replicate. It was expected that most sequences would be common for all 
conditions and that the controls might have some sequences that were not 
identified in the experimental conditions due to the cell death experienced 
during the treatment with palmitate and the additional week of culture in 
absence of DOX between T0 and T7. Venn diagrams representing these 
overlaps were drawn for replicate A (Figure 4.14) and replicate B (Figure 4.15) 
and confirm that this was the case. 
The number of reads in replicate B was lower than in replicate A and in turn the 
number of potential shRNA targeting sequences and the number of expected 
targeting sequences detected in replicate B were also lower. The palmitate 
sample in replicate A has the highest number of potential targeting sequences 
identified but not the highest number of reads or expected targeting sequences. 
The palmitate sample is exposed to a toxic stimulus that greatly reduces the 
number of cells. This results in less template DNA which should lead to less 
targeting sequences being detected. Upon investigation of the potential 
targeting sequences it was evident that a large proportion of the potential 
targeting sequences (6,188 sequences) had only one read in the sequencing 
data. This could indicate that those sequences might be derived from other 
sequences by a polymerase-introduced error at either the PCR amplification or 
the sequencing processes. 
Equivalently to the approach implemented for the analysis of the data in 
Chapter 3, a threshold was established for the number of reads that a targeting 
sequence had to have been assigned for it to be considered present in the 
dataset. This threshold was used only in the control samples (T0 and C). 
Targeting sequences with lower amounts of reads were set to “missing” in the 
Stata dataset so that they were not used in any further calculations. 
Variability between replicates was assessed using correlations. Table 4.10 
shows the correlation matrix for the raw reads amongst all conditions and 
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replicates. These correlations are all above 0.500 indicating an acceptable 
degree of correlation between replicates and between conditions in each 
replicate. 
Raw reads were converted to reads per million per pool (rpmp) as explained in 
section 3.2.8. A correlation matrix for rpmp is shown in Table 4.11. All 
correlations coefficients are higher than 0.600 again indicating a high degree of 
correlation. 
For each experimental condition (T7, T14 and Palmitate) a ratio of experimental 
condition to control was calculated. For the proliferation experiments (T7 and 
T14) T0 was used as a control. For Palmitate, vehicle only was used as the 
control to account for potential changes in cell representation from T0 due to 
proliferation during the 96 hours of exposure or to effects of the vehicle (ethanol) 
rather than treatment (palmitate) on cells. A correlation matrix for these ratios is 
available in Table 4.12. 
The logarithm of these ratios (correlation matrix in Table 4.13) was used to build 
a robust z-score as explained in section 4.2.16. The correlation matrix for this 
metric is shown Table 4.14. 
The degree of correlation of the replicates decreases with the transformation 
steps performed as was observed in Chapter 3. The palmitate sample in 
replicate B has a consistently low correlation with the rest of the samples in both 
replicates. It was expected that the palmitate samples would have the lowest 
correlation with other samples as the treatment with palmitate would reduce the 
representation of the shRNA targeting sequences, potentially causing a 
sampling effect in the PCR amplification and sequencing effects. The highest 
correlation coefficient after data transformation and calculation of the z-scores 
corresponds to the T7 samples between both replicates. This indicates that the 
reproducibility of the proliferation screen is high even taking into account that 
the sequencing depth was lower than expected. The low reproducibility of the 
death by lipids screen highlighted the need for a higher representation of the 
shRNA targeting sequences and an improvement in the PCR amplification and 
sequencing steps. Both optimizations were included in the final library-wide 
screen.
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Figure 4.13. Overrepresented sequences in the pilot project as identified by FastQC in the sequencing run for A) replicate A and B) repl icate B.
A) 
B) 
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Screening condition Reads in replicate A Reads in replicate B 
T0 401,685 313,819 
T7 266,097 267,653 
P 262,059 207,584 
C 183,300 220,750 
Table 4.7. Number of sequencing reads containing an exact match for the sequencing 
primers in each replicate of the pilot project for  each screening condition 
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Table 4.8. Number of different potential shRNA targeting sequences (19 bp preceding the 
loop sequence) found in the sequencing data for the four different conditions in the two 
replicates. 
Screening condition Replicate A Replicate B 
T0 9,984 1,819 
T7 6,441 1,013 
P 12,734 1,137 
C 7,787 1,454 
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Table 4.9. Number of constructs designed to be in the library that had at least one read in 
each condition of the two replicates of the pilot project.  
 In brackets, percentage of the expected constructs identified in the sequencing data. 
Screening condition Replicate A Replicate B 
T0 602 (78.39%) 560 (72.92%) 
T7 557 (72.53%) 406 (52.86%) 
P 565 (73.57%) 411 (53.52%) 
C 451 (58.72%) 472 (61.46%) 
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 T0A T7A PA CA T0B T7B PB CB 
T0A 1        
T7A 0.710 1       
PA 0.629 0.800 1      
CA 0.787 0.673 0.589 1     
T0B 0.848 0.848 0.750 0.769 1    
T7B 0.640 0.862 0.777 0.573 0.867 1   
PB 0.635 0.635 0.757 0.572 0.775 0.843 1  
CB 0.649 0.721 0.665 0.639 0.801 0.680 0.680 1 
Table 4.10. Correlation coefficients between all pairs of samples from the pilot project  
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 T0A T7A PA CA T0B T7B PB CB 
T0A 1        
T7A 0.797 1       
PA 0.697 0.831 1      
CA 0.803 0.807 0.690 1     
T0B 0.874 0.887 0.803 0.793 1    
T7B 0.751 0.895 0.825 0.744 0.933 1   
PB 0.775 0.877 0.810 0.768 0.886 0.880 1  
CB 0.703 0.785 0.734 0.689 0.830 0.831 0.779 1 
Table 4.11. Correlation matrix for reads per million per pool (rpmp).  
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 T7A T7B PA PB 
T7A 1    
T7B 0.467 1   
PA 0.319 0.164 1  
PB 0.037 0.006 0.010 1 
Table 4.12. Correlation matrix of the ratios of (experimental condition) to (control 
condition) 
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 T7A T7B PA PB 
T7A 1    
T7B 0.458 1   
PA 0.385 0.219 1  
PB 0.047 0.099 0.072 1 
Table 4.13. Correlation matrix of the ln(ratios) 
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 T7A T7B PA PB 
T7A 1    
T7B 0.467 1   
PA 0.381 0.221 1  
PB 0.053 0.100 0.084 1 
Table 4.14. Correlation matrix of the robust z-scores. 
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Figure 4.14. Venn diagram of the overlap in identified targeting sequences expected from 
the library composition of the two pools included in the pilot.  
Only replicate A is represented. 
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Figure 4.15. Venn diagram of the overlap in identified targeting sequences expected from 
the library composition of the two pools included in the pilot.  
Only replicate B is represented. 
305 
 
4.3.7. Running a genome-wide shRNA screening process 
After checking that the variability in the pilot project was acceptable, the entire 
shRNA library was used on a screening process carried out as explained in 
4.3.2. 
The reproducibility pilot project highlighted some potential sources of variability 
that could be addressed to increase the quality of the screening process. R7T1 
cells were plated at a higher density before being transduced to increase the 
representation of the shRNA targeting sequences. 
To improve the sequencing data, the sequencing libraries for the different 
samples were prepared in-house using a PCR based preparation method. This 
removes the ligation step on the library preparation protocol and should limit the 
presence of Illumina adaptor dimers in the sequencing data. Primers for PCR 
amplification were therefore designed with a region that would anneal with the 
primers used for the sequencing library preparation. A first round of 
amplification was performed with these primers. Each condition was amplified 
with a sample specific primer so that the samples could be de-multiplexed after 
sequencing. This first PCR amplification was performed in parallel for each of 
the pools. Then, PCR products were purified and quantified using a Qubit. 
Equal amounts of each pool were mixed for each condition. 
The mixtures were then used as templates for the second round of amplification 
using the primers containing the Illumina adaptor sequences. This second 
round of amplification introduced a different combination of Illumina indexes for 
each sample so an additional level of de-multiplexing was possible. This 
removed the possible uncertainty in assigning sequencing reads to the correct 
sample that was present in the pilot project. The new de-multiplexing strategy 
will be explained in section 4.3.8. 
Products of the second round of PCR amplification were purified using the 
Agencourt AMPure beads and quantified using a Qubit and a Tapestation. The 
results obtained using the Tapestation are depicted in Figure 4.16. A peak of 
the expected size after the two rounds of amplification (approximately 270 bp) is 
visible in both the digital electrophoresis separation gel and the peak profile. 
Three other peaks are visible that might be derived from the first and/or second 
rounds of amplification. A small peak of approximately 150 bp may correspond 
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to the products of the first round of PCR amplification. These products would 
not contain the Illumina adaptor sequence and subsequently would not be 
sequenced. Two heavier peaks approximately 660 and 1,200 bp may be the 
result of secondary structures formed by more than one shRNA construct. Such 
structures have been described in the literature (Du, Ge et al. 2006). As it was 
unknown whether the presence of that peak would decrease the number of 
reads obtained, the sample was sent to the University of Exeter Sequencing 
Service and three times the number of reads estimated to produce good quality 
quantitative data was requested. 
Not all pools completed the screening process in all conditions, due to either 
contamination of the cultures during the screening or to complete cell death in 
some of the pools. Out of the 73 pools the library is divided into, 67 pools 
completed the screening process in all conditions. Two pools did not complete 
the screening in T14 and four were not screened in the death by lipids screen.
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Figure 4.16. Tapestation quantification results.  
A) Digital gel. Lane A0(L): ladder. A1: sample not analysed in this thesis. B1: β cell PCR amplified sample. The expected band f or the 
amplification (approximately 270 bp) is highlighted in orange. B) Peak profile for the β cell sample. “Lower” and “Upper” are size markers 
introduced by the software. The expected peak is highlighted in orange.  
A) B) 
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4.3.8. Sequencing output of the screening process 
The introduction of sample specific combinations of Illumina indexes resulted in 
the sequencing output being different from the output received for the screen in 
Chapter 3. De-multiplexing of the samples using the Illumina indexes was 
performed by the University of Exeter Sequencing Server. As a result, 
one .fastq file was received per condition. Reads in each file corresponded to 
the sample for which the Illumina indexes were used and therefore the sample-
specific primers used for the first round of PCR amplification were not used for 
de-multiplexing as they had been used in the pilot project and in Chapter 3. The 
number of sequencing reads obtained for each screening condition is shown in 
Table 4.15. The vehicle-only control for the death by lipids screen, named C, 
had the lowest number of reads. If every sequence in the 62 pools that 
completed the screen had been sequenced the average representation of the 
sequences in this condition would have been 395 reads. 
Quality control analysis performed by the Sequencing Service using the 
software package FastQC indicated that no Illumina indexes were 
overrepresented in the samples as expected. However, overrepresented 
sequences were detected in all the samples. The FastQC output for this 
diagnostic test for all samples is available in Figure 4.17. The frequency of 
these overrepresented sequences is lower than the frequency of the Illumina 
indexes detected in the pilot sequencing data and the data from the screen in 
Chapter 3. All the overrepresented sequences start with the sequence of the 
primer used in the first round of PCR amplification indicating they are not 
external contamination from other samples with the same Illumina index. These 
sequences could be overrepresented due to their higher representation in the 
samples themselves or they could be a result of contamination of the PCR 
reactions. A no-template control was amplified in parallel with the samples and 
no bands were visible in the agarose gel used to purify the amplified samples 
suggesting that the reactions were not contaminated. The overrepresented 
sequences are common to all samples which indicates that if they are due to 
contamination this contamination was present in a similar degree in all samples, 
and if they are just highly represented sequences they are so in all samples. In 
both cases the data analysis pipeline is expected to correct the 
overrepresentation as the experimental samples are normalized to their 
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corresponding controls where the sequences are equally overrepresented. 
Therefore I proceeded with the analysis process and noted these sequences. 
As the sequencing reads were already separated into sample specific .fastq 
files, the sequence of the shRNA loop that separates both reverse-complement 
targeting sequences was used to extract the potential shRNA targeting 
sequences in each sample. The commands used for this are indicated in 
Appendix 8. Briefly, the “grep” command was used to identify sequencing reads 
containing an exact match to the shRNA construct loop. Reads where the loop 
was identified were placed in a file containing reads with potential shRNA 
constructs. The numbers of reads containing the shRNA loop for each condition 
are shown in Table 4.16. 
The shRNA targeting sequences and the number of sequencing reads for each 
targeting sequence identified in each of the screening conditions were extracted 
using a custom Python script as explained in section 3.2.8 (script in Appendix 3). 
The files were imported into Stata and processed as discussed in section 3.2.8. 
Table 4.17 shows the number of shRNA sequences and the proportion of those 
designed to be in the library detected in each condition. Most of the sequences 
expected to be in the library are identified in at least one sequencing read for all 
the conditions. However, sequences with very low representation can lead to 
artefacts in the analysis and therefore a threshold was used to exclude targeting 
sequences with low representation in the control conditions as in (Sims, 
Mendes-Pereira et al. 2011). Similarly to the approach taken in Chapter 3, 
targeting sequences with less than 50 sequencing reads in the control 
conditions (T0 and C) were coded as “missing” data in Stata. Ratios and 
therefore z-scores cannot be calculated with “missing” data so those targeting 
sequences were in effect eliminated from any further analysis. All targeting 
sequences that were expected to be a part of one of the library pools that did 
not complete the screening process were also discarded as they were predicted 
to be residual contamination. These sequences had very low numbers of 
sequencing reads. The numbers of the targeting sequences that were screened, 
hence, were identified to have more than 50 sequencing reads in the T0 and C 
samples, are shown in Table 4.18. The percentage of the library screened is still 
over 70% for T0 and T7, for which more library pools were screened. As less 
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pools completed the death by lipids screen it is not unexpected to have 
identified less targeting sequences in the P and C samples. 
The different measures of targeting sequence abundance (raw reads, rpmp, 
ratios of rpmp and z-scores) were expected to be correlated specially amongst 
the proliferation screening samples. 
Table 4.19 shows the correlation matrix for raw number of reads. Correlation 
coefficients are notably low for any pair of conditions that include T14 indicating 
a possible bias in T14. These correlation coefficients are however much higher 
when reads per million per pool (rpmp) are used instead of raw sequencing 
reads (Table 4.20). Correlation coefficients are much lower when the ratios of 
the experimental conditions to their controls are used (Table 4.21). This is not 
unexpected for the correlations between the proliferation conditions and the 
death condition but it is for the correlation between the two proliferation 
conditions. This correlation increases when the variation in each pool for each 
condition is taken into account by the calculation of a robust z-score (Table 
4.22). It has been previously discussed that the additional seven days of culture 
of R7T1 cells in absence of DOX between T7 and T14 introduces a high level of 
cell death. The low correlation between T14 and other conditions can be a 
consequence of this cell death. If the increase in proliferation rate due to the 
effect of any particular targeting sequence is not strong enough to overcome the 
high rate of cell death, the cells containing that targeting sequence will not be 
present when the T14 sample is obtained. This results in the equivalent to a 
sampling effect in T14, where the representation of targeting sequences is 
highly variable and different from T7.
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Condition Number of reads 
T0 14,638,600 
T7 16,457,499 
T14 15,629,863 
P 12,926,085 
C 9,404,944 
Table 4.15. Number of sequencing reads obtained for each condition in the sequencing 
data for the library-wide screen. 
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Figure 4.17. FastQC report for overrepresented sequences in the library-wide screen 
sequencing data in the T0 (A), T7 (B), T14 (C), Palmitate (D) and Control (E) samples.  
 
C) 
B) 
A) 
D) 
E) 
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Sample Number of reads containing the loop 
T0 13,114,383 (89.59%) 
T7 15,053,328 (91.47%) 
T14 14,168,888 (90.65%) 
P 11,533,202 (89.22%) 
C 8,142,763 (86.58%) 
Table 4.16. Number of sequencing reads containing the sequence of the shRNA loop 
identified in each sample.  
In brackets, percentage of the total sequencing reads that contain the loop.  
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Condition Number of targeting sequences 
T0 25,692 (91.67%) 
T7 25,896 (92.38%) 
T14 22,766 (81.23%) 
P 23,355 (83.31%) 
C 23,990 (85.58%) 
Table 4.17. Number of shRNA targeting sequences expected to be in the shRNA library 
identified with at least one sequencing read in each sample.  
In brackets, percentage of the shRNA library identified in each sample. All 73 pools were 
considered for this calculation. 
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Condition Number of targeting sequences 
T0 20,508 (79.71%) 
T7 20,953 (81.44%) 
T14 19,020 (73.93%) 
P 18,155 (75.05%) 
C 17,862 (73.83%) 
Table 4.18. Number of shRNA targeting sequences identified in the sequencing data and 
expected to be in the library pools which completed the screening process.  
For the T0 and C conditions only sequences with more than 50 sequencing reads were 
considered as identified. 
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 T0 T7 T14 P C 
T0 1     
T7 0.783 1    
T14 0.280 0.164 1   
P 0.886 0.791 0.254 1  
C 0.855 0.715 0.174 0.773 1 
Table 4.19. Correlation matrix of raw reads for the pairs of conditions screened.  
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 T0 T7 T14 P C 
T0 1     
T7 0.988 1    
T14 0.705 0.651 1   
P 0.824 0.781 0.786 1  
C 0.836 0.834 0.578 0.837 1 
Table 4.20. Correlation matrix for rpmp
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 T7 T14 P 
T7 1   
T14 0.020 1  
P -0.038 0.012 1 
Table 4.21. Correlation coefficients for the ratios of rpmp of each condition to its control.  
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 T7 T14 P 
T7 1   
T14 0.204 1  
P -0.043 0.027 1 
Table 4.22. Correlation matrix for the z-scores 
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4.3.9. Selection of genes potentially involved in β cell proliferation 
Analysis of the sequencing results and prioritization of any candidate genes 
from the proliferation screen were performed similarly to the approaches used 
for the screen in Chapter 3. However, differences in the experimental screen 
and the biology studied resulted in the implementation of a few changes. 
The proliferation screen performed in R7T1 was composed of two conditions 
(T7 and T14) and a control (T0) in a similar manner to the two co-cultures and 
plastic approach in the neighbour suppression screen. However, T7 and T14 
are expected to have a similar distribution of targeting sequences except for the 
potential ‘drop outs’ resulting from the high level of cell death when cells are 
cultured for an extended period of time in the absence of DOX. Therefore there 
is no equivalent in this screening process to the two threshold system used in 
Chapter 3 to prioritize targeting sequences. On the contrary, targeting 
sequences were prioritized using the changes in their representation in the 
experimental conditions compared to their control samples. 
Genes of interest (GOI) for β cell proliferation were defined as those with 
targeting sequences whose z-score was in the top 5% of the z-score distribution 
of the whole dataset in either T7 or T14. In the T7 dataset, 492 constructs were 
selected as targeting GOIs. In total 477 genes were prioritized as GOI with 15 
genes being targeted by both sequences. In the T14 data 317 targeting 
sequences were prioritized. The T14 GOI list was composed of 313 genes, with 
four genes targeted by both constructs. Of the targeting sequences prioritized, 
38 were selected in both T7 and T14. 
To further refine the GOI list and prioritize genes that may be translatable to 
human β-cell biology an RNA sequencing (RNA-seq) dataset was used to 
identify genes that are expressed in human β-cells. The dataset used was made 
publicly available by Nica and collaborators (Nica, Ongen et al. 2013). It 
contains expression data normalized as reads per kilobase per million (RPKM), 
a commonly used measure of expression in RNA-seq datasets. The file 
contains data for eleven non-diabetic individuals, with expression data for whole 
islets, FACS separated preparations of β-cells and non-β-cells of the islets. 
Expression data from β-cells in Individual_1 was used for analysis. 
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Gene names in the screening output were first assigned a human homologue 
gene name using the approach explained in section 3.3.11.4 which identifies 
homologues based on sequence homology. The RNASeq data was then 
aligned to the output of the screens. Expression data was available for 14,461 
of the 20,508 targeting sequences in the control condition of the proliferation 
screen. A flow diagram with the number of targeting sequences in each step of 
the analysis is presented in Figure 4.18. To filter for genes expressed in β-cells, 
a threshold was set up that corresponded to the expression level in individual 1 
of CFTR, a gene known to be expressed in pancreas ductal epithelia but not in 
β-cells. Any gene expressed above that threshold (0.095815 RPKM) was 
considered to be expressed in human β-cells. After applying this filter, 336 
constructs remained in the T7 data that corresponded to 329 GOI, with seven 
genes targeted by two sequences. These seven genes are ZMYND11, HAX1, 
ANAPC10, BCR, ARHGEF1, PPIA and N4BP2. 
In the T14 dataset 194 targeting sequences remained after filtering for 
expression in human β-cells. No genes were found to be targeted by two 
targeting sequences and therefore the GOI list for T14 is composed of 194 
genes. Of these 194 GOI, 29 are also part of the T7 GOI list. A list of genes 
included in both GOI lists and their z-scores in both samples of the proliferation 
screen is available in Table 4.23. 
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Figure 4.18.Number of shRNA targeting sequences in both control conditions after each 
analysis or thresholding step. 
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Human gene name Z-score (T7) Z-score (T14) 
PWP2 6.927 4.910 
TMEM165 6.760 5.271 
SNRNP27 6.509 6.123 
ZMYND11 6.344 5.354 
MKRN2 5.538 3.793 
KCNA5 5.465 3.883 
ARHGAP26 5.423 4.479 
FARSB 5.045 3.605 
NAP1L1 4.921 3.558 
ZNF8 4.527 3.708 
NAA20 4.520 6.535 
EPHA4 4.315 3.983 
ATP6V0E1 4.268 3.859 
GOT2 4.136 5.332 
CDH20 4.040 4.068 
PABPC1L 4.016 5.443 
ATG5 3.921 3.647 
WDR25 3.848 3.588 
GEMIN6 3.796 5.263 
NAT6 3.757 4.229 
PDZK1 3.730 3.643 
PRICKLE2 3.703 4.364 
SPTB 3.664 3.728 
CACNB2 3.576 6.042 
PLCD4 3.519 4.256 
SRSF7 3.486 3.588 
SNX7 3.334 3.653 
GPATCH2 3.311 4.550 
UROS 3.270 3.582 
Table 4.23. List of genes found in both the T7 and T14 GOI lists and their z-scores in both 
datasets.  
Genes are ordered by their z-score in T7. 
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4.3.10. Selection of genes potentially involved in β cell resistance to death 
caused by chronic exposure to lipids 
The same approach used to prioritize targeting sequences in the proliferation 
screens was used in the death screen. Targeting sequences were considered 
as having increased resistance to chronic exposure to lipids if their z-score was 
on the top 5% of the z-score distribution for sample P. Of the constructs 
screened, 320 identified as such. The GOI list was composed of 308 genes, 12 
genes were targeted by two sequences. 
A step that filtered for genes that are expressed in human β-cells was included 
using the same dataset and approach as in section 4.3.9. After this filtering step 
204 targeting sequences remained in the list of prioritized sequences. The GOI 
list was composed of 195 genes, of which nine were targeted by two different 
targeting sequences: LRIT3, EPRS, MGA, CHRNB1, TBC1D10C, ZBED3, CP, 
SPON2 and HIC2. 
 
- Overlap with the proliferation screen 
Genes identified in this screen could result in resistance to death caused by the 
chronic exposure to palmitate. However, it was hypothesized that the effect of 
some of the targeting sequences could be due to an increase in proliferation 
that would overcome the cell death rate. As this is independent of the death-
inducing stimulus, these genes would also be more highly represented in the 
vehicle-only control, but the high cell death rate could drastically reduce the 
proportion of other constructs and generate high z-scores in the palmitate 
sample. Therefore to identify genes that might exert their effect through an 
increase in proliferation rate, the overlap between this GOI list and the 
proliferation screen GOI lists was investigated. A Venn diagram has been used 
in Figure 4.19 to represent the degree of overlap between the two screens. The 
GOI lists used were those which had been filtered for expression in human β-
cells. Only one gene is present in all GOI lists: MKRN2. As expected given the 
different biological mechanisms of both screens, more genes are common 
between both samples of the proliferation screen (T7 and T14) than between 
the death screen and any of the two proliferation samples. Table 4.24 contains 
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the names of the genes overlapping the death screen and each of the 
proliferation screen samples.
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Figure 4.19. Venn diagram showing the overlap of the proliferation (T7, T14) and death 
(palmitate) GOI lists. 
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Genes in P and T7 GOI lists Genes in P and T14 GOI lists 
BEX4 LRIT3 
FAM189B CHRNE 
CHD6 IMPA1 
NRG3 TSPAN32 
ARNTL LTBR 
LIG3 ZMYND8 
RALGPS2 PPP1R14C 
DPP4 VAV3 
AIP REEP6 
PLCL2 SLC4A5 
AGBL5 SUCLA2 
Table 4.24. Genes present in the death screen and each one the proliferation screen 
samples. 
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4.3.11. Genes differentially expressed upon exposure to palmitate 
The mechanism of action of palmitate as a lipotoxic agent is not well understood, 
but efforts have been made to study the effect that palmitate exposure has on 
β-cells. Specifically, gene expression changes upon exposure to palmitate have 
been studied to attempt to elucidate its effects. 
It was hypothesized that as the death screen was designed to detect genes 
which upon knockdown would protect the β-cells from the toxic effects of 
exposure to palmitate, the GOIs might be enriched in palmitate-regulated genes. 
A dataset of genes differentially expressed in human islets after 48h exposure 
to palmitate was obtained. This dataset was produced by Hall and collaborators 
(Hall, Volkov et al. 2014) and made publicly available. It contains only those 
genes with a q-value <0.05 for differential expression upon exposure to 
palmitate compared to a vehicle-only control. The authors stated that no cell 
death was observed in the course of this experiment, suggesting that palmitate 
exerts a lower cell toxicity to human beta cells. This might be of importance 
since a high level of cell death was observed in the course of the lipotoxicity 
screen. 
The GOI list obtained from the screen was merged with the expression dataset. 
Of the 195 genes in the GOI list, 22 were found to be differentially expressed in 
the dataset. A random sampling approach was used to evaluate the statistical 
significance of this finding. Using an adapted version to the script prepared for 
the random sampling performed in section 3.3.10.3, 1000 iterations of 195 gene 
names were randomly drawn from a list containing the names of the screened 
genes. No statistically significant enrichment for genes differentially expressed 
after 48h exposure to palmitate was detected. 
The list of genes found to be differentially expressed in the dataset and the 
direction of change detected by the authors are available in Table 4.25. 
Although a high proportion of the genes identified in my screen that are also 
differentially expressed in response to palmitate are down-regulated by 
palmitate, the majority of genes differentially regulated by palmitate are 
downregulated. As such, no enrichment for down-regulated genes was found 
using a random sampling approach. 
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Gene Direction of effect 
SPON2 Down-regulated 
SEZ6L Up-regulated 
TMEM50A Down-regulated 
PRKAA1 Down-regulated 
PLEKHB1 Down-regulated 
HNRNPK Down-regulated 
PTPRG Down-regulated 
WWTR1 Down-regulated 
METTL7A Down-regulated 
SMAD3 Down-regulated 
ACADM Down-regulated 
MLEC Down-regulated 
BEX4 Up-regulated 
REEP6 Down-regulated 
PLSCR4 Down-regulated 
MAPKAP1 Down-regulated 
SPTLC3 Down-regulated 
PRIM1 Down-regulated 
ODC1 Up-regulated 
AIP Up-regulated 
ACSS1 Down-regulated 
FOS Up-regulated 
Table 4.25. Genes in the lipotoxicity screen GOI list found to be de-regulated in the 
presence of palmitate for 48 hours.  
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4.3.12. Network analysis of genes potentially involved in β-cell 
proliferation 
The advantages of a network analysis approach to prioritize candidate genes 
from an RNAi screen have been described in section 3.3.10. A similar pipeline 
was used in the analysis of the screen described in this chapter. One important 
difference was implemented however: as the screen was performed in mouse 
β-cells, the analysis was first performed using the mouse gene names. As the 
expression data in human β-cells was used to filter the GOI lists these reduced 
GOI lists composed of human gene names were then used to perform the same 
analyses. 
4.3.12.1 Network analysis of the candidate mouse genes identified, using 
STRING. 
STRING was used as described in section 3.3.10.1. Briefly, a confidence 
threshold of 0.7 was used and “textmining” was not used as a source of 
evidence for protein interactions to enrich for functional interactions. The 
resulting interactions were downloaded and inputted into Cytoscape for 
visualization. 
The GOI lists for the proliferation screen samples, T7 and T14 were first 
inputted separately and then merged to constitute a “proliferation GOI list”. 
Mouse gene names were used and no filtering was performed. 
Upon inputting of the T7 GOI list, STRING mapped 464 gene names of the 477 
GOIs. A view of the network is shown in Figure 4.20. The interaction enrichment 
analysis produced by STRING indicates that there 117 interactions in the GOI 
list inputted when 62 were expected. The p-value for the enrichment in 
interactions is 2.27x10-10 which indicates that the GOI list is enriched for 
interacting genes or gene products. 
Of the 319 gene names in the T14 GOI list, STRING mapped 304. The network 
produced (Figure 4.21) is composed of 100 interactions when 38 were expected 
by STRING, which indicates that the T14 GOI list is also enriched for 
interactions (p-value for enrichment calculated by STRING is 1.11x10-16). 
Inputting the proliferation GOI list (T7+T14) produced a network with 348 
interactions when the expected number calculated by STRING was 174. The p-
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value for this apparent enrichment in connections is reported as 0, indicating the 
network is statistically enriched in interacting genes. This proliferation network is 
represented in Figure 4.22. 
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Figure 4.20. Protein interaction network for the GOI list of the T7 proliferation sample.  
 Network was calculated using STRING and visualized with Cytoscape. Nodes represent genes and are colour-coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue.  
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Figure 4.21. Protein interaction network for the GOI list of the T14 proliferation sample.  
Network was calculated using STRING and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue.  
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Figure 4.22. Protein interaction network for the proliferation GOI list, which includes the T7 and T14 GOI lists.  
Network was calculated using STRING and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue.  
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4.3.12.2 Network analysis of the candidate mouse genes identified using 
FunCoup 
FunCoup was used to construct gene interaction networks for the reasons 
explained in section 3.3.10.2. The same parameters used to construct the 
interaction networks for the screen results in Chapter 3 (section 3.3.10.2) were 
used. Briefly, the Mus musculus database was used, the confidence threshold 
was set to 0.8 and the expansion depth used was 0, which means that the 
networks were built using only the gene names inputted and no additional 
genes were added by FunCoup. Therefore the whole network was comprised of 
genes identified in my screen. 
The networks produced with FunCoup were imported into Cytoscape for 
visualization. The T7 network (Figure 4.23) is composed of 159 genes and 598 
connections. The T14 network (Figure 4.24) is smaller, with 90 genes 
connected by 253 edges. Similarly to the results found in section 3.3.10.2 when 
the GOI lists for both co-culture samples were merged, the union of the GOI 
lists for both proliferation samples produced a network that includes more nodes 
and edges than the sum of both if they were completely independent. However 
in this case it is not unexpected that the GOI from both lists interact, as both T7 
and T14 are samples derived from the same phenotype: an increase in 
proliferation. The network built from the combination of both GOI lists is 
depicted in Figure 4.26. The outside of the circles representing the genes are 
colour coded to distinguish which GOI list they were identified in. 
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Figure 4.23. Protein interaction network for the GOI list of the T7 proliferation sample.  
Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour-coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue.  
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Figure 4.24. Protein interaction network for the GOI list of the T14 proliferation sample.  
 Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue.  
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Figure 4.25. Protein interaction network for the proliferation GOI list, which includes the T7 and T 14 GOI lists.  
Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions tha n those in blue. Pink circles 
represent genes with more than 50 interactors in the sample.  
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Figure 4.26. Protein interaction network for the proliferation GOI list, which includes the T7 and T14 GOI lists.  
 Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in bl ue. Pink circles 
represent genes with more than 50 interactors in the sample. The border colour corresponds to the GOI list they were identifi ed in. Blue: T7, 
pink: T14. Yellow border indicates that the gene was identified in both GOI lists. 
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4.3.12.3 Hyperconnected mouse GOIs 
“Hyperconnected” genes or hubs were identified using the same approach used 
in section 3.3.10.3. Briefly, a custom script was written in Python to produce 
1,000 random samples of the size of the GOI lists for each gene in the network. 
Each of those 1,000 random samples for one gene includes the gene being 
studied. The script counts how many connectors the GOI has in each of the 
1,000 samples and reports the number of random samples with at least as 
many genes that interact with the gene being investigated as that found in the 
GOI list. The proportion of samples with at least as many connectors as the GOI 
list is used as a p-value. 
This random sampling approach provides a measure of the enrichment in 
connectors of each gene in the GOI list. If less than 5% of the random samples 
contain at least the same number of connectors for a given gene than the GOI 
list, this gene is determined as being “hyperconnected” with a p-value<0.05. 
In the T7 GOI list, 19 genes were determined as being hyperconnected (Table 
4.26). In the T14 GOI list, 13 genes were considered hyperconnected (Table 
4.27). When the GOI lists were combined, 44 genes were found to be 
hyperconnected (Table 4.28). From these 44 genes it was expected that some 
might be hyperconnected in the individual GOI lists. The overlap among the 
different GOI lists is represented by a Venn diagram in Figure 4.27. 
Although most of the genes in the individual GOI lists are included in the 
combined GOI list, three hyperconnected genes in each of the individual lists 
are found to be hyperconnected in the combined GOI list. This is not 
unexpected in the case of genes which have a low number of potential 
connectors amongst the screened genes. These potential connectors might not 
have been included in many of the 1,000 random samples due to a small 
sample size when assessing the individual GOI list they were identified in. 
However, combining both GOI lists results in a larger sample size which can 
more easily lead to the sampling of those few potential connectors. In the T7 
GOI list, the three genes that are not hyperconnected in the combined list are 
Glo1, Slc27a2 and Clic4. Although the number of connectors in the screened 
gene list is not very low (18, 7 and 38 respectively), the fraction of the 
connectors identified in the GOI list is not high (1/6) compared to other of the 
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hyperconnected genes which remained as hyperconnected in the combined 
GOI list.  
The three genes which were detected as hyperconnected in T14 but not in the 
combined list are Cldn7, Ntrk3 and Fgfr2 (5, 26 and 24 connectors in the 
screened genes).  
Another factor contributing to genes not being in the combined list might be that 
while some genes may have connectors in the other individual GOI list, some 
may not. This could result from either the connectors not having an effect strong 
enough to be in the GOI list or from the connectors not having been screened in 
the other sample. This is a possibility for the hyperconnected genes in T7 
because some of the pools that were screened in T7 were not screened in T14. 
The effect of combining the GOI lists in the number of connectors found for 
each gene in each of the individual networks was calculated as (number of 
connectors in the combined list)-(number of connectors in T7)-(number of 
connectors in T14). The distribution for the number of connectors gained when 
a network is built from the combined GOI list is depicted in Figure 4.28. Most of 
the genes either gained no connectors or a small number of them when the GOI 
lists were combined to draw a proliferation network. The highest number of 
connectors gained was 28 (Cirh1a and H2afz). Some genes have a negative 
number of additional connectors, meaning that the connectors for those genes 
overlap between both lists and their combination produces less connectors than 
expected if the number of connectors in both lists is simply summed. 
The six genes that went from hyperconnected in their respective individual GOI 
lists to not hyperconnected in the combined GOI list network have either not 
gained any additional connectors or their connectors overlapped with the other 
GOI list. When the random sample size was increased to model the combined 
list it resulted in more random samples having at least the same number of 
connectors than the combined list and therefore they were not identified as 
hyperconnected.  
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Gene Potential interactors 
screened 
Interactors in GOI list p-value 
B3gat1 1 1 <0.001 
Gli2 1 1 <0.001 
Neurl1b 1 1 <0.001 
Rgs4 4 2 <0.001 
Ryr3 1 1 <0.001 
Slc24a1 1 1 <0.001 
Foxc1 2 1 0.001 
Mbnl1 5 2 0.001 
Rce1 2 1 0.002 
Arxes1 7 2 0.003 
Map3k11 9 2 0.004 
Slc50a1 7 2 0.005 
Rfx5 14 3 0.008 
Cep97 5 1 0.013 
Mark4 33 5 0.018 
Glo1 18 3 0.025 
Slc27a2 7 1 0.034 
Scmh1 11 2 0.038 
Clic4 38 4 0.043 
Table 4.26. Genes found to be enriched (p-value<0.05) in interactors in the T7 GOI list. 
343 
 
Gene Potential interactors 
screened 
Interactors in GOI 
list 
p-value 
Chrm4 2 1 0.003 
Kcns3 2 1 0.003 
Epcam 3 1 0.006 
Gemin4 40 4 0.011 
Pde1a 4 1 0.011 
Oprk1 5 1 0.012 
Cldn7 5 1 0.018 
Ntrk3 26 3 0.018 
Ccr6 6 1 0.019 
H1foo 8 1 0.02 
Serinc4 7 1 0.023 
Plxna1 6 1 0.035 
Fgfr2 24 2 0.048 
Table 4.27. Genes found to be enriched (p-value<0.05) in interactors in the T14 GOI list. 
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Gene Potential interactors 
screened 
Interactors in GOI list p-value 
B3gat1 1 1 <0.001 
Gli2 1 1 <0.001 
Neurl1b 1 1 <0.001 
Pcsk1n 2 2 <0.001 
Rce1 2 2 <0.001 
Ryr3 1 1 <0.001 
Scmh1 11 4 <0.001 
Slc24a1 1 1 <0.001 
Arxes1 7 3 0.001 
Rab3b 4 2 0.001 
Rgs4 4 2 0.001 
Socs3 2 1 0.004 
Rasa4 6 2 0.005 
Brdt 6 2 0.006 
Ccr6 6 2 0.006 
Ifi204 2 1 0.009 
Kcns3 2 1 0.009 
Chrm4 2 1 0.01 
Foxc1 2 1 0.01 
H1foo 8 2 0.011 
Mbnl1 5 2 0.011 
Slc50a1 7 2 0.011 
Rap1gap 3 1 0.012 
Serinc4 7 2 0.012 
Gemin4 40 7 0.013 
Plxna1 6 2 0.017 
Map3k11 9 2 0.024 
Rfx5 14 3 0.024 
Rims2 4 1 0.025 
Epha4 51 8 0.026 
Phc1 57 9 0.026 
Mark4 33 6 0.028 
Crkl 18 4 0.03 
Xpa 9 2 0.032 
Oprk1 5 1 0.035 
Ehmt1 95 13 0.036 
Epcam 3 1 0.036 
Jtb 95 12 0.038 
Arntl 16 3 0.039 
Hdhd1a 48 8 0.039 
Pde1a 4 1 0.039 
Cep97 5 1 0.04 
Rnf113a1 11 2 0.042 
Ldb1 68 10 0.048 
Table 4.28. Genes found to be enriched (p-value<0.05) in interactors in the combined (T7, 
T14) GOI list. 
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Figure 4.27. Venn diagram depicting the partial overlap in hyperconnected genes between 
proliferation GOI lists and the combined proliferation GOI list (T7T14).  
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Figure 4.28. Histogram showing the distribution of the number of additional connectors for 
each gene in a combined GOI list compared to the sum of the connectors in each list.  
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4.3.12.4 Network analysis of the candidate human genes identified using 
STRING 
The GOI lists filtered for expression in human β-cells as explained in section 
4.3.9 were used to build gene networks in STRING following the approach in 
4.3.12.1 but using the human database. 
STRING mapped all the 329 genes in the T7 GOI list and produced a network 
(Figure 4.29) where 93 genes are connected by 91 edges. This number of 
edges is higher than the number expected by STRING (68), which produced an 
enrichment in connections with a p-value of 4x10-5 as calculated by STRING, 
indicating that the network is more highly connected than expected in a random 
gene list of the same size. 
The network produced by STRING (Figure 4.30) for the T14 human GOI list is 
composed of 65 genes connected by 69 edges. According to the enrichment 
calculations performed by STRING, this network is not enriched in connections 
(p-value = 0.15). 
The combination of both GOI lists to produce a “proliferation” GOI list, an 
approach already explained in section 4.3.12.1, produced a network formed of 
171 genes connected by 246 edges. STRING indicates that the network is 
significantly enriched in connections with a p-value of 6.66x10-16. As the T14 
network had been determined as not being enriched in connections it might 
seem that this enrichment in the combined list is a result of the enrichment in T7. 
However, although the number of connected genes (171) in the combined GOI 
list is not much higher than the sum of both lists (158), the high number of 
connections between pairs of genes indicates that genes from both GOI lists 
are connected. This is not unexpected as both lists are comprised of genes 
involved in the same phenotype, i.e. an increase in proliferation. These 
connections across GOI lists are visible in Figure 4.31, where the borders of the 
circles representing the genes have been colour coded.
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Figure 4.29. Protein interaction network for the human GOI list of the T7 proliferation sample.  
Network was calculated using STRING and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue  
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Figure 4.30. Protein interaction network for the human GOI list of the T14 proliferation sample.  
Network was calculated using STRING and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue 
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Figure 4.31 Protein interaction network for the human proliferation combined GOI list.  
Network was calculated using STRING and visualized with Cytoscape. Nodes  represent genes and are colour-coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue. Th e border colour 
corresponds to the GOI list they were identified in. Blue: T7, pink: T14. Yellow border indicates that the gene was identified in both GOI lists.  
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4.3.12.5 Network analysis of the identified human candidate genes using 
FunCoup 
Gene interaction networks were produced using FunCoup as described in 
section 4.3.12.2 but using the lists filtered for expression in human β-cells. 
The network produced using the T7 GOI list is depicted in Figure 4.32. In this 
network, 121 genes were found to be connected by 489 edges. The network for 
the T14 GOI list has the same number of genes as the network produced for the 
same list using STRING in section 4.3.12.4 , 65 genes, but in contrast with the 
69 edges connecting the STRING network FunCoup reports 222 connections in 
the network. The combined GOI list produced a network (Figure 4.34) with not 
many more genes than expected by the simple combination of both networks 
(199 in the combined GOI list versus 186 expected). However, the number of 
edges in this combined network is higher than the sum of the connections in 
both individual networks with 1,112 edges versus 711 expected edges. This 
agrees with the results from STRING indicating that both networks are highly 
interconnected.
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Figure 4.32. Protein interaction network for the human GOI list of the T7 proliferation sample.  
Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour-coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue  
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Figure 4.33. Protein interaction network for the human GOI list of the T14 proliferation sample.  
Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interactions than those in blue  
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Figure 4.34. Protein interaction network for the human proliferation GOI list, which includes the T 7 and T14 GOI lists.  
Network was calculated using FunCoup and visualized with Cytoscape. Nodes represent genes and are colour -coded for the number of genes 
they interact with in the GOI list. Green nodes correspond to genes with higher number of interacti ons than those in blue. Pink circles 
represent genes with more than 50 interactors in the sample.  
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4.3.12.6 Hyperconnected human GOI 
To complement the network analysis performed with the human GOI, the 
FunCoup results were used to look for GOI which had more connections in the 
GOI list than expected by chance. The approach implemented in section 
3.3.10.3 and used with the mouse GOI list in this screen in section 4.3.12.3 was 
adapted to the data. 
Although the principle of the analysis and therefore the script used remained 
unchanged, the GOI list in this case is formed of human gene names. Therefore, 
I built an interaction database for pairs of human genes similar to the mouse 
database in section 3.3.10.3. Briefly, the FunCoup database of interactions for 
human genes was downloaded from http://funcoup.sbc.su.se/downloads/. A 
more compact file was produced by the removal of any interactions with a 
confidence score lower than 0.8, the threshold used for building the networks in 
FunCoup. The gene names in this file are expressed as Ensembl IDs. As the 
RNA-seq data used to filter the screen results for expression in human β-cells 
already contains the Ensembl ID, no further conversion was necessary. 
The results of this random sampling approach indicate that in the T7 GOI list 
there are 14 genes which are hyperconnected in the network produced using 
FunCoup (Table 4.29). The same analysis of the T14 network produced a list of 
seven hyperconnected genes, available in Table 4.30. Following the analysis 
performed on the mouse GOI lists, the combined T7T14 network was also 
searched for hyperconnected nodes. In this case 28 genes were found to have 
a p-value for enrichment in connections below 0.05 and were therefore 
considered enriched or hyperconnected (Table 4.31). The same phenomenon 
of previously not-hyperconnected genes now appearing as hyperconnected is 
seen using the human β-cell expressed genes. Only half of the hyperconnected 
genes in the combined list were found to be hyperconnected in their respective 
individual lists (Figure 4.35). Three genes from the T7 hyperconnected list lost 
their hyperconnection status when transferred to the combined list: Arl3, Pcca 
and Nr2c2. From the T14 GOI list network, four hyperconnected genes were not 
found to be enriched in the combined list: F11R, PYGB, GEMIN6 and HGSNAT 
as above. 
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Gene Screened interactors Interactors in GOI P-value 
Fbxo31 2 1 0.002 
Slc50a1 16 3 0.002 
Ank3 3 1 0.003 
Zscan12 2 1 0.004 
Mbnl1 3 1 0.007 
Acadsb 11 2 0.009 
Maged1 11 2 0.010 
Hmmr 10 2 0.011 
Znf768 4 1 0.013 
Rce1 12 2 0.015 
Arid1b 13 2 0.027 
Arl3 34 4 0.035 
Pcca 38 4 0.043 
Nr2c2 8 1 0.044 
Table 4.29. List of hyperconnected genes (p-value <0.05) in the T7 GOI list as determined 
using a random sampling approach. 
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Gene Screened interactors Interactors in GOI P-value 
Cldn7 7 2 <0.001 
Dhrs11 4 1 0.004 
Epcam 4 1 0.004 
F11r 6 1 0.014 
Pygb 60 4 0.028 
Gemin6 105 6 0.035 
Hgsnat 13 1 0.047 
Table 4.30. List of hyperconnected genes (p-value <0.05) in the T14 GOI list as 
determined using a random sampling approach.
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Gene Screened interactors Interactors in GOI P-value 
Fbxo27 1 1 <0.001 
Il6r 1 1 <0.001 
Npas4 1 1 <0.001 
Socs3 5 2 0.002 
Fbxo31 2 1 0.003 
Rce1 12 3 0.003 
Arid1b 13 3 0.005 
Maged1 11 3 0.005 
Pcsk1n 2 1 0.005 
Zscan12 2 1 0.006 
Mbnl1 3 1 0.011 
Slc50a1 16 3 0.011 
Map4k2 3 1 0.012 
Cldn7 7 2 0.013 
Ank3 3 1 0.014 
Dhrs11 4 1 0.015 
Rap1gap 3 1 0.016 
Pim1 3 1 0.018 
Znf768 4 1 0.02 
Hmmr 10 2 0.024 
Pten 78 10 0.028 
Acadsb 11 2 0.029 
Vav3 5 1 0.035 
Ankhd1 18 3 0.041 
Epcam 4 1 0.044 
Myof 15 2 0.044 
Scmh1 5 1 0.045 
Tssc4 12 2 0.048 
Table 4.31. List of hyperconnected genes in the combined GOI list. 
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Figure 4.35. Venn diagram representing the overlap amongst the hyperconnected gene 
lists for both individual proliferation networks and the combined network  
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4.3.13. Network analysis of genes potentially involved in β-cell resistance 
to death by lipids 
The approach used in 4.3.12 was applied to the resistance to death by lipids 
screen to identify essential genes or pathways in the phenotype studied. 
STRING and FunCoup were used to produce gene networks using the mouse 
dataset and the data after filtering for expression in human β-cells. 
4.3.13.1 Network analysis of the mouse GOI using STRING 
The GOI list obtained in 4.3.10, genes involved in protection from palmitate 
induced death, was used to produce a protein network using STRING. The 
resulting network is composed of 56 genes connected by 57 genes. According 
to STRING, this network (Figure 4.36) is enriched in interactions with a p-value 
of 0.00336. The network is simpler than the networks produced for the 
proliferation samples in 4.3.12.1, which could be an effect of fewer GOIs being 
identified in the death screen. However, the T14 GOI list is composed of only 
five genes more than the death screen GOI list and its network is formed of 70 
genes connected by 100 edges. 
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Figure 4.36. Protein interaction network for the mouse GOI list obtained from the resistance to death by lipids screen.  
The network was produced using STRING and visualized using Cytoscape. Genes are colour -coded according to the number of interactors 
they have in the GOI list. Genes in green tones have more interactors than genes in blue.  
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4.3.13.2 Network analysis of the mouse GOI using FunCoup 
The mouse GOI list produced for the resistance to death by lipids was used to 
produce a network using FunCoup (Figure 4.37). This network is formed of 79 
genes connected by 288 interactions. Networks produced by FunCoup in this 
screen and the screen in Chapter 3 all contain more genes and connections 
than the same networks drawn by STRING. However, the death screen network 
is especially enriched in edges in comparison. This network in STRING was 
compared in 4.3.13.1 with the network for T14 as the number of GOI is similar 
to the death screen. The same comparison using the FunCoup network 
indicates that although the number of genes is higher in the T14 network (90), 
the genes in the death screen network are more highly connected with 288 
edges compared to 253 in T14.
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Figure 4.37. Protein interaction network for the mouse GOI list obtained from the resistance to death by lipids screen.  
The network was produced using FunCoup and visualized using Cytoscape. Genes are colour-coded according to the number of interactors 
they have in the GOI list. Genes in green tones have more interactors than genes in blue.  
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4.3.13.3 Hyperconnected mouse GOI 
The same approach explained in 4.3.12.3 was used to produce a list of 
hyperconnected genes in the mouse network. Only one gene was determined 
as being hyperconnected with a p-value below 0.05: Vav3. 
4.3.13.4 Network analysis of the human filtered GOI using STRING 
The death screen GOI list was filtered for expression in human β-cells as 
described in 4.3.10. This filtered GOI list was used to construct a gene 
interaction network in STRING as previously described. The resulting network is 
formed of 46 nodes connected by 28 edge, which STRING determined as not 
enriched in gene interactions. The network as visualized using Cytoscape is 
available in Figure 4.38. 
4.3.13.5 Network analysis of the human filtered GOI using FunCoup 
The filtered GOI list used with STRING in section 4.3.13.4 was used to 
construct a network in FunCoup. The network was visualized with Cytoscape 
and is available in Figure 4.39. 
4.3.13.6 Hyperconnected human GOI 
The human FunCoup network was examined for hyperconnected genes using 
the random sampling approach as described in previous sections. Only three 
genes were found to be significantly enriched in connections in this network: 
AAK1, CHRM3 and PCBD2. 
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Figure 4.38. Protein interaction network of the human filtered GOI list for the death screen.  
 The network was produced using STRING and visualized in Cytoscape. Genes are colour -coded according to the number of interactors in the 
GOI list. Genes in green have more interactors in the list than genes in blue
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Figure 4.39. Protein interaction network of the human filtered GOI list for the death scr een.  
The network was produced using FunCoup and visualized in Cytoscape. Genes are colour -coded according to the number of interactors in the 
GOI list. Genes in green have more interactors in the list than genes in blue.
367 
 
 
4.3.14. Functional enrichment analysis of GOI 
The reasons to implement a functional enrichment analysis approach into the 
analysis of the screens have been described in section 3.3.11. In the case of 
the screening process in this chapter, it was hypothesized that the functional 
enrichment analysis of the GOI lists could highlight novel pathways or 
mechanisms involved in β-cell proliferation or in the toxicity of palmitate. 
The approach used for the analysis of the GOI lists in the screen in Chapter 3 
was followed for the human GOI lists. Each of the analyses was performed in 
both the proliferation and the death screens. The results for both screens are 
indicated in the following sub-sections. 
4.3.14.1. Functional enrichment analysis of the proliferation human GOI list 
using STRING 
The GOI lists for the T7 and T14 samples were filtered for genes expressed in 
human β-cells as previously explained. The enrichment analysis produced by 
STRING when the networks in section 4.3.12.4 were constructed revealed a 
total of 94 functional categories significantly enriched in the T7 human GOI list. 
From those, 40 are biological processes, 11 molecular functions and 42 cellular 
component terms. 
In the T14 human GOI list no enrichment was found in the biological process 
GO category and only 13 terms (ten cellular components and three molecular 
functions) were determined as being enriched. 
The combined list was determined to be enriched in 119 biological processes, 
30 molecular functions and 43 cellular components. The top 15 enriched GO 
terms are available in Table 4.34. 
The overlap among the different human proliferation lists is available in Figure 
4.40.
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Pathway ID Pathway description Observed gene count FDR 
GO.0044422 organelle part 179 2.86x10-10 
GO.0044446 intracellular organelle part 174 8.51x10-10 
GO.0044444 cytoplasmic part 167 4.20x10-09 
GO.0005622 intracellular 245 1.46x10-08 
GO.0044424 intracellular part 240 1.83x10-08 
GO.0005737 cytoplasm 203 6.57x10-08 
GO.0043229 intracellular organelle 217 3.01x10-07 
GO.0043231 intracellular membrane-bounded organelle 204 9.49x10-07 
GO.0005829 cytosol 88 1.09x10-06 
GO.0043227 membrane-bounded organelle 219 1.09x10-06 
GO.0043226 organelle 226 2.00x1006 
GO.0005488 binding 208 2.22x10-0 
GO.0005623 cell 250 2.23x10-05 
GO.0044464 cell part 248 5.34x1005 
GO.0044428 nuclear part 90 0.000106 
Table 4.32. Top 15 enriched GO terms in the T7 proliferation human GOI list ordered by their false discovery rate (FDR) according to STRING
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Pathway ID Pathway description Observed gene count FDR 
GO.0043167 ion binding 87 0.000966 
GO.0005488 binding 122 0.00393 
GO.0003674 molecular_function 138 0.0107 
GO.0034719 SMN-Sm protein complex 4 0.00997 
GO.0043234 protein complex 58 0.00997 
GO.0098805 whole membrane 35 0.00997 
GO.0030670 phagocytic vesicle membrane 5 0.0302 
GO.0032797 SMN complex 3 0.0302 
GO.0045335 phagocytic vesicle 6 0.0302 
GO.0097504 Gemini of coiled bodies 3 0.0302 
GO.0030666 endocytic vesicle membrane 7 0.0328 
GO.0005737 cytoplasm 111 0.0357 
GO.0016604 nuclear body 11 0.0415 
Table 4.33. Enriched GO terms in the T14 proliferation human GOI list ordered by their false discovery rate (FDR) according to STR ING 
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Pathway ID Pathway description Observed gene count FDR 
GO.0005488 binding 308 7.01x10-11 
GO.0044422 organelle part 246 3.85x10-10 
GO.0005737 cytoplasm 294 4.35x10-10 
GO.0044444 cytoplasmic part 233 6.26x10-10 
GO.0044446 intracellular organelle part 239 6.66x10-10 
GO.0005622 intracellular 350 1.09x10-09 
GO.0044424 intracellular part 343 1.15x10-09 
GO.0043227 membrane-bounded organelle 318 9.99x10-09 
GO.0003674 molecular_function 344 2.08x10-08 
GO.0005829 cytosol 121 2.36x10-07 
GO.0043226 organelle 323 4.97x10-07 
GO.0043229 intracellular organelle 302 1.69x10-06 
GO.0043231 intracellular membrane-bounded organelle 285 1.95x10-06 
GO.0005515 protein binding 157 2.31x10-06 
GO.0043234 protein complex 135 2.40x10-06 
Table 4.34. Top 15 enriched GO terms in the combined proliferation GOI list ordered by false discovery rate (FDR), as determined by STR ING.
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Figure 4.40. Venn diagram representing the overlap among the proliferation human GOI 
lists (t7 and t14) and the combination of both lists (t7t14) in enriched functional categories 
according to STRING. 
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4.3.14.2. Functional enrichment analysis of the human resistance to death 
by lipids GOI list using STRING 
The functional enrichment analysis performed by STRING on the resistance to 
death by lipids GOI list after filtering for genes expressed in human β-cells 
indicates that only one biological process and 17 cellular components were 
enriched (Table 4.35). The lack of enriched functional categories may be a 
result of the lack of knowledge of the specific mechanism of toxicity induced by 
palmitate in β-cells. If a known apoptotic process was used this should have 
been identified, particularly effector pathways. This absence of enrichment may 
therefore indicate that the apoptotic process involved in palmitate toxicity is not 
shared with other stimuli for which the effector pathways have been 
characterised.
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Pathway ID Pathway description Observed gene count FDR 
GO.0043227 membrane-bounded organelle 136 4.48x10-05 
GO.0005622 intracellular 146 4.75x10-05 
GO.0043231 intracellular membrane-bounded organelle 124 0.000166 
GO.0043226 organelle 136 0.000367 
GO.0044424 intracellular part 140 0.000367 
GO.0005634 nucleus 90 0.000536 
GO.0005737 cytoplasm 118 0.000588 
GO.0043229 intracellular organelle 127 0.000794 
GO.0070013 intracellular organelle lumen 60 0.00273 
GO.0031981 nuclear lumen 52 0.00399 
GO.0005654 nucleoplasm 44 0.0162 
GO.0044428 nuclear part 53 0.0162 
GO.0044446 intracellular organelle part 90 0.0193 
GO.0005623 cell 144 0.0299 
GO.0044422 organelle part 90 0.0398 
Table 4.35. Top 15 enriched GO terms in the human resistance to death by lipids GOI list ordered by FDR, according to STRING.
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4.3.14.3. Functional enrichment analysis of the human GOI lists using 
FunCoup 
FunCoup performs a basic functional enrichment analysis using GO categories 
when it calculates a protein network. Results of the functional enrichment 
analysis were obtained when the different networks were produced. However, 
similarly to the analysis in Chapter 3, no categories were found to be enriched 
with a q-value below 0.05 in any of the human GOI lists. 
4.3.14.4. Functional enrichment analysis of the human proliferation GOI 
lists using DAVID 
The use of the on-line resource DAVID to perform functional enrichment 
analyses has been previously discussed in section 3.3.11.3. Functional 
enrichment analysis using DAVID was performed on the proliferation GOI lists 
(T7, T14 and combined T7T14) after filtering for genes expressed in human β-
cells.  
The whole genome of Homo sapiens was used as the background for the 
enrichment analysis resulting in the same limitations for this analysis method 
discussed in Chapter 3. 
Analysis of the T7 human GOI list resulted in one functional term being 
determined as enriched with an FDR under 0.05: “phosphoprotein”. Using a p-
value threshold of 0.05 to determine enrichment, 136 categories are enriched. 
The top 10 categories with lower Benjamini-adjusted p-value are listed in Table 
4.36. 
In the T14 GOI list no categories were found to be enriched with an FDR lower 
than 0.05 and 144 categories were enriched with a p-value under 0.05. Table 
4.37 contains the top 10 categories as ranked by their Benjamini-adjusted p-
value. 
Analysis of the combined proliferation GOI list indicated that four categories 
were enriched with an FDR below 0.05 and 245 had a p-value under 0.05. The 
10 categories with lower Benjamini-adjusted p-value are available on Table 4.38.
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Category Term % of GOI in the term P-Value Fold Enrichment Benjamini 
SP_PIR_KEYWORDS phosphoprotein 56.42633 7.79x10-12 1.499069 2.60x10-09 
SP_PIR_KEYWORDS cytoplasm 25.07837 3.63x10-04 1.452279 0.029866 
SP_PIR_KEYWORDS nucleus 31.03448 2.02x10-04 1.398145 0.033191 
SP_PIR_KEYWORDS GTPase activation 3.448276 3.14x10-04 4.184664 0.034386 
SP_PIR_KEYWORDS transferase 12.22571 0.001553 1.692259 0.098608 
SMART SM00233:PH 4.702194 0.001019 2.762037 0.146121 
SP_PIR_KEYWORDS disease mutation 13.16614 0.002837 1.596777 0.146257 
SP_PIR_KEYWORDS transport 13.47962 0.003933 1.557461 0.171423 
SP_PIR_KEYWORDS DNA damage 3.134796 0.007101 2.950606 0.232371 
SP_PIR_KEYWORDS magnesium 5.015674 0.006774 2.18959 0.247073 
Table 4.36. Top 10 categories in the functional enrichment analysis of the T7 human GOI list performed using DAVID, ranked by their 
Benjamini-adjusted p-value.
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Category Term % of GOI in 
the term 
P-Value Fold 
Enrichment 
Benjamini 
SP_PIR_KEYWORDS phosphoprotein 51.5625 8.83x10-05 1.365558 0.025381 
SP_PIR_KEYWORDS metal-binding 25 6.28x10-04 1.618018 0.059114 
SP_PIR_KEYWORDS disease mutation 16.14583 4.87x10-04 1.952012 0.068371 
SP_PIR_KEYWORDS transferase 14.0625 0.001396 1.940403 0.096642 
SP_PIR_KEYWORDS acetylation 21.875 0.00207 1.596833 0.113622 
SP_PIR_KEYWORDS serine/threonine-protein kinase 5.729167 0.004889 2.892402 0.184322 
SP_PIR_KEYWORDS lyase 3.125 0.006492 5.094015 0.189886 
SP_PIR_KEYWORDS zinc-finger 15.10417 0.006232 1.691086 0.203396 
SP_PIR_KEYWORDS prenylation 3.645833 0.004695 4.495359 0.20407 
SP_PIR_KEYWORDS zinc 17.70833 0.009498 1.556052 0.22312 
Table 4.37. Top 10 categories in the functional enrichment analysis of the T14 human GOI list performed using DAVID, ranked by their 
Benjamini-adjusted p-value.
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Category Term % of GOI in the 
term 
P-Value Fold Enrichment Benjamini 
SP_PIR_KEYWORDS phosphoprotein 5.01258 4.89x10-14 1.447097 2.02x10-11 
SP_PIR_KEYWORDS disease mutation 1.316044 9.67x10-06 1.734413 0.00199 
SP_PIR_KEYWORDS transferase 1.161215 3.02x10-05 1.746636 0.00414 
SP_PIR_KEYWORDS GTPase activation 0.27095 1.58x10-04 3.573097 0.010791 
SP_PIR_KEYWORDS acetylation 1.838591 1.06x10-04 1.463042 0.010908 
SP_PIR_KEYWORDS nucleus 2.690149 2.33x10-04 1.316984 0.011949 
SP_PIR_KEYWORDS serine/threonine-protein 
kinase 
0.445133 2.05x10-04 2.449721 0.011994 
SP_PIR_KEYWORDS cytoplasm 2.206309 1.48E-04 1.388397 0.012109 
SP_PIR_KEYWORDS nucleotide-binding 1.257983 3.18E-04 1.564479 0.01444 
SMART SM00233:PH 0.406425 1.61E-04 2.597357 0.029749 
Table 4.38. Top 10 categories in the functional enrichment analysis of the combined proliferation human GOI list performed using DAVID,  
ranked by their Benjamini-adjusted p-value.
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4.3.14.5. Functional enrichment analysis of the human resistance to 
lipotoxicity GOI list using DAVID. 
The human GOI list for resistance to lipotoxicity was found to be enriched in two 
functional categories with an FDR under 0.05 and 48 with a p-value below 0.05. 
The list of the ten functional terms with the lowest Benjamini-adjusted p-values 
is available on Table 4.39.
379 
 
Category Term % of GOI in the 
term 
P-Value Fold 
Enrichment 
Benjamini 
SP_PIR_KEYWORDS phosphoprotein 53.36787565 7.32x10-06 1.420731935 0.00201734 
SP_PIR_KEYWORDS acetylation 24.87046632 3.56x10-05 1.824952562 0.004895105 
SP_PIR_KEYWORDS nucleus 34.19689119 1.22x10-04 1.543785022 0.011182769 
SP_PIR_KEYWORDS rna-binding 8.29015544 3.36x10-04 2.968364198 0.022903168 
SP_PIR_KEYWORDS transcription regulation 17.61658031 0.002972563 1.681242802 0.151537876 
SP_PIR_KEYWORDS Transcription 17.61658031 0.004182524 1.644711693 0.175352749 
SP_PIR_KEYWORDS alternative splicing 47.66839378 0.008480025 1.230872173 0.285220373 
SP_PIR_KEYWORDS cytoplasm 24.35233161 0.010602688 1.413135567 0.307706813 
GOTERM_BP_FAT GO:0016072~rRNA 
metabolic process 
3.626943005 9.01E-04 6.203878407 0.393508302 
SP_PIR_KEYWORDS rrna processing 2.07253886 0.022769176 6.569330601 0.470432235 
Table 4.39. Top 10 categories in the functional enrichment analysis of the human resistance to lipotoxicity GOI list performed using DA VID, 
ranked by their Benjamini-adjusted p-value.
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4.3.14.6. Functional enrichment analysis using FunRich 
The use of FunRich as a tool to analyse a list of genes for functional enrichment 
has been discussed in this thesis in section 3.3.11.4. 
Only the human GOI lists (human gene names filtered for expression in human 
β-cells) were used to perform this analysis. Functional enrichment was 
considered in “cellular component”, “molecular function”, “biological process” 
and “transcription factor”.  
In the T7 human GOI list 24 terms were found to be enriched with a Benjamini-
adjusted p-value under 0.05. The 15 terms with the lowest Benjamini p-value 
are listed in Table 4.40. Only two of them are not transcription factors: “GTPase 
activator activity” and “Cytoplasm”. The other 13 indicate enrichment for genes 
with transcription factor binding sites for each of the transcription factors in the 
table. 
Analysis of the T14 human GOI list found six functional terms enriched with a 
Benjamini adjusted p-value lower than 0.05, all of them transcription factor 
binding sites. Table 4.41 contains the 15 functional terms with the lowest 
Benjamini adjusted p-value. 
In the combined list, 40 terms were found to be enriched with a Benjamini-
adjusted p-value under 0.05, the majority are transcription factors. A list of the 
15 functional terms with the lowest Benjamini adjusted p-value is available in 
Table 4.42. 
The analysis of the human GOI list from the resistance to death by chronic 
exposure to lipids did not find any functional terms enriched with a Benjamini-
adjusted p-value under 0.05. The 15 functional terms with the lowest Benjamini-
adjusted p-values are listed in Table 4.43. As opposed to the lists for the 
proliferation GOI lists, transcription factors are not the main category of the 
enriched terms.
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Term % of GOI in the 
term 
Fold 
Enrichment 
Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and 
Tibshirani q-value 
SP1 59.5959596 1.273943 6.32x10-06 0.001213 0.000118 
KLF7 39.73063973 1.36854 5.68x10-05 0.003636 0.000354 
SP4 39.05723906 1.377023 5.25x10-05 0.00504 0.000354 
NKX2-1 9.764309764 2.174731 0.0001381 0.006603 0.000643 
RAB40B 10.43771044 2.030947 0.0002611 0.008333 0.000812 
RARA 10.43771044 2.030947 0.00026 0.01 0.000812 
POU4F3 9.090909091 2.090137 0.000459 0.012598 0.001227 
ZNF238 9.764309764 1.928922 0.000976 0.017039 0.001659 
GTPase activator activity 3.095975232 4.339353 0.000257 0.017986 0.004163 
ZNF513 9.764309764 1.928922 0.000976 0.018743 0.001659 
PLAU 11.78451178 1.800485 0.000893 0.019053 0.001659 
Cytoplasm 49.82578397 1.279078 0.000129 0.019399 0.003722 
ATF1 11.78451178 1.800485 0.000893 0.021434 0.001659 
NFYA 23.23232323 1.423751 0.001647 0.026344 0.002566 
POU3F4 5.387205387 2.391388 0.002355 0.02826 0.002752 
Table 4.40. Top 15 functional terms (by Benjamini p-value) enriched in the T7 human GOI list. Analysis was performed using FunRich.
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Term % of GOI in 
the term 
Fold Enrichment Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and 
Tibshirani q-value 
TCF12 15.88235294 2.280834 8.64 x10-05 0.015721 0.003287 
RARA 12.35294118 2.440331 0.000272 0.016526 0.003455 
SP1 59.41176471 1.272722 0.000669 0.024363 0.005093 
RAB40B 12.35294118 2.440331 0.000272 0.024789 0.003455 
NR4A2 14.11764706 2.152615 0.00056 0.025483 0.005093 
CTCF 26.47058824 1.574659 0.001411 0.042793 0.008946 
Energy pathways 15.34391534 1.754941 0.003399 0.067971 0.021331 
Transaminase activity 1.587301587 16.5044 0.001752 0.09285 0.054785 
Metabolism 14.81481481 1.645235 0.009657 0.096575 0.030307 
Carbohydrate mediated 
signalling 
0.529100529 65.1961 0.020989 0.104945 0.032933 
Cell communication 26.45502646 1.308567 0.030231 0.120923 0.037948 
JUNB 17.64705882 1.584272 0.011197 0.135863 0.028404 
Hemopoiesis 0.529100529 40.35949 0.04154 0.138465 0.043453 
Reproductive behaviour 0.529100529 65.1961 0.020989 0.139926 0.032933 
BARHL1 7.058823529 2.296262 0.012374 0.14076 0.029427 
Table 4.41. Top 15 functional terms (by Benjamini p-value) enriched in the T14 human GOI list. Analysis was performed using FunRich.
383 
 
Term % of GOI in 
the term 
Fold Enrichment Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and 
Tibshirani q-value 
SP1 60.32110092 1.288208125 8.12 x10-09 1.58 x10-06 2.63 x10-07 
KLF7 39.44954128 1.356197245 2.15 x10-06 0.000209 3.49 x10-05 
RAB40B 10.55045872 2.029650963 7 x10-06 0.000339 5.67 x10-05 
RARA 10.55045872 2.029650963 7 x10-06 0.000453 5.67 x10-05 
NKX2-1 9.174311927 2.022808482 3.36 x10-05 0.001088 0.000182 
SP4 37.3853211 1.315783094 3.19 x10-05 0.001238 0.000182 
ZNF238 9.633027523 1.881160888 0.000108 0.002615 0.000437 
ZNF513 9.633027523 1.881160888 0.000108 0.002989 0.000437 
PITX1 9.633027523 1.776311126 0.000367 0.007121 0.00119 
NR4A2 11.23853211 1.677806593 0.000407 0.007181 0.0012 
OTX1 9.633027523 1.776311126 0.000367 0.007912 0.00119 
GTPase activator activity 2.725366876 3.726596475 0.00011 0.008925 0.003687 
Signal transduction 28.1512605 1.299140477 0.000574 0.010043 0.002159 
Auxiliary transport protein 
activity 
4.402515723 2.493737491 0.000249 0.010078 0.004163 
Cell communication 27.10084034 1.325740604 0.000332 0.011603 0.002159 
Table 4.42. Top 15 functional terms (by Benjamini p-value) enriched in the combined proliferation human GOI list. Analysis was performed 
using FunRich
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Term % of GOI in 
the term 
Fold 
Enrichment 
Unadjusted 
p-value 
Benjamini 
adjusted p-value 
Storey and 
Tibshirani q-value 
Cell-cell signaling 1.041666667 17.46714288 0.01242225 0.068322377 0.028557109 
Regulation of circadian rhythm 0.520833333 92.71021992 0.010717276 0.078593358 0.028557109 
LHX4 7.514450867 3.165241267 0.000548949 0.104300322 0.044951126 
NRF1 21.96531792 1.684252985 0.001213177 0.115251795 0.049670968 
Secretory pathway 0.520833333 92.71021992 0.010717276 0.117890036 0.028557109 
Spindle microtubule 1.724137931 14.39888524 0.002572104 0.119602849 0.058177902 
Signal complex formation 0.520833333 49.08188114 0.031810236 0.139965037 0.058502016 
Regulation of endocytosis 0.520833333 39.7329514 0.04218833 0.154690545 0.064656924 
Regulation of nucleobase, 
nucleoside, nucleotide and 
nucleic acid metabolism 
22.39583333 1.477686531 0.007044393 0.154976652 0.028557109 
Aminoacyl-tRNA synthetase 
multienzyme complex 
0.574712644 82.15834522 0.012085851 0.160569166 0.078104972 
LHX3 14.45086705 1.88807312 0.002652585 0.167997041 0.072402999 
Invadopodium membrane 0.574712644 82.15834522 0.012085851 0.187330694 0.078104972 
Nucleus 48.27586207 1.21444344 0.016347063 0.190034613 0.092437723 
AP-2 adaptor complex 1.149425287 36.82960303 0.002110082 0.196237662 0.058177902 
Signal peptidase complex 0.574712644 82.15834522 0.012085851 0.224796833 0.078104972 
Table 4.43. Top 15 functional terms (by Benjamini p-value) enriched in the resistance to lipotoxicity human GOI list. Analysis was performed 
using FunRich
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4.3.14.7. Gene set enrichment analysis of the human GOI lists 
The GSEA software has been previously described in this thesis in section 
3.3.11.5. Briefly, the “Preranked” tool implemented in GSEA was used to 
analyse the enrichment in genes belonging to certain gene sets in the top 
positions of the list of screened genes. The genes were ranked by the 
phenotype of interest in each case. Similarly to the analyses produced in 
Chapter 3, several approaches were taken to produce gene set enrichment 
reports. As the method of removing duplicate gene names in the lists did not 
seem to make a big difference in the results, duplications were resolved by 
keeping the targeting sequence with the highest z-score. Therefore, the lists 
analysed were as follows: 
1) Genes screened in the T7 proliferation sample, ranked by z-score in T7. 
2) Genes screened in the T14 proliferation sample, ranked by z-score in 
T14. 
3) Genes screened in the T14 and T7 proliferation samples, ranked by the 
sum of z-scores in both samples. 
4) Genes screened in the resistance to lipotoxicity sample, ranked by z-
score in P. 
Enrichment was considered only in the top of the list, which corresponds to the 
highest z-scores in each list. 
Analysis of the T7 ranked list using the Preranked tool identified 133 gene sets 
enriched in the top of the list. The 15 gene sets with the lowest p-values are 
listed in Table 4.44.  
Using the T14 z-scores to rank the list of genes, 73 gene sets resulted enriched 
in the top of the list. Table 4.45 contains the 15 gene sets with the lowest p-
values for enrichment according to GSEA. 
In the list ranked by the sum of T7 and T14 z-scores, 89 gene sets were 
identified as being enriched in the top of the list. The 15 gene sets with the 
lowest p-values are available in Table 4.46. 
A degree of overlap of the T7+T14 ranked list with the analysis of the lists 
ordered by the T7 or T14 z-scores was expected. An overlap is indeed 
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observed as depicted in Figure 4.41 although this is for a few gene sets. The 
relatively low percentage of gene sets that overlap between conditions may be 
due to the smaller sample size in T14, which leads to the list ranked by T7+T14 
being shorter than the T7 ranked lists. Genes in the enriched gene sets might 
have not been included in the T7+T14 analysis due to not having a z-score 
available in the T14 sample. 
In the list ranked by the resistance to lipotoxicity z-score, 93 gene sets were 
determined as enriched at the top of the list with a p-value under 0.05. The 15 
gene sets with the lowest p-values are listed in Table 4.47.
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Name of the gene set P-value 
LI_WILMS_TUMOR_VS_FETAL_KIDNEY_2_UP <0.001 
HONMA_DOCETAXEL_RESISTANCE <0.001 
SAKAI_CHRONIC_HEPATITIS_VS_LIVER_CANCER_DN <0.001 
AZARE_STAT3_TARGETS 0.001931 
REACTOME_LATENT_INFECTION_OF_HOMO_SAPIENS_WITH_MYCOBACTERIUM_TUBERCULOSIS 0.001969 
KEGG_PARKINSONS_DISEASE 0.00198 
PUJANA_CHEK2_PCC_NETWORK 0.00198 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17 0.002024 
BIOCARTA_AKT_PATHWAY 0.002058 
TARTE_PLASMA_CELL_VS_PLASMABLAST_DN 0.004049 
SHEPARD_CRUSH_AND_BURN_MUTANT_DN 0.005682 
VANHARANTA_UTERINE_FIBROID_WITH_7Q_DELETION_DN 0.005941 
RIZ_ERYTHROID_DIFFERENTIATION 0.005976 
YOSHIMURA_MAPK8_TARGETS_DN 0.005976 
ALONSO_METASTASIS_EMT_UP 0.006122 
Table 4.44. Top 15 gene sets enriched in the top of the T7 ranked list.
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Name of gene set P-value 
GUTIERREZ_CHRONIC_LYMPHOCYTIC_LEUKEMIA_DN <0.001 
MIKKELSEN_ES_LCP_WITH_H3K4ME3 <0.001 
MIKKELSEN_IPS_LCP_WITH_H3K4ME3 0.001961 
PARK_HSC_MARKERS 0.001969 
KEGG_VIBRIO_CHOLERAE_INFECTION 0.001972 
LEE_BMP2_TARGETS_DN 0.001996 
SENGUPTA_NASOPHARYNGEAL_CARCINOMA_DN 0.003795 
BRACHAT_RESPONSE_TO_CAMPTOTHECIN_DN 0.003802 
PID_P53_REGULATION_PATHWAY 0.003854 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17 0.003914 
BLUM_RESPONSE_TO_SALIRASIB_DN 0.003953 
FEVR_CTNNB1_TARGETS_DN 0.00396 
BIOCARTA_WNT_PATHWAY 0.004049 
BIOCARTA_CHREBP2_PATHWAY 0.004228 
FERRANDO_T_ALL_WITH_MLL_ENL_FUSION_DN 0.005747 
Table 4.45. Top 15 gene sets enriched in the top of the T14 ranked list.  
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Name of the gene set P-value 
REACTOME_LATENT_INFECTION_OF_HOMO_SAPIENS_WITH_MYCOBACTERIUM_TUBERCULOSIS <0.001 
SHEDDEN_LUNG_CANCER_POOR_SURVIVAL_A6 <0.001 
MODY_HIPPOCAMPUS_POSTNATAL <0.001 
MIKKELSEN_ES_LCP_WITH_H3K4ME3 <0.001 
PID_PTP1B_PATHWAY <0.001 
REACTOME_IRON_UPTAKE_AND_TRANSPORT 0.001942 
GROSS_HYPOXIA_VIA_HIF1A_UP 0.001996 
CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_DN 0.00202 
YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_17 0.002049 
RODWELL_AGING_KIDNEY_DN 0.003992 
MIYAGAWA_TARGETS_OF_EWSR1_ETS_FUSIONS_DN 0.006012 
CREIGHTON_AKT1_SIGNALING_VIA_MTOR_UP 0.006073 
REACTOME_MITOCHONDRIAL_PROTEIN_IMPORT 0.006135 
BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_D 0.007921 
PID_RAC1_PATHWAY 0.008282 
Table 4.46. Top 15 gene sets enriched in the top of the T7+T14 ranked list.
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Figure 4.41. Venn diagram representing the overlap in gene set enrichment in the lists 
ranked by the z-score in T7, T14 or T7+T14.
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Name of gene set P-value 
BHATI_G2M_ARREST_BY_2METHOXYESTRADIOL_UP <0.001 
DURCHDEWALD_SKIN_CARCINOGENESIS_DN <0.001 
ZHANG_TLX_TARGETS_36HR_DN <0.001 
RAO_BOUND_BY_SALL4_ISOFORM_B <0.001 
BIDUS_METASTASIS_UP <0.001 
HOFFMANN_LARGE_TO_SMALL_PRE_BII_LYMPHOCYTE_UP 0.002 
IGARASHI_ATF4_TARGETS_DN 0.002012 
GRADE_METASTASIS_DN 0.002028 
HOFMANN_CELL_LYMPHOMA_UP 0.002066 
BIOCARTA_ALK_PATHWAY 0.002079 
BORCZUK_MALIGNANT_MESOTHELIOMA_UP 0.002141 
MARCHINI_TRABECTEDIN_RESISTANCE_DN 0.003883 
FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP 0.003914 
DACOSTA_UV_RESPONSE_VIA_ERCC3_DN 0.004082 
HAMAI_APOPTOSIS_VIA_TRAIL_UP 0.004246 
Table 4.47. Top 15 gene sets enriched in the palmitate z-score ranked list.
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4.3.15. Transcription factor binding site enrichment analysis. 
The approach taken in section 3.3.12 was used to analyse the potential 
enrichment in transcription factor binding sites in the human GOI lists. The 
human single site analysis was used for this analyses, leaving all options were 
used as predetermined 
The human T7 GOI list was analysed using as a background a list of the human 
homologues for the genes screened in T7 and expressed in human β-cells. The 
10 transcription factor binding sites with the highest Fisher scores are listed in 
Table 4.48. As explained in section 3.3.12, OPPOSSUM recommends 
visualizing the distribution of the transcription factors z-scores against the GC 
composition of their binding sites as a clustering on any of the extremes (high or 
low GC content) may be an indicative of a bias in analysis produced by a 
differential composition in binding sites in the background used (the screened 
genes in this case). The website provides this graphical representation. For the 
T7 GOI list (Figure 4.42) there is no evident bias and the graphical 
representation indicates that the transcription factor with the highest Fisher 
score (INSM1) is separate from the rest of the transcription factors detected as 
potentially enriched. 
Equivalently to the analysis performed in the T7 human GOI list, the human T14 
GOI list was searched for enrichment using as a background the list of human 
homologues for genes screened in T14 which are expressed in human β-cells. 
Table 4.49 contains the ten transcription factors with the highest Fisher scores. 
The graphical representation obtained from OPOSSUM indicates no apparent 
bias in %GC content in the background of the GOI list, and RORA_1 is separate 
from the rest of the transcription factors. 
The GOI list composed of GOI in both proliferation samples which are 
expressed in human β-cells was analysed using as a background the genes 
screened in any of the samples which were determined as being expressed in 
human β-cells. The results of this analysis are in Table 4.50. Fisher scores were 
plotted against %GC Figure 4.44 and no bias was apparent. RORA_1 is 
maintained separate from other transcription factors as in the T14 GOI list, 
indicating that it might be important for the control of proliferation-related genes. 
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The list of genes from the lipotoxicity GOI list which are expressed in human β-
cells were examined for enrichment in transcription factor binding sites using 
the list of genes expressed in human β-cells which were screened. The top 10 
transcription factors with the highest Fisher scores as determined by 
OPOSSUM are listed in Table 4.51. The graphical representation obtained from 
OPOSSUM indicates that there is no apparent bias in %GC in the background 
used, although the transcription factors with higher Fisher score are 
asymmetrically distributed towards the low end of the %GC distribution. HNF1B 
and Foxq1 are apparently separated from the main cluster of transcription 
factors, indicating they may potentially be regulating more genes than expected 
by chance.
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Name Class Family Target 
gene hits 
Target gene 
non-hits 
Background 
gene hits 
Background 
gene non-hits 
Fisher 
score 
Z-score 
INSM1 Zinc-
coordinating 
BetaBetaAlpha-
zinc finger 
166 161 2929 3895 5.749 -0.131 
NFYA Other Alpha-
Helix 
NFY CCAAT-
binding 
135 192 2370 4454 4.658 3.574 
HNF4A Zinc-
coordinating 
Hormone-nuclear 
Receptor 
139 188 2453 4371 4.623 2.37 
RORA_1 Zinc-
coordinating 
Hormone-nuclear 
Receptor 
175 152 3209 3615 4.374 5.029 
Zfp423 Zinc-
coordinating 
BetaBetaAlpha-
zinc finger 
123 204 2192 4632 3.773 4.518 
Zfx Zinc-
coordinating 
BetaBetaAlpha-
zinc finger 
204 123 3872 2952 3.701 -13.547 
Tcfcp2l1 Other CP2 205 122 3899 2925 3.631 -8.037 
NFE2L2 Zipper-Type Leucine Zipper 120 207 2151 4673 3.522 3.77 
CTCF Zinc-
coordinating  
BetaBetaAlpha-
zinc finger 
75 252 1276 5548 3.349 5.114 
USF1 Zipper-Type Helix-Loop-Helix 187 140 3547 3277 3.299 -2.825 
Table 4.48. Top 10 enriched transcription factor binding sites in the T7 human GOI list.
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Figure 4.42. Distribution of Fisher scores for the transcription factors analysed by 
OPOSSUM and the percentage of GC in their binding sites for the T7 GOI list.  
The red line indicates a threshold set by OPOSSUM for graphical representation which 
may vary between samples. In this case, the threshold chosen is 1 standard deviation 
from the mean Fisher score for the transcription factors.
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Name Class Family Target 
gene hits 
Target gene 
non-hits 
Background 
gene hits 
Background 
gene non-hits 
Fisher 
score 
Z-score 
RORA_1 Zinc-
coordinating 
Hormone-nuclear 
Receptor 
113 80 3063 3478 7.082 10.464 
HNF1A Helix-Turn-
Helix 
Homeo 46 147 1124 5417 4.364 4.916 
STAT1 Ig-fold Stat 84 109 2315 4226 4.34 7.734 
RORA_2 Zinc-
coordinating 
Hormone-nuclear 
Receptor 
50 143 1315 5226 3.432 8.966 
HLF Zipper-Type Leucine Zipper 72 121 2014 4527 3.393 3.773 
NFIL3 Zipper-Type Leucine Zipper 83 110 2374 4167 3.37 0.901 
ELK4 Winged Helix-
Turn-Helix 
Ets 80 113 2292 4249 3.213 -1.383 
NFYA Other Alpha-
Helix 
NFY CCAAT-
binding 
79 114 2270 4271 3.112 -0.586 
CTCF Zinc-
coordinating  
BetaBetaAlpha-
zinc finger 
46 147 1227 5314 3.012 5.033 
TEAD1 Helix-Turn-
Helix 
Homeo 67 126 1906 4635 2.869 2.322 
Table 4.49. Top 10 transcription factor binding sites enriched in the T14 human GOI list ranked by Fisher score.
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Figure 4.43. Distribution of Fisher scores for the transcription factors analysed by 
OPOSSUM and the percentage of GC in their binding sites for the T14 GOI list.  
The red line indicates a threshold set by OPOSSUM for graphical representation which 
may vary between samples. In this case, the threshold chosen is 1 standard deviation  
from the mean Fisher score for the transcription factors.
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Name Class Family Target 
gene hits 
Target gene 
non-hits 
Background 
gene hits 
Background 
gene non-hits 
Fisher 
score 
Z-score 
RORA_1 Zinc-coordinating Hormone-nuclear 
Receptor 
266 217 3209 3616 7.91 9.256 
NFYA Other Alpha-Helix NFY CCAAT-
binding 
199 284 2370 4455 5.986 2.102 
CTCF Zinc-coordinating  BetaBetaAlpha-
zinc finger 
115 368 1276 5549 5.504 8.066 
INSM1 Zinc-coordinating BetaBetaAlpha-
zinc finger 
234 249 2929 3896 4.58 -1.497 
Zfp423 Zinc-coordinating BetaBetaAlpha-
zinc finger 
180 303 2192 4633 4.447 5.012 
STAT1 Ig-fold Stat 197 286 2429 4396 4.37 7.689 
ELK4 Winged Helix-
Turn-Helix 
Ets 194 289 2393 4432 4.283 -1.38 
Tcfcp2l1 Other CP2 301 182 3899 2926 4.254 -8.07 
Zfx Zinc-coordinating BetaBetaAlpha-
zinc finger 
299 184 3872 2953 4.226 -11.295 
NFE2L2 Zipper-Type Leucine Zipper 174 309 2151 4674 3.761 4.611 
Table 4.50. Top 10 enriched transcription factor binding sites in the T7T14 human GOI lis t.
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Figure 4.44. Distribution of Fisher scores for the transcription factors analysed by 
OPOSSUM and the percentage of GC in their binding sites for the combined proliferation 
GOI list.  
The red line indicates a threshold set by OPOSSUM for graphical representation which 
may vary between samples. In this case, the threshold chosen is 1 standard deviation 
from the mean Fisher score for the transcription factors.
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Name Class Family Target 
gene hits 
Target gene 
non-hits 
Background 
gene hits 
Background 
gene non-hits 
Fisher 
score 
Z-score 
HNF1B Helix-Turn-Helix Homeo 59 134 1417 4753 4.588 11.707 
Foxq1 Winged Helix-
Turn-Helix 
Forkhead 98 95 2611 3559 4.421 12.034 
CEBPA Zipper-Type Leucine 
Zipper 
139 54 4034 2136 3.45 2.489 
Pou5f1 Helix-Turn-Helix Homeo 49 144 1211 4959 3.431 1.965 
Foxd3 Winged Helix-
Turn-Helix 
Forkhead 126 67 3625 2545 3.223 5.311 
FOXF2 Winged Helix-
Turn-Helix 
Forkhead 54 139 1376 4794 3.206 4.469 
TEAD1 Helix-Turn-Helix Homeo 68 125 1798 4372 3.178 2.126 
Ddit3::Cebpa Zipper-Type Leucine 
Zipper 
71 122 1906 4264 3.005 -2.272 
MEF2A Other Alpha-Helix MADS 85 108 2363 3807 2.771 -1.513 
HLF Zipper-Type Leucine 
Zipper 
71 122 1934 4236 2.732 0.755 
Table 4.51. Top 10 transcription factors enriched in the human lipotoxicity GOI list.  
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Figure 4.45. Distribution of Fisher scores for the transcription factors analysed by 
OPOSSUM and the percentage of GC in their binding sites for the resistance to 
lipotoxicity GOI list.  
The red line indicates a threshold set by OPOSSUM for graphical representation which 
may vary between samples. In this case, the threshold chosen is 1 standard deviation 
from the mean Fisher score for the transcription factors.
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4.4. Discussion 
4.4.1. In vitro model used for this screen. 
These shRNA screens used R7T1, a reversibly immortalised mouse β-cell line, 
as an in vitro model of β-cells. The use of a cell line was necessary due to the 
scale of the screening process, which required a large number of β-cells with a 
stable phenotype. The choice of a reversibly immortalised cell line responded 
principally to the objective of screening for genes involved in proliferation control. 
Immortalisation of cells using SV40 large T antigen increases the proliferation 
rate of the cells via at least the pRb and p53 pathways (Ali and DeCaprio 2001). 
Cells therefore are not proliferating in a way which may be physiologically 
relevant and therefore any results obtained on mechanisms of proliferation may 
not be translated to an in vivo situation. Also, detection of an increase in 
proliferation in a rapidly proliferating cell line may have been difficult as the 
baseline of proliferation could be too high to discern any further effects. 
I observed a decline in proliferation rate after withdrawal of doxycycline in a 
similar pattern to the decline in oncoprotein content in the cells. The cells did 
not stop proliferating completely as indicated by the incorporation of BrDU. 
However, the rate of BrDU incorporation had greatly reduced and β-cells still 
proliferate, albeit slowly, in vivo (Dor, Brown et al. 2004, Georgia and Bhushan 
2004, Meier, Butler et al. 2008).  
4.4.2. Screening process 
This genome-wide RNAi screen was performed in parallel for two phenotypes 
with their own independent controls, constituting two different screens. The 
design of the screen has many potential limitations. 
Firstly, cells were transduced in parallel tissue culture vessels for the different 
samples of the same screen. In a genome-wide RNAi screen cells are usually 
transduced together as a pool and then separated into the screening conditions 
by dissociation from the tissue culture surface and seeding into the screening 
vessels (Luo, Cheung et al. 2008, Silva, Marran et al. 2008, Sims, Mendes-
Pereira et al. 2011). This process however induced a high level of cell death in 
R7T1 and so cells were transduced in parallel in the wells where the screening 
was performed. 
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Second, the period of doxycycline withdrawal necessary to reduce the 
expression of the immortalizing oncogene may introduce a bias in shRNA 
targeting sequence representation if any targeting sequence affects growth in 
the presence of the oncoprotein or as its expression is reduced. However, the 
control condition for the proliferation screen, T0, is harvested after the 
withdrawal period and therefore it is expected that such effects would already 
be present in the control. As the proportion of targeting sequences in the 
screening time points (T7 and T14) is normalised to the proportion in T0, such 
effects would be discarded. 
The use of palmitate as an apoptotic stimulus relevant to T2D may also be 
discussed. Although free fatty acid levels are elevated in T2D patients (Reaven, 
Hollenbeck et al. 1988, Boden and Shulman 2002), the levels of free fatty acids 
are measured in blood samples and the concentration to which β-cells are 
exposed in the islet are unknown.  
Another limitation to these screens is that only one replicate was performed. 
However, the scale of the screens limited this possibility. The NKI library has a 
two-fold redundancy, which is not a solution for the lack of additional biological 
replicates but increases the confidence on those GOI targeted by two shRNA 
constructs. 
4.4.3. PCR amplification and sequencing 
The two-step PCR amplification and Illumina library preparation used in this 
screen replaces the PCR amplification followed by library preparation using a 
PCR-free approach in Chapter 3. Performing two PCR amplifications may have 
reduced the linearity of amplification, but the number of PCR cycles was kept to 
a minimum. This resulted in a higher proportion of shRNA targeting sequences 
being identified in the sequencing data than in the screen in Chapter 3 or in the 
pilot project in this screen.  
PCR amplification also needed the addition of betaine to relax the potential 
tertiary structures detected in the first PCR amplification reactions. The addition 
of betaine produced PCR amplification without tertiary structures. It cannot be 
excluded that secondary structure resulted in some sequences not being 
analysed. However, this would occur equally in the experimental and control 
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samples so it would not affect the results obtained but some biologically active 
genes may not have been assayed. This would have affected the network 
analysis as this was done in the absence of first neighbours. 
This two-step PCR and library preparation in the presence of betaine resulted in 
the sequencing dataset with the highest quality as judged by the absence of 
primer dimers in the sequencing lane and the proportion of sequencing reads 
which contained a shRNA construct with a perfect match to the loop between 
complementary strands of the targeting sequence. 
The improvement in shRNA construct identification may have also be a result of 
the samples being identified by their Illumina indexes instead of the PCR primer 
used to amplify them. Using the PCR primers for deconvolution of the 
sequencing output as in Chapter 3 could only identify those sequencing reads 
with a perfect match to the primer sequence, which may have been modified in 
the sequencing reads by a PCR or sequencing polymerase error. 
4.4.4. Sequencing data analysis. 
Identification of potential genes of interest (GOIs) was performed using the 
same strategy as in Chapter 3. The use of a z-score of the ratio between 
experimental condition and control has already been discussed in section 3.4.2.  
A step of filtering for genes expressed in human β-cells was implemented to 
reduce the number of GOI to those which may be of interest for human biology. 
Using only one RNA sequencing dataset and only one individual is a limitation 
in this process. Ideally, several datasets including multiple individuals should be 
integrated to produce a better threshold of expression. However, this analysis 
was performed using only the individual with the median level of expression for 
CFTR for simplicity in these screens. This aspect may be re-considered in the 
future in order to produce a better dataset. Nevertheless, highly expressed or 
essential genes are not likely to not be expressed in one individual alone and 
therefore a more convoluted approach could result in more lowly expressed 
genes or genes expressed heterogeneously in the population being included. 
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4.4.5. Function of GOI targeted by two shRNA constructs. 
Unlike the screen in Chapter 3, no confirmation experiments with a second 
targeting sequence were performed. As such, the closest to a confirmation 
experiment available at the moment are those GOI for which two targeting 
sequence have been considered to have had an effect, or those selected in T7 
and T14. 
In T7, seven genes were targeted by two sequences with an effect: Zmynd11, 
Hax1, Anapc10, Bcr, Arhgef1, Ppia and N4bp2. No gene was targeted by two 
sequences in T14.  
Zmynd11 was also selected as a GOI in T14. It is also known as Bs69 and 
encodes a protein which binds adenovirus and inhibits Adenovirus serotype 5 
E1A 289R (13S) (Hateboer, Gennissen et al. 1995), a nuclear phosphoprotein 
which transactivates cellular genes and other adenovirus early genes. Bs69 
also binds and inhibits the transcriptional activity of c-Myb (Ladendorff, Wu et al. 
2001) and acts as a gene expression co-repressor upon binding with Ets-2 (Wei, 
Schaffner et al. 2003). This protein regulates genes involved in growth, 
differentiation and survival of normal and tumour cells and has been identified 
as a potential tumour suppressor (Ansieau and Sergeant 2003). Zmynd11 has 
also been identified as a mediator of transcription elongation by histone 
H3.3K36me3, and binding of this histone seems to confer Zmynd11 its tumour 
suppressor activity (Wen, Li et al. 2014). Based on this information, knockdown 
of this GOI may induce cell proliferation in R7T1 cells. 
Hax1 encodes an anti-apoptotic protein related to Bcl-2 (Chao, Parganas et al. 
2008) and therefore its knockdown would be expected to have the opposite 
effect of that detected in this screen. Bcl-2 reduces glucose signalling in β-cells 
(Luciani, White et al. 2013) and it can protect β-cells from apoptosis in vitro 
(Allison, Thomas et al. 2000). 
Anapc10, also known as Apc10 is part of the anaphase-promoting complex or 
cyclosome which is essential for cell cycle progression (Chang, Zhang et al. 
2014). Its knockdown should produce the opposite effect to the observed. 
Not much is known about Bcr in its complete form outside of the fusion protein 
BCR/ABL. Bcr is a tyrosine kinase that inactivates Rac1 (Chuang, Xu et al. 
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1995) and a negative modulator of the Wnt pathway (Ress and Moelling 2005). 
Thus, its knockdown may upregulate cell proliferation. 
Arhgef1 encodes a Rho-guanine exchange factor which stimulates RhoA 
activation (Croisé, Brunaud et al. 2016). RhoA has been associated with cell 
proliferation and malignancy (Fritz, Brachetti et al. 2002, Horiuchi, Imai et al. 
2003, Kamai, Tsujii et al. 2003) and therefore knockdown of Arhgef1 may result 
in cell proliferation. Inhibition of RhoA has been shown to increase the level of 
human β-cell proliferation stimulation in vitro when used as a complement to 
Wnt signalling activation (Aly, Rohatgi et al. 2013). 
Ppia encodes a protein also known as Cyclophilin A. Its downregulation has 
been shown to reduce cell proliferation (Obchoei, Weakley et al. 2011), which 
contradicts the results from the screen. 
N4bp2 binds Bcl-3 and its expression is upregulated in tumours (Zheng, Qin et 
al. 2007). Based on this information, knockdown of N4bp2 should decrease cell 
proliferation. 
From the genes found in both T7 and T14, only those with a sum of z-scores 
higher than 10 will be discussed. 
The function of Snrnp27 is not very well known. It is also known as Ry1 and 
was discovered by the alteration of its expression following the integration of 
human T lymphotropic virus type 1 (Nakamura, Moriuchi et al. 1994). I therefore 
cannot comment on the possible effects of its knockdown. 
Tmem165 seems to have a role in glycosylation (Foulquier, Amyere et al. 2012). 
Pwp2 encodes the Periodic Tryptophan Protein Homolog in humans. Not much 
information is available on the human protein, but the yeast protein is necessary 
for ribosome assembly (Dosil and Bustelo 2004). 
Znf8 binds Smad1 (Jiao, Zhou et al. 2002), which mediates the effects of 
transforming growth factor (TGF-β) and bone morphogenetic proteins (BMPs) in 
determining cell fate (Kretzschmar, Doody et al. 1997) 
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In the resistance to lipotoxicity screen, nine GOI were targeted by two shRNA 
sequences: Mkrn2, Lrit2, Eprs, Mga, Chrnb1, Tbc1d10c, Zbed3, Cp, Spon2 and 
Hic2. 
Mkrn2 was detected in all GOI lists. It is a highly conserved gene antisense of 
Raf1 (Gray, Azama et al. 2001), although the expression of both genes does 
not seem to be correlated (Lee, Chan et al. 2014). Overexpression of Mkrn2 
induces cell proliferation (Lee, Chan et al. 2014), which contradicts the results 
of the screens. However, if the antisense sequence of Raf1 in Mkrn2 was 
regulating the expression of Raf1, a reduction of expression in Mkrn2 could 
increase the expression of Raf1 thereby causing an increase in proliferation. 
Raf1 activation in β-cells in mice through the deletion of a gene coding an 
inhibitory kinase increases β-cell mass (Pardo, Altirriba et al. 2012). 
Lrit3 has been identified as a regulator of fibroblast growth factor receptors (Fgfr) 
(Kim, Liu et al. 2012) which signal through Ras/MAPK pathways (Kouhara, 
Hadari et al. 1997), so its effect might be on proliferation. Lrit3 was also found to 
be a GOI in the T14 sample. 
Eprs is part of the gamma-interferon-activated inhibitor of translation (GAIT) 
which regulates gene expression in response to inflammation (Arif, Jia et al. 
2009). 
Mga encodes a protein which participates in c-Myc mediated signalling (Hurlin, 
Steingrìmsson et al. 1999). It also binds Bs69/Zmynd11 (Ansieau and Leutz 
2002). Thus, its effect in survival to lipotoxicity may be mediated through an 
effect on proliferation. 
Chrnb1 encodes a subunit of the muscle acetylcholine receptor (Le Novère, 
Corringer et al. 2002). 
Tbcdc10c encodes a protein named Carabin, which can bind Calcineurin and 
inhibit Ras signalling (Pan, Sun et al. 2007). Knockdown of this protein may 
therefore deregulate cell proliferation or apoptosis in a non-palmitate specific 
manner. Suppression of calcineurin activity in β-cells in mice causes a decrease 
in β-cell mass (Heit, Apelqvist et al. 2006), therefore activation of proliferation 
may be independent of calcineurin. 
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The product of Zbed3 interacts with Axin, a modulator of Wnt/β-catenin pathway 
(Chen, Li et al. 2009). A single nucleotide polymorphism (SNP) has been 
proposed to be associated with T2D risk (Ohshige, Iwata et al. 2011). More 
recently, secretion of ZBED3 protein was detected and higher levels were 
identified in serum of T2D patients versus non-diabetic controls (Jia, Yuan et al. 
2014). ZBED3 knockdown inhibits cancer cell proliferation (Fan, Jiang et al. 
2015), which indicates that the effect detected in the screen may not be due to 
over-proliferation but to protection from cell death. 
Cp encodes ceruloplasmin, a metalloprotein which binds copper (Holmberg and 
Laurell 1948) and oxidises Fe2+ to Fe3+ (Roeser, Lee et al. 1970) which is then 
transported by transferrin (Eid, Hémadi et al. 2014). Its expression is regulated 
by the GAIT complex (Sampath, Mazumder et al. 2003), providing a potential 
link with Eprs.  
Spon2 was found to be targeted by two constructs and it was also 
downregulated upon palmitate treatment in the dataset used in section 4.3.11. 
Spon2, also known as Mindin, interacts with PPARα (Zhu, Wang et al. 2014). 
PPARα is a transcription factor which controls lipid metabolism (Ziouzenkova, 
Perrey et al. 2003) and has been shown to protect human islets from lipotoxicity 
(Lalloyer, Vandewalle et al. 2006). Downregulation of Spon2 should then reduce 
the protection against lipotoxicity contrary to my findings. 
Finally, Hic2 was identified as a homologue of the putative tumour suppressor 
Hic1 (Deltour, Pinte et al. 2001). It has been proposed to be involved in cardiac 
development (Dykes, van Bueren et al. 2014). 
4.4.6. Hyperconnected genes 
Although far from being a confirmation assay, evidence of a higher number of 
genes interacting with certain GOI as detected in 4.3.12.6 support the indication 
that those genes are involved in the phenotype as downregulation of their 
interacting genes has the same effect more often than expected. 
Most of the genes detected as hyperconnected only have one or two connecting 
genes in the shRNA library targeted genes, which makes the interpretation of 
hyperconnection difficult. However, some of the genes have a high number of 
potential interacting proteins in the library and still were detected as 
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hyperconnected. I will discuss some of the genes showing that pattern in the 
combined proliferation and lipotoxicity GOI list. 
In the proliferation GOI list, Pten has the highest number of potential connectors 
in the hyperconnected gene list. Of the 78 connectors in the library, 10 were 
included in the GOI list. PTEN is a tumour suppressor mutated in numerous 
cancers (Li, Yen et al. 1997) and negatively regulates the PI3K/AKT pathway 
(Maehama and Dixon 1998, Stambolic, Suzuki et al. 1998). Deletion of Pten in 
β-cells increases proliferation in vivo (Stiles, Kuralwalla-Martinez et al. 2006, 
Yang, Bayan et al. 2014). The effect of its knockdown in R7T1 cells is therefore 
not unexpected. 
In the resistance to lipotoxicity screen only three genes were hyperconnected: 
Aak1, Chrm3 and Pcbd2, while in the proliferation list 28 genes were detected 
as hyperconnected. This low number of hyperconnected genes may possibly be 
the result of two conditions: the lipotoxicity GOI list is too short for enrichment in 
connections to be detected, and the mechanism of lipotoxicity may be less 
studied and described than proliferation. Gene networks would therefore be less 
described for these genes, resulting in smaller networks. The gene network for 
the lipotoxicity screen was found to be smaller than the T14 network despite the 
GOI list being only five genes shorter (section 4.3.13.1). 
Aak1 is implicated in endocytosis (Conner and Schmid 2002) and has been 
identified as a positive regulator of the Notch1 signalling pathway (Gupta-Rossi, 
Ortica et al. 2011). 
Chrm3 is a muscarinic acetylcholine receptor which can stimulate 
phospholipase C (PLC) (Evellin, Nolte et al. 2002). PLC is involved in the 
palmitate-induced stress response in podocytes (Xu, Nam et al. 2015). 
Therefore, Chrm3 knockdown may protect from palmitate-induced lipotoxicity by 
downregulating PLC activity.  
Pcbd2 is also known as Dcoh2. It is a co-activator of Hnf1a (Rose, Pullen et al. 
2004). Heterozygous mutations in HNF1A cause MODY3 (Yamagata, Oda et al. 
1996) and mice expressing a dominant negative form of Hnf1a have reduced β-
cell mass (Yang, Yamagata et al. 2002). HNF1A has been shown to be de-
regulated in rat β-cells in the presence of palmitate (Johnstone, Diakogiannaki 
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et al. 2011), although only in one (BRIN-BD11) of two cell lines tested (INS1 
and BRIN-BD11). Hnf1a was not screened in the lipotoxicity and therefore no 
data is available on its knockdown effect in this study. However, transcriptional 
regulation of Hnf1a may be a mechanism for the effect of Pcbd2 in protecting 
R7T1 cells from lipotoxicity. 
4.4.7. Functional and gene set enrichment 
Functional enrichment analysis was performed with the objective of potentially 
finding functional categories which may be implicated in the phenotypes studied 
and to reduce the GOI list. The major limitation of the enrichment analysis using 
FunCoup, STRING, DAVID and FunRich is that the entire human genome was 
used as the background to determine enrichment. 
The functional enrichment analysis of the human GOI lists using FunCoup, 
STRING and DAVID produced an extensive overlap of enriched categories for 
all of them. However, the enriched categories seem to be of a broad nature and 
not very specific, such as “regulation of cellular macromolecule biosynthetic 
process”. This may be a result of the source of functional category definition in 
these websites. 
Analysis using FunRich indicated that all the proliferation GOI lists were 
enriched in binding sites for certain transcription factors. However, the same 
transcription factors were not detected in the analysis using OPOSSUM. This 
discordance may be due to the analysis being performed using the screened 
genes in OPOSSUM and the human genome in FunRich. 
In contrast with the proliferation GOI lists, the enriched categories detected 
using FunRich in the resistance to lipotoxicity GOI list were not mainly 
transcription factors but functional categories related to endocitosis, molecule 
transport using channels and secretion process. This may indicate that uptake 
and release of molecules is important for the lipotoxicity of palmitate. 
The gene set enrichment performed using GSEA PreRanked indicates that 
several gene sets defined by cancer datasets are enriched in the proliferation 
GOI lists, as well as proliferation-related pathways such as AKT. The resistance 
to lipotoxicity GOI list is also enriched in cancer-related gene sets, some of 
them overlapping the proliferation GOI lists, which may indicate an effect of 
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higher proliferation rate in the overrepresentation of targeting sequences in the 
screen dataset. It may also represent a bias in the GSEA database of gene sets 
towards cancer-related gene sets, which may be a result of the extensive 
research performed in cancer biology. An apoptosis-related gene set is also 
present in the list of enriched gene sets in the lipotoxicity GOI list, which is 
encouraging. However, the GSEA results would need to be analysed in more 
detail to provide a good interpretation of the data. 
4.4.8. Concluding remarks and future work 
The main limitation of this study in relation to interpreting and drawing 
conclusions from the GOI lists is the absence of replication studies, especially in 
the lipotoxicity screen as not much information is available about the 
mechanisms at play. Extensive validation will be needed to assess the role of 
the GOI in the mechanism of lipotoxicity. To reduce the list of GOI to be 
validated it may be necessary to produce new analysis methods which can 
mine and interpret available functional data.  
Validation may be performed similarly to the Chapter 3, with additional targeting 
sequences used to evaluate the effects of the knockdown of some of the GOI. 
Chemical inhibitors are available for some of the GOIs or pathways detected in 
the screen and could also be used for validation of the effect of gene activity 
reduction.  
Replication of the GOIs in other β-cell lines, and especially in human β-cell lines 
will be necessary to extrapolate these results to human biology. Confirmation of 
gene expression in human β-cells and comparison of expression data between 
T2D patients and non-diabetic controls could be also used as a validation 
approach.
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 Chapter 5. Final discussion and conclusions 
5.1 Design and development of functional genomic screens 
I have presented in this thesis the development and analysis of three genome-
wide RNAi screens in two in vitro models of complex diseases: suppression of 
tumorigenesis, β-cell proliferation and resistance of β-cells to lipotoxicity. I 
performed these three sets of experiments in parallel, using a similar set of 
techniques. Several general aspects of this work can be applied to any 
functional genomics screening approach. I will discuss these aspects and their 
implementation in the screens I performed for this thesis. 
5.1.1 Choice of an adequate in vitro model.  
The in vitro model chosen needs to reflect the biology being studied. Cell lines 
are known to differ at the transcriptomic and proteomic level from primary cells 
(Sandberg and Ernberg 2005, Olsavsky, Page et al. 2007, Pan, Kumar et al. 
2009). These differences make difficult the translation of results from screens 
performed in cell lines to primary cells or to the in vivo situation. 
Researchers have proposed and developed methods to perform RNAi screens 
using primary cells (Ovcharenko, Jarvis et al. 2005). High-throughput RNAi 
screening may be feasible in certain types of primary cells, especially those 
which are more easily obtained. For example, Wermke and colleagues 
performed a large-scale shRNA screen in primary leukaemia cells (Wermke, 
Camgoz et al. 2015) and Galeev and collaborators used a genome-wide shRNA 
library to find genes involved in renewal and differentiation of hematopoietic 
stem cells (Galeev, Baudet et al. 2016).  
The screens presented in this thesis required prolonged culturing of cells and 
primary cells can only be cultured for a limited number of passages before they 
become senescent (Hayflick 1965) or progress through crisis and 
spontaneously immortalise. A large number of cells was required for both 
screens, which I would have needed to obtain from multiple donors. Variability 
amongst donors would then have introduced a new source of variability in the 
screening. Primary β-cells are extremely scarce and difficult to source, more so 
to achieve the numbers needed for the screens. Additionally, isolating primary 
cells for the neighbour suppression screen would require me to identify cells 
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within a tissue that have acquired an oncogenic mutation but have not formed a 
tumour. These cells would need to be cultured with normal cells from the tissue, 
which are more frequent but less likely to grow in cell culture conditions. 
5.1.2 Choice of knockdown technology 
Many RNAi and genome editing technologies are available for disrupting gene 
expression in mammalian cells, as presented in the introduction of this thesis. 
The choice of one needs to be evaluated in relation to the screen design and 
biology. If the screen is designed to evaluate a phenotype for a short period of 
time, siRNA may be adequate. siRNA molecules are delivered to the cytoplasm 
(Chiu, Ali et al. 2004) and downregulate the expression of the targeted gene 
whilst they are present (Yang, Tutton et al. 2001). However, screens observing 
a longer period of time may need the use of shRNA, usually coupled with virus 
delivery to the cell. shRNA molecules can be inserted into the genome of the 
cell. Once inserted, the shRNA molecules are transcribed by the cell’s 
machinery and the reduction of gene expression is maintained. As the shRNA 
sequence is inserted in the genome it will be inherited by the daughter cells, 
maintaining the reduction of gene expression in the next generations as well.  
The main criticism of RNAi approaches has been the existence of off-target 
effects (Scacheri, Rozenblatt-Rosen et al. 2004). It was first hypothesized that 
close sequence similarity between the targeting sequence and the unintended 
target mRNAs was the reason behind off-target effects. However, the first 
studies specifically looking at off-target effects of siRNA disagreed. Measuring 
genome-wide gene expression, Jackson and collaborators found that siRNA 
designed to target MAPK14 and IGFR1 affected expression levels of many 
other genes with varying degrees of similarity (Jackson, Bartz et al. 2003). The 
authors concluded that although a certain degree of similarity was needed, not 
all similar mRNA transcripts were downregulated. They could not find patterns 
to predict off-target effects and suggested that increasing the number of siRNA 
constructs against each gene of interest may help discern the true phenotype 
associated with its decreased expression (Jackson, Bartz et al. 2003). 
It was later discovered that complementarity of siRNA nucleotides 2-7 or 2-8 
(known as “seed region”) to the 3’ UTR contributes to the off-target effects 
(Birmingham, Anderson et al. 2006, Jackson, Burchard et al. 2006) and that the 
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magnitude of the off-target effect was influenced by the number of times the 
complementary region was present in the unintended target (Lin, Ruan et al. 
2005). Partial mismatch at positions 9 and 10 of the sequences seem to 
produce changes in protein levels rather than mRNA levels (Alemán, Doench et 
al. 2007). Furthermore, the RNA-induced silencing complex (RISC) can load 
either of the sense and antisense strands of the shRNA molecule (Gu, Jin et al. 
2011, Kwak and Tomari 2012, Schürmann, Trabuco et al. 2013) 
Integration of this knowledge about the mechanisms of siRNA-induced RNAi led 
to building databases to predict off-target effects of targeting sequences such 
as SeedSeq (Das, Ghosal et al. 2013) and to the design and generation of new 
libraries. For example, Kampmann and colleagues (Kampmann, Horlbeck et al. 
2015) examined many of the factors in library construction and used machine 
learning approaches to design an algorithm which could predict shRNA 
efficiency. Using that algorithm they have designed libraries targeting the 
human and mouse genome with 25 targeting sequences per gene (Kampmann, 
Horlbeck et al. 2015). This approach can be compared with the relatively simple 
design process for the NKI library, which can be divided into ten steps (Berns, 
Hijmans et al. 2004): 
1) Does not contain stretches of more than three T or A. 
2) Its GC content is between 30 and 70%. 
3) Lies within coding sequence of the target gene. 
4) The first nucleotide is a G or C. 
5) Begins after an AA dimer in the 5’ flanking sequence. 
6) Ends just before a TT, TG or GT in the 3’ flanking sequence. 
7) Does not contain XhoI or EcoRI restriction-enzyme sites. 
8) Minimize similarity with other genes. 
9) Targets all the RefSeq mRNAs for that gene. 
10) Does not overlap with the other targeting sequence in the library for the 
same gene. 
Apart from the design of the targeting sequences, off-target effects may be 
limited with other approaches to promote the loading of only the antisense 
strand by RISC. The introduction of “decoy” sequences which sequester the 
sense strand of the shRNA leaving the antisense free to be loaded by RISC can 
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increase specificity of the targeting sequences (Mockenhaupt, Grosse et al. 
2015) 
Increasing the redundancy of the libraries to discern off-target effects has been 
the tendency in the last few years. In Table 5.1. I have compiled information 
about the shRNA libraries used in published functional genomics screens 
available on PubMed. Several of the libraries were used in more than one 
screen and only the earliest publication is shown. Two of the libraries (van de 
Weijer, Bassik et al. 2014, Shukla, Somwar et al. 2016) stand out for their high-
coverage, although the library used by Shukla and colleagues has a very 
variable redundancy ranging from 1 to 58 shRNA targeting sequences per 
targeted transcript, with a median of 5. Most of the shRNA libraries used in 
publications in the last five years have a five-fold or lower redundancy.  
CRISPR/Cas9 can also be used in screening processes. CRISPR/Cas9 
systems are available not only for reducing gene expression but also to 
knockout and overexpress a gene. Similarly to RNAi, researchers have reported 
off-target effects using CRISPR/Cas9 (Cradick, Fine et al. 2013, Fu, Foden et al. 
2013), although methods have been proposed to reduce off-target effects 
(Pattanayak, Lin et al. 2013) and to predict and analyse these (Hsu, Scott et al. 
2013). Another limitation of the CRISPR/Cas9 system is that knockdown is 
produced at the DNA level in contrast to mature mRNA in RNAi. Therefore, 
knockdown of specific transcripts is not plausible.  
The screens presented in this thesis used retroviral-delivered shRNA to 
produce stable knockdowns. The first genome-scale CRISPR screens 
performed were published in 2014 (Shalem, Sanjana et al. 2014, Wang, Wei et 
al. 2014), when the screens were already being performed and therefore the 
use of CRISPR was not considered. 
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Library Species Transcripts targeted Targeting 
sequences per 
gene 
Year of 
publication 
Reference 
shRNAmir 2.16 (Open 
Biosystems) 
Mus musculus Approx. 28,000 2-3 2007 (Gazin, Wajapeyee et al. 2007) 
Hannon-Elledge second 
generation 
Homo sapiens 32,293 2-3 2010 (O'Connell, Adamson et al. 2010) 
Systems Bioscience Mus musculus Approx. 39,000 3-5 2011 (Wang, Studach et al. 2011) 
TRC Mus musculus Approx. 13,000 5 2011 (Colombi, Molle et al. 2011) 
TRC "80k" Homo sapiens 16,056 4-5 2011 (Marcotte, Brown et al. 2012) 
GeneNET Human 50k  Homo sapiens 38,500 5 2012 (Yoshino, Hara et al. 2012) 
Unknown Homo sapiens Approx. 20,000 30 2012 (Jiang, Pan et al. 2012) 
GIPZ shRNAmir human 
genome-wide library 
Homo sapiens 16,487 3-4 2012 (Mendes-Pereira, Sims et al. 2012) 
 pSM2c shRNAmir library 
(version 1.15) 
Homo sapiens Approx. 20,000 2-3 2012 (Angus and Nevins 2012) 
Expression Arrest™ GIPZ 
lentiviral shRNA 
Homo sapiens Approx. 20,000 2-3 2012 (Iorns, Ward et al. 2012) 
Unknown Homo sapiens 11,255 4-5 2012 (Simpson, Hurren et al. 2012) 
Decode RNAi Homo sapiens 11,954 2-3 2013 (Yang, Fan et al. 2013) 
Unknown Homo sapiens Approx. 18,000 30 2014 (van de Weijer, Bassik et al. 2014) 
MISSION™ human genome-
wide shRNA 
Homo sapiens 15,000 5-6 2016 (Gari, Gearheart et al. 2016) 
pGIPZ lentiviral shRNAmir  Homo sapiens 21,416 3-4 2016 (Kurahara, Bohl et al. 2016) 
Sigma-Aldrich shRNA Human 
Genome Library 
Homo sapiens 11,748 1-58 (median of 5) 2016 (Shukla, Somwar et al. 2016) 
Table 5.1. Genome-wide shRNA libraries used for functional genomics screens in publications indexed on PubMed.
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5.1.3 Choice of library 
Several libraries and collections of RNAi inducing molecules are now available, 
for example: (Berns, Hijmans et al. 2004, Silva, Li et al. 2005, Moffat, 
Grueneberg et al. 2006). Table 5.1. has information on some genome-wide 
shRNA libraries used in published screens. 
Depending on the phenotype studied and the hypothesis being tested one 
needs to consider whether an unbiased library would yield any more information 
than a focused library targeting only part of the genome. For example, if the 
phenomenon under study is known to involve kinases and the aim of the screen 
is to define which kinases are involved a kinome library would suffice. For the 
same experimental effort, there is a trade-off between the number of genes 
targeted and the redundancy of the library. For example, with 6,000 plasmids a 
research study may benefit more from targeting 3,000 genes with two plasmids 
each while another study may find it more beneficial to target 1,000 genes with 
six plasmids each.  
For the screens reported in this thesis, the aim was to uncover new molecular 
effectors for phenotypes where little or no molecular mechanism is known. 
Therefore I used an unbiased approach with a two-fold redundancy. 
The choice of an RNAi library may also depend on the delivery method to be 
used, as libraries are available in plasmids suitable for direct transfection and 
for retroviral (Berns, Hijmans et al. 2004), lentiviral (Root, Hacohen et al. 2006) 
and adenoviral (Oehmig, Klotzbücher et al. 2008) delivery. 
Apart from the targeting sequence design discussed above in section 5.1.3, 
shRNA libraries also differ in how the targeting sequences are designed and 
how the hairpins will be processed in the cell. The first libraries constructed 
used RNA pol III promoters to drive the expression of hairpins mimicking the 
pre-miRNA structures in the RNAi pathway. These include the NKI library used 
in this thesis and the first TRC (Moffat, Grueneberg et al. 2006) and Hannon-
Elledge (Paddison, Silva et al. 2004) libraries. A second generation of shRNA 
libraries replaced the simple hairpins with structures similar to pri-miRNA which 
are transduced by RNA pol II, the enzyme responsible for transcription of pri-
miRNA in human cells (Lee, Kim et al. 2004). The second generation Hannon-
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Elledge library uses this structure, which they termed shRNA-mir (Silva, Li et al. 
2005). 
5.1.4 Choice of phenotype to be studied and method of assessment. 
Pooled shRNA screens are evaluated in terms of changes in cell number as 
indicated by the change in representation of the targeting sequences in the 
library (Strezoska, Licon et al. 2012). As such, two types of phenotypes are 
readily assayed: changes in proliferation rate (enrichment screens) and 
protection from a depleting stimulus (depletion screens).  
The targeting sequence may be used as a molecular barcode as they are 
unique in the library (Berns, Hijmans et al. 2004). Some libraries have a 
barcode outside of the targeting sequence (Silva, Li et al. 2005) which can be 
used to identify the targeting sequence without amplification of the hairpin 
structure. However, the use of a barcode separated from the hairpin may be a 
source of error in screen evaluation (Sack, Davoli et al. 2016). Retroviruses 
carry two viral genomes (Bender and Davidson 1976) and recombination may 
occur between both copies and produce recombinant sequences (Hu and 
Temin 1990). Sack and colleagues found that integration of the targeting 
sequences in the genomic DNA produced recombinant sequences where the 
barcode was no longer associated with the original targeting sequence (Sack, 
Davoli et al. 2016). Although reducing the distance between the barcode and 
the targeting sequence decrease the recombination rate, Sack and colleagues 
estimated a recombination rate of approximately 6% when the distance 
between both sequences is 96 bp (Sack, Davoli et al. 2016). 
Changes in targeting sequence or accompanying barcode representation have 
been detected using two methods: hybridization to microarrays and next-
generation sequencing (NGS) (Sims, Mendes-Pereira et al. 2011). The use of 
microarrays requires the design of custom microarrays with probes hybridizing 
to the barcodes used in the library, and only one sample can be used per 
microarray. NGS approaches do not require a customized platform and are not 
restricted to the detection of a predefined set of sequences as microarrays are. 
NGS has higher sensitivity and dynamic range than microarrays (Marioni, 
Mason et al. 2008) and can be easily multiplexed for the analysis of several 
samples simultaneously. However, the use of NGS to evaluate screens requires 
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extensive optimisation of the PCR amplification prior to sequencing, and 
sequencing libraries need to be prepared (Sims, Mendes-Pereira et al. 2011, 
Strezoska, Licon et al. 2012). For the screen in Chapter 3 sequencing libraries 
were prepared using a PCR-free approach which resulted in the 
overrepresentation of Illumina adapter dimers in the sequencing output, 
resulting in a loss of sequencing reads. This limitation was solved in Chapter 4 
by preparation of libraries using a two-step PCR amplification approach. 
Although this two-step PCR protocol for the preparation of sequencing libraries 
required an extra step of optimization for the inclusion of the second PCR 
amplification, the sequencing data received did not include adapter primers and 
therefore the sequencing depth obtained was higher. Sequencing depth needs 
considering if NGS is used to detect changes in number. The higher the depth, 
the more resolution is obtained and smaller the changes which can be detected 
(Strezoska, Licon et al. 2012). 
The results of the screens presented in this thesis were evaluated using next 
generation sequencing (NGS) and a molecular barcode system whereby the 
representation of each unique targeting sequence is used as a proxy for the 
number of cells containing that sequence. 
5.1.5 Analysis method for quantification of effect 
Analysis of the screening output needs considerable optimisation and 
consideration. Researchers have made available their methods implemented in 
different programming languages such as R, Perl or Python (Kumar, Goh et al. 
2013, Dai, Sheridan et al. 2014). However, the methods used need to be 
assessed for each screen as they may not be adequate for all. Analysis 
methods for arrayed and pooled screens will have different requirements, and 
assessing pooled screens using microarrays or NGS will also dictate the type of 
analysis used. I will only discuss analysis methods for screens which use NGS 
for detecting changes in representation as it was the method used in this thesis. 
The first step in the analysis of NGS data from pooled shRNA screen is to 
obtain the sequencing reads for each of the samples. If the samples were mixed 
before library construction as in Chapter 3 of this thesis, sequencing reads will 
need separating on the basis of the sequence of the primer used to amplify 
each sequence. This separation can be performed in the UNIX command line 
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using the “grep” function, which looks for lines in a file containing an exact 
match to the sequence of characters provided. The sequences containing that 
sequence can be copied into a new file. This process is easy to use and does 
not require the installation of any software, but relies on exact matches to the 
expected PCR primer. Polymerase errors during PCR amplification or sequence 
may have introduced errors in the primer sequence, and molecules carrying 
those errors will not be considered as sequencing reads for the samples using 
“grep”. There are utilities such as OBITools (Boyer, Mercier et al. 2016), a meta-
barcoding package for UNIX which include functions to separate samples 
amplified with different PCR. In OBITools this utility is called “ngsfilter” and 
provides an option to allow for partial matches. OBITools requires installation 
and files need to be prepared in a certain format. 
If the samples are not mixed and libraries are prepared separately as in Chapter 
4, this step is not necessary. The Illumina adapter sequences are different and 
therefore sequencing reads for each sample are already separated. This 
eliminates the need for PCR primer identification in the sample and the 
associated loss of sequencing reads due to errors in amplification, but requires 
an extra step in the sample preparation protocol.  
After sequencing reads have been assigned to the correct sample, it is 
necessary to provide a count of how many sequencing reads contain each 
targeting sequence in each sample. I performed this step using a custom 
Python screen which identifies the targeting sequence as a 19bp long sequence 
before the sequence of the shRNA loop. This method has the advantage of 
allowing the identification of not pre-defined sequences but requires the 
sequencing reads to have a perfect match to the shRNA loop sequence. Any 
PCR errors in the loop sequence would result in the targeting sequence not 
being identified. 
Other methods have been developed which do not rely on perfect matches. For 
example, the shALIGN program developed by Sims and colleagues (Sims, 
Mendes-Pereira et al. 2011) trims the sequencing reads to obtain the 19bp 
targeting sequence and then aligns each of those 19mers to the expected 
composition of the library allowing for mismatches. This approach has two main 
disadvantages: it requires the user to provide the position where the 19mer is 
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expected and restricts the analysis to those sequences contained in the library. 
In the sequencing data obtained from the screens in this thesis, the 19mers 
were not found in a constant position but rather it could be shifted a few 
nucleotides. This shift appears to be due to polymerase errors resulting in the 
inclusion or deletion of nucleotides in the first bases of the sequencing reads. 
Therefore I decided to use the loop sequence as an indication of the targeting 
sequence position. 
Another example of software package which includes an alignment utility is 
edgeR (Dai, Sheridan et al. 2014), which can be used as a part of R. The 
alignment strategy in this case also requires the user’s input on the expected 
position of the targeting sequence but it allows a shift in the location of the 
sequence. It requires the user to provide a file with the expected composition of 
the library in a pre-defined format and it also requires the use of the R software. 
Although allowing for shifts in the position of the targeting sequence is a strong 
advantage of this method, I wanted to study the presence of sequences not 
present in the original library design and therefore did not consider using this 
method. 
Once a count of the sequencing reads obtained for each targeting sequence 
has been obtained, a method needs to be used to detect those sequences with 
an effect in the phenotype studied. Many aspects of the screening process will 
influence the choice of an analysis method. The goal of the analysis should be 
to inform on the effect of knockdown in the phenotype as accurately as possible. 
The biological basis of the phenotype needs to be considered carefully to select 
the appropriate control conditions. In the screen in Chapter 3, I used a control 
for growth of tumorigenic cells in the absence of interactions with normal cells 
(termed “plastic” condition) and two experimental conditions: growth in contact 
with a suppressive monolayer (3T3supp+ cells) and a non-suppressive monolayer 
(3T3supp-). At the same time, these experimental conditions were used as 
controls for each other to control for non-specific changes in growth due to cell-
cell interactions. This experimental design was reflected in the analysis method 
via a normalisation of each co-culture sample to the “plastic” control and the 
implementation of a double threshold method for detection of effects which 
accounted for effects common to both co-cultures. In the case of the β-cell 
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screens in Chapter 4, different controls were used for each of the screens. In 
the proliferation screen, a control sample was established after reversal of 
oncogene expression to account for possible effects of gene knockdowns in the 
reversal process. For the resistance to lipotoxicity screen, the control sample 
was treated with the vehicle used to deliver the toxic stimulus such that effects 
due to unspecific toxicity of the vehicle could be controlled for. 
Different aspects of the analysis will depend on the design of the library used. If 
the library is subdivided in smaller pools of sequences and each pool is used 
individually, variation may be introduced in the screening process. The analysis 
method chosen then needs to introduce a normalisation step in which this 
variation is eliminated or at least mitigated. In the case of both screens in this 
thesis, I calculated the relative abundance of each sequence inside the pool 
where it was predicted to originate from. This step also normalised the 
abundance for the differences in read depth which were detected between 
pools derived from an imperfect proportion of PCR products sequenced from 
each pool.  
The subdivision of the library can also produce differences in the level of 
variability in representation inside each pool. This variability may be present in 
the plasmid pool already if each plasmid is not represented equally. It may also 
be introduced after transfection or transduction if any sequences have an effect 
on cell viability, or during the screening process if the culture conditions are 
changed and growth is affected by this change. To reduce the impact of this 
variability the analysis method should normalise the change in representation 
observed for each sequence by the change in representation observed in other 
sequences in the same pool. A robust z-score was used in this thesis, but other 
statistical methods are available. Many methods have been adopted from high 
throughput screening of chemical compounds and as such are more valid for 
arrayed screens than pooled screens (Birmingham, Selfors et al. 2009). One 
example is the “Percentage of control”, where each value is divided by the 
mean of several negative of positive controls. This is easily implemented in 
arrayed screens where a number of plates with negative or positive controls can 
be exposed to same screening conditions as the screen plates. In some simple 
pooled screens it may also be possible to introduce shRNA constructs which 
have been demonstrated to produce an effect in the same in vitro model and 
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conditions used in the screen (for example, a targeting sequence against a 
tumour suppressor in the study of tumorigenesis potential). Such controls were 
not available for the screens presented in this thesis and therefore this analysis 
method was not adequate. 
A threshold needs to be chosen to discern targeting sequences with an effect in 
the phenotype studied from those with no effects. This has usually been done 
arbitrarily or using a probabilistic method (Birmingham, Selfors et al. 2009). In 
the screens presented in this thesis, the threshold for determination of effects 
was chosen based on the distribution of the targeting sequence z-scores. It is 
possible that this method may have failed to identify targeting sequences with 
small effects and included false positives. 
5.1.6 False positives and the need for integrative analysis 
RNAi screens are prone to the detection of false positives, in part due to off-
target effects (discussed above) and in part to deficient analysis methods. The 
analysis of RNAi screens has changed since the first genome-wide screens and 
multiple approaches are now used to reduce the proportion of false positives. 
Recently, researchers have implemented integrative analysis pipelines and 
used several sources of data to interpret RNAi screens more fully. Expression 
data can be used to estimate whether the knockdown of a gene is likely to affect 
the phenotype. Network biology can be used to detect “essential” genes or hubs 
(Jiang, Wang et al. 2015), and functional or gene set enrichment can provide 
information on pathways involved in a phenotype (Huang, Wang et al. 2008). 
Analysis packages are available now which integrate all these steps (Diaz, Qin 
et al. 2015, Dutta, Azhir et al. 2016). 
No expression data was available for the screen in Chapter 3, but network 
analysis and functional and gene set enrichment analysis approaches were 
implemented. I also used these methods for the analysis of the screen in 
Chapter 4. Expression data was included in this last screen to study only those 
genes which are expressed in human β-cells as targeting sequences designed 
against genes which are not expressed will most probably be acting through an 
off-target effect.  
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5.1.7 Validation strategies 
Validation is critical in RNAi screens due to the high proportion of false positives, 
an issue already raised when reports of genome-wide screens started to be 
published (Echeverri, Beachy et al. 2006). The method of validation varies 
between screens. It is common to design additional targeting sequences 
binding different sites in the mRNA (Westbrook, Martin et al. 2005, Li, Ding et al. 
2013, Landi, Vermeire et al. 2014), although this approach may yield false 
negative results if the level of knockdown is very different from the discovery 
sequence. However, a different sequence is unlikely to result in the same off-
target effects as the discovery sequence. Some studies have also used the 
same targeting sequence to validate the results e.g. (Cooper and Brockdorff 
2013). In this case, the level of knockdown should be equivalent to the original 
experiment and therefore false negatives are unlikely. However, if the effect 
detected in the first screen was due to an off-target effect this will be replicated, 
resulting in the perpetuation of a false positive. 
Some studies have validated the effect of the knockdown by rescuing the 
phenotype by introducing an expression plasmid containing a transcript which 
cannot be downregulated by the targeting sequence used to produce the 
knockdown (Zhou, Ding et al. 2015). This approach would not replicate an effect 
due to off-target reduction of gene expression as the rescue would not be 
possible unless the targeted gene was expressed. However, phenotype rescue 
may not always be possible, which implies a risk of reporting false negatives 
(Datler and Grimm 2013). Phenotype rescue is not feasible on a large scale 
screen. 
Chemical inhibitors are available for some proteins and they could be used to 
validate the effect produced by an shRNA construct. However, the level of 
inhibition may also be different to the screen and produce false negatives. 
Inhibitors are also rarely specific. Furthermore, although activity of the protein is 
inhibited, some of its activities may be conserved, such as serving as a scaffold 
for other proteins and this activity will be eliminated by the knockdown (Weiss, 
Taylor et al. 2007). The same limitation can be extrapolated to the knockdown 
of the gene using other technologies (e.g. siRNA or CRISPR/Cas9). 
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Other validation strategies may be implemented that use publicly available data 
to analyse the correlation of a reduction in expression of a gene in vivo. This 
approach was implemented in Chapter 3 with the study of gene expression 
levels in tumour samples and their correlation with distant metastasis free 
survival in patients. Although it is not a validation study per se in that it does not 
replicate and observe the effect of a reduction in expression, it does provide 
information about the association of that reduction with a phenotype of interest. 
This method depends on the availability of data which is relevant to the 
phenotype of interest. 
426 
 
5.2 Overlaps in the screens. 
The screens in Chapter 3 and 4 in this thesis have been performed with the 
same shRNA library and analysed using similar approaches. Therefore 
analysing the overlap between the screens may inform us about false positive 
effects. It is important to consider that certain true positive effects may cause an 
overlap. This is expected especially in the case of genes with an effect in 
proliferation which could have been detected as increasing colony size in the 
co-cultures in Chapter 3 and any of the screens in Chapter 4. 
5.2.1 Overlap in GOI lists. 
There is a partial overlap in the GOI lists amongst the screens as depicted in 
Figure 5.1. The overlap was calculated using the human GOI lists from the β-
cell screens and with the human homologues of the neighbour suppression 
screen. For this last screen, GOI lists from the 3T3supp+ and 3T3supp- were 
pooled together. 
Only one gene was found in all screens: Impa1. This gene encodes the protein 
inositol monophosphatase 1, a cytoplasmic enzyme which hydrolyses inositol 
monophosphate to produce inositol. This enzyme is required for embryo 
development (Cryns, Shamir et al. 2008). Due to its function in inositol signalling 
it may have a role in cellular proliferation. 
The overlap between the neighbour suppression GOI list and the β-cell 
lipotoxicity screen GOI list is the smallest as expected from their distinct biology. 
Eleven genes are common between these two GOI lists: Myocd, Fopnl, Odc1, 
Ube2v1, Pcbd2, Slk, Olig3, Eif2s1, Sh3gl3, Thsd7a and Rps9. 
I performed a literature search for functions of the overlapping GOI which may 
explain why they were selected as GOI in both lists.  
Myocd inhibits cell proliferation (Tang, Zheng et al. 2008) and may be 
increasing the cell number in the lipotoxicity screen and in the neighbour 
suppression screen as it was detected as a GOI in the 3T3supp+ sample.  
Pcbd2 has already been discussed in section 4.4.6 as a hyperconnected GOI in 
the lipotoxicity screen. It was reasoned that it may protect β-cells through 
regulation of HNF1A. Being a GOI in the neighbour suppression list does not 
invalidate its possible importance in the resistance to lipotoxicity but it does 
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make it more probable that it may be a false positive. It was included in the 
3T3supp- GOI list. 
Olig3 is regulated by canonical Wnt signalling but not required for proliferation 
of spinal cord neurons in mice (Zechner, Muller et al. 2007), however I could not 
find published data on other cell types and may be involved in cell proliferation. 
It was included in the 3T3supp- GOI list and therefore an effect in cell proliferation 
is not logical for both screens. 
Eif2s1 inhibition protects from ER apoptosis (Boyce, Bryant et al. 2005) and 
hence it may protect from lipotoxicity, although it was detected as a GOI in the 
3T3supp- sample and protection from apoptosis is not a logical mechanism to 
decrease colony size.  
Sh3gl3 is associated with invasion of glioma and decreasing its expression in 
vitro in glioma cells inhibits invasion (Delic, Lottmann et al. 2012). It was also 
included in the 3T3supp- GOI list which may be logical with the effect in glioma 
cells. 
Decreased expression of Thsd7a enhances migration of human umbilical vein 
endothelial cells in vitro (Wang, Su et al. 2010). It was included in the 3T3supp- 
GOI list. 
Depletion of For20, the protein encoded by Fopnl, inhibits cell cycle progression 
(Shen, Cai et al. 2013) and therefore it is more likely a false positive as it would 
decrease proliferation in the screens as it was included in the 3T3supp+ screen.  
Similarly, downregulation of Odc1 expression in mouse myoblasts decreases 
cell number (Lee, Skinner et al. 2011), although in the neighbour suppression 
screen it was included in the 3T3supp- GOI list where a decrease in cell number 
is a plausible mechanism for decrease in colony size. 
Ube2v1 is also known as Uev1a and it has been linked to tumorigenesis 
through regulation of metalloproteinases (Wu, Shen et al. 2014) but its inhibition 
decreases proliferation and survival in in vitro models of diffuse large B-cell 
lymphoma (Pulvino, Liang et al. 2012). This effect of the targeting sequence is 
logical with its inclusion in the 3T3supp- GOI list but not with an increase in cell 
number.  
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Inhibition of Slk should decrease proliferation according to experiments in 
mouse fibroblasts (O'Reilly, Wagner et al. 2005) and it was indeed included in 
the 3T3supp- GOI list.  
Decrease of Rps9 expression inhibits proliferation of glioma and osteosarcoma 
in vitro models (Lindstrom and Nister 2010), which agrees with its inclusion as a 
GOI in the 3T3supp- list. 
Of the eleven overlapping genes between the resistance to lipotoxicity and the 
neighbour suppression screen, nine were detected as GOI for 3T3supp-. 
Although the function of most of these genes may provide a potential 
mechanism for this effect in tumour cell colony size it does not readily explain 
their effect in resistance to lipotoxicity. They may be false positives or be acting 
through a mechanism not considered here.  
A larger overlap is observed between the neighbour suppression and the β-cell 
proliferation GOI lists. The list of these overlapping GOI is in Table 5.2 along 
with the neighbour suppression GOI list each of the GOI was included in. A 
larger proportion of GOI (13 of 30) originated from the 3T3supp+ list than in the 
overlap with the lipotoxicity screen (2 of 11). This may be a consequence of the 
proliferation and 3T3supp+ higher similarity in terms of mechanisms, as a higher 
proliferation rate may result in larger tumour cell colony size. The same logic 
cannot be applied to 17 GOI overlapping between the 3T3supp- and β-cell 
proliferation lists as a higher proliferation rate cannot explain a smaller colony 
size. These genes and maybe part of the overlap with the 3T3supp+ may be false 
positives in one or both screens or they may have different effects in each of the 
screens.
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Figure 5.1. Venn diagram depicting the overlap in the GOI lists from the three screens 
presented in this thesis. 
“Neighbour supp”: GOI list from both co-cultures. “Beta-cell prolif”: β-cell proliferation GOI 
list. “Beta-cell toxici”: β-cell resistance to lipotoxicity GOI list.
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GOI Neighbour suppression GOI list 
Ankhd1 3T3supp+ 
Lpar1 3T3supp+ 
Best1 3T3supp+ 
Tp53 3T3supp+ 
Osbpl8 3T3supp+ 
F11r 3T3supp+ 
Ppp2cb 3T3supp+ 
Wnt4 3T3supp+ 
Tuba4a 3T3supp+ 
Fbxo30 3T3supp+ 
Zfp606 3T3supp+ 
Ogdhl 3T3supp+ 
Flna 3T3supp+ 
Ube4a 3T3supp- 
Capza2 3T3supp- 
Rnaseh2b 3T3supp- 
Slc25a23 3T3supp- 
Sema6d 3T3supp- 
Emd 3T3supp- 
Ttc7a 3T3supp- 
Cxadr 3T3supp- 
Arhgap44 3T3supp- 
Zbtb20 3T3supp- 
Oaz2 3T3supp- 
Pabpc1l 3T3supp- 
Atp8a2 3T3supp- 
Ppia 3T3supp- 
H3f3c 3T3supp- 
Clic5 3T3supp- 
Sipa11 3T3supp- 
Table 5.2. GOI detected in the neighbour suppression screen and the β -cell proliferation 
screen. 
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5.2.2 Overlap in the functional and gene set enrichment analysis 
To investigate whether the same functional terms and gene sets may have 
been detected in the neighbour suppression and β-cell screens I examined the 
overlap in functional enrichment as determined by FunRich and gene set 
enrichment analysed with GSEA. I did not consider the functional enrichment 
analysis performed with the other approaches as they were done with different 
backgrounds (mouse genome for the neighbour suppression screen and human 
genome for the β-cell screens). 
The overlap for the functional enrichment analysis performed using FunRich is 
depicted in Figure 5.2. The combined β-proliferation list results were used for 
the β-cell proliferation categories. All categories with an uncorrected p-value 
under 0.05 were used to calculate the overlap. 
No functional categories were found enriched in all the GOI lists. Six were 
enriched in both the 3T3supp- and the β-cell proliferation GOI lists, all of them 
transcription factors: FOS, FOSB, JUN, JUNB, JUND and NKX2-1. “Signal 
transduction” is enriched in both neighbour suppression GOI lists and the β-cell 
proliferation list. The 3T3supp+ and β-cell proliferation GOI lists share five 
enrichment functional categories: “Nuclear body”, “Receptor signalling complex 
scaffold activity”, “Cell communication” and two transcription factors: POU6F1 
and IRF1. One category was found to be enriched in both β-cell screens and 
the 3T3supp- GOI lists: “Centrosome”. Four categories are enriched in both β-cell 
screens and the 3T3supp+ screens: “Cytoplasm”, “Nucleus” and transcription 
factors ELF3 and HOXB4. The resistance to lipotoxicity and 3T3supp+ GOI lists 
share two enriched functional categories: “Extracellular matrix structural 
constituent” and transcription factor ARID3A. Finally the overlap between the 
resistance to lipotoxicity and 3T3supp- is also composed of two functional 
categories: transcription factor FOXA1 and “Regulation of nucleobase, 
nucleoside, nucleotide and nucleic acid metabolism”.  
Most of the shared functional terms are broad and refer to either cellular 
components such as “Nucleus” and “Cytoplasm” or to transcription factors. 
However there are other categories such as “Cell communication” which are 
logical for both GOI lists: cell-cell contact is known to be required for neighbour 
suppression (Mehta, Bertram et al. 1986, Alexander, Ichikawa et al. 2004) and 
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therefore its enrichment in 3T3supp+ was expected, and β-cells function is 
improved in vitro when cells are in close contact as 3D structures  (Beattie, 
Rubin et al. 1996). The “Extracellular matrix structural constituent” is also logical 
for the 3T3supp+ GOI list as components of the extracellular matrix are 
differentially expressed in 3T3supp+ and 3T3supp- cells (Allard et al, unpublished 
data). Decreasing the expression of genes in this category may perhaps 
contribute to the resistance to lipotoxicity by altering the uptake of palmitate.  
For the gene set enrichment overlap I used the combined β-cell proliferation 
and the “Genes screened, ranked by (3T3supp+-3T3supp-) z-scores, duplicates 
removed using (3T3supp+-3T3supp-) z-scores” criteria for ordering the 
neighbour suppression GOIs (case 7 in section 3.3.11.5).  
The overlap for enriched gene sets is represented in Figure 5.3. No gene sets 
were found to be enriched in all the screens, while seven are common to the 
resistance to lipotoxicity and the neighbour suppression and eight gene sets are 
enriched in both the β-cell proliferation and the neighbour suppression screen.  
The seven gene sets shared between the resistance to lipotoxicity in β-cells 
screen and the neighbour suppression screen are 
“HAMAI_APOPTOSIS_VIA_TRAIL_UP”, 
“FLECHNER_BIOPSY_KIDNEY_TRANSPLANT_OK_VS_DONOR_UP”, 
“MORI_LARGE_PRE_BII_LYMPHOCYTE_UP”, 
“SHEN_SMARCA2_TARGETS_UP”, 
“KIM_ALL_DISORDERS_CALB1_CORR_UP”, 
“BROWNE_HCMV_INFECTION_10HR_UP” and 
“NEMETH_INFLAMMATORY_RESPONSE_LPS_DN”.  
Enrichment in the “apoptosis via TRAIL” gene set in both screens may indicate 
a role for apoptosis in neighbour suppression and an involvement of the TRAIL 
(TNF-related apoptosis-inducing ligand) pathway or part of it in the apoptotic 
response of β-cells to palmitate. 
The gene sets enriched in both the β-cell proliferation and the neighbour 
suppression screens are 
“KEGG_EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER_PYLORI_INF
ECTION”, “MUELLER_PLURINET”, “ST_P38_MAPK_PATHWAY”, 
“ZAMORA_NOS2_TARGETS_UP”, 
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“KEGG_VIBRIO_CHOLERAE_INFECTION”, “BIOCARTA_WNT_PATHWAY”, 
“WHITEFORD_PEDIATRIC_CANCER_MARKERS” and 
“LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN”. 
The “Biocarta Wnt Pathway” is perhaps the most interesting set in this case as 
the Wnt pathway is known to be involved in β-cell proliferation and aberrantly 
regulated in cancer. Signalling through p38 has also been suggested to be 
involved in β-cell proliferation in MIN6 cells (Burns, Squires et al. 2000) and in 
many aspects of tumourigenesis including signal transduction in tumour cells  
(Koul, Pal et al. 2013). Therefore the overlap in both screens is not unexpected 
and may not be a result of off-target effects of the targeting sequences. In the 
case of the β-cell proliferation it may indicate that signalling through p38 is also 
involved in proliferation of R7T1 cells after decreasing the expression of the 
oncogene. This suggests a possible role of p38 signalling in β-cell proliferation 
independent of oncogene expression. Signal transduction through p38 in 
tumour cells may also be involved in the response of tumour cells to signals 
from normal cells. 
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Figure 5.2 Venn diagram representing the overlap in functional enrichment between the 
neighbour suppression screen GOI lists (3T3supp+ and 3T3supp-) and the β-cell 
proliferation (Beta-cell prolif) and resistance to lipotoxicity (Beta-cell lipoto).
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Figure 5.3. Venn diagram depicting the overlap in enriched gene sets as determined by 
GSEA in the neighbour suppression (Neighbour suppre), and β-cell resistance to 
lipotoxicity (Beta-cell lipoto) and proliferation (Beta-cell prolif) screens. 
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5.3 Limitations of the screens 
In the discussion sections of Chapter 3 and Chapter 4 and above in this chapter 
I have analysed some of the limitations encountered by the screening process. 
Although extensive optimisation was implemented in both the functional assays 
and the analysis process, several limitations remain. 
5.2.1. In vitro model used 
The use of mouse cell lines has been extensively discussed through the results 
and discussion chapters. I have already discussed why the use of primary 
human cells was not a feasible option for the screening processes. I 
acknowledge that using a mouse model may be a challenge for translation of 
results into human biology. However, there were two main reason for this 
decision. 
Firstly, previous work in the biology of neighbour suppression has been done 
using the cell lines in Chapter 3 (Stoker, Shearer et al. 1966, Allard, Stoker et al. 
2003, Flaberg, Guven et al. 2012, Nicholls 2015) and by using the same model 
the results of this screen can be integrated with the data available from these 
previous studies. Furthermore, as discussed in Chapter 3, the availability of a 
non-suppressive cell line (3T3supp-) is a strong advantage which allows the study 
of neighbour suppression by detecting genes necessary for the response to 
suppression but also those which can elicit a similar response in absence of 
suppression. 
Secondly, the screen in Chapter 4 required the use of a reversibly immortalised 
β-cell line. A reversibly immortalised human β-cell line was developed in 2014 
(Scharfmann, Pechberty et al. 2014), when the screening process had already 
been started. 
5.2.2. Limitations derived from the use of RNAi and the NKI library 
RNAi is now a well-established method for the study of functional genomics. 
However, there are aspects of the technology which need to be considered 
when designing experiments and drawing conclusions from the results 
produced. 
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Principally, RNAi targeting sequences in libraries are designed using predictive 
computer algorithms and their performance is unknown, which may lead to the 
knockdown of unwanted genes (Boutros, Bras et al. 2006) and to variable levels 
of knockdown (Sims, Mendes-Pereira et al. 2011). 
The shRNA targeting sequences in the NKI library have not been validated. 
Although the theoretical composition of the library is approximately 28,000 
constructs targeting 14,000 genes, some of those constructs may not provide 
sufficient reduction of gene expression or may have off-target effects, meaning 
that the real coverage of the library is unknown. Furthermore, the sequences in 
the library are not equally represented (Nicholls 2015) and so some of the 
sequences may not have been transfected or transduced, further reducing the 
coverage of the library. 
RNAi libraries are now available with a high level of redundancy (Kampmann, 
Horlbeck et al. 2015) which may alleviate the impact of off-target effects on 
coverage. The NKI library was designed with a two-fold redundancy which is not 
optimal for coverage in case of off-target effects but as discussed earlier it 
allows a genome-wide scale screening process easier than high-redundancy 
libraries. 
5.2.3. Limitations of the sequencing and analysis 
The number of sequencing reads per targeting sequence (sequencing depth) 
achieved in the screens is lower than the recommended levels (Hu, Kim et al. 
2009, Sims, Mendes-Pereira et al. 2011). Many sequencing reads in Chapter 3 
and the pilot project in Chapter 4 did not contain an exact match to the primer 
used for amplification and so they could not be assigned to a sample, reducing 
the sequencing depth obtained. 
In the process of data analysis functional enrichment was used to produce a list 
of potential mechanisms or pathways involved in both phenotypes studied. As I 
discussed in Chapter 3 and Chapter 4, these functional enrichments are relative 
to the whole genome. The correct background for these analyses would be the 
list of genes for which the library contains targeting sequences producing a 
significant level of knockdown. This list is not available and it is unlikely to be 
available not only because it would require extensive validation of each 
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sequence but also because the “significant level of knockdown” may be different 
for each phenotype assayed. 
5.2.4. Validation 
As previously discussed, RNAi screens require validation of the genes identified. 
For the screen in Chapter 3 I performed some validation experiments using 
other targeting sequences for the genes of interest (GOI). While some of the 
GOI showed the same effect as detected in the screen, the experiments were 
very variable in terms of effect size. 
In Chapter 4 I did not perform any validation experiments, which limits the 
conclusions that can be extracted from the results. Validation work is ongoing at 
the moment. 
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5.4 Future work 
There are two main lines of future work for the screens in this thesis: in silico 
and in vitro. 
The analysis pipeline can be further refined by implementing some changes and 
additions to the methods: 
- Allow mismatches in the identification of primers to sort sequencing 
reads into samples. This could increase the sequencing depth in Chapter 
3. 
- Allow mismatches between targeting sequences detected in the 
sequencing data and the targeting sequences in the library. This is 
already implemented in packages such as edgeR (Dai, Sheridan et al. 
2014) and could increase the sequencing depth in both screens. 
- Predict efficiency of the targeting sequences would allow a better 
understanding and selection of GOI. Algorithms such as sherWOOD 
(Knott, Maceli et al. 2014) could be used to inform on the potential effects 
of the targeting sequences. 
After refining the analysis the main objective on the in vitro work should be 
validation experiments to produce an informative list of genes involved in the 
phenotypes studied in both screens.  
For the genes in the neighbour suppression screen for which a second targeting 
sequence has produced a difference in tumour cell colony size, the first step 
would be to confirm that the targeted gene is expressed in the SVE cell line and 
that the targeting sequence does reduce its expression. This could be done 
using qRTPCR. The protein levels before and after introduction of the targeting 
sequences also need to be examined, for example using western blots. If the 
gene is expressed and the targeting sequence reduces expression and protein 
levels, the pathway through which the gene is altering colony size should be 
examined. This could be done by investigation of genes known to operate 
upstream or downstream the candidate gene. 
As the in vitro model of neighbour suppression that I have used for the screen is 
composed of two co-culture conditions, the candidate genes could be 
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overexpressed in the tumour cells to observe the effect of overexpression on 
the other co-culture. 
Then, the same process should be performed in another in vitro co-culture 
model of neighbour suppression to investigate whether the effect is translatable 
to other cell types and not specific to 3T3supp+, 3T3supp- and SVE6 cells. It should 
also be investigated if the effect is independent of the oncogene used to 
transform the cells. For this, tumorigenic cell lines transformed with other 
oncogenes could be used. 
Further validation experiments to translate the uncovered mechanisms to 
human cancer biology should be performed by repeating the validation 
experiments in human cell lines or primary cells. 
In vivo validation should also be performed to investigate whether the same 
effect is observed. For this, mice may be injected with tumorigenic cells carrying 
the targeting sequence for the validated genes or with a control sequence. 
Tumour growth in the control and experimental conditions should then be 
compared. 
 
The β-cell screens require more work as no validation has yet been performed. 
The first step would be to select a number of GOI from both screens, design 
new targeting sequences and evaluate if any changes are present in 
proliferation rate or resistance to death by palmitate after their delivery to the 
cells. This target validation is currently ongoing using R7T1 cells. The same 
process planned for the neighbour suppression GOI validation above should 
then be performed: assessment of expression and protein levels before and 
after the introduction of the targeting sequences, investigation of the pathway 
involved in the effect and validation experiments in other cell lines. Those cell 
lines should be reversibly immortalized, or ideally primary cells. A reversibly 
immortalized human β-cell line is available (Scharfmann, Pechberty et al. 2014) 
which could be used to validate the results in a human in vitro model of β-cells. 
In vivo experiments could be performed by producing conditional knockdown 
mice (i.e. the targeting sequence is expressed under the control of a β-cell 
specific promoter). The mice should then be exposed to diabetogenic conditions 
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and their glycaemia levels could be measured along with number, proliferation 
and apoptosis rate in their β-cells post-mortem. Changes in these 
measurements with respect to control mice (i.e. without expression of the 
targeting sequence) would indicate whether the effect of the GOI is validated in 
vivo. 
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5.5 Conclusions 
RNAi has been extensively used in the recent years to study the molecular 
effectors underlying a wide array of phenotypes. Designing, optimising and 
implementing an RNAi genome-wide screen is a complex process which 
requires attention to detail. Genome-wide screens have significantly evolved in 
every aspect from experimental aspects to analysis, and efforts should be made 
to refine even further these approaches.  
In Chapter 3 I presented a genome-wide screen for the detection of molecular 
effectors involved in the response of tumorigenic cells to suppressive cues from 
their neighbouring non-tumorigenic cells. The results from that screen provide a 
basic insight into the possible mechanisms responsible for the response of 
tumorigenic cells to their surrounding normal tissue in the early stages of 
tumorigenesis. From a methodological point of view, it introduces a pooled 
screen in a co-culture in vitro model and an analysis pipeline which accounts for 
one control condition and two experimental conditions which are also controls 
for each other. 
In Chapter 4 I described the (to my knowledge) first genome-wide RNAi screen 
in a reversibly immortalised model of β-cells. Upon validation of the results 
obtained, this screen could inform on the mechanisms of proliferation in β-cells 
and how to potentially manipulate their growth, and also on the mechanism of 
resistance to lipotoxicity.
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Appendices 
Appendix 1. Reannotation of the shRNA library using BLAST 
- Bulding the RefSeq mRNA reference to align the library to:  
I downloaded a fasta file with the refseq mrna database for Mus musculus from NCBI nucleotide 
(http://www.ncbi.nlm.nih.gov/nuccore, search "Mus musculus"[porgn:__txid10090] , check "mRNA(78059)" and "RefSeq(78059)", 
"Send to: File, Fasta" 
 
I made the database from the fasta in Standalone Blast from Window's command line: 
C:\Program Files\NCBI\blast-2.2.30+\db>makeblastdb -in mouserefseqmrna.fasta -dbtype "nucl" -out mouserefseqmrna 
 
Output on command line: 
"Building a new DB, current time: 03/17/2015 14:27:39 
New DB name:   mouserefseqmrna 
New DB title:  mouserefseqmrna.fasta 
Sequence type: Nucleotide 
Keep Linkouts: T 
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Keep MBits: T 
Maximum file size: 1000000000B 
Adding sequences from FASTA; added 78059 sequences in 5.26591 seconds." 
 
- Blasting the library against the reference database: 
blastn -query libquery.fasta -out libblastmousemrnadb.xml -outfmt "6 qseqid nident evalue stitle" -db "mouserefseqmrna" -
max_target_seqs 1 -num_threads 4 -task blastn-short -evalue 1000 -word_size 7
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Appendix 2. Grep commands for the neighbour suppression screen (Chapter 3) 
Format of command: 
grep “primer” “Original file to grep from” > “File to move the grepped lines to” 
Examples: 
grep TCGAGGTCGACGGTA 
/mnt/Data10/lb428/Fibroblast_sequences/Project_2053/Sample_A/raw_illumina_reads/A_TCGAAG_L006_R1_001.fastq 
> /mnt/Data10/lb428/Fibroblast_sequences/Project_2053/Sample_A/raw_illumina_reads/MreadsAinc.txt 
 
grep ATCTCTCGAGGTCGACGGTA 
/mnt/Data10/lb428/Fibroblast_sequences/Project_2053/Sample_A/raw_illumina_reads/A_TCGAAG_L006_R1_001.fastq 
> /mnt/Data10/lb428/Fibroblast_sequences/Project_2053/Sample_A/raw_illumina_reads/EreadsAinc.txt 
 grep GAGGTCGACGGTA 
/mnt/Data10/lb428/Fibroblast_sequences/Project_2053/Sample_A/raw_illumina_reads/A_TCGAAG_L006_R1_001.fastq 
> /mnt/Data10/lb428/Fibroblast_sequences/Project_2053/Sample_A/raw_illumina_reads/PreadsAinc.txt 
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Appendix 3. Python script to extract targeting sequences  
#Arguments: input file, output file. Prints a sequence of 19 bp before the 
beginning of the loop sequence - the shRNA 19mer in NKI library - and counts 
how many times that sequence is in the file 
 
#1) check arguments, outputs usage error message if incorrect 
import sys 
import re 
if len(sys.argv)!=3: 
    sys.stderr.write("USAGE: %s <InFile> <OutFile>" % sys.argv[0]) 
    sys.exit(1) 
 
#2) Open input and output file 
inputf= open(sys.argv[1]) 
outf=open (sys.argv[2], 'w+') 
 
#3) Re-direct output to file 
sys.stdout=outf 
from collections import Counter 
 
#4) Initiate variables 
fseq="" 
seq="" 
seq_list=[] 
loopseqs=[] 
setlist=[] 
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#5) Loop through lines in input 
for line in inputf: 
    #6) Search for exact matches of hairpin 
    seq=re.search("(.19TCTCTTGAA)", line) 
    #7) If hairpin is found, select the previous 19bp as a sequence and append to 
the list of sequences found 
    if seq is not None: 
        fseq=seq.group()[:19] 
        seq_list.append(fseq) 
    seq="" 
#8) Count occurrence of sequences 
seq_dict=Counter(seq_list) 
for sequence in seq_list: 
    loopseqs.append(str('%s %d' %(sequence, seq_dict[sequence]))) 
 
seqset=set(loopseqs) 
setlist=list(seqset) 
 
#9) Print to file sequences and occurrence 
print ("\n".join(setlist)) 
 
#10) Close files 
inputf.close() 
outf.close()
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Appendix 4. Stata do-file for transformation and calculation of z-
scores 
replace Preads=. if Preads<51 
levelsof pool, local(levels) 
gen Prpmpool=. 
gen Mrpmpool=. 
gen Erpmpool=. 
foreach l of local levels { 
 egen totalpoolP=sum(Preads) if pool==`l' 
 replace Prpmpool=(Preads/totalpoolP)*1000000 if pool==`l' 
 drop totalpoolP 
 egen totalpoolM=sum(Mreads) if pool==`l' 
 replace Mrpmpool=(Mreads/totalpoolM)*1000000 if pool==`l' 
 drop totalpoolM 
 egen totalpoolE=sum(Ereads) if pool==`l' 
 replace Erpmpool=(Ereads/totalpoolE)*1000000 if pool==`l' 
 drop totalpoolE 
      } 
gen EtoPfoldrpm=Erpmpool/Prpmpool 
gen MtoPfoldrpm=Mrpmpool/Prpmpool 
gen lnMtoPfoldrpm=log(MtoPfoldrpm) 
gen lnEtoPfoldrpm=log(EtoPfoldrpm) 
 
levelsof pool, local(levels) 
gen lnEtoPfoldmed =. 
gen lnMtoPfoldmed=. 
449 
 
 
 
foreach l of local levels { 
 qui sum lnEtoPfoldrpm if pool==`l', detail 
 qui replace lnEtoPfoldmed = r(p50) if pool ==  `l' 
 qui sum lnMtoPfoldrpm if pool==`l', detail 
 qui replace lnMtoPfoldmed = r(p50) if pool ==  `l' 
  
      } 
bysort pool: egen lnEtoPfoldmad=mad(lnEtoPfoldrpm) 
bysort pool: egen lnMtoPfoldmad=mad(lnMtoPfoldrpm) 
gen zscorelnEtoP=(lnEtoPfoldrpm-lnEtoPfoldmed)/lnEtoPfoldmad 
gen zscorelnMtoP=(lnMtoPfoldrpm-lnMtoPfoldmed)/lnMtoPfoldmad
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Appendix 5. Random sampling approach for recursive partitioning 
results 
#Program to get a distribution of the number of genes  from a number of 
random groups that are significant in our recursive partitioning datasets. 
#Written for my fibroblast screen data but can be used for any other type of 
input as long as we know sample size and have an input file organized in lines 
#outputs a matrix (repetitions, number of datasetsx2) 
import sys 
import random 
#1) Set the sample size and number of repetitions; and a header for the file (to 
discern the datasets) 
 
size=312 
repetitions=500 
 
header="taylorprim_highisgood taylorprim_lowisgood taylorall_highisgood 
taylorall_lowisgood shed_highisgood shed_lowisgood loitamox_highisgood 
loitamox_lowisgood loinot_highisgood loinot_lowisgood des3_highisgood 
des3_lowisgood des1_highisgood des1_lowisgood desall_highisgood 
desall_lowisgood" 
 
def check(n, variable, value): 
    if lineS[n]==value: 
        variable+=1 
        return variable 
    else: 
        return variable 
451 
 
 
 
 
#2) Open the output file and set the standard output to the file so data is printed 
to it directly 
 
with open (r"\\isad.isadroot.ex.ac.uk\UOE\User\Fibroblast screen\Recursive 
partitioning\smallMallscreenedpoolsrandom.txt", "w+") as outfile: 
    sys.stdout=outfile 
    print (header) 
    n=0  
    while n<repetitions: 
        with open (r"\\isad.isadroot.ex.ac.uk\UOE\User\Fibroblast 
screen\Recursive partitioning\allscreenedpoolsresults.txt") as infile: 
            sample=[] 
            genenames=[] 
            tayphigh=0 
            tayplow=0 
            tayahigh=0 
            tayalow=0 
            shedhigh=0 
            shedlow=0 
            loithigh=0 
            loitlow=0 
            loinhigh=0 
            loinlow=0 
            des3high=0 
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            des3low=0 
            des1high=0 
            des1low=0 
            desahigh=0 
            desalow=0 
            sample=random.sample(infile.readlines(), size) 
            for line in sample: 
                line = line.strip() 
                lineS=line.split("\t") 
                if len(lineS)>1: 
                    if lineS[0] not in genenames: 
                        genenames.append(lineS[0]) 
                        tayphigh=check(1, tayphigh, "TRUE") 
                        tayplow=check(1, tayplow, "FALSE") 
                        tayahigh=check(2, tayahigh, "TRUE") 
                        tayalow=check(2, tayalow, "FALSE") 
                        shedhigh=check(3, shedhigh, "TRUE") 
                        shedlow=check(3, shedlow, "FALSE") 
                        loithigh=check(4, loithigh, "TRUE") 
                        loitlow=check(4, loitlow, "FALSE") 
                        loinhigh=check(5, loinhigh, "TRUE") 
                        loinlow=check(5, loinlow, "FALSE") 
                        des3high=check(6, des3high, "TRUE") 
                        des3low=check(6, des3low, "FALSE") 
                        des1high=check(7, des1high, "TRUE") 
                        des1low=check(7, des1low, "FALSE") 
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                        desahigh=check(8, desahigh, "TRUE") 
                        desalow=check(8, desalow, "FALSE") 
 
            print (tayphigh, tayplow, tayahigh, tayalow, shedhigh, shedlow, loithigh, 
loitlow, loinhigh, loinlow, des3high, des3low, des1high, des1low, desahigh, 
desalow) 
            n+=1 
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Appendix 6. Random sampling approach for detection of “hub” 
genes in network analysis 
#Takes a list of nodes and outputs the number of interactors in a number of 
random samples 
import sys 
import random 
from collections import Counter 
 
#1) Input a list of nodes with gene name and ensembl ID separated by tab 
samplesize= 592 #integer of size=hit list size-1 
repetitions= 1000 #number of random samples to draw 
#open output file 
with open (r"PATH_TO_FILE/FILENAME"w+") as outfile: 
    sys.stdout=outfile 
    with open (r "PATH_TO_FILE/LIBRARY FILENAME”) as librarygenes: 
        libraryg=[] 
        for gene in librarygenes.readlines(): 
            gene=gene.strip() 
            libraryg.append(gene) 
    with open (r "PATH_TO_FILE/SAMPLEINTERACTIONSFILENAME”) as 
nodelist: 
        for line in nodelist: 
            line=line.strip() 
            if len(line.split("\t"))>2: 
                node=line.split("\t")[2] 
                nodesymbol=line.split("\t")[0] 
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                geneinteractions=int(line.split("\t")[1]) 
             
          
         
        # Find interactors in file and build list of interactors 
                interactors=[] 
                with open (r" PATH_TO_FILE/INTERACTION DATABASE 
FILENAME ") as interactions: 
                    for interaction in interactions: 
                        interaction=interaction.strip() 
                     
                        if interaction.split("\t")[0] == node: 
                            if interaction.split("\t")[1] in libraryg: 
                                interactors.append(interaction.split("\t")[1]) 
 
                        if interaction.split("\t")[1] == node: 
                            if interaction.split("\t")[0] in libraryg: 
                         
                                interactors.append(interaction.split("\t")[0]) 
                    possibleinteractions=len(interactors) 
         
         
            
                           # For 1 to n: 
                    repeat=0 
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                    highconnected=0 
                    while repeat<repetitions: 
                    #open the file with the gene names and ensemblIDs of the 
screened genes 
                        with open (r" PATH_TO_FILE/SCREENED GENES FILENAME ") 
as library: 
            #draw random sample from library ensembl ids 
                            sample=random.sample(library.readlines(), samplesize) 
                            interactorsinsample=[] 
                            numberinteractors=0 
                             
            #count interactors in random sample 
                            for line in sample: 
                                line=line.strip() 
                                if len(line.split("\t"))>1: 
                                    if line.split("\t")[1] in interactors: 
                                        if line.split("\t")[1] not in interactorsinsample: 
                                            interactorsinsample.append(line.split("\t")[1]) 
                                            numberinteractors+=1 
            #output node name and number of interactors in random sample 
                            if numberinteractors>geneinteractions: 
                                highconnected+=1 
                             
 
                             
                            repeat+=1 
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                            if repeat==repetitions-1: 
                                print (nodesymbol, possibleinteractions, geneinteractions, 
highconnected) 
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Appendix 7. Stata do-file for transformation and calculation of z-
scores in the β-cell screen. 
levelsof pool, local(levels) 
gen T0rpmpool=. 
gen T7rpmpool=. 
gen T14rpmpool=. 
gen Controlrpmpool=. 
gen Palmitaterpmpool=. 
foreach l of local levels { 
 egen totalpoolT0=sum(T0reads) if pool==`l' 
 replace T0rpmpool=(T0reads/totalpoolT0)*1000000 if pool==`l' 
 drop totalpoolT0 
 egen totalpoolT7=sum(T7reads) if pool==`l' 
 replace T7rpmpool=(T7reads/totalpoolT7)*1000000 if pool==`l' 
 drop totalpoolT7 
 egen totalpoolT14=sum(T14reads) if pool==`l' 
 replace T14rpmpool=(T14reads/totalpoolT14)*1000000 if pool==`l' 
 drop totalpoolT14 
 egen totalpoolPalm=sum(Palmitatereads) if pool==`l' 
 replace Palmitaterpmpool=(Palmitatereads/totalpoolPalm)*1000000 if 
pool==`l' 
 drop totalpoolPalm 
 egen totalpoolControl=sum(Controlreads) if pool==`l' 
 replace Controlrpmpool=(Controlreads/totalpoolControl)*1000000 if 
pool==`l' 
 drop totalpoolControl 
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      } 
gen T7toT0foldrpm=T7rpmpool/T0rpmpool 
gen T14toT0foldrpm=T14rpmpool/T0rpmpool 
gen PalmtoContfoldrpm=Palmitaterpmpool/Controlrpmpool 
gen lnT7toT0foldrpm=log(T7toT0foldrpm) 
gen lnT14toT0foldrpm=log(T14toT0foldrpm) 
gen lnPalmtoContfoldrpm=log(PalmtoContfoldrpm) 
 
levelsof pool, local(levels) 
gen lnT7toT0foldmed =. 
gen lnT14toT0foldmed=. 
gen lnPalmtoContfoldmed=. 
 
 
foreach l of local levels { 
 qui sum lnT7toT0foldrpm if pool==`l', detail 
 qui replace lnT7toT0foldmed = r(p50) if pool ==  `l' 
 qui sum lnT14toT0foldrpm if pool==`l', detail 
 qui replace lnT14toT0foldmed = r(p50) if pool ==  `l' 
 qui sum lnPalmtoContfoldrpm if pool==`l', detail 
 qui replace lnPalmtoContfoldmed = r(p50) if pool ==  `l' 
  
      } 
bysort pool: egen lnT7toT0foldmad=mad(lnT7toT0foldrpm) 
bysort pool: egen lnT14toT0foldmad=mad(lnT14toT0foldrpm) 
bysort pool: egen lnPalmtoContfoldmad=mad(lnPalmtoContfoldrpm) 
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gen zscorelnT7toT0=(lnT7toT0foldrpm-lnT7toT0foldmed)/lnT7toT0foldmad 
gen zscorelnT14toT0=(lnT14toT0foldrpm-lnT14toT0foldmed)/lnT14toT0foldmad 
gen zscorelnPalmtoCont=(lnPalmtoContfoldrpm-
lnPalmtoContfoldmed)/lnPalmtoContfoldmad 
 
gen PalmtoT0foldrpm=Palmitaterpmpool/T0rpmpool 
gen lnPalmtoT0foldrpm=log(PalmtoT0foldrpm) 
levelsof pool, local(levels) 
gen lnPalmtoT0foldmed=. 
foreach l of local levels { 
 qui sum lnPalmtoT0foldrpm if pool==`l', detail 
 qui replace lnPalmtoT0foldmed = r(p50) if pool ==  `l' 
 } 
bysort pool: egen lnPalmtoT0foldmad=mad(lnPalmtoT0foldrpm) 
gen zscorelnPalmtoT0=(lnPalmtoT0foldrpm-
lnPalmtoT0foldmed)/lnPalmtoT0foldmad 
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Appendix 8. Grep commands for the β-cell screen (Chapter 4) 
Format of command: 
grep “shRNA loop” “Original file to grep from” > “File to move the grepped lines to” 
 
Examples: 
grep TCTCTTGAA /mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta2/raw_illumina_reads/Beta2_AAGAGGCA-
CTCTCTAT_L002_R1_001.fastq > 
/mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta2/raw_illumina_reads/T7loopFW.txt 
grep TCTCTTGAA /mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta3/raw_illumina_reads/Beta3_AAGAGGCA-
TATCCTCT_L002_R1_001.fastq > 
/mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta3/raw_illumina_reads/T14loopFW.txt 
grep TCTCTTGAA /mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta4/raw_illumina_reads/Beta4_AAGAGGCA-
AGAGTAGA_L002_R1_001.fastq > 
/mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta4/raw_illumina_reads/PalmloopFW.txt 
grep TCTCTTGAA /mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta5/raw_illumina_reads/Beta5_AAGAGGCA-
GTAAGGAG_L002_R1_001.fastq > 
/mnt/Data10/lb428/Fibroblast_sequences/project2235/Sample_Beta5/raw_illumina_reads/ContloopFW.txt
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Appendix 9. List of functional terms found to be enriched in the 
3T3supp+, 3T3supp- and combined GOI lists using DAVID 
 
phosphoprotein 
acetylation 
GO:0005829~cytosol 
nucleus 
GO:0043085~positive regulation of catalytic activity 
GO:0044093~positive regulation of molecular function 
cytoplasm 
GO:0045944~positive regulation of transcription from RNA polymerase II 
promoter 
metal-binding 
nucleotide-binding 
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Appendix 10. List of functional terms found to be enriched in the 
3T3supp+ and combined GOI lists using DAVID 
GO:0006793~phosphorus metabolic process 
GO:0006796~phosphate metabolic process 
isopeptide bond 
GO:0030029~actin filament-based process 
ubl conjugation 
Transcription 
GO:0016310~phosphorylation 
GO:0048538~thymus development 
GO:0010648~negative regulation of cell communication 
GO:0030036~actin cytoskeleton organization 
GO:0000159~protein phosphatase type 2A complex 
mmu05410:Hypertrophic cardiomyopathy (HCM) 
GO:0032553~ribonucleotide binding 
GO:0032555~purine ribonucleotide binding 
GO:0001822~kidney development 
transcription regulation 
GO:0003700~transcription factor activity 
GO:0009968~negative regulation of signal transduction 
GO:0017076~purine nucleotide binding 
GO:0001558~regulation of cell growth 
GO:0000166~nucleotide binding 
kinase 
GO:0001882~nucleoside binding 
GO:0030016~myofibril 
GO:0006350~transcription 
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GO:0045449~regulation of transcription 
GO:0032559~adenyl ribonucleotide binding 
GO:0008287~protein serine/threonine phosphatase complex 
GO:0006357~regulation of transcription from RNA polymerase II promoter 
GO:0003677~DNA binding 
GO:0001883~purine nucleoside binding 
GO:0005604~basement membrane 
GO:0043292~contractile fiber 
GO:0030554~adenyl nucleotide binding 
cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO) 
GO:0030054~cell junction 
GO:0043009~chordate embryonic development 
GO:0009792~embryonic development ending in birth or egg hatching 
GO:0006355~regulation of transcription, DNA-dependent 
GO:0044459~plasma membrane part 
GO:0043408~regulation of MAPKKK cascade 
serine/threonine-protein kinase 
domain:CTCK 
centromere 
actin-binding 
IPR003349:Transcription factor jumonji, JmjN 
GO:0051252~regulation of RNA metabolic process 
mmu05414:Dilated cardiomyopathy 
GO:0007015~actin filament organization 
GO:0030528~transcription regulator activity 
domain:JmjN 
GO:0005626~insoluble fraction 
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cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) 
IPR006207:Cystine knot, C-terminal 
GO:0000267~cell fraction 
GO:0001756~somitogenesis 
GO:0016323~basolateral plasma membrane 
SM00545:JmjN 
GO:0044420~extracellular matrix part 
GO:0007548~sex differentiation 
GO:0006979~response to oxidative stress 
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Appendix 11. List of functional terms found to be enriched in the 
3T3supp- and combined GOI lists using DAVID 
dna-binding 
GO:0010557~positive regulation of macromolecule biosynthetic process 
GO:0009891~positive regulation of biosynthetic process 
GO:0042995~cell projection 
GO:0045941~positive regulation of transcription 
GO:0051173~positive regulation of nitrogen compound metabolic process 
GO:0050768~negative regulation of neurogenesis 
DNA binding 
GO:0033674~positive regulation of kinase activity 
GO:0016477~cell migration 
GO:0010721~negative regulation of cell development 
GO:0045935~positive regulation of nucleobase, nucleoside, nucleotide and nucleic 
acid metabolic process 
GO:0010628~positive regulation of gene expression 
GO:0051347~positive regulation of transferase activity 
GO:0031328~positive regulation of cellular biosynthetic process 
GO:0010604~positive regulation of macromolecule metabolic process 
GO:0048870~cell motility 
GO:0051674~localization of cell 
GO:0006970~response to osmotic stress 
GO:0043549~regulation of kinase activity 
GO:0006928~cell motion 
GO:0051338~regulation of transferase activity 
zinc finger region:C2H2-type 3 
IPR013087:Zinc finger, C2H2-type/integrase, DNA-binding 
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GO:0045859~regulation of protein kinase activity 
GO:0030182~neuron differentiation 
GO:0048732~gland development 
GO:0051495~positive regulation of cytoskeleton organization 
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